<!DOCTYPE html>
<html lang="en" class="scroll-smooth">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Respiratory Study Guide - Enhanced v2</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&family=Fira+Code:wght@400;500&family=Orbitron:wght@400;500;700&display=swap" rel="stylesheet">
    <style>
        :root {
            --sidebar-width: 288px; /* w-72 */
            --bg-background: #0d1117; /* Very dark grey/blue - GitHub Dark Dimmed inspired */
            --bg-foreground: #161b22; /* Darker foreground elements */
            --bg-muted: #21262d;    /* Muted background elements */
            --text-primary: #c9d1d9; /* Primary text - light grey */
            --text-secondary: #8b949e; /* Secondary text - medium grey */
            --text-heading: #e6edf3;   /* Brighter text for headings */
            --accent-cyan: #30b6ff;   /* Adjusted Cyan */
            --accent-fuchsia: #f778ba; /* Adjusted Fuchsia */
            --accent-lime: #a3e635;   /* Kept Lime */
            --border-color: #30363d; /* Subtle border */
            --border-accent: var(--accent-cyan);
            --glow-fuchsia: rgba(247, 120, 186, 0.3);
            --glow-cyan: rgba(48, 182, 255, 0.3);
            --glow-lime: rgba(163, 230, 53, 0.3);
        }

        @keyframes subtleGlowPulse {
            0%, 100% { box-shadow: 0 0 8px var(--glow-cyan); }
            50% { box-shadow: 0 0 16px var(--glow-cyan); }
        }
         @keyframes subtleRotate {
             from { transform: rotate(0deg); }
             to { transform: rotate(360deg); }
         }
         @keyframes fadeInSlideUp {
            from { opacity: 0; transform: translateY(20px); }
            to { opacity: 1; transform: translateY(0); }
        }

        body {
            font-family: 'Inter', sans-serif;
            background-color: var(--bg-background);
            color: var(--text-primary);
            line-height: 1.7;
            transition: padding-left 0.3s ease-in-out; /* Smooth transition for sidebar toggle */
        }
        body.sidebar-hidden {
            padding-left: 0;
        }
        @media (min-width: 1024px) {
            body:not(.sidebar-hidden) {
                padding-left: var(--sidebar-width);
            }
        }

        /* --- Scrollbar --- */
        ::-webkit-scrollbar { width: 10px; height: 10px; }
        ::-webkit-scrollbar-track { background: var(--bg-foreground); }
        ::-webkit-scrollbar-thumb { background: var(--accent-cyan); border-radius: 5px; border: 2px solid var(--bg-foreground); }
        ::-webkit-scrollbar-thumb:hover { background: var(--accent-fuchsia); }

        /* --- Sidebar --- */
        #sidebar {
            position: fixed;
            top: 0;
            left: 0;
            height: 100vh;
            width: var(--sidebar-width);
            background-color: rgba(13, 17, 23, 0.85); /* --bg-background opacity */
            backdrop-filter: blur(8px);
            border-right: 1px solid var(--border-color);
            box-shadow: 3px 0 15px rgba(0, 0, 0, 0.2);
            transition: transform 0.3s ease-in-out;
            z-index: 100;
            display: flex;
            flex-direction: column;
            overflow-y: auto;
        }
        body.sidebar-hidden #sidebar {
            transform: translateX(-100%);
        }

        #sidebar-header {
            padding: 1rem 1.5rem;
            border-bottom: 1px solid var(--border-color);
        }
        #sidebar-title {
            font-family: 'Orbitron', sans-serif;
            font-weight: 500;
            font-size: 1.25rem;
            color: var(--accent-cyan);
            text-shadow: 0 0 6px var(--glow-cyan);
        }
        #sidebar-nav {
             flex-grow: 1;
             padding: 1rem 0.5rem;
        }
        #sidebar-nav a {
            display: block;
            padding: 0.6rem 1rem;
            margin-bottom: 0.25rem;
            border-radius: 6px;
            font-size: 0.9rem;
            color: var(--text-secondary);
            border-left: 3px solid transparent;
            transition: all 0.2s ease-in-out;
            position: relative;
        }
        #sidebar-nav a:hover {
            background-color: var(--bg-muted);
            color: var(--text-heading);
            border-left-color: var(--accent-lime);
        }
        .active-link {
            background-color: var(--accent-cyan) !important;
            color: var(--bg-background) !important;
            font-weight: 600;
            border-left-color: var(--accent-fuchsia) !important;
            box-shadow: inset 3px 0 8px rgba(0,0,0,0.2);
        }

        /* --- Sidebar Toggle Button --- */
        #sidebar-toggle {
            position: fixed;
            top: 1rem;
            left: 1rem;
            z-index: 110;
            background-color: var(--accent-fuchsia);
            color: var(--bg-background);
            border: none;
            padding: 0.5rem 0.8rem;
            border-radius: 5px;
            cursor: pointer;
            box-shadow: 0 0 10px var(--glow-fuchsia);
            transition: all 0.3s ease;
            font-weight: bold;
        }
        #sidebar-toggle:hover {
             background-color: var(--accent-cyan);
             color: var(--bg-background);
             box-shadow: 0 0 15px var(--glow-cyan);
             transform: scale(1.05);
        }
         body:not(.sidebar-hidden) #sidebar-toggle {
             /* Optional: Move button slightly when sidebar is open */
             /* left: calc(var(--sidebar-width) + 1rem); */
         }

        /* --- Main Content Area --- */
        #main-content {
             padding: 2rem;
             transition: margin-left 0.3s ease-in-out; /* Match body padding transition */
             max-width: 1200px; /* Optional: Limit max width for readability */
             margin-left: auto; /* Center content area */
             margin-right: auto;
        }
        @media (max-width: 1023px) {
            #main-content {
                margin-left: 0 !important; /* Override desktop margin */
                padding: 1.5rem;
            }
        }
        @media (max-width: 640px) {
            #main-content { padding: 1rem; }
        }


        .content-section {
            background-color: var(--bg-foreground);
            padding: 2rem; /* Increased padding */
            margin-bottom: 3rem;
            border-radius: 8px;
            border: 1px solid var(--border-color);
            box-shadow: 0 1px 3px rgba(0,0,0,0.1), 0 5px 15px rgba(0,0,0,0.1);
            opacity: 0; /* Start hidden for animation */
            animation: fadeInSlideUp 0.6s ease-out forwards;
            animation-delay: 0.1s; /* Stagger animation slightly */
        }
         .content-section:hover {
            border-color: var(--border-accent); /* Subtle hover border */
         }

        /* --- Headings --- */
        h1, h2, h3, h4 {
             color: var(--text-heading);
             margin-bottom: 1.25rem;
             font-family: 'Orbitron', sans-serif;
             letter-spacing: 0.5px;
             line-height: 1.3;
        }
         h1 { font-size: 2.25rem; font-weight: 700; border-bottom: 2px solid var(--accent-fuchsia); padding-bottom: 0.75rem; margin-bottom: 2.5rem; text-shadow: 0 0 8px var(--glow-fuchsia); }
         h2 { font-size: 1.6rem; font-weight: 500; border-bottom: 1px solid var(--border-color); padding-bottom: 0.6rem; margin-top: 3rem; margin-bottom: 1.75rem; display: flex; align-items: center; color: var(--accent-cyan); text-shadow: 0 0 5px var(--glow-cyan); }
         h3 { font-size: 1.25rem; font-weight: 500; color: var(--accent-lime); margin-top: 2.5rem; margin-bottom: 1.25rem; text-shadow: 0 0 4px var(--glow-lime); }
         h4 { font-size: 1.1rem; font-weight: 500; color: var(--accent-cyan); margin-top: 2rem; margin-bottom: 1rem; }

        /* --- Details/Summary (Accordion Style) --- */
        details {
            background-color: transparent; /* Use parent background */
            border: 1px solid var(--border-color);
            border-radius: 6px;
            margin-bottom: 1rem;
            transition: background-color 0.3s ease;
            overflow: hidden;
        }
        details[open] {
             background-color: var(--bg-muted); /* Highlight when open */
             border-color: var(--accent-fuchsia);
        }
        summary {
            cursor: pointer;
            font-weight: 500; /* Slightly less bold */
            color: var(--accent-cyan);
            outline: none;
            list-style: none;
            position: relative;
            padding: 0.8rem 1.5rem; /* Consistent padding */
            padding-left: 2.5rem; /* Space for icon */
            transition: background-color 0.2s ease, color 0.2s ease;
            border-bottom: 1px solid var(--border-color); /* Separator */
        }
         details[open] summary {
             background-color: rgba(247, 120, 186, 0.1); /* Fuchsia tint */
             color: var(--accent-fuchsia);
             border-bottom-color: transparent; /* Hide separator when open */
         }
         summary::-webkit-details-marker { display: none; }
         summary::before { /* Chevron icon */
            content: '›';
            position: absolute;
            left: 1rem;
            top: 50%;
            transform: translateY(-50%) rotate(0deg);
            font-size: 1.5em; /* Larger icon */
            font-weight: bold;
            color: var(--accent-cyan);
            transition: transform 0.3s ease, color 0.3s ease;
         }
         details[open] > summary::before {
            transform: translateY(-50%) rotate(90deg);
            color: var(--accent-fuchsia);
         }
         summary:hover {
             background-color: var(--bg-muted);
             color: var(--accent-lime);
         }
         summary:hover::before {
             color: var(--accent-lime);
         }
        details > div.details-content { /* Wrap content in a div for padding */
            padding: 1rem 1.5rem 1.5rem 1.5rem; /* Padding for content */
            border-top: 1px solid var(--border-color); /* Separator for open state */
            animation: fadeInContent 0.4s ease forwards;
            opacity: 0;
        }

        @keyframes fadeInContent {
            from { opacity: 0; transform: translateY(-5px); }
            to { opacity: 1; transform: translateY(0); }
        }

        /* --- Code/Mono font --- */
        code, .mono {
            font-family: 'Fira Code', monospace;
            background-color: var(--bg-muted);
            padding: 0.2rem 0.5rem;
            border-radius: 4px;
            font-size: 0.9em;
            color: var(--accent-lime);
            border: 1px solid var(--border-color);
            word-wrap: break-word; /* Prevent long code overflow */
            white-space: pre-wrap; /* Wrap long code lines */
        }
        pre code {
             display: block;
             padding: 1rem;
             overflow-x: auto;
             background-color: var(--bg-background); /* Darker background for blocks */
             border: 1px solid var(--border-color);
             border-radius: 6px;
             margin: 1rem 0;
        }

        /* --- Text Elements --- */
        p { margin-bottom: 1rem; color: var(--text-primary); }
        strong { color: var(--text-heading); font-weight: 600; }
        em { color: var(--accent-fuchsia); font-style: italic; text-shadow: 0 0 2px var(--glow-fuchsia); }

        ul { list-style: none; padding-left: 0; margin-bottom: 1rem; }
        ol { list-style: none; padding-left: 0; margin-bottom: 1rem; counter-reset: list-counter; }
        li {
            margin-bottom: 0.6rem;
            position: relative;
            padding-left: 1.8rem; /* More indent for icon */
            color: var(--text-secondary); /* Slightly dimmer list items */
        }
        li strong { color: var(--text-primary); } /* Make strong text in lists stand out */

        ul > li::before {
            content: '▹'; /* Different bullet */
            position: absolute;
            left: 0.5rem;
            top: 0.1em; /* Adjust vertical alignment */
            color: var(--accent-cyan);
            font-weight: bold;
            font-size: 1.1em;
            line-height: 1.4;
        }
         ol > li { counter-increment: list-counter; }
         ol > li::before {
            content: counter(list-counter);
            position: absolute;
            left: 0;
            top: 0;
            color: var(--bg-background);
            background-color: var(--accent-lime);
            font-weight: bold;
            font-size: 0.8em;
            line-height: 1.4;
            border-radius: 50%;
            width: 1.4em;
            height: 1.4em;
            text-align: center;
            padding-top: 0.1em; /* Fine-tune number position */
         }
         /* Indent nested lists */
         ul ul, ol ol, ul ol, ol ul {
             margin-left: 1.5rem;
             margin-top: 0.5rem;
             margin-bottom: 0.5rem;
         }

        /* --- Table styling --- */
        .table-container { overflow-x: auto; margin: 1.5rem 0; } /* Allow horizontal scroll on small screens if needed */
        table {
            width: 100%;
            border-collapse: separate; /* Use separate for rounded corners */
            border-spacing: 0;
            border: 1px solid var(--border-color);
            border-radius: 8px; /* Rounded corners for table */
            font-size: 0.9rem;
            box-shadow: 0 1px 3px rgba(0,0,0,0.1);
        }
        th, td {
            border-bottom: 1px solid var(--border-color);
            padding: 0.8rem 1rem;
            text-align: left;
            vertical-align: top;
        }
        th {
            background-color: var(--bg-foreground); /* Header background */
            font-weight: 600;
            color: var(--accent-cyan);
            font-family: 'Inter', sans-serif; /* Use Inter for table headers */
            letter-spacing: 0.5px;
            position: sticky; /* Make header sticky if table scrolls */
            top: 0;
            z-index: 10;
        }
        th:first-child { border-top-left-radius: 8px; }
        th:last-child { border-top-right-radius: 8px; }
        tbody tr { transition: background-color 0.2s ease; }
        tbody tr:last-child td { border-bottom: none; } /* Remove bottom border on last row */
        tbody tr:last-child td:first-child { border-bottom-left-radius: 8px; }
        tbody tr:last-child td:last-child { border-bottom-right-radius: 8px; }

        tbody tr:nth-child(even) {
             background-color: rgba(33, 38, 45, 0.3); /* --bg-muted opacity */
        }
         tbody tr:hover {
             background-color: var(--bg-muted);
             color: var(--text-heading);
         }

        /* --- Case Study Styling (Card-like) --- */
        .case-study {
            border: 1px solid var(--border-color);
            padding: 1.5rem;
            margin-top: 2.5rem;
            margin-bottom: 2.5rem;
            border-radius: 8px;
            background-color: var(--bg-foreground); /* Use foreground color */
            box-shadow: 0 2px 5px rgba(0,0,0,0.15);
            border-left: 5px solid var(--accent-lime); /* Accent border */
        }
        .case-study .case-title {
            font-weight: 600; /* Less bold */
            color: var(--accent-lime);
            font-size: 1.2rem; /* Slightly smaller */
            margin-bottom: 1rem;
            border-bottom: 1px solid var(--border-color);
            padding-bottom: 0.75rem;
            font-family: 'Inter', sans-serif; /* Use Inter */
            text-shadow: none; /* Remove shadow */
        }
        .case-study p:not(.case-title) {
             margin-bottom: 0.75rem;
             color: var(--text-secondary);
        }
        .case-study details { /* Style details within case studies */
             border-color: var(--border-color);
             border-left: 3px solid var(--accent-lime); /* Thinner accent */
             margin-top: 1rem;
        }
         .case-study summary { color: var(--accent-lime); padding: 0.6rem 1rem; padding-left: 2rem; }
         .case-study summary::before { color: var(--accent-lime); left: 0.5rem; font-size: 1.2em; }
         .case-study details[open] summary { color: var(--accent-fuchsia); background-color: rgba(247, 120, 186, 0.05); }
         .case-study details[open] > summary::before { color: var(--accent-fuchsia); }
         .case-study details > div.details-content { padding: 1rem; }

        /* --- SVG/Pixel Art Styling --- */
        .section-svg {
            width: 32px; /* Smaller */
            height: 32px;
            margin-right: 0.8rem;
            display: inline-block;
            vertical-align: middle;
            fill: currentColor; /* Inherit color from H2 */
            transition: transform 0.3s ease;
            flex-shrink: 0; /* Prevent shrinking */
        }
         h2:hover .section-svg {
             transform: rotate(-10deg) scale(1.1);
             /* animation: subtleRotate 5s linear infinite; */ /* Optional continuous rotation */
         }
         /* Pixel Art Divider */
         .pixel-art-divider {
             height: 5px; /* Thinner */
             background-image: linear-gradient(45deg, var(--accent-cyan) 25%, transparent 25%), linear-gradient(-45deg, var(--accent-cyan) 25%, transparent 25%), linear-gradient(45deg, transparent 75%, var(--accent-fuchsia) 75%), linear-gradient(-45deg, transparent 75%, var(--accent-fuchsia) 75%);
             background-size: 10px 10px;
             background-position: 0 0, 0 5px, 5px -5px, -5px 0px;
             margin: 3rem auto; /* Center it */
             width: 80%;
             opacity: 0.5;
         }

        /* --- Mobile Responsiveness Refinements --- */
        @media (max-width: 640px) {
             /* Stack table cells using grid for better control */
             .table-container { overflow-x: visible; } /* Disable horizontal scroll for stacked */
             table { border-radius: 0; border: none; box-shadow: none; }
             thead { display: none; }
             tbody, tr, td { display: block; width: 100%; }
             tr {
                 border: 1px solid var(--border-color);
                 border-radius: 6px;
                 margin-bottom: 1rem;
                 padding: 1rem;
                 background-color: var(--bg-foreground);
             }
             td {
                 display: flex;
                 justify-content: space-between;
                 align-items: center;
                 text-align: right;
                 border: none;
                 padding: 0.5rem 0;
                 border-bottom: 1px dashed var(--border-color);
             }
             td:last-child { border-bottom: none; }
             td::before {
                 content: attr(data-label);
                 font-weight: 600;
                 text-align: left;
                 margin-right: 1rem;
                 color: var(--accent-lime);
                 flex-basis: 40%; /* Allocate space for label */
                 flex-shrink: 0;
             }
             td > * { /* Ensure content within TD aligns right */
                 text-align: right;
                 margin-left: auto;
             }
             td details { width: 100%; } /* Make details take full width in table cell */
             h1 { font-size: 1.6rem; }
             h2 { font-size: 1.3rem; }
             h3 { font-size: 1.1rem; }
             .content-section { padding: 1.2rem; }
        }

    </style>
</head>
<body>

    <!-- Sidebar Toggle Button -->
    <button id="sidebar-toggle" title="Toggle Sidebar">☰</button>

    <!-- Sidebar -->
    <aside id="sidebar">
        <div id="sidebar-header">
            <h2 id="sidebar-title">Resp Study Guide</h2>
        </div>
        <nav id="sidebar-nav">
            <!-- Links need to match section IDs -->
            <a href="#abg-pft">ABG & PFTs</a>
            <a href="#imaging-procedures">Imaging & Procedures</a>
            <a href="#hoarseness-sinusitis">Hoarseness & Sinusitis</a>
            <a href="#radiology-basics">Radiology Basics</a>
            <a href="#tuberculosis">Tuberculosis</a>
            <a href="#ntm-leprosy">NTM & Leprosy</a>
            <a href="#pediatric-pulmonology">Pediatric Pulmonology</a>
            <a href="#obstructive-sleep-apnea">Obstructive Sleep Apnea</a>
            <a href="#pathology">Pathology</a>
            <a href="#pharmacology-rhinitis-allergy">Pharma: Rhinitis/Allergy</a>
            <a href="#pharmacology-resp-infections">Pharma: Resp Infections</a>
            <a href="#pharmacology-asthma-copd">Pharma: Asthma/COPD</a>
            <a href="#microbiology-summary">Microbiology Summary</a>
            <a href="#pharmacology-cil">Pharma CIL</a>
            <a href="#cil-antimicrobials">Antimicrobials CIL</a> <!-- Corrected ID -->
            <a href="#asthma-copd-cil">Asthma/COPD CIL</a>
        </nav>
    </aside>

    <!-- Main Content Area -->
    <main id="main-content">

        <h1>Respiratory Exam 2 Study Guide</h1>

        <!-- Section: ABG & PFTs -->
        <div id="abg-pft" class="content-section">
             <svg viewBox="0 0 16 16" xmlns="http://www.w3.org/2000/svg" class="section-svg"><path fill-rule="evenodd" clip-rule="evenodd" d="M1 3H2V4H1V3ZM1 5H2V6H1V5ZM1 7H2V8H1V7ZM1 9H2V10H1V9ZM1 11H2V12H1V11ZM1 13H2V14H1V13ZM3 2H4V3H3V2ZM4 2H5V3H4V2ZM5 2H6V3H5V2ZM6 2H7V3H6V2ZM7 2H8V3H7V2ZM8 2H9V3H8V2ZM9 2H10V3H9V2ZM10 2H11V3H10V2ZM11 2H12V3H11V2ZM12 2H13V3H12V2ZM13 2H14V3H13V2ZM14 2H15V3H14V2ZM15 3H16V4H15V3ZM15 4H16V5H15V4ZM15 5H16V6H15V5ZM15 6H16V7H15V6ZM15 7H16V8H15V7ZM15 8H16V9H15V8ZM15 9H16V10H15V9ZM15 10H16V11H15V10ZM15 11H16V12H15V11ZM15 12H16V13H15V12ZM15 13H16V14H15V13ZM14 14H15V15H14V14ZM13 14H14V15H13V14ZM12 14H13V15H12V14ZM11 14H12V15H11V14ZM10 14H11V15H10V14ZM9 14H10V15H9V14ZM8 14H9V15H8V14ZM7 14H8V15H7V14ZM6 14H7V15H6V14ZM5 14H6V15H5V14ZM4 14H5V15H4V14ZM3 14H4V15H3V14ZM2 13H3V14H2V13ZM2 12H3V13H2V12ZM2 11H3V12H2V11ZM2 10H3V11H2V10ZM2 9H3V10H2V9ZM2 8H3V9H2V8ZM2 7H3V8H2V7ZM2 6H3V7H2V6ZM2 5H3V6H2V5ZM2 4H3V5H2V4ZM2 3H3V4H2V3ZM3 3H4V4H3V3ZM4 4H5V5H4V4ZM5 5H6V6H5V5ZM6 6H7V7H6V6ZM7 7H8V8H7V7ZM8 8H9V9H8V8ZM9 9H10V10H9V9ZM10 10H11V11H10V10ZM11 11H12V12H11V11ZM12 12H13V13H12V12ZM13 13H14V14H13V13ZM4 13H5V14H4V13ZM5 12H6V13H5V12ZM6 11H7V12H6V11ZM7 10H8V11H7V10ZM8 9H9V10H8V9ZM9 8H10V9H9V8ZM10 7H11V8H10V7ZM11 6H12V7H11V6ZM12 5H13V6H12V5ZM13 4H14V5H13V4ZM14 3H15V4H14V3Z" fill="currentColor"/></svg>
            <h2>Arterial Blood Gases & PFTs</h2>

            <h3>Arterial Blood Gases</h3>
            <details>
                <summary>Normal ranges</summary>
                <div class="details-content">
                    <ul>
                        <li>pH: <code class="mono">7.35 - 7.45</code></li>
                        <li>HCO3: <code class="mono">22 - 26</code> mEq/L</li>
                        <li>PCO2: <code class="mono">35 - 45</code> mmHg</li>
                        <li>PO2: <code class="mono">80 - 100</code> mmHg</li>
                    </ul>
                </div>
            </details>

            <h4>Alveolar-arterial O2 gradient (A-a gradient)</h4>
            <details>
                <summary>Calculation</summary>
                <div class="details-content">
                    <p>PAO2 = FiO2 x (PB – PH20) – (PaCO2 / R)</p>
                    <p>Where: FiO2 = fraction inspired O2, PB = barometric pressure, PH2O = water vapor pressure (47 mmHg), PaCO2 = arterial CO2, R = respiratory quotient (~0.8)</p>
                    <p>Simplified (sea level, room air): PAO2 ≈ 150 - (1.25 x PaCO2)</p>
                    <p><strong>A-a O2 gradient = PAO2 – PaO2</strong></p>
                    <p>Normal gradient increases with age, roughly (Age/4) + 4.</p>
                </div>
            </details>
             <details>
                <summary>Causes of Increased A-a Gradient (V/Q mismatch, Shunt)</summary>
                <div class="details-content">
                    <p><strong>V/Q mismatch occurs in:</strong></p>
                    <ul>
                        <li>COPD (Chronic Bronchitis, Emphysema)</li>
                        <li>Asthma</li>
                        <li>Pulmonary Embolism (PE)</li>
                        <li>Interstitial Lung Disease (ILD)</li>
                    </ul>
                    <p><strong>Shunts occur in:</strong> (Extreme V/Q mismatch, unresponsive to O2)</p>
                     <ul>
                         <li>Congestive Heart Failure (CHF) with pulmonary edema</li>
                         <li>Acute Respiratory Distress Syndrome (ARDS)</li>
                         <li>Lobar Pneumonia</li>
                         <li>Intracardiac shunts</li>
                     </ul>
                     <p><em>Note: Hypoventilation and low FiO2 cause hypoxemia with a NORMAL A-a gradient.</em></p>
                 </div>
            </details>

            <h4>Acidosis and Alkalosis</h4>
            <details>
                <summary>Basic Compensation</summary>
                <div class="details-content">
                    <ul>
                        <li><strong>Metabolic Acidosis:</strong> Lungs compensate by increasing ventilation (↓PCO2). Kidneys compensate slowly by generating HCO3-.</li>
                        <li><strong>Metabolic Alkalosis:</strong> Lungs compensate by decreasing ventilation (↑PCO2). Kidneys compensate slowly by excreting HCO3-.</li>
                        <li><strong>Respiratory Acidosis:</strong> Kidneys compensate slowly by retaining HCO3-.</li>
                        <li><strong>Respiratory Alkalosis:</strong> Kidneys compensate slowly by excreting HCO3-.</li>
                        <li>If pH is normal, but PCO2 or HCO3- are abnormal → suspect <strong>fully compensated or mixed acid-base disorder</strong>.</li>
                    </ul>
                </div>
            </details>
             <details>
                <summary>Approach to the Patient (Anion Gap)</summary>
                <div class="details-content">
                     <p>Calculate anion gap: AG = Na+ - (Cl- + HCO3-)</p>
                     <ul>
                         <li>Normal range <code class="mono">8-12</code> mEq/L (varies slightly by lab).</li>
                         <li><strong>Increased AG Metabolic Acidosis (MUDPILES):</strong> Methanol, Uremia, DKA, Propylene glycol, Iron/Isoniazid, Lactic acidosis, Ethylene glycol, Salicylates.</li>
                         <li><strong>Normal AG Metabolic Acidosis (HARDUPS):</strong> Hyperalimentation, Acetazolamide, Renal tubular acidosis, Diarrhea, Ureteroenteric fistula, Pancreaticoduodenal fistula, Spironolactone.</li>
                     </ul>
                 </div>
            </details>
            <details>
                <summary>Treatment Considerations</summary>
                <div class="details-content">
                    <p><strong>Respiratory Acidosis (Hypercapnia):</strong></p>
                    <ul>
                        <li>Treat underlying cause (e.g., COPD exacerbation, opioid overdose).</li>
                        <li>Improve ventilation: Non-invasive ventilation (BiPAP) or tracheal intubation and mechanical ventilation.</li>
                        <li>Oxygen titrated carefully (avoid worsening hypercapnia in chronic retainers).</li>
                    </ul>
                     <p><strong>Respiratory Alkalosis (Hypocapnia):</strong></p>
                     <ul>
                         <li>Treat underlying cause (e.g., anxiety, pain, hypoxia, PE, sepsis).</li>
                         <li>Rebreathing from a paper bag (use cautiously only if hyperventilation syndrome confirmed, generally discouraged).</li>
                         <li>Address anxiety/pain. Correct hypoxia.</li>
                     </ul>
                 </div>
            </details>

            <hr class="my-6 border-[--border-color] border-dashed opacity-50">

            <h3>Pulmonary Function Tests (PFTs)</h3>
            <h4>Obstructive vs. Restrictive vs. Pulmonary Vascular Disease</h4>
            <div class="table-container">
                <table>
                    <thead>
                        <tr>
                            <th>Category</th>
                            <th>Obstructive</th>
                            <th>Restrictive</th>
                            <th>Disease of pulmonary vasculature</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td data-label="Category"><strong>Diseases</strong></td>
                            <td data-label="Obstructive">Asthma, COPD (Emphysema, Chronic Bronchitis), Bronchiectasis, Bronchiolitis</td>
                            <td data-label="Restrictive"><strong>Parenchymal:</strong> ILD (IPF, Sarcoidosis, Pneumoconiosis), Drugs, Radiation.<br><strong>Extraparenchymal:</strong> Chest wall (Kyphoscoliosis, Obesity, Ascites), Pleural (Effusion, Thickening), Neuromuscular (MG, ALS, Muscular Dystrophy, Guillain-Barre).</td>
                            <td data-label="Pulmonary Vasculature">Pulmonary Embolism (PE), Pulmonary Hypertension (PAH), Pulmonary Veno-occlusive Disease (PVOD)</td>
                        </tr>
                        <tr>
                            <td data-label="Category"><strong>Key PFT Finding</strong></td>
                            <td data-label="Obstructive">↓ FEV1/FVC ratio</td>
                            <td data-label="Restrictive">↓ TLC</td>
                            <td data-label="Pulmonary Vasculature">↓ DLCO (often isolated early)</td>
                        </tr>
                        <tr>
                            <td data-label="Category"><strong>FEV1/FVC</strong></td>
                            <td data-label="Obstructive"><strong>Decreased</strong> (< 0.7 or < lower limit of normal)</td>
                            <td data-label="Restrictive">Normal or Increased</td>
                            <td data-label="Pulmonary Vasculature">Normal</td>
                        </tr>
                         <tr>
                            <td data-label="Category"><strong>FEV1</strong></td>
                            <td data-label="Obstructive">Decreased (indicates severity)</td>
                            <td data-label="Restrictive">Decreased or Normal</td>
                            <td data-label="Pulmonary Vasculature">Normal (usually)</td>
                        </tr>
                         <tr>
                            <td data-label="Category"><strong>FVC</strong></td>
                            <td data-label="Obstructive">Normal or Decreased</td>
                            <td data-label="Restrictive">Decreased</td>
                            <td data-label="Pulmonary Vasculature">Normal (usually)</td>
                        </tr>
                         <tr>
                            <td data-label="Category"><strong>TLC</strong></td>
                            <td data-label="Obstructive">Normal or Increased (due to air trapping)</td>
                            <td data-label="Restrictive"><strong>Decreased</strong> (< 80% predicted)</td>
                            <td data-label="Pulmonary Vasculature">Normal</td>
                        </tr>
                         <tr>
                             <td data-label="Category"><strong>DLCO</strong></td>
                             <td data-label="Obstructive">
                                <details>
                                    <summary>Variable</summary>
                                    <div class="details-content">↓ in Emphysema (destruction of alveolar surface area)<br>Normal/↑ in Asthma/Chronic Bronchitis</div>
                                </details>
                             </td>
                             <td data-label="Restrictive">
                                <details>
                                    <summary>Variable</summary>
                                    <div class="details-content">↓ in Parenchymal ILD (thickened membrane)<br>Normal in Extraparenchymal (Neuromuscular/Chest wall)</div>
                                 </details>
                             </td>
                             <td data-label="Pulmonary Vasculature"><strong>Decreased</strong> (Loss of capillary bed)</td>
                         </tr>
                        <tr>
                            <td data-label="Category"><strong>Flow-Volume Loop</strong></td>
                            <td data-label="Obstructive">"Scooped out" expiratory limb (concave shape)</td>
                            <td data-label="Restrictive">"Witch's hat" shape (narrow, tall), overall smaller loop, preserved shape</td>
                            <td data-label="Pulmonary Vasculature">Usually Normal</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <details>
                <summary>DLCO Low in Isolation</summary>
                <div class="details-content">
                    <p>If DLCO is low with normal spirometry and lung volumes, consider:</p>
                    <ul>
                        <li>Anemia (less Hb to bind CO)</li>
                        <li>Congestive Heart Failure (CHF)</li>
                        <li>Interstitial Lung Disease (ILD - early stages)</li>
                        <li>Pulmonary Vascular Disease (e.g., Pulmonary Hypertension, PE)</li>
                    </ul>
                </div>
            </details>
            <details>
                <summary>Flow-Volume Loops Examples</summary>
                <div class="details-content">
                     <!-- Pixel Art Placeholder: Simple SVGs representing Obstructive, Restrictive loops -->
                     <div class="flex flex-wrap justify-around mt-4 gap-4">
                         <div>
                             <p class="text-center font-semibold mb-2">Obstructive</p>
                             <svg width="100" height="100" viewBox="0 0 100 100" xmlns="http://www.w3.org/2000/svg">
                                 <path d="M50 10 C 80 10, 90 40, 90 50 S 80 90, 50 90 S 20 90, 10 50 C 10 40, 20 10, 50 10 M 50 50 C 40 50, 20 60, 20 80 C 20 85, 30 90, 50 90" stroke="var(--accent-cyan)" fill="none" stroke-width="2"/>
                             </svg>
                             <p class="text-xs text-center text-gray-400">(Concave expiratory limb)</p>
                         </div>
                         <div>
                             <p class="text-center font-semibold mb-2">Restrictive</p>
                             <svg width="100" height="100" viewBox="0 0 100 100" xmlns="http://www.w3.org/2000/svg">
                                 <path d="M50 30 C 65 30, 70 45, 70 50 S 65 70, 50 70 S 35 70, 30 50 C 30 45, 35 30, 50 30" stroke="var(--accent-lime)" fill="none" stroke-width="2"/>
                             </svg>
                             <p class="text-xs text-center text-gray-400">(Smaller overall loop)</p>
                         </div>
                         <div>
                             <p class="text-center font-semibold mb-2">Normal</p>
                             <svg width="100" height="100" viewBox="0 0 100 100" xmlns="http://www.w3.org/2000/svg">
                                 <path d="M50 10 C 80 10, 90 40, 90 50 S 80 90, 50 90 S 20 90, 10 50 C 10 40, 20 10, 50 10" stroke="var(--text-secondary)" fill="none" stroke-width="2"/>
                             </svg>
                              <p class="text-xs text-center text-gray-400">(Reference shape)</p>
                         </div>
                     </div>
                 </div>
            </details>

            <!-- COPD Staging -->
            <h4>Gold stages of COPD Severity (Based on FEV1 % predicted)</h4>
             <details>
                 <summary>GOLD 1: Mild</summary>
                 <div class="details-content"><p>FEV1 ≥ 80% predicted</p></div>
             </details>
             <details>
                 <summary>GOLD 2: Moderate</summary>
                 <div class="details-content"><p>FEV1 50% to 79% predicted</p></div>
             </details>
             <details>
                 <summary>GOLD 3: Severe</summary>
                 <div class="details-content"><p>FEV1 30% to 49% predicted</p></div>
             </details>
             <details>
                 <summary>GOLD 4: Very Severe</summary>
                 <div class="details-content"><p>FEV1 < 30% predicted (or FEV1 < 50% with chronic respiratory failure)</p></div>
             </details>
             <p class="text-sm italic text-[--text-secondary] mt-2">Note: COPD assessment now primarily uses symptom scores (CAT, mMRC) and exacerbation history (GOLD groups A, B, E) for treatment decisions, not just FEV1 stages.</p>

            <!-- Methacholine Challenge -->
            <h4>Methacholine challenge</h4>
             <details>
                 <summary>Purpose and Procedure</summary>
                 <div class="details-content">
                     <p>Bronchoprovocation test used to help diagnose asthma, particularly when baseline spirometry is normal but symptoms suggest asthma.</p>
                     <p>Procedure: Baseline spirometry is performed. Patient inhales increasing concentrations of methacholine (a cholinergic agonist that causes bronchoconstriction). Spirometry is repeated after each dose.</p>
                 </div>
             </details>
             <details>
                 <summary>Positive Result Criteria</summary>
                 <div class="details-content"><p>The test is considered positive for airway hyperresponsiveness (suggestive of asthma) if the FEV1 drops by <strong>20% or more</strong> from baseline at a specific concentration of methacholine (PC20).</p></div>
             </details>
        </div> <!-- End Section: ABG & PFTs -->

        <div class="pixel-art-divider"></div>

        <!-- Section: Imaging & Procedures -->
        <div id="imaging-procedures" class="content-section">
            <svg viewBox="0 0 16 16" xmlns="http://www.w3.org/2000/svg" class="section-svg"><path fill-rule="evenodd" clip-rule="evenodd" d="M1 2H2V3H1V2ZM2 1H3V2H2V1ZM3 1H13V2H3V1ZM13 2H14V3H13V2ZM14 3H15V4H14V3ZM15 4H16V12H15V4ZM15 12H14V13H15V12ZM14 13H13V14H14V13ZM13 14H3V15H13V14ZM3 14H2V13H3V14ZM2 13H1V12H2V13ZM1 12H0V4H1V12ZM1 4H2V3H1V4ZM3 3H4V4H3V3ZM4 4H5V5H4V4ZM5 5H6V6H5V5ZM6 6H7V7H6V6ZM7 7H9V8H7V7ZM9 8H10V7H9V8ZM10 7H11V6H10V7ZM11 6H12V5H11V6ZM12 5H13V4H12V5ZM13 4H14V3H13V4ZM3 13H4V12H3V13ZM4 12H5V11H4V12ZM5 11H6V10H5V11ZM6 10H7V9H6V10ZM7 9H9V10H7V9ZM9 10H10V9H9V10ZM10 9H11V10H10V9ZM11 10H12V11H11V10ZM12 11H13V12H12V11ZM13 12H14V13H13V12ZM5 3H6V4H5V3ZM7 3H8V4H7V3ZM9 3H10V4H9V3ZM11 3H12V4H11V3ZM5 13H6V12H5V13ZM7 13H8V12H7V13ZM9 13H10V12H9V13ZM11 13H12V12H11V13Z" fill="currentColor"/></svg>
            <h2>Imaging Studies & Procedures</h2>

            <div class="grid grid-cols-1 md:grid-cols-2 gap-x-6 gap-y-4">
                <details>
                    <summary><strong>Radiography (X-Ray)</strong></summary>
                    <div class="details-content"><p>Initial evaluation of chest symptoms. Detects gross abnormalities: consolidation (pneumonia), effusions, pneumothorax, masses, atelectasis, cardiomegaly, tube/line placement.</p></div>
                </details>
                <details>
                    <summary><strong>Ultrasound (US)</strong></summary>
                    <div class="details-content"><p>Excellent for pleural abnormalities (effusions, loculations), guiding thoracentesis/biopsies. Evaluates diaphragmatic motion. Point-of-care US (POCUS) for pneumothorax, effusions, consolidation.</p></div>
                </details>
                <details>
                    <summary><strong>Nuclear Medicine (V/Q Scan)</strong></summary>
                    <div class="details-content"><p>Ventilation/Perfusion scan. Primarily used for suspected Pulmonary Embolism (PE) when CT contrast is contraindicated (allergy, renal failure). Assesses probability of PE based on matched/mismatched defects.</p></div>
                </details>
                <details>
                    <summary><strong>Computed Tomography (CT)</strong></summary>
                    <div class="details-content">
                        <p>Detailed cross-sectional images. Excellent for lung parenchyma, mediastinum, pleura, chest wall.</p>
                        <ul>
                            <li><strong>Standard CT:</strong> Detects masses, nodules, adenopathy, effusions.</li>
                            <li><strong>High-Resolution CT (HRCT):</strong> Thin slices, best for evaluating lung parenchyma (Interstitial Lung Disease - ILD, emphysema, bronchiectasis, ground-glass opacities - GGO).</li>
                            <li><strong>CT Angiography (CTA):</strong> With IV contrast, gold standard for diagnosing Pulmonary Embolism (PE). Also evaluates aorta, other vessels.</li>
                            <li><strong>Low-Dose CT (LDCT):</strong> Used for lung cancer screening in high-risk individuals.</li>
                        </ul>
                    </div>
                </details>
                <details>
                    <summary><strong>Virtual Bronchoscopy</strong></summary>
                    <div class="details-content"><p>CT reconstruction technique providing 3D view inside airways. Can help evaluate airway stenosis, masses, plan for real bronchoscopy.</p></div>
                </details>
                <details>
                    <summary><strong>PET scan (Positron Emission Tomography)</strong></summary>
                    <div class="details-content"><p>Uses radioactive tracer (FDG) to detect metabolically active tissue. Used for evaluating solitary pulmonary nodules (malignancy risk), staging lung cancer, detecting metastatic disease.</p></div>
                </details>
                <details>
                    <summary><strong>MRI (Magnetic Resonance Imaging)</strong></summary>
                    <div class="details-content"><p>Less commonly used for primary lung evaluation (poorer spatial resolution, motion artifact). Useful for: evaluating chest wall/mediastinal invasion by tumors (e.g., Pancoast tumor), evaluating vascular structures (MRA - Magnetic Resonance Angiography), cardiac evaluation.</p></div>
                </details>
                <details>
                    <summary><strong>Pulmonary Angiography</strong></summary>
                    <div class="details-content"><p>Invasive procedure involving catheter insertion into pulmonary arteries and contrast injection. Historically gold standard for PE, now largely replaced by CTA. Used occasionally for complex vascular issues or interventions.</p></div>
                </details>
                <details>
                    <summary><strong>Sputum Analysis</strong></summary>
                    <div class="details-content"><p>Microscopic examination (Gram stain, AFB stain) and culture of expectorated or induced sputum. Identifies bacterial, fungal, mycobacterial pathogens. Cytology for malignancy.</p></div>
                </details>
                <details>
                    <summary><strong>Percutaneous Needle Aspiration/Biopsy</strong></summary>
                    <div class="details-content"><p>CT or US-guided needle insertion through chest wall to biopsy peripheral lung nodules/masses or pleural abnormalities.</p></div>
                </details>
                <details>
                    <summary><strong>Thoracentesis</strong></summary>
                    <div class="details-content"><p>Needle aspiration of pleural fluid from pleural space. Diagnostic (analysis of fluid - Light's criteria, cell count, culture, cytology) and therapeutic (drain large effusions for dyspnea relief).</p></div>
                </details>
                <details>
                    <summary><strong>Bronchoscopy (General)</strong></summary>
                    <div class="details-content"><p>Direct visualization of airways using a bronchoscope. Can be rigid (less common, for foreign body removal, massive hemoptysis control) or flexible.</p></div>
                </details>
                <details>
                    <summary><strong>Flexible Fiberoptic Bronchoscopy</strong></summary>
                    <div class="details-content">
                        <p>Most common type. Allows visualization down to segmental bronchi. Used for: evaluating hemoptysis, chronic cough, suspected malignancy, foreign body, infection. Can perform procedures:</p>
                        <ul>
                            <li><strong>Washings/Lavage (BAL):</strong> Saline instilled and suctioned back for culture/cytology.</li>
                            <li><strong>Brushings:</strong> Brush scrapes cells for cytology/culture.</li>
                            <li><strong>Biopsies (Endobronchial/Transbronchial):</strong> Forceps obtain tissue samples from visible lesions or lung parenchyma.</li>
                        </ul>
                    </div>
                </details>
                <details>
                    <summary><strong>Transbronchial Needle Aspiration (TBNA)</strong></summary>
                    <div class="details-content"><p>Needle passed through bronchoscope wall into adjacent structures (lymph nodes, masses) to aspirate cells for diagnosis/staging.</p></div>
                </details>
                <details>
                    <summary><strong>Endobronchial Ultrasound (EBUS)</strong></summary>
                    <div class="details-content"><p>Bronchoscope with ultrasound probe at tip. Allows real-time visualization of structures outside airway wall (lymph nodes, vessels). Used to guide TBNA (EBUS-TBNA) for accurate sampling of mediastinal/hilar nodes for cancer staging or diagnosing other conditions (sarcoidosis, lymphoma).</p></div>
                </details>
                <details>
                    <summary><strong>Medical Thoracoscopy (Pleuroscopy)</strong></summary>
                    <div class="details-content"><p>Minimally invasive procedure using scope inserted into pleural space. Allows direct visualization of pleura, biopsy of pleural lesions, drainage of complex effusions, pleurodesis (scarring pleura together).</p></div>
                </details>
                <details>
                    <summary><strong>Mediastinoscopy / Mediastinotomy</strong></summary>
                    <div class="details-content"><p>Surgical procedures involving incision in neck (mediastinoscopy) or chest (mediastinotomy) to directly access and biopsy mediastinal lymph nodes or masses. Primarily for cancer staging.</p></div>
                </details>
                <details>
                    <summary><strong>Video-Assisted Thoracoscopic Surgery (VATS)</strong></summary>
                    <div class="details-content"><p>Minimally invasive surgical technique using small incisions and camera. Used for lung biopsies (wedge resection), lobectomy, pleural procedures (decortication, pleurodesis), mediastinal mass resection.</p></div>
                </details>
                <details>
                    <summary><strong>Thoracotomy</strong></summary>
                    <div class="details-content"><p>Open chest surgery involving larger incision. Used for complex resections, procedures not feasible with VATS.</p></div>
                </details>
            </div> <!-- End Grid -->
        </div> <!-- End Section: Imaging & Procedures -->

        <div class="pixel-art-divider"></div>

        <!-- Section: Hoarseness & Sinusitis -->
        <div id="hoarseness-sinusitis" class="content-section">
             <svg viewBox="0 0 16 16" xmlns="http://www.w3.org/2000/svg" class="section-svg"><path fill-rule="evenodd" clip-rule="evenodd" d="M1 3H2V4H1V3ZM3 2H4V3H3V2ZM4 1H12V2H4V1ZM12 2H13V3H12V2ZM14 3H15V4H14V3ZM15 4H16V12H15V4ZM15 12H14V13H15V12ZM13 14H14V15H13V14ZM12 15H4V16H12V15ZM4 15H3V14H4V15ZM2 13H3V14H2V13ZM1 12H2V13H1V12ZM0 11H1V12H0V11ZM0 5H1V6H0V5ZM1 4H2V5H1V4ZM2 3H3V4H2V3ZM5 3H6V4H5V3ZM7 3H8V4H7V3ZM9 3H10V4H9V3ZM11 3H12V4H11V3ZM13 4H14V5H13V4ZM13 6H14V7H13V6ZM13 8H14V9H13V8ZM13 10H14V11H13V10ZM13 12H14V13H13V12ZM11 14H12V13H11V14ZM9 14H10V13H9V14ZM7 14H8V13H7V14ZM5 14H6V13H5V14ZM3 12H4V13H3V12ZM3 10H4V11H3V10ZM3 8H4V9H3V8ZM3 6H4V7H3V6ZM3 4H4V5H3V4ZM5 5H6V6H5V5ZM6 7H7V8H6V7ZM7 9H8V10H7V9ZM8 11H9V12H8V11ZM10 11H11V12H10V11ZM11 9H12V10H11V9ZM12 7H13V8H12V7ZM11 5H12V6H11V5ZM9 5H10V6H9V5ZM7 5H8V6H7V5ZM8 7H9V8H8V7ZM9 9H10V10H9V9ZM10 7H11V8H10V7Z" fill="currentColor"/></svg>
            <h2>Hoarseness & Sinusitis</h2>

            <h3>Hoarseness</h3>
            <div class="case-study">
                <p class="case-title">Case 1:</p>
                <p>28 yo female with cc of sinus pressure and pain. Unable to work recently since she can't concentrate and is very tired. She is a receptionist, and her voice is hoarse to the point of being hard to understand. Feels pain in her cheeks every step she takes steps up the stairs to the third floor of her apartment. Pain started 10 days ago, getting worse. She has tried IBU and acetaminophen. Sleeping is hard due to bad cough. This has happened 3-4 times/year for last year. She's been treated with ABX 4 times this year. Three episodes of this in spring. She has felt warm but has not taken her temp. Her R ear is occasionally painful, "stuffy". She has been using the “neti pot" but hasn't helped. Has no allergies and isn't taking any meds. PE: BP 110/68, pulse 85, temp 38°C, RR 20 and unlabored. Hoarse hypo nasal voice with diminished volume, dark circles surround her eyes, mouth breathing during interview. R tympanic membrane is retracted and lacks a good cone of light. Erythematous, boggy inferior turbinates and thick clear nasal discharge, posterior oropharynx shows post-nasal drainage and cobblestoning. Indirect laryngoscopy with mirror shows edema of true and false vocal cords. High arched palate with crowding of maxillary teeth. No cervical lymphadenopathy is appreciated. Lungs show diffuse wheezing.</p>
                <details>
                    <summary>What is cobble stoning?</summary>
                    <div class="details-content"><p>Inflammation of minor salivary glands in posterior oropharynx, giving appearance similar to a cobble stone road. Can be caused by post-nasal drip or laryngopharyngeal reflux (LPR).</p></div>
                </details>
                 <details>
                    <summary>The most common causative bacteria in acute sinusitis is?</summary>
                    <div class="details-content">
                        <ul>
                            <li>Staphylococcus aureus</li>
                            <li><strong>Streptococcus pneumoniae</strong> → Strep pneumoniae, Haemophilus influenzae (non-typeable), and Moraxella catarrhalis are the three most common bacterial causes.</li>
                            <li>Pseudomonas aeruginosa</li>
                            <li>Mycoplasma pneumoniae</li>
                            <li>Streptococcus viridans group</li>
                        </ul>
                    </div>
                </details>
                 <details>
                    <summary>Timeframe for Sinusitis</summary>
                    <div class="details-content">
                        <ul>
                            <li><strong>Acute:</strong> < 4 weeks</li>
                            <li><strong>Subacute:</strong> 4-12 weeks</li>
                            <li><strong>Chronic:</strong> > 12 weeks</li>
                            <li><strong>Recurrent Acute:</strong> ≥ 4 episodes/year with resolution between episodes.</li>
                        </ul>
                    </div>
                </details>
                 <details>
                    <summary>Distinguishing Viral vs Bacterial Sinusitis</summary>
                    <div class="details-content">
                        <p>Features suggesting <strong>Bacterial</strong> Acute Rhinosinusitis (ARS):</p>
                        <ul>
                            <li>Persistent symptoms or signs of ARS lasting <strong>≥ 10 days without improvement</strong>.</li>
                            <li>Onset of <strong>severe symptoms</strong> (e.g., fever ≥ 39°C/102.2°F, purulent nasal discharge, facial pain) lasting for ≥ 3-4 consecutive days at beginning of illness.</li>
                            <li><strong>Worsening symptoms</strong> ("double sickening") after initial improvement of a typical viral URI (new onset fever, headache, or increase in nasal discharge after 5-6 days).</li>
                        </ul>
                        <p><em>Note: Color of discharge (yellow/green) and presence of fever are NOT reliable distinguishing features alone. Facial pain/pressure is common in sinusitis vs simple URI.</em></p>
                    </div>
                </details>
                 <details>
                    <summary>Major and Minor Criteria for Sinusitis (Case 1 Patient)</summary>
                    <div class="details-content">
                        <p><strong>Major Criteria Examples:</strong></p>
                        <ul><li>Facial pain/pressure/fullness</li><li>Nasal obstruction/blockage</li><li>Nasal discharge (purulent or discolored postnasal drip)</li><li>Hyposmia/anosmia (decreased/lost sense of smell)</li><li>Fever (as major symptom)</li></ul>
                        <p><strong>Minor Criteria Examples:</strong></p>
                        <ul><li>Headache</li><li>Fever (as minor symptom)</li><li>Halitosis</li><li>Fatigue</li><li>Dental pain</li><li>Cough</li><li>Ear pain/pressure/fullness</li></ul>
                        <p><strong>Case 1 Patient Findings:</strong></p>
                        <ul>
                            <li>Major: Facial pain/pressure, Nasal discharge (postnasal drip noted).</li>
                            <li>Minor: Cough, Ear pain, Fever (38°C), Fatigue.</li>
                        </ul>
                         <p><strong>Diagnosis Criteria (Clinical):</strong></p>
                        <ul>
                            <li>≥ 2 major criteria OR</li>
                            <li>1 major and ≥ 2 minor criteria</li>
                        </ul>
                         <p><em>This patient meets criteria based on symptoms.</em></p>
                    </div>
                </details>
                 <details>
                    <summary>Pathophysiology of Bacterial Sinusitis</summary>
                    <div class="details-content"><p>Often follows viral URI. Viral inflammation → mucosal edema → sinus ostia obstruction → impaired drainage/ventilation → negative pressure, retained secretions → favorable environment for bacterial overgrowth → bacterial infection and further inflammation.</p></div>
                </details>
                 <details>
                    <summary>Treatment Goal and Approach</summary>
                    <div class="details-content">
                        <p><strong>Goal:</strong> Reduce inflammation, promote drainage, eradicate infection (if bacterial).</p>
                        <p><strong>Viral ARS:</strong> Supportive care (analgesics, saline irrigation, intranasal steroids may help symptoms).</p>
                        <p><strong>Bacterial ARS:</strong></p>
                        <ul>
                            <li>Watchful waiting vs. Antibiotics (based on severity/duration).</li>
                            <li><strong>Antibiotics:</strong> Amoxicillin-clavulanate first-line.</li>
                            <li><strong>Adjunctive:</strong> Intranasal corticosteroids, saline irrigation.</li>
                            <li>Oral/Topical Decongestants: Limited benefit, potential side effects (oral - BP elevation; topical - rhinitis medicamentosa).</li>
                        </ul>
                    </div>
                </details>
            </div> <!-- End Case 1 -->

            <div class="case-study">
                <p class="case-title">Case 2:</p>
                <p>28 yo female, cannot breathe through her nose, both ears plugged, every spring and early fall she has similar symptoms. She was asymptomatic for several years after giving her birth to her first child. Vital signs normal. BP: 140/94, RR 16. PE: b/l retracted tympanic membrane with air fluid levels in middle ear. Inferior turbinates are blue, boggy, thin rhinorrhea. High arched palate, cobblestoning of posterior oropharynx and visible postnasal drainage.</p>
                <details>
                    <summary>Discussion points</summary>
                    <div class="details-content">
                        <p>Presentation strongly suggests <strong>Allergic Rhinitis</strong> with secondary Eustachian Tube Dysfunction (ETD) causing middle ear effusion/retraction.</p>
                        <ul>
                            <li>Seasonal pattern (spring/fall).</li>
                            <li>Symptoms: Nasal congestion ("cannot breathe through nose"), rhinorrhea, plugged ears.</li>
                            <li>PE findings: Pale/bluish, boggy turbinates (classic allergic), clear rhinorrhea, cobblestoning (from postnasal drip), retracted TMs with air-fluid levels (ETD).</li>
                            <li>High arched palate can suggest chronic mouth breathing, often associated with chronic nasal obstruction from childhood.</li>
                            <li>Elevated BP (140/94) needs consideration for medication choices.</li>
                        </ul>
                    </div>
                </details>
                 <details>
                    <summary>Which med is indicated for nasal congestion due to allergic rhinitis?</summary>
                    <div class="details-content">
                        <ul>
                            <li>Cromolyn sodium (Mast cell stabilizer - less effective, prophylactic).</li>
                            <li>Ipratropium bromide nasal spray (Targets rhinorrhea, not congestion).</li>
                            <li><strong>Fluticasone nasal spray → Intranasal corticosteroids are most effective single agent for allergic rhinitis, especially congestion.</strong></li>
                            <li>Azelastine nasal spray (Topical antihistamine - good option, effective for congestion, but generally second-line to INS).</li>
                            <li>Diphenhydramine (Oral 1st gen antihistamine - sedating, poor for congestion).</li>
                        </ul>
                    </div>
                </details>
                 <details>
                    <summary>1st versus 2nd generation antihistamines</summary>
                    <div class="details-content">
                        <ul>
                            <li><strong>1st gen (e.g., Diphenhydramine, Chlorpheniramine, Hydroxyzine):</strong> Lipophilic, readily cross Blood-Brain Barrier (BBB) causing sedation, cognitive impairment. Significant anticholinergic effects (dry mouth, urinary retention, blurred vision).</li>
                            <li><strong>2nd gen (e.g., Loratadine, Cetirizine, Fexofenadine, Levocetirizine, Desloratadine):</strong> Less lipophilic, less BBB penetration (minimal sedation, though cetirizine/levocetirizine can cause some). Minimal anticholinergic activity. Preferred for allergic rhinitis.</li>
                        </ul>
                    </div>
                </details>
                 <details>
                    <summary>Which med would be CONTRAINDICATED given her classical presentation (HTN)?</summary>
                    <div class="details-content">
                        <ul>
                            <li>Guaifenesin (Expectorant - irrelevant).</li>
                            <li><strong>Pseudoephedrine → Systemic decongestant (alpha-1 agonist), causes vasoconstriction, can significantly increase BP. Contraindicated in uncontrolled HTN, use with caution in controlled HTN.</strong></li>
                            <li>Diphenhydramine (Antihistamine - no direct BP effect).</li>
                            <li>Mometasone nasal (Intranasal corticosteroid - minimal systemic absorption/effect on BP).</li>
                            <li>Montelukast (Leukotriene receptor antagonist - no direct BP effect).</li>
                        </ul>
                    </div>
                </details>
                <details>
                    <summary>Initial approach to treatment of her allergies?</summary>
                    <div class="details-content">
                        <p>Multifaceted approach:</p>
                        <ol>
                            <li><strong>Allergen Avoidance:</strong> Identify potential triggers (pollens, dust mites, molds) and implement avoidance strategies (e.g., stay indoors during high pollen, use HEPA filters, dust mite covers).</li>
                            <li><strong>Pharmacotherapy:</strong>
                                <ul>
                                    <li><strong>Intranasal Corticosteroids (INS):</strong> First-line (e.g., Fluticasone, Mometasone). Most effective for all symptoms, especially congestion.</li>
                                    <li>Oral Antihistamines (2nd gen): Good for itching, sneezing, rhinorrhea (e.g., Loratadine, Cetirizine).</li>
                                    <li>Topical Antihistamines (Nasal/Ocular): Azelastine, Olopatadine. Rapid onset.</li>
                                    <li>Saline Irrigation: Helps clear mucus and allergens.</li>
                                </ul>
                            </li>
                            <li><strong>Immunotherapy (Allergy Shots/Drops):</strong> Consider if symptoms severe, persistent, refractory to meds, or patient preference. Modifies immune response long-term.</li>
                        </ol>
                        <p><em>Investigating her environment is part of avoidance strategies.</em></p>
                    </div>
                </details>
                 <details>
                    <summary>Systemic steroids adverse effects</summary>
                    <div class="details-content">
                        <p>Generally avoided for allergic rhinitis due to side effect profile.</p>
                        <ul>
                            <li><strong>Short-term:</strong> Hyperglycemia, insomnia, mood changes (irritability, euphoria, psychosis), increased appetite, fluid retention, HTN.</li>
                            <li><strong>Long-term:</strong> Cushingoid appearance (moon facies, buffalo hump), weight gain, osteoporosis/fractures, adrenal suppression, cataracts, glaucoma, immunosuppression, skin thinning/bruising, myopathy, avascular necrosis.</li>
                        </ul>
                    </div>
                </details>
                 <details>
                    <summary>Immunotherapy indications in allergic rhinitis</summary>
                    <div class="details-content">
                        <ul>
                            <li>Symptoms inadequately controlled by pharmacotherapy and avoidance measures.</li>
                            <li>Patient preference to avoid long-term medication use or side effects.</li>
                            <li>Presence of comorbid conditions like allergic asthma.</li>
                            <li>Desire for potential long-term remission of symptoms after discontinuation.</li>
                            <li>Requires confirmed IgE-mediated allergy to relevant allergens.</li>
                        </ul>
                    </div>
                </details>
            </div> <!-- End Case 2 -->

             <div class="case-study">
                <p class="case-title">Case 3:</p>
                <p>45 yo male with cc left ear pain. Noticed this three months ago after a trip to the lake. Seen by PCP who said nothing was wrong. It has progressively gotten worse over time, and has a dull burning quality. Modulating factors that precipitated include chewing and swallowing food. Hx of bad ear infections as child. Has been to loud concerts with loud ringing. Lost appetite and 10 lb in last month. No meds. Smoker 1ppd for 28 years, occasional alcohol, and marijuana. Vitals okay, slightly HTN. PE: ears show no sign of infection, good cone of light. Pretty good.</p>
                 <details>
                    <summary>With no positive findings thus far, what additional physical exam should be performed?</summary>
                     <div class="details-content">
                         <p>Focus on potential sources of <strong>referred otalgia</strong> (ear pain originating elsewhere).</p>
                         <ul>
                            <li>Palpate Temporomandibular Joint (TMJ) during opening/closing (Pain with chewing suggests TMJ dysfunction).</li>
                            <li>Examine teeth and gums (Dental pathology is common cause).</li>
                            <li>Visualize oropharynx and nasopharynx (mirror or flexible scope - looking for tonsillitis, tumor, inflammation).</li>
                            <li>Palpate neck for lymphadenopathy or masses.</li>
                            <li>Cranial nerve exam (esp. V, VII, IX, X which innervate ear/pharynx).</li>
                            <li>(Rigid rhinoscopy, thyroid palpation, carotid auscultation are less likely initial steps based on chewing pain).</li>
                         </ul>
                     </div>
                 </details>
                 <details>
                     <summary>What nerves provides sensation to the ear?</summary>
                     <div class="details-content">
                         <p>Complex innervation, leading to referred pain potential:</p>
                         <ul>
                             <li><strong>Auriculotemporal nerve (branch of CN V3 - Trigeminal):</strong> Supplies external auditory canal (EAC), anterior auricle, TMJ.</li>
                             <li><strong>Facial Nerve (CN VII):</strong> Small sensory branch to EAC and concha.</li>
                             <li><strong>Glossopharyngeal Nerve (CN IX - Jacobson's nerve):</strong> Supplies middle ear, mastoid air cells, Eustachian tube.</li>
                             <li><strong>Vagus Nerve (CN X - Arnold's nerve):</strong> Supplies EAC and concha.</li>
                             <li><strong>Cervical Plexus (C2, C3 - Great Auricular, Lesser Occipital):</strong> Supply posterior auricle and skin over mastoid.</li>
                         </ul>
                     </div>
                 </details>
                 <details>
                     <summary>What additional tests?</summary>
                     <div class="details-content">
                         <p>Based on Hx (smoking, weight loss, chronic pain) and exam:</p>
                         <ul>
                            <li><strong>Dental referral for evaluation of teeth & TMJ:</strong> High yield given pain with chewing.</li>
                            <li>Flexible fiberoptic laryngoscopy/nasopharyngoscopy: To visualize pharynx, larynx, nasopharynx thoroughly, rule out malignancy (esp. given smoking history and weight loss).</li>
                            <li>Consider CT/MRI of neck/skull base if suspicion for tumor remains high after initial eval.</li>
                            <li>(EMG, neuro referral, barium swallow less likely initial steps).</li>
                         </ul>
                     </div>
                 </details>
                 <details>
                     <summary>Ten T's of Otalgia (Differential Diagnosis)</summary>
                     <div class="details-content">
                         <p>Mnemonic for causes of ear pain, especially referred:</p>
                         <ul>
                             <li><strong>T</strong>MJ Dysfunction</li>
                             <li><strong>T</strong>eeth (Dental abscess, caries, impacted wisdom tooth)</li>
                             <li><strong>T</strong>onsillitis / Pharyngitis / Peritonsillar Abscess</li>
                             <li><strong>T</strong>hroat (Laryngitis, Laryngeal Cancer)</li>
                             <li><strong>T</strong>ongue (Base of tongue tumor, ulcer)</li>
                             <li><strong>T</strong>hyroiditis / Thyroid Cancer</li>
                             <li><strong>T</strong>ube (Eustachian Tube Dysfunction)</li>
                             <li><strong>T</strong>emporomandibular joint (Overlap with TMJ) / Temporal Arteritis</li>
                             <li><strong>T</strong>rauma (to ear or surrounding structures)</li>
                             <li><strong>T</strong>umor (Nasopharynx, Oropharynx, Larynx, Skull Base, Parotid)</li>
                             <li>*(Also includes direct ear causes like Otitis Media/Externa)*</li>
                             <li>*(CN "Ten" - Vagus nerve irritation is a mechanism, not a distinct cause)*</li>
                         </ul>
                     </div>
                 </details>
            </div> <!-- End Case 3 -->

             <div class="case-study">
                 <p class="case-title">Case 4:</p>
                 <p>Obese 63 yo male with cc "I can't talk right". Change in voice for two months. Course breathing quality to his voice with intermittent “cracking". It has progressed gradually and is worse first thing in the morning, improves slightly during the day. Denies fever, chills, or night sweats. Can only read 5-6 sentences before having to take a breath. Hx includes COPD, degenerative joint disease, diabetes, chronic pain. Surgery: C5-C6 anterior cervical fusion spine, cholecystectomy, tonsillectomy as a child. Meds: oxycodone, ipratropium bromide, insulin, and metformin. Social: 1ppd x 45 years, occasional few beers/week, gained 30 lbs in the last year. 144/83 BP, RR 24, pain 0/10, BMI 36. PE: appears to be older than stated age, breathy quality to voice with intermittent bursts of harsh graveled tones. Could not see larynx with mirror due to gag reflex.</p>
                 <details>
                     <summary>What term best characterizes the voice change?</summary>
                     <div class="details-content">
                         <ul>
                             <li><strong>Dysphonia:</strong> General term for any impairment or abnormality of the voice. (Most appropriate broad term).</li>
                             <li>Dyplophonia: Producing two distinct pitches simultaneously.</li>
                             <li>Aphonia: Complete loss of voice.</li>
                             <li>Stridor: High-pitched breathing sound due to upper airway obstruction (not primarily a voice change).</li>
                             <li>Hoarse: Subjective quality (breathy, rough, strained) - often a component of dysphonia.</li>
                         </ul>
                     </div>
                 </details>
                 <details>
                     <summary>Which historical factor would be most helpful in determining the cause?</summary>
                      <div class="details-content">
                          <ul>
                             <li>Recent cold like symptoms (Suggests acute laryngitis - less likely given 2-month duration).</li>
                             <li>Works as an auctioneer (Suggests vocal overuse/nodules - possible, but other factors stronger).</li>
                             <li>Heartburn (Suggests Laryngopharyngeal Reflux - LPR, common cause, fits morning worsening).</li>
                             <li>Itchy, watery nose, and eyes (Suggests allergies - less likely direct cause of persistent dysphonia).</li>
                             <li><strong>Onset of symptom after his recent surgery</strong> (Anterior cervical spine surgery carries risk of Recurrent Laryngeal Nerve (RLN) injury, leading to vocal cord paresis/paralysis - strong possibility given timing and breathy voice).</li>
                         </ul>
                      </div>
                 </details>
                 <details>
                     <summary>Knowing his left vocal cord is not functioning properly (implied), what test should be ordered?</summary>
                      <div class="details-content">
                          <p>If left vocal cord paresis/paralysis is confirmed (e.g., by flexible laryngoscopy), need to evaluate the entire course of the RLN.</p>
                          <ul>
                             <li>Mononucleosis titers (Irrelevant).</li>
                             <li>CT scan of the brain with contrast (Only if central cause suspected - rare).</li>
                             <li>EKG (Irrelevant).</li>
                             <li>Barium swallow study (Assess swallowing function/aspiration risk due to poor glottic closure, but not diagnostic for nerve cause).</li>
                             <li>Pulmonary function test (May show reduced flows if glottic incompetence severe, not diagnostic for cause).</li>
                             <li><strong>CT Scan of Neck and Chest with contrast:</strong> To visualize the RLN path from skull base through neck into chest (around aortic arch on left), looking for compression, mass, surgical changes, aneurysm etc. This is the standard imaging workup for unexplained vocal cord paralysis.</li>
                         </ul>
                      </div>
                 </details>
                 <details>
                     <summary>Along with left vocal cord paresis, you notice reflux findings on exam. What therapies are most beneficial?</summary>
                     <div class="details-content">
                         <p>Requires addressing both issues:</p>
                         <ul>
                            <li><strong>Voice Therapy:</strong> To help compensate for vocal cord weakness/paralysis.</li>
                            <li><strong>Treatment for LPR:</strong>
                                <ul>
                                    <li><strong>Lifestyle changes:</strong> Elevate head of bed, avoid late meals, trigger foods (caffeine, alcohol, acidic, fatty).</li>
                                    <li>Proton Pump Inhibitors (PPIs): Often requires higher doses/longer duration (BID dosing for ≥3 months) than for typical GERD.</li>
                                </ul>
                             </li>
                            <li>Consideration for Vocal Fold Injection/Medialization: Surgical options if voice therapy insufficient and paralysis persistent.</li>
                         </ul>
                     </div>
                 </details>
                  <details>
                     <summary>Typical laryngeal findings with LPR (Laryngopharyngeal Reflux)</summary>
                      <div class="details-content">
                          <ul>
                             <li>Erythema and edema, especially of the posterior larynx (interarytenoid area, arytenoid cartilages).</li>
                             <li>Posterior commissure hypertrophy ("cobblestoning").</li>
                             <li>Ventricular obliteration (swelling of false cords).</li>
                             <li>Diffuse laryngeal edema.</li>
                             <li>Vocal fold edema/erythema.</li>
                             <li>Pseudosulcus vocalis (subglottic edema).</li>
                             <li>Granulomas or contact ulcers (often on vocal processes).</li>
                             <li>Thick endolaryngeal mucus.</li>
                          </ul>
                      </div>
                 </details>
            </div> <!-- End Case 4 -->

            <h4>Hoarseness Causes</h4>
            <details>
                <summary>General Categories (MNEMONIC: VINDICATE - adapted)</summary>
                 <div class="details-content">
                     <ul>
                         <li><strong>V</strong>ascular (rare - e.g., aortic aneurysm compressing RLN)</li>
                         <li><strong>I</strong>nflammatory/<strong>I</strong>nfectious (Laryngitis - viral, bacterial, fungal; LPR; Allergies; Autoimmune)</li>
                         <li><strong>N</strong>eoplastic (Benign - nodules, polyps, cysts, papillomas; Malignant - Squamous cell carcinoma)</li>
                         <li><strong>D</strong>egenerative / <strong>D</strong>ysfunctional (Vocal fold atrophy - presbylaryngis; Muscle tension dysphonia)</li>
                         <li><strong>I</strong>atrogenic/<strong>I</strong>ntoxication (Post-surgical nerve injury; Intubation trauma; Smoking; Medications)</li>
                         <li><strong>C</strong>ongenital (Webs, cysts, laryngomalacia)</li>
                         <li><strong>A</strong>utoimmune (e.g., Rheumatoid arthritis affecting cricoarytenoid joint)</li>
                         <li><strong>T</strong>rauma (Vocal overuse/abuse; External neck trauma)</li>
                         <li><strong>E</strong>ndocrine/Metabolic (Hypothyroidism - myxedema; Amyloidosis)</li>
                         <li><strong>N</strong>eurologic (Vocal cord paralysis/paresis - RLN injury, stroke, ALS, Parkinson's; Spasmodic dysphonia)</li>
                     </ul>
                 </div>
            </details>
             <details>
                <summary>Most common causes</summary>
                 <div class="details-content">
                     <ul>
                         <li>Acute Laryngitis (usually viral)</li>
                         <li>Benign Vocal Fold Lesions (Nodules, Polyps, Cysts - often related to voice use)</li>
                         <li>Laryngopharyngeal Reflux (LPR)</li>
                         <li>Muscle Tension Dysphonia</li>
                         <li>Vocal Fold Paralysis/Paresis</li>
                         <li>Presbylaryngis (Age-related changes)</li>
                         <li>Malignancy (especially in smokers or those with other risk factors)</li>
                     </ul>
                 </div>
            </details>
             <details>
                <summary>When to refer to Otolaryngology (ENT)?</summary>
                 <div class="details-content">
                     <p>Referral for laryngoscopy is indicated for:</p>
                     <ul>
                        <li>Hoarseness lasting <strong>> 2-4 weeks</strong> (especially in absence of obvious acute URI).</li>
                        <li>Associated symptoms like: significant throat pain, dysphagia, odynophagia, hemoptysis, neck mass, shortness of breath/stridor, significant weight loss.</li>
                        <li>Professional voice users with persistent hoarseness.</li>
                        <li>Suspicion of malignancy (e.g., smoker with new persistent hoarseness).</li>
                        <li>History of neck surgery or trauma preceding hoarseness.</li>
                     </ul>
                 </div>
            </details>

            <h4>Pain (Referred Otalgia Context)</h4>
             <details>
                <summary>Two major types of ear pain</summary>
                 <div class="details-content"><p><strong>Primary Otalgia:</strong> Pain originating from the ear itself (e.g., Otitis Media, Otitis Externa, Mastoiditis, Trauma, Cerumen impaction).</p>
                 <p><strong>Referred Otalgia:</strong> Pain felt in the ear but originating from another site innervated by nerves shared with the ear (CN V, VII, IX, X, C2, C3). Common sources include TMJ, dental problems, pharyngitis/tonsillitis, laryngitis, tumors, cervical spine issues.</p></div>
            </details>
             <details>
                <summary>Four key areas to examine for referred otalgia</summary>
                 <div class="details-content">
                     <ol>
                         <li><strong>Ear:</strong> Rule out primary ear pathology (Otoscopy).</li>
                         <li><strong>Oral Cavity/Teeth:</strong> Check for dental caries, abscesses, mucosal lesions.</li>
                         <li><strong>TMJ:</strong> Palpate joint for tenderness, clicking; assess jaw movement.</li>
                         <li><strong>Oropharynx/Larynx:</strong> Visualize tonsils, pharynx, base of tongue, larynx (mirror or scope) for inflammation, masses, asymmetry.</li>
                     </ol>
                 </div>
            </details>
             <details>
                <summary>Treatment Principle</summary>
                 <div class="details-content"><p>Identify and treat the <strong>underlying cause</strong> of the otalgia, whether primary or referred.</p></div>
            </details>
        </div> <!-- End Section: Hoarseness & Sinusitis -->

        <div class="pixel-art-divider"></div>

        <!-- Section: Radiology Basics -->
        <div id="radiology-basics" class="content-section">
            <svg viewBox="0 0 16 16" xmlns="http://www.w3.org/2000/svg" class="section-svg"><path fill-rule="evenodd" clip-rule="evenodd" d="M1 1H0V2H1V1ZM1 2H0V3H1V2ZM1 3H0V4H1V3ZM1 4H0V5H1V4ZM1 5H0V6H1V5ZM1 6H0V7H1V6ZM1 7H0V8H1V7ZM1 8H0V9H1V8ZM1 9H0V10H1V9ZM1 10H0V11H1V10ZM1 11H0V12H1V11ZM1 12H0V13H1V12ZM1 13H0V14H1V13ZM1 14H0V15H1V14ZM1 15H0V16H1V15ZM2 1H3V2H2V1ZM4 1H5V2H4V1ZM6 1H7V2H6V1ZM8 1H9V2H8V1ZM10 1H11V2H10V1ZM12 1H13V2H12V1ZM14 1H15V2H14V1ZM15 2H16V3H15V2ZM15 3H16V4H15V3ZM15 4H16V5H15V4ZM15 5H16V6H15V5ZM15 6H16V7H15V6ZM15 7H16V8H15V7ZM15 8H16V9H15V8ZM15 9H16V10H15V9ZM15 10H16V11H15V10ZM15 11H16V12H15V11ZM15 12H16V13H15V12ZM15 13H16V14H15V13ZM15 14H16V15H15V14ZM14 15H15V16H14V15ZM13 15H12V16H13V15ZM11 15H10V16H11V15ZM9 15H8V16H9V15ZM7 15H6V16H7V15ZM5 15H4V16H5V15ZM3 15H2V16H3V15ZM2 14H1V15H2V14ZM2 4H3V5H2V4ZM4 4H5V5H4V4ZM6 4H7V5H6V4ZM8 4H9V5H8V4ZM10 4H11V5H10V4ZM12 4H13V5H12V4ZM14 4H15V5H14V4ZM2 7H3V8H2V7ZM4 7H5V8H4V7ZM6 7H7V8H6V7ZM8 7H9V8H8V7ZM10 7H11V8H10V7ZM12 7H13V8H12V7ZM14 7H15V8H14V7ZM2 10H3V11H2V10ZM4 10H5V11H4V10ZM6 10H7V11H6V10ZM8 10H9V11H8V10ZM10 10H11V11H10V10ZM12 10H13V11H12V10ZM14 10H15V11H14V10ZM2 13H3V14H2V13ZM4 13H5V14H4V13ZM6 13H7V14H6V13ZM8 13H9V14H8V13ZM10 13H11V14H10V13ZM12 13H13V14H12V13ZM14 13H15V14H14V13Z" fill="currentColor"/></svg>
            <h2>Radiology Basics</h2>

             <h3>Nuclear Medicine</h3>
            <details>
                <summary>V/Q Scanning</summary>
                <div class="details-content"><p>Used for suspected thromboembolism (Pulmonary Embolism - PE), especially when CT contrast allergy or severe renal failure prevents Contrast-Enhanced CT Angiography (CTA). Compares distribution of inhaled radioactive gas (Ventilation) to injected radioactive particles (Perfusion). Mismatched defects (perfused but not ventilated) suggest PE.</p></div>
            </details>

            <h3>Technique Selection</h3>
            <div class="grid grid-cols-1 md:grid-cols-2 gap-x-6 gap-y-4">
                <div>
                    <h4>Portable Chest Radiograph (CXR)</h4>
                     <details>
                        <summary>Uses</summary>
                        <div class="details-content">
                         <ul>
                             <li>Monitoring cardiopulmonary status in ICU/inpatients.</li>
                             <li>Confirming position of central lines, endotracheal tubes, nasogastric tubes.</li>
                             <li>Monitoring disease progression or response to therapy (e.g., pneumonia, heart failure).</li>
                             <li>Initial evaluation of acute chest symptoms when standard PA/Lat views not feasible.</li>
                             <li>Limitations: Technically inferior to standard views (AP projection, often supine/semi-erect, less inspiration).</li>
                         </ul>
                         </div>
                    </details>
                    <h4>Fluoroscopy</h4>
                     <details>
                        <summary>Uses</summary>
                        <div class="details-content">
                         <ul>
                             <li>Real-time X-ray imaging.</li>
                             <li>Assessing diaphragmatic motion ("sniff test") for suspected paralysis.</li>
                             <li>Guiding procedures like biopsies, catheter placements.</li>
                             <li>Identifying calcifications (e.g., within pulmonary nodules, coronary arteries - less common now).</li>
                         </ul>
                         </div>
                    </details>
                    <h4>CT (Computed Tomography)</h4>
                     <details>
                        <summary>Uses</summary>
                        <div class="details-content">
                         <ul>
                             <li>Detailed evaluation of mediastinal and chest wall abnormalities.</li>
                             <li>Assessing extent of known disease (e.g., cancer staging).</li>
                             <li><strong>HRCT:</strong> Evaluating interstitial lung disease (ILD - fibrosis, honeycombing), emphysema, bronchiectasis, ground-glass opacities (GGO), consolidation.</li>
                             <li><strong>CTA:</strong> Gold standard for diagnosing Pulmonary Embolism (PE).</li>
                             <li>Characterizing pulmonary nodules (size, density, margins, calcification, fat).</li>
                         </ul>
                         </div>
                    </details>
                </div>
                <div>
                    <h4>MRI (Magnetic Resonance Imaging)</h4>
                     <details>
                        <summary>Uses</summary>
                        <div class="details-content">
                         <ul>
                             <li>Superior soft tissue contrast compared to CT.</li>
                             <li>Evaluating chest wall, pleural, and mediastinal invasion by tumors (esp. Pancoast tumors).</li>
                             <li>Assessing mediastinal/hilar masses.</li>
                             <li>Evaluating vascular structures (MRA) without contrast or radiation (e.g., aortic dissection, congenital anomalies).</li>
                             <li>Cardiac MRI for function and morphology.</li>
                             <li>Limited use for lung parenchyma due to motion artifact and lower spatial resolution for fine detail.</li>
                         </ul>
                         </div>
                    </details>
                    <h4>US (Ultrasound)</h4>
                     <details>
                        <summary>Uses</summary>
                        <div class="details-content">
                         <ul>
                             <li>Evaluating pleural effusions (detecting small effusions, characterizing complexity/loculations).</li>
                             <li>Guiding procedures: thoracentesis, chest tube placement, pleural/peripheral lung biopsies.</li>
                             <li>Assessing diaphragmatic function.</li>
                             <li>Point-of-care evaluation for pneumothorax (lung sliding), consolidation, effusions, pulmonary edema (B-lines).</li>
                             <li>Evaluating pericardial effusions.</li>
                         </ul>
                         </div>
                    </details>
                </div>
            </div>

            <h3>OVERVIEW: 5 (+1) Basic Radiographic Densities</h3>
            <ol>
                <li>
                    <strong>Air (Gas):</strong> Most radiolucent (blackest). Found in lungs, trachea, stomach bubble, bowel gas. Pathologic air: pneumothorax, pneumomediastinum, subcutaneous emphysema.
                </li>
                <li>
                    <strong>Fat:</strong> Gray, darker than soft tissue/fluid. Seen in subcutaneous layers, around organs.
                </li>
                <li>
                    <strong>Fluid / Soft Tissue:</strong> Similar gray density. Includes water, blood, pus, muscle, organs (heart, liver), non-calcified masses/nodes.
                    <details>
                        <summary>Specific Appearances</summary>
                        <div class="details-content">
                            <ul>
                                <li><strong>Consolidation (Pus/Fluid in Alveoli):</strong> Opacity that obscures underlying vessels, often with air bronchograms (air-filled bronchi visible against opaque alveoli). Typically space-occupying (no volume loss). Fluffy margins common. (e.g., Pneumonia).</li>
                                <li><strong>Pulmonary Edema (Water):</strong> Increased interstitial markings, Kerley B lines, peribronchial cuffing, effusions. Can progress to alveolar edema appearing like consolidation, often bilateral/perihilar ("bat-wing").</li>
                                <li><strong>Pleural Effusion (Water):</strong> Homogeneous opacity obscuring costophrenic angle (blunting) and diaphragm. Meniscus sign often seen on upright films. Layering on decubitus views.</li>
                                <li><strong>Hemorrhage (Blood):</strong> Can appear as consolidation or diffuse GGO.</li>
                                <li><strong>Mass/Nodule (Cells/Soft Tissue):</strong> Discrete opacity, usually well-defined.</li>
                            </ul>
                        </div>
                    </details>
                </li>
                 <li>
                    <strong>Bone (Calcium):</strong> Radiopaque (white). Ribs, clavicles, vertebrae, sternum. Calcified granulomas, nodules, or plaques are also this density.
                </li>
                <li>
                    <strong>Metal:</strong> Most radiopaque (brightest white). Surgical clips, pacemakers, foreign bodies, contrast agents (though contrast is technically fluid density, it appears very bright).
                </li>
                 <li>
                    <strong>Atelectasis (Collapsed Lung):</strong> Increased opacity due to <strong>volume loss</strong>. Signs: displacement of fissures/hila TOWARDS collapse, elevation of hemidiaphragm, crowding of vessels/bronchi, compensatory hyperinflation of adjacent lung. Can be linear/plate-like, segmental, or lobar.
                </li>
            </ol>

            <h4>Discern Atelectasis from Pneumonia</h4>
            <div class="grid grid-cols-1 md:grid-cols-2 gap-6 mt-4">
                <div>
                    <h5>Atelectasis</h5>
                    <div class="details-content bg-[--bg-muted] p-4 rounded">
                        <ul>
                            <li><strong>Key Feature: Volume Loss</strong></li>
                            <li>Shift of mobile structures (trachea, heart, hila, fissures) <strong>TOWARDS</strong> the opacity.</li>
                            <li>Elevation of ipsilateral hemidiaphragm.</li>
                            <li>Crowding of ribs on affected side.</li>
                            <li>Compensatory hyperinflation of remaining lung.</li>
                            <li>Opacity may have sharp margins if abutting a fissure (e.g., RUL collapse and horizontal fissure elevation).</li>
                            <li>Linear or wedge-shaped opacities common.</li>
                        </ul>
                         <!-- Placeholder for Atelectasis Images description -->
                         <p class="mt-4 text-sm italic text-[--text-secondary]">(Image description: Left image shows LLL collapse with downward displacement of L hilum, silhouetting of L hemidiaphragm, retrocardiac opacity. Right image shows RUL collapse with elevation of horizontal fissure ("Golden S sign" if central mass present), tracheal deviation to right.)</p>
                     </div>
                </div>
                 <div>
                    <h5>Pneumonia (Consolidation)</h5>
                    <div class="details-content bg-[--bg-muted] p-4 rounded">
                        <ul>
                            <li><strong>Key Feature: Normal or Increased Volume</strong> (Space-occupying process).</li>
                            <li><strong>No significant shift</strong> of mediastinum or fissures (or shift AWAY if very large effusion develops).</li>
                            <li>Opacity represents alveoli filled with inflammatory exudate.</li>
                            <li><strong>Air bronchograms</strong> often visible within the consolidation.</li>
                            <li>Margins often indistinct or "fluffy" unless abutting a fissure.</li>
                            <li>Lobar or segmental distribution common.</li>
                        </ul>
                        <!-- Placeholder for Pneumonia Images description -->
                         <p class="mt-4 text-sm italic text-[--text-secondary]">(Image description: Chest X-ray showing RML pneumonia obscuring the right heart border (silhouette sign) with air bronchograms, no volume loss.)</p>
                         <p class="mt-2 text-sm italic text-[--text-secondary]">(Image description: Chest X-ray showing LLL pneumonia obscuring the left hemidiaphragm (silhouette sign), no volume loss.)</p>
                    </div>
                </div>
            </div>
        </div> <!-- End Section: Radiology Basics -->

        <div class="pixel-art-divider"></div>

        <!-- Section: Tuberculosis -->
        <div id="tuberculosis" class="content-section">
            <svg viewBox="0 0 16 16" xmlns="http://www.w3.org/2000/svg" class="section-svg"><path d="M1 1H2V2H1V1ZM2 2H3V3H2V2ZM3 3H4V4H3V3ZM4 4H5V5H4V4ZM5 5H6V6H5V5ZM6 6H7V7H6V6ZM7 7H8V8H7V7ZM8 8H9V9H8V8ZM9 9H10V10H9V9ZM10 10H11V11H10V10ZM11 11H12V12H11V11ZM12 12H13V13H12V12ZM13 13H14V14H13V13ZM14 14H15V15H14V14ZM15 15H16V16H15V15ZM14 1H15V2H14V1ZM13 2H14V3H13V2ZM12 3H13V4H12V3ZM11 4H12V5H11V4ZM10 5H11V6H10V5ZM9 6H10V7H9V6ZM8 7H9V8H8V7ZM7 8H8V9H7V8ZM6 9H7V10H6V9ZM5 10H6V11H5V10ZM4 11H5V12H4V11ZM3 12H4V13H3V12ZM2 13H3V14H2V13ZM1 14H2V15H1V14ZM4 6H5V7H4V6ZM5 7H6V8H5V7ZM6 8H7V9H6V8ZM7 9H8V10H7V9ZM8 10H9V11H8V10ZM9 11H10V12H9V11ZM10 12H11V13H10V12ZM11 13H12V14H11V13ZM12 14H13V15H12V14ZM11 9H12V10H11V9ZM10 8H11V9H10V8ZM9 7H10V8H9V7ZM8 6H9V7H8V6ZM7 5H8V6H7V5ZM6 4H7V5H6V4ZM5 3H6V4H5V3ZM4 2H5V3H4V2ZM3 1H4V2H3V1ZM2 15H3V16H2V15ZM4 15H5V16H4V15ZM6 15H7V16H6V15ZM8 15H9V16H8V15ZM10 15H11V16H10V15ZM12 15H13V16H12V15ZM14 15H15V16H14V15Z" fill="currentColor"/></svg>
            <h2>Tuberculosis</h2>
             <details>
                <summary>General Info</summary>
                <div class="details-content">
                    <ul>
                        <li>Caused by <em>Mycobacterium tuberculosis</em>, an acid-fast bacillus (AFB).</li>
                        <li>Transmission: Inhalation of airborne droplet nuclei.</li>
                        <li>Pathogenesis involves cell-mediated immunity (Th1 response) leading to granuloma formation.</li>
                        <li><strong>Primary TB:</strong> Initial infection, often asymptomatic or mild flu-like. Typically involves middle/lower lobes. Forms Ghon complex (peripheral lesion + hilar node involvement). Usually contained.</li>
                        <li><strong>Latent TB Infection (LTBI):</strong> Immune system contains infection, but bacilli remain viable. Patient is asymptomatic, not infectious. Positive TST/IGRA, negative CXR/symptoms. Risk of reactivation.</li>
                        <li><strong>Secondary (Reactivation) TB:</strong> Reactivation of LTBI, often due to weakened immunity. Typically affects <strong>apical and posterior segments of upper lobes</strong> (higher O2). Prone to <strong>cavitation</strong>. Symptomatic and infectious.</li>
                        <li><strong>Risk factors for progression/reactivation:</strong> HIV/immunosuppression, recent infection (<2 yrs), diabetes, CKD/dialysis, silicosis, malnutrition, certain meds (TNF-alpha inhibitors), IVDU, smoking.</li>
                    </ul>
                </div>
            </details>
            <details>
                <summary>Symptoms of Active TB</summary>
                <div class="details-content">
                    <p>Often insidious onset:</p>
                    <ul>
                        <li><strong>Pulmonary:</strong> Chronic cough (>3 weeks), sputum production (may be bloody - hemoptysis), pleuritic chest pain, dyspnea (late).</li>
                        <li><strong>Constitutional:</strong> Fever (often low-grade, diurnal variation), night sweats, weight loss, anorexia, malaise, fatigue.</li>
                        <li>Other: Anemia, leukocytosis (variable), elevated ESR/CRP, clubbing (chronic disease).</li>
                    </ul>
                </div>
            </details>

            <h3>Extra pulmonary TB (EPTB)</h3>
             <details>
                <summary>Common Sites & Features</summary>
                <div class="details-content">
                     <ul>
                        <li>Can affect almost any organ system, more common in HIV/immunosuppressed. Diagnosis often requires biopsy/fluid analysis from affected site.</li>
                        <li><strong>Lymph node (TB lymphadenitis / Scrofula):</strong> Most common site (~35%). Painless swelling of lymph nodes (often cervical). May suppurate and form draining sinus tracts.</li>
                        <li><strong>Pleural TB:</strong> (~20%) Pleural effusion (usually exudative, lymphocytic predominant). Diagnosis via pleural fluid ADA (adenosine deaminase) levels, PCR, or pleural biopsy (granulomas).</li>
                        <li><strong>Genitourinary (GU) TB:</strong> (~10-15%) Can affect kidneys, bladder, genital tract. Often presents with sterile pyuria (WBCs in urine, no bacteria on standard culture), hematuria, flank pain, infertility. Requires 3+ morning urine samples for AFB culture.</li>
                        <li><strong>Skeletal TB (Bone/Joint):</strong> (~10%) Affects spine (<strong>Pott's disease</strong> - vertebral destruction, kyphosis, abscess), large weight-bearing joints (hip, knee). Pain, swelling, decreased range of motion.</li>
                        <li><strong>TB Meningitis:</strong> (~5%) Headache, fever, neck stiffness, altered mental status. Often subacute onset. CSF: high protein, low glucose, lymphocytic pleocytosis (initially may be neutrophilic). AFB smear often negative, culture/PCR needed. High morbidity/mortality. Common in children, HIV patients.</li>
                        <li><strong>Miliary (Disseminated) TB:</strong> Hematogenous spread. Diffuse small (1-2 mm, "millet seed") nodules throughout lungs on CXR/CT. Can involve liver, spleen, bone marrow, other organs. Often presents with non-specific constitutional symptoms, organomegaly.</li>
                        <li><strong>GI TB:</strong> Abdominal pain, diarrhea, weight loss. Can mimic Crohn's disease, malignancy. Often affects ileocecal region.</li>
                        <li>Other sites: Pericardial, cutaneous, ocular, adrenal.</li>
                     </ul>
                 </div>
            </details>

            <h3>TB Screening & Diagnosis</h3>
             <details>
                <summary>TB Skin Test (TST / PPD)</summary>
                <div class="details-content">
                     <p>Intradermal injection of purified protein derivative (PPD). Read 48-72 hours later. Measures diameter of <strong>induration</strong> (palpable swelling), not erythema.</p>
                     <p><strong>Interpretation (Cutoff for Positive):</strong></p>
                     <ul>
                         <li><strong>≥ 5 mm:</strong> HIV+, recent TB contacts, fibrotic changes on CXR consistent with old TB, organ transplant recipients, immunosuppressed (e.g., ≥15mg/day prednisone for >1 month, TNF-alpha inhibitors).</li>
                         <li><strong>≥ 10 mm:</strong> Recent immigrants (<5 yrs) from high-prevalence countries, IV drug users, residents/employees of high-risk settings (prisons, nursing homes, hospitals, homeless shelters), mycobacteriology lab personnel, persons with high-risk clinical conditions (silicosis, diabetes, CKD, certain malignancies), children < 4 yrs, infants/children/adolescents exposed to high-risk adults.</li>
                         <li><strong>≥ 15 mm:</strong> Persons with no known risk factors for TB.</li>
                     </ul>
                     <p><strong>Limitations:</strong> False positives (BCG vaccination, infection with non-tuberculous mycobacteria). False negatives (anergy due to immunosuppression, recent TB infection, overwhelming TB disease, very young age, improper technique/reading).</p>
                 </div>
            </details>

            <details>
                <summary>Interferon Gamma Release Assay (IGRA)</summary>
                <div class="details-content">
                     <p>Blood test measuring T-cell release of interferon-gamma in response to specific M. tuberculosis antigens (not present in BCG or most NTM).</p>
                     <ul>
                         <li>Examples: QuantiFERON-TB Gold Plus, T-SPOT.TB.</li>
                         <li><strong>Advantages over TST:</strong> Requires single visit, results in 24h, not affected by BCG vaccination, less subjective reading.</li>
                         <li><strong>Preferred for:</strong> People with history of BCG vaccination, those unlikely to return for TST reading.</li>
                         <li><strong>Limitations:</strong> More expensive, requires lab processing, may have lower sensitivity in young children/severely immunocompromised, potential for indeterminate results.</li>
                         <li><strong>Interpretation:</strong> Positive result indicates TB infection (latent or active). Does not distinguish between LTBI and active disease. Requires clinical evaluation and CXR to rule out active TB.</li>
                     </ul>
                 </div>
            </details>

             <details>
                <summary>Diagnosing Active TB Disease</summary>
                <div class="details-content">
                    <p>Requires microbiologic confirmation whenever possible.</p>
                     <ul>
                        <li><strong>Sputum Smear Microscopy:</strong> Acid-fast bacilli (AFB) staining (e.g., Ziehl-Neelsen, Kinyoun, fluorochrome). Rapid, inexpensive, but low sensitivity (requires high bacillary load). Specificity issues with NTM.</li>
                        <li><strong>Nucleic Acid Amplification Tests (NAAT):</strong> e.g., Xpert MTB/RIF assay. Detects M. tuberculosis DNA directly from sputum. Rapid (hours), high sensitivity/specificity. Can also detect Rifampin resistance (Xpert). Recommended as initial test on at least one sputum sample.</li>
                        <li><strong>Mycobacterial Culture:</strong> Gold standard. Most sensitive. Allows for species identification and drug susceptibility testing (DST). Takes weeks (liquid media faster than solid media). Obtain <strong>3 sputum specimens</strong> (preferably early morning) 8-24 hours apart.</li>
                        <li><strong>Chest X-ray (CXR):</strong> Essential. Findings vary: Primary TB (hilar adenopathy, middle/lower lobe infiltrate, effusion), Reactivation TB (apical/posterior upper lobe infiltrates, cavitation), Miliary TB (diffuse small nodules). Can be normal in HIV/immunosuppressed or EPTB.</li>
                        <li>Other samples for EPTB: Biopsy, CSF, urine, pleural fluid, etc. for AFB smear, culture, NAAT, histology.</li>
                     </ul>
                 </div>
            </details>

            <h3>Latent vs. Active TB Treatment</h3>
             <details>
                <summary>Key Differences & Goals</summary>
                <div class="details-content">
                    <div class="table-container">
                        <table class="mt-2">
                             <thead>
                                 <tr><th>Feature</th><th>Latent TB (LTBI)</th><th>Active TB Disease</th></tr>
                             </thead>
                             <tbody>
                                 <tr><td data-label="Feature"><strong>Status</strong></td><td data-label="Latent TB (LTBI)">Infected, contained by immune system. No active disease. Asymptomatic. Not infectious.</td><td data-label="Active TB Disease">Active bacterial replication. Symptomatic (usually). Infectious (if pulmonary/laryngeal).</td></tr>
                                 <tr><td data-label="Feature"><strong>Screening/Dx</strong></td><td data-label="Latent TB (LTBI)">Positive TST or IGRA. <strong>Negative</strong> CXR. No symptoms.</td><td data-label="Active TB Disease">Symptoms present. CXR often abnormal (infiltrate, cavity, effusion, adenopathy). Positive TST/IGRA. <strong>Positive</strong> sputum AFB smears/NAAT/cultures (pulmonary).</td></tr>
                                 <tr><td data-label="Feature"><strong>Goal of Tx</strong></td><td data-label="Latent TB (LTBI)">Prevent progression to active disease.</td><td data-label="Active TB Disease">Cure active disease, prevent transmission, prevent relapse, prevent drug resistance.</td></tr>
                                 <tr><td data-label="Feature"><strong>Treatment Regimens (Preferred)</strong></td><td data-label="Latent TB (LTBI)">
                                    <ul>
                                        <li>Isoniazid (INH) + Rifapentine (RPT) weekly x 3 months (12 doses) - 3HP</li>
                                        <li>Rifampin (RIF) daily x 4 months - 4R</li>
                                        <li>INH + RIF daily x 3 months - 3HR</li>
                                        <!-- <li>INH daily x 6 or 9 months (less preferred now due to duration/hepatotoxicity)</li> -->
                                    </ul>
                                 </td><td data-label="Active TB Disease">Standard regimen for drug-susceptible TB (Total 6 months):<br>
                                    <strong>Intensive Phase (2 months):</strong> 4 drugs daily: <strong>R</strong>ifampin (RIF), <strong>I</strong>soniazid (INH), <strong>P</strong>yrazinamide (PZA), <strong>E</strong>thambutol (EMB) - <strong>RIPE</strong>.<br>
                                    <strong>Continuation Phase (4 months):</strong> 2 drugs daily: <strong>I</strong>soniazid (INH) + <strong>R</strong>ifampin (RIF) - <strong>IR</strong>.<br>
                                    (Duration may be extended for cavitation, delayed culture conversion, bone/joint/CNS disease). Requires Directly Observed Therapy (DOT) often. Treatment adjusted based on DST results.
                                 </td></tr>
                             </tbody>
                         </table>
                     </div>
                 </div>
            </details>
        </div> <!-- End Section: Tuberculosis -->

        <div class="pixel-art-divider"></div>

        <!-- Section: NTM & Leprosy -->
        <div id="ntm-leprosy" class="content-section">
             <svg viewBox="0 0 16 16" xmlns="http://www.w3.org/2000/svg" class="section-svg"><path d="M1 1H2V2H1V1ZM3 1H4V2H3V1ZM5 1H6V2H5V1ZM7 1H8V2H7V1ZM9 1H10V2H9V1ZM11 1H12V2H11V1ZM13 1H14V2H13V1ZM15 1H16V2H15V1ZM1 3H2V4H1V3ZM3 3H4V4H3V3ZM5 3H6V4H5V3ZM7 3H8V4H7V3ZM9 3H10V4H9V3ZM11 3H12V4H11V3ZM13 3H14V4H13V3ZM15 3H16V4H15V3ZM1 5H2V6H1V5ZM3 5H4V6H3V5ZM5 5H6V6H5V5ZM7 5H8V6H7V5ZM9 5H6V7H9V6H10V5H9ZM11 5H12V6H11V5ZM13 5H14V6H13V5ZM15 5H16V6H15V5ZM1 7H2V8H1V7ZM3 7H4V8H3V7ZM4 8H5V9H4V8ZM5 9H6V10H5V9ZM6 10H7V11H6V10ZM7 11H8V12H7V11ZM8 12H9V13H8V12ZM9 11H10V12H9V11ZM10 10H11V11H10V10ZM11 9H12V10H11V9ZM12 8H13V9H12V8ZM13 7H14V8H13V7ZM15 7H16V8H15V7ZM1 9H2V10H1V9ZM3 9H4V10H3V9ZM13 9H14V10H13V9ZM15 9H16V10H15V9ZM1 11H2V12H1V11ZM3 11H4V12H3V11ZM5 11H6V12H5V11ZM11 11H12V12H11V11ZM13 11H14V12H13V11ZM15 11H16V12H15V11ZM1 13H2V14H1V13ZM3 13H4V14H3V13ZM5 13H6V14H5V13ZM7 13H8V14H7V13ZM9 13H10V14H9V13ZM11 13H12V14H11V13ZM13 13H14V14H13V13ZM15 13H16V14H15V13ZM1 15H2V16H1V15ZM3 15H4V16H3V15ZM5 15H6V16H5V15ZM7 15H8V16H7V15ZM9 15H10V16H9V15ZM11 15H12V16H11V15ZM13 15H14V16H13V15ZM15 15H16V16H15V15Z" fill="currentColor"/></svg>
            <h2>Leprosy & Non-TB Mycobacteria (NTM)</h2>
            <h3>Leprosy (Hansen's Disease)</h3>
            <details>
                <summary>Agent & Spectrum</summary>
                <div class="details-content">
                    <p>Chronic infectious disease caused by <em>Mycobacterium leprae</em>, an obligate intracellular acid-fast bacillus. Primarily affects skin, peripheral nerves, upper respiratory tract, eyes, testes. Exists on a clinical and immunological spectrum based on host cell-mediated immunity (CMI):</p>
                    <ul>
                        <li><strong>Tuberculoid (TT):</strong> Strong CMI (Th1 response). Few lesions, well-defined borders, often anesthetic. Paucibacillary (few bacteria). Low infectivity.</li>
                        <li><strong>Lepromatous (LL):</strong> Weak CMI (Th2 response). Numerous, widespread, poorly defined lesions (macules, papules, nodules). Symmetric nerve involvement, often late sensory loss. Multibacillary (many bacteria). Higher infectivity. Classic "leonine facies".</li>
                        <li><strong>Borderline (BT, BB, BL):</strong> Intermediate features between TT and LL. Unstable, prone to reactions.</li>
                    </ul>
                </div>
            </details>
            <div class="table-container">
                 <table class="mt-4">
                     <thead>
                         <tr>
                             <th>Feature</th>
                             <th>Tuberculoid (TT/BT)</th>
                             <th>Borderline (BB)</th>
                             <th>Lepromatous (BL/LL)</th>
                         </tr>
                     </thead>
                     <tbody>
                         <tr>
                             <td data-label="Feature"><strong>Skin lesions</strong></td>
                             <td data-label="Tuberculoid (TT/BT)">One or few (<5). Sharply defined, hypopigmented or erythematous macules or plaques. Often annular with raised borders, central clearing. Dry, scaly, hairless. <strong>Marked anesthesia</strong>.</td>
                             <td data-label="Borderline (BB)">Intermediate number, size, definition. More numerous than TT, less than LL. Annular lesions common. Variable sensation.</td>
                             <td data-label="Lepromatous (BL/LL)">Multiple (>5), symmetric, poorly defined macules, papules, nodules, or diffuse infiltration. Skin thickening. Loss of eyebrows/eyelashes (madarosis). Leonine facies. <strong>Sensation often intact early</strong>, late diffuse hypesthesia.</td>
                         </tr>
                         <tr>
                             <td data-label="Feature"><strong>Nerve involvement</strong></td>
                             <td data-label="Tuberculoid (TT/BT)">Early, severe, asymmetric involvement of one or few peripheral nerves. Nerves may be enlarged, tender. Anesthesia in skin lesions is prominent.</td>
                             <td data-label="Borderline (BB)">Moderate number of nerves involved, often asymmetric initially, becoming more symmetric. Nerve enlargement common. Sensory/motor deficits variable.</td>
                             <td data-label="Lepromatous (BL/LL)">Late, slow, symmetric involvement of many peripheral nerves. Diffuse infiltration rather than enlargement. Distal sensory loss (glove-and-stocking) common later. Motor deficits less prominent initially.</td>
                         </tr>
                         <tr>
                             <td data-label="Feature"><strong>Immunity (CMI)</strong></td>
                             <td data-label="Tuberculoid (TT/BT)">Strong Th1 response. Positive lepromin skin test. Low antibody titers.</td>
                             <td data-label="Borderline (BB)">Intermediate/Unstable.</td>
                             <td data-label="Lepromatous (BL/LL)">Poor Th1, dominant Th2 response. Negative lepromin skin test. High antibody titers (non-protective).</td>
                         </tr>
                         <tr>
                             <td data-label="Feature"><strong>Bacteriology (Slit-skin smear)</strong></td>
                             <td data-label="Tuberculoid (TT/BT)">Few or no bacilli (Paucibacillary - PB).</td>
                             <td data-label="Borderline (BB)">Variable bacilli.</td>
                             <td data-label="Lepromatous (BL/LL)">Numerous bacilli (Multibacillary - MB).</td>
                         </tr>
                          <tr>
                             <td data-label="Feature"><strong>WHO Treatment</strong></td>
                             <td data-label="Tuberculoid (TT/BT)"><strong>Paucibacillary (PB):</strong> Rifampin (monthly supervised) + Dapsone (daily self-admin) for <strong>6 months</strong>.</td>
                             <td data-label="Borderline (BB)">Treated as Multibacillary.</td>
                             <td data-label="Lepromatous (BL/LL)"><strong>Multibacillary (MB):</strong> Rifampin (monthly supervised) + Clofazimine (monthly supervised + daily self-admin) + Dapsone (daily self-admin) for <strong>12 months</strong>.</td>
                         </tr>
                     </tbody>
                 </table>
             </div>
             <details>
                <summary>Leprosy Complications</summary>
                <div class="details-content">
                    <ul>
                        <li><strong>Peripheral Neuropathy:</strong> Sensory loss (touch, pain, temp), motor weakness (claw hand - ulnar/median; wrist drop - radial; foot drop - peroneal), autonomic dysfunction (anhidrosis). Leads to injuries, ulcers (esp. plantar), infections, deformities, amputations.</li>
                        <li><strong>Lepra Reactions:</strong> Acute inflammatory episodes.
                            <ul>
                                <li><strong>Type 1 (Reversal Reaction):</strong> Upgrading (towards TT) or downgrading (towards LL) shift in CMI. Occurs in Borderline patients. Inflammation of existing skin lesions and nerves (neuritis - pain, swelling, loss of function). Requires prompt treatment with corticosteroids to prevent nerve damage.</li>
                                <li><strong>Type 2 (Erythema Nodosum Leprosum - ENL):</strong> Immune complex mediated vasculitis. Occurs in BL/LL patients, often during/after treatment. Crops of tender subcutaneous nodules, fever, malaise, arthritis, uveitis, orchitis. Treated with corticosteroids or thalidomide.</li>
                            </ul>
                        </li>
                        <li><strong>Eye involvement:</strong> Lagophthalmos (inability to close eye), corneal ulcers, cataracts, glaucoma, blindness.</li>
                        <li>Other: Testicular atrophy, gynecomastia, amyloidosis, renal failure.</li>
                    </ul>
                </div>
            </details>

            <hr class="my-6 border-[--border-color] border-dashed opacity-50">

            <h3>Non-TB Mycobacterial (NTM) Infections</h3>
             <details>
                <summary>General Info</summary>
                <div class="details-content">
                     <ul>
                        <li>Mycobacteria other than M. tuberculosis complex and M. leprae.</li>
                        <li>Ubiquitous environmental organisms (water, soil, dust).</li>
                        <li>Not typically transmitted person-to-person (exception: M. abscessus in CF patients).</li>
                        <li>Opportunistic pathogens, cause disease primarily in susceptible individuals.</li>
                        <li>Common species causing human disease:
                            <ul>
                                <li><strong><em>M. avium</em> complex (MAC):</strong> Most common cause of NTM lung disease. Also causes disseminated disease in advanced HIV, lymphadenitis in children.</li>
                                <li><strong><em>M. kansasii:</em></strong> Causes lung disease similar to TB.</li>
                                <li><strong><em>M. abscessus:</em></strong> Rapidly growing mycobacterium. Causes lung disease (esp. CF), skin/soft tissue infections, disseminated disease. Often highly drug-resistant.</li>
                                <li>Others: <em>M. fortuitum, M. chelonae</em> (rapid growers - skin/soft tissue); <em>M. marinum</em> ("fish tank granuloma" - skin); <em>M. xenopi, M. malmoense, M. simiae</em> (lung disease).</li>
                            </ul>
                        </li>
                     </ul>
                 </div>
            </details>
             <details>
                <summary>Predisposing Factors for Pulmonary NTM Disease</summary>
                <div class="details-content">
                     <ul>
                        <li><strong>Underlying structural lung disease:</strong> Bronchiectasis (major risk factor), COPD, previous TB, cystic fibrosis (CF), silicosis/pneumoconiosis.</li>
                        <li>Impaired airway clearance: Primary ciliary dyskinesia (PCD).</li>
                        <li>Genetic factors: Alpha-1 antitrypsin deficiency, specific immune defects (e.g., IFN-gamma pathway defects).</li>
                        <li>Host factors: Advanced age, low BMI, ?postmenopausal women ("Lady Windermere syndrome" - nodular bronchiectasis often in RML/lingula in thin, older women without prior lung disease).</li>
                        <li>Immunosuppression (less common for pulmonary NTM than TB, but major risk for disseminated MAC).</li>
                     </ul>
                 </div>
            </details>
             <details>
                <summary>Clinical Manifestations</summary>
                <div class="details-content">
                     <ul>
                        <li><strong>Pulmonary Disease:</strong> Most common form. Often insidious onset. Symptoms: chronic cough (often productive), fatigue, malaise, dyspnea, weight loss, low-grade fever, hemoptysis. Radiographic patterns:
                            <ul>
                                <li><strong>Nodular bronchiectatic form:</strong> Multiple small nodules and cylindrical bronchiectasis, often involving right middle lobe and lingula. Common with MAC, esp. in older women.</li>
                                <li><strong>Fibrocavitary form:</strong> Upper lobe cavities and fibrosis, resembling reactivation TB. More common in smokers with underlying COPD. Often caused by MAC or M. kansasii.</li>
                                <li>Hypersensitivity pneumonitis-like pattern ("Hot tub lung"): Diffuse GGOs/nodules after exposure to contaminated aerosols (often MAC).</li>
                            </ul>
                        </li>
                        <li><strong>Disseminated Disease:</strong> Primarily MAC in patients with severe immunosuppression (e.g., HIV with CD4 < 50). Widespread infection involving lymph nodes, liver, spleen, bone marrow. Presents with fever, night sweats, weight loss, abdominal pain, diarrhea, anemia, organomegaly.</li>
                        <li><strong>Lymphadenitis:</strong> Usually cervical lymphadenitis in young children (1-5 yrs). Typically caused by MAC. Presents as unilateral, firm, non-tender node(s).</li>
                        <li><strong>Skin and Soft Tissue Infection:</strong>
                            <ul>
                                <li><em>M. marinum:</em> Granulomatous lesions ("fish tank granuloma") on extremities after exposure to contaminated water (pools, aquariums).</li>
                                <li>Rapid growers (<em>M. fortuitum, M. chelonae, M. abscessus</em>): Infections related to trauma, surgery, cosmetic procedures, contaminated injections. Can cause abscesses, cellulitis, osteomyelitis.</li>
                            </ul>
                        </li>
                        <li>Other: Skeletal infections, catheter-related infections.</li>
                     </ul>
                 </div>
            </details>
             <details>
                <summary>Diagnosis</summary>
                <div class="details-content">
                     <p>Diagnosis of NTM lung disease requires a combination of clinical, radiographic, and microbiologic criteria (ATS/IDSA guidelines):</p>
                     <ul>
                        <li><strong>Clinical Criteria:</strong> Compatible symptoms (cough, fatigue, weight loss, etc.) AND exclusion of other diagnoses (like TB).</li>
                        <li><strong>Radiographic Criteria:</strong> Compatible findings on CXR or HRCT (nodules, cavities, bronchiectasis, infiltrates).</li>
                        <li><strong>Microbiologic Criteria:</strong>
                            <ul>
                                <li>Positive culture from <strong>≥ 2 separate expectorated sputum samples</strong> OR</li>
                                <li>Positive culture from <strong>≥ 1 bronchial wash or lavage (BAL)</strong> sample OR</li>
                                <li><strong>Transbronchial or lung biopsy</strong> yielding NTM OR biopsy showing granulomatous inflammation/AFB + positive NTM culture from sputum/bronchial sample.</li>
                            </ul>
                        </li>
                        <li><em>Note: Isolation of NTM from a single sputum sample may represent colonization or contamination, hence the need for multiple positive samples or invasive sampling.</em></li>
                        <li>AFB smear and culture are essential. Culture identifies species and allows for drug susceptibility testing (DST), which is crucial for guiding treatment (esp. for MAC and M. abscessus).</li>
                     </ul>
                 </div>
            </details>
             <details>
                <summary>Treatment</summary>
                <div class="details-content">
                     <ul>
                        <li>Treatment decisions are complex, considering species, drug susceptibility, extent of disease, patient comorbidities, and potential drug toxicity. Not all patients with NTM isolation require treatment.</li>
                        <li>Requires multi-drug regimens for prolonged periods (often 12 months AFTER culture conversion).</li>
                        <li><strong>MAC Lung Disease:</strong> Typically 3 drugs: <strong>Macrolide (Azithromycin or Clarithromycin) + Ethambutol + Rifamycin (Rifampin or Rifabutin)</strong>.</li>
                        <li><strong><em>M. kansasii</em> Lung Disease:</strong> Usually susceptible to standard TB drugs: Rifampin + Isoniazid + Ethambutol.</li>
                        <li><strong><em>M. abscessus</em> Lung Disease:</strong> Very difficult to treat due to drug resistance. Requires combination therapy based on DST, often including IV agents (e.g., amikacin, tigecycline, imipenem) plus oral agents (macrolide - if susceptible, clofazimine, linezolid, bedaquiline). Treatment often prolonged and may involve surgery.</li>
                        <li>Surgical resection may be considered for localized disease (e.g., cavities, severe bronchiectasis) failing medical therapy.</li>
                     </ul>
                 </div>
            </details>
        </div> <!-- End Section: NTM & Leprosy -->

        <div class="pixel-art-divider"></div>

        <!-- Section: Pediatric Pulmonology -->
        <div id="pediatric-pulmonology" class="content-section">
            <svg viewBox="0 0 16 16" xmlns="http://www.w3.org/2000/svg" class="section-svg"><path d="M1 1H2V2H1V1ZM3 1H4V2H3V1ZM5 1H6V2H5V1ZM7 1H9V2H7V1ZM9 2H10V3H9V2ZM10 3H11V4H10V3ZM11 4H12V5H11V4ZM12 5H13V6H12V5ZM13 6H14V7H13V6ZM14 7H15V8H14V7ZM15 8H16V10H15V8ZM15 10H16V11H15V10ZM14 11H15V12H14V11ZM13 12H14V13H13V12ZM12 13H13V14H12V13ZM11 14H12V15H11V14ZM10 15H11V16H10V15ZM9 15H8V16H9V15ZM7 15H6V16H7V15ZM5 15H4V16H5V15ZM3 15H2V16H3V15ZM1 15H2V14H1V15ZM1 13H2V14H1V13ZM1 11H2V12H1V11ZM1 9H2V10H1V9ZM1 7H2V8H1V7ZM1 5H2V6H1V5ZM1 3H2V4H1V3ZM3 4H4V5H3V4ZM4 5H5V6H4V5ZM5 6H6V7H5V6ZM6 7H7V8H6V7ZM7 8H8V9H7V8ZM8 9H9V10H8V9ZM9 10H10V11H9V10ZM10 11H11V12H10V11ZM11 12H12V13H11V12ZM12 11H13V12H12V11ZM13 10H14V11H13V10ZM14 9H15V10H14V9ZM14 5H15V6H14V5ZM13 4H14V5H13V4ZM12 3H13V4H12V3ZM11 2H12V3H11V2ZM5 12H6V13H5V12ZM6 13H7V14H6V13ZM7 14H8V15H7V14ZM8 14H9V15H8V14ZM9 14H10V15H9V14ZM10 13H11V14H10V13ZM11 12H12V13H11V12Z" fill="currentColor"/></svg>
            <h2>Pediatric Pulmonology</h2>

            <h3>Embryology</h3>
             <details>
                <summary>Key Points</summary>
                <div class="details-content">
                     <ul>
                         <li>Lung development occurs in stages: Embryonic, Pseudoglandular, Canalicular, Saccular, Alveolar.</li>
                         <li>Trachea and esophagus develop from foregut; errors in separation lead to Tracheoesophageal Fistula (TEF).</li>
                         <li>Surfactant production by Type II pneumocytes begins in the Canalicular stage (around 20-24 weeks) and increases significantly in the Saccular stage.</li>
                         <li>First major viability milestone (potential for survival outside womb with significant support) is around <strong>23-25 weeks</strong> gestation, largely dependent on sufficient surfactant production and capillary development.</li>
                         <li>Alveolar development continues significantly after birth.</li>
                     </ul>
                 </div>
            </details>

            <h3>Congenital Malformations</h3>
             <details>
                <summary>Pulmonary hypoplasia</summary>
                <div class="details-content"><p>Incomplete development of lung tissue (fewer airways, alveoli, vessels). Often secondary to conditions limiting thoracic space (Congenital Diaphragmatic Hernia - CDH, severe skeletal dysplasia) or reducing fetal breathing movements/lung fluid (Oligohydramnios - e.g., Potter sequence due to renal agenesis). Leads to respiratory insufficiency at birth.</p></div>
            </details>
             <details>
                <summary>Bronchogenic cysts</summary>
                <div class="details-content"><p>Abnormal budding of the ventral foregut/tracheobronchial tree during development. Fluid or mucus-filled cysts, usually in mediastinum or lung parenchyma. Do not communicate with airway typically. Risk of infection, compression of adjacent structures (airway, esophagus). Tx: Surgical resection.</p></div>
            </details>
             <details>
                <summary>Congenital lobar emphysema (CLE)</summary>
                <div class="details-content"><p>Marked hyperinflation (overdistension) of one or more lung lobes, usually due to bronchial cartilage abnormality causing a "ball-valve" effect (air trapping on expiration). Most commonly affects LUL, RML, RUL. Can cause respiratory distress due to compression of adjacent lung and mediastinal shift. Tx: Observation if mild, lobectomy if severe respiratory compromise.</p></div>
            </details>
             <details>
                <summary>Congenital pulmonary airway malformations (CPAM)</summary>
                <div class="details-content"><p>Formerly Congenital Cystic Adenomatoid Malformation (CCAM). Hamartomatous lesion of lung with cystic and solid components; abnormal bronchiolar structures. Does not function in gas exchange. Classified into types based on cyst size/histology. Most common primary congenital lung malformation. Risk of infection, pneumothorax, rarely malignant transformation (pleuropulmonary blastoma). Tx: Surgical resection, often electively in infancy (e.g., around 6 months).</p></div>
            </details>
             <details>
                <summary>Pulmonary sequestration</summary>
                <div class="details-content">
                    <p>Area of non-functioning lung tissue that lacks normal connection to the tracheobronchial tree and receives anomalous systemic arterial blood supply (usually from aorta or branches).</p>
                    <ul>
                        <li><strong>Intralobar (ILS):</strong> Within normal lung lobe (usually posterior basal segment of lower lobe), shares visceral pleura. Presents later in childhood/adulthood with recurrent infections or incidentally.</li>
                        <li><strong>Extralobar (ELS):</strong> Has its own separate pleura, located outside normal lung (often between lower lobe and diaphragm). Usually presents in infancy with respiratory distress, cyanosis, or associated with other congenital anomalies (esp. CDH).</li>
                    </ul>
                    <p>Risk of infection, hemorrhage. Tx: Surgical resection.</p>
                </div>
            </details>
             <details>
                <summary>Congenital Diaphragmatic Hernia (CDH)</summary>
                <div class="details-content"><p>Defect in diaphragm allowing abdominal contents (stomach, bowel, liver, spleen) to herniate into chest cavity. Most common type is posterolateral Bochdalek hernia (usually left side). Causes pulmonary hypoplasia and pulmonary hypertension due to lung compression in utero. Presents at birth with severe respiratory distress, scaphoid abdomen, bowel sounds in chest. Tx: Immediate intubation (avoid bag-mask ventilation), NGT for gastric decompression, stabilization (manage pulmonary HTN), delayed surgical repair.</p></div>
            </details>
             <details>
                <summary>Laryngomalacia</summary>
                <div class="details-content"><p>Most common cause of congenital stridor. Immature/floppy supraglottic structures (epiglottis, arytenoids, aryepiglottic folds) collapse inward during inspiration, causing intermittent inspiratory <strong>stridor</strong>. Worse when supine, crying, feeding, or agitated. Usually presents in first few weeks of life, peaks around 4-8 months. Dx: Flexible nasopharyngoscopy shows dynamic collapse. Tx: Usually benign and resolves spontaneously by 1-2 years. Surgery (supraglottoplasty) reserved for severe cases with failure to thrive, significant respiratory distress, apnea, or feeding difficulties. <strong>Albuterol is ineffective or may worsen symptoms.</strong></p></div>
            </details>
             <details>
                <summary>Choanal atresia</summary>
                <div class="details-content"><p>Congenital blockage of posterior nasal passage(s) by bone or soft tissue. Bilateral atresia presents at birth with severe respiratory distress and cyanosis, as infants are obligate nasal breathers. Cyanosis often improves with crying (mouth breathing). Unilateral atresia may present later with chronic nasal discharge/obstruction. Dx: Inability to pass small catheter through nose into pharynx; confirmed with CT scan. Tx: Secure airway immediately (oral airway, intubation if needed), surgical repair.</p></div>
            </details>
             <details>
                <summary>TE fistula (Tracheoesophageal Fistula)</summary>
                <div class="details-content"><p>Abnormal connection between trachea and esophagus. Most common type (Type C, ~85%) involves Esophageal Atresia (EA) with a distal TEF (lower esophagus connects to trachea). Presents shortly after birth with excessive secretions, coughing/choking/cyanosis during feeding, respiratory distress, abdominal distension (air enters stomach via fistula). Dx: Inability to pass NGT into stomach (coils in upper esophageal pouch on CXR); air in stomach/bowel on CXR confirms distal fistula. Tx: NGT to suction upper pouch, elevate head of bed, surgical repair.</p></div>
            </details>
             <details>
                <summary>Pectus Deformities</summary>
                <div class="details-content">
                     <ul>
                        <li><strong>Excavatum ("Funnel Chest"):</strong> Concave depression of sternum and costal cartilages. Most common chest wall deformity. Usually cosmetic concern, but severe cases can cause restrictive lung physiology, decreased exercise tolerance, cardiac compression/displacement. Tx: Surgical repair (Nuss procedure or Ravitch procedure) for significant symptoms or severe cosmetic concerns.</li>
                        <li><strong>Carinatum ("Pigeon Chest"):</strong> Protrusion of sternum and costal cartilages. Less common. Usually asymptomatic, primary concern is cosmetic. Tx: Bracing (in younger patients) or surgical repair for cosmetic reasons.</li>
                     </ul>
                 </div>
            </details>

            <h3>Problems with Neonatal Transition</h3>
             <details>
                <summary>Transient tachypnea of newborn (TTN)</summary>
                <div class="details-content"><p>Delayed clearance/resorption of fetal lung fluid after birth, leading to mild respiratory distress ("wet lung"). Risk factors: <strong>Cesarean section delivery</strong> (especially without labor), maternal diabetes, precipitous delivery, male gender. Presents within hours of birth with tachypnea (RR > 60), mild retractions, grunting, possible cyanosis. CXR: Increased interstitial markings, perihilar streaking, fluid in fissures, mild hyperinflation, mild cardiomegaly. Tx: Supportive care, supplemental O2 (usually low requirement), typically resolves within 24-72 hours.</p></div>
            </details>
             <details>
                <summary>Meconium aspiration syndrome (MAS)</summary>
                <div class="details-content"><p>Aspiration of meconium-stained amniotic fluid into the lungs before, during, or immediately after birth. Occurs primarily in term or post-term infants experiencing fetal distress. Meconium causes airway obstruction (ball-valve effect, air trapping), chemical pneumonitis, surfactant inactivation, and pulmonary hypertension. Presents with respiratory distress (tachypnea, retractions, grunting, cyanosis) in infant born through meconium-stained fluid. Barrel chest, rales/rhonchi common. CXR: Patchy infiltrates, hyperinflation, atelectasis, possible pneumothorax/pneumomediastinum. Tx: Supportive care (O2, mechanical ventilation), surfactant therapy, inhaled nitric oxide for pulmonary HTN, antibiotics often given empirically. Routine endotracheal suctioning at birth only for non-vigorous infants.</p></div>
            </details>
            <details>
                <summary>Persistent pulmonary HTN of newborn (PPHN)</summary>
                <div class="details-content"><p>Failure of the normal postnatal drop in pulmonary vascular resistance (PVR), leading to continued high PVR and right-to-left shunting of deoxygenated blood across the ductus arteriosus and/or foramen ovale into systemic circulation. Causes severe hypoxemia. Can be primary (idiopathic) or secondary to other conditions (MAS, CDH, RDS, sepsis, pneumonia). Presents with significant respiratory distress and cyanosis, often labile (oxygenation changes rapidly), typically within first 12-24 hours. Pre-ductal vs. post-ductal SpO2 difference (>5-10%) suggests R-to-L shunting. Dx: <strong>Echocardiogram confirms elevated pulmonary artery pressures</strong>, R-to-L shunting, rules out structural heart disease. Tx: Treat underlying cause. Supportive care (maintain temp, glucose, electrolytes), minimal stimulation, sedation, supplemental O2, mechanical ventilation (gentle settings), maintain systemic BP, inhaled nitric oxide (iNO - selective pulmonary vasodilator), ECMO if refractory severe hypoxemia.</p></div>
            </details>

            <h3>Problems with Premature Delivery</h3>
            <details>
                <summary>Neonatal RDS (Respiratory Distress Syndrome)</summary>
                <div class="details-content"><p>Caused by surfactant deficiency in premature infants (lungs not mature enough to produce adequate amounts). Surfactant reduces surface tension, preventing alveolar collapse (atelectasis). Deficiency leads to atelectasis, decreased lung compliance, increased work of breathing, V/Q mismatch, hypoxemia, hypercapnia. Presents shortly after birth with tachypnea, grunting, nasal flaring, retractions, cyanosis. CXR: Classic findings include low lung volumes, diffuse reticulogranular ("ground glass") opacities, and air bronchograms. Prevention: Antenatal corticosteroids given to mother at risk of preterm delivery. Tx: Exogenous surfactant administration via endotracheal tube, respiratory support (CPAP or mechanical ventilation), supportive care (thermoregulation, nutrition, fluid management). Patent Ductus Arteriosus (PDA) is a common comorbidity, may require treatment (indomethacin/ibuprofen or surgical ligation).</p></div>
            </details>
            <details>
                <summary>Chronic lung disease of prematurity/Bronchopulmonary Dysplasia (BPD)</summary>
                <div class="details-content"><p>Lung injury in premature infants leading to requirement for supplemental oxygen at 36 weeks post-menstrual age (or at 28 days of life if born >32 weeks). Multifactorial pathogenesis: lung immaturity, O2 toxicity, ventilator-induced lung injury (volutrauma/barotrauma), inflammation, infection, poor nutrition. Characterized by impaired alveolarization and vascular development. CXR: Variable; "New BPD" often shows diffuse hazy opacities and decreased lung volumes, while "Old BPD" (less common now) had cystic changes and hyperinflation. Long-term consequences: increased risk of respiratory infections, asthma-like symptoms, pulmonary hypertension, neurodevelopmental impairment. Tx: Minimize lung injury (gentle ventilation strategies, judicious O2 use), nutritional support, diuretics (for fluid overload), bronchodilators (limited role), inhaled steroids (controversial), caffeine (for apnea), possible home O2.</p></div>
            </details>
            <details>
                <summary>Apnea of prematurity</summary>
                <div class="details-content"><p>Developmental disorder in premature infants (<34 weeks gestation) characterized by cessation of breathing for > 20 seconds OR shorter pauses associated with bradycardia (HR < 100 bpm) or oxygen desaturation (SpO2 < 85%). Due to immature respiratory control centers in brainstem and weak respiratory muscle responses. Can be central (no effort), obstructive (effort but no airflow), or mixed (most common). Distinct from periodic breathing (short pauses <10 sec followed by rapid breaths, normal). Tx: Tactile stimulation, supplemental O2 (use cautiously), CPAP, methylxanthine therapy (<strong>Caffeine</strong> citrate is drug of choice - stimulates respiratory drive).</p></div>
            </details>

            <h3>Respiratory Issues Found in Peds</h3>
            <details>
                <summary>Pneumothorax</summary>
                <div class="details-content">
                     <p>Air in the pleural space, causing lung collapse.</p>
                     <ul>
                        <li><strong>Primary Spontaneous Pneumothorax (PSP):</strong> Occurs without underlying lung disease. Most common in tall, thin adolescent males. Often due to rupture of subpleural apical blebs.</li>
                        <li><strong>Secondary Spontaneous Pneumothorax (SSP):</strong> Occurs due to underlying lung disease (e.g., Cystic Fibrosis, asthma, BPD, infection, Marfan syndrome).</li>
                        <li><strong>Traumatic Pneumothorax:</strong> Due to penetrating or blunt chest trauma.</li>
                        <li><strong>Iatrogenic Pneumothorax:</strong> Complication of medical procedures (e.g., central line placement, mechanical ventilation, thoracentesis).</li>
                        <li><strong>Tension Pneumothorax:</strong> Life-threatening emergency. Air enters pleural space but cannot exit, causing progressive lung collapse, mediastinal shift away from affected side, impaired venous return, cardiovascular collapse. Requires immediate needle decompression followed by chest tube.</li>
                     </ul>
                     <p>Tx: Small/stable PSP may be observed with supplemental O2. Larger or symptomatic pneumothorax requires drainage: needle aspiration or tube thoracostomy (chest tube). Recurrent PSP or persistent air leak may require VATS with blebectomy and pleurodesis (chemical or mechanical).</p>
                 </div>
            </details>
            <details>
                <summary>Asthma Mimics</summary>
                <div class="details-content">
                     <p>Conditions presenting with wheezing or cough that can be mistaken for asthma:</p>
                     <ul>
                        <li><strong>Foreign body aspiration:</strong> Sudden onset cough, choking, wheezing, or stridor, often in toddlers (peak 1-3 yrs). May have unilateral wheeze or decreased breath sounds. CXR may show object (if radiopaque), unilateral hyperinflation (air trapping), atelectasis, or be normal. Requires rigid bronchoscopy for diagnosis and removal.</li>
                        <li><strong>Vascular ring/sling:</strong> Congenital anomalies of aortic arch/pulmonary artery compressing trachea and/or esophagus. Presents in infancy/early childhood with stridor (often biphasic), persistent wheezing unresponsive to bronchodilators, cough, feeding difficulties (dysphagia). Dx: Barium swallow, CT/MRI Angiography, Echocardiogram. Tx: Surgical division of ring/sling.</li>
                        <li><strong>Vocal cord dysfunction (VCD) / Paradoxical Vocal Fold Motion (PVFM):</strong> Abnormal adduction (closing) of vocal cords during inspiration (sometimes expiration). Presents with episodic shortness of breath, throat tightness, inspiratory stridor or wheeze, often triggered by exercise, stress, irritants. PFTs may show inspiratory loop flattening during episode. Misdiagnosed as refractory asthma. Dx: Direct visualization via laryngoscopy during symptoms is gold standard. Tx: Speech therapy (breathing techniques), managing triggers, counseling.</li>
                        <li>Others: Bronchomalacia/Tracheomalacia, GERD with aspiration, Cystic Fibrosis, PCD, Congenital heart disease, Interstitial lung disease, Bronchiolitis Obliterans.</li>
                     </ul>
                 </div>
            </details>
            <details>
                <summary>Cystic Fibrosis (CF)</summary>
                <div class="details-content">
                     <ul>
                        <li>Autosomal recessive disorder caused by mutations in the CFTR (Cystic Fibrosis Transmembrane conductance Regulator) gene on Chromosome 7. Defective CFTR protein leads to abnormal chloride and water transport across epithelial surfaces.</li>
                        <li>Results in thick, sticky mucus in multiple organs.</li>
                        <li><strong>Dx:</strong> Newborn screening (includes immunoreactive trypsinogen - IRT, +/- DNA testing). Confirmed by <strong>Sweat Chloride Test</strong> (pilocarpine iontophoresis, chloride > 60 mmol/L is diagnostic). Genetic testing identifies specific CFTR mutations.</li>
                        <li><strong>Clinical Manifestations:</strong>
                            <ul>
                                <li><strong>Pulmonary:</strong> Chronic cough, recurrent pulmonary infections (<em>S. aureus, H. influenzae</em> early; <em>P. aeruginosa</em> later; also <em>Burkholderia cepacia, S. maltophilia, NTM</em>), bronchiectasis, wheezing, digital clubbing, eventual respiratory failure. Nasal polyps, chronic sinusitis common.</li>
                                <li><strong>Gastrointestinal:</strong> Pancreatic insufficiency (in ~85%) leading to malabsorption (fat, protein), steatorrhea (fatty, foul stools), failure to thrive. Meconium ileus at birth (~15-20%). Distal intestinal obstruction syndrome (DIOS) later in life. Rectal prolapse.</li>
                                <li><strong>Hepatobiliary:</strong> Focal biliary cirrhosis, portal hypertension.</li>
                                <li><strong>Endocrine:</strong> CF-related diabetes (CFRD).</li>
                                <li><strong>Reproductive:</strong> Infertility (azoospermia due to congenital bilateral absence of the vas deferens - CBAVD in >95% males; thickened cervical mucus in females).</li>
                                <li><strong>Sweat Glands:</strong> Salty sweat (basis for sweat test).</li>
                            </ul>
                        </li>
                        <li><strong>Tx:</strong> Multidisciplinary approach. Airway clearance techniques (chest physiotherapy, vest therapy), inhaled therapies (dornase alfa/Pulmozyme - mucolytic; hypertonic saline), chronic antibiotics (inhaled tobramycin/aztreonam for Pseudomonas), treatment of exacerbations. Pancreatic enzyme replacement therapy (PERT), fat-soluble vitamin supplementation (A, D, E, K), nutritional support. **CFTR Modulator therapies** (e.g., ivacaftor, lumacaftor, tezacaftor, elexacaftor) targeted to specific mutations, significantly improve outcomes. Lung transplantation for end-stage disease.</li>
                     </ul>
                 </div>
            </details>
             <details>
                <summary>Primary Ciliary Dyskinesia (PCD)</summary>
                <div class="details-content">
                     <ul>
                        <li>Group of inherited disorders (mostly autosomal recessive) affecting structure and/or function of motile cilia. Impaired mucociliary clearance leads to chronic sinopulmonary disease.</li>
                        <li><strong>Clinical Manifestations:</strong>
                            <ul>
                                <li>Neonatal respiratory distress (in ~80% term infants).</li>
                                <li>Chronic, wet cough starting in infancy.</li>
                                <li>Chronic rhinosinusitis, nasal polyps.</li>
                                <li>Chronic otitis media with effusion, conductive hearing loss.</li>
                                <li>Recurrent pneumonia, leading to bronchiectasis.</li>
                                <li><strong>Situs Inversus Totalis</strong> (in ~50% - Kartagener Syndrome = PCD + Situs Inversus + Chronic Sinusitis + Bronchiectasis). Situs ambiguus (heterotaxy) also possible.</li>
                                <li>Infertility (immotile sperm in males, impaired fallopian tube function in females).</li>
                            </ul>
                        </li>
                        <li><strong>Dx:</strong> Often delayed. Suggestive clinical features + Low nasal nitric oxide (nNO) level (screening test) + Definitive test: Transmission electron microscopy (TEM) of ciliary biopsy showing ultrastructural defects (e.g., absent dynein arms) OR Genetic testing identifying biallelic pathogenic mutations in known PCD genes.</li>
                        <li><strong>Tx:</strong> Similar to CF airway management: regular airway clearance, prompt treatment of infections, surveillance cultures, hearing/sinus management (tympanostomy tubes, sinus surgery). No specific therapy to correct ciliary defect currently.</li>
                     </ul>
                 </div>
            </details>
             <details>
                <summary>SIDS (Sudden Infant Death Syndrome)</summary>
                <div class="details-content">
                     <ul>
                        <li>Sudden, unexpected death of an infant < 1 year of age that remains unexplained after thorough case investigation (autopsy, death scene investigation, review of clinical history).</li>
                        <li>Leading cause of post-neonatal infant mortality. Peak age 2-4 months.</li>
                        <li>Exact cause unknown, likely multifactorial (Triple Risk Model: vulnerable infant + critical developmental period + exogenous stressor).</li>
                        <li><strong>Risk Factors:</strong> Prone or side sleeping position, soft bedding/co-sleeping in unsafe manner, overheating, maternal smoking during pregnancy, prenatal substance exposure, prematurity/low birth weight, male gender, lack of prenatal care, young maternal age, poverty, recent illness.</li>
                        <li><strong>Protective Factors:</strong> Supine sleeping ("Back to Sleep"), firm sleep surface, room-sharing (without bed-sharing), breastfeeding, pacifier use at sleep time, immunizations.</li>
                        <li><strong>Prevention:</strong> Focuses on safe sleep practices.</li>
                     </ul>
                 </div>
            </details>
             <details>
                <summary>Brief Resolved Unexplained Event (BRUE)</summary>
                <div class="details-content">
                     <ul>
                        <li>Formerly Apparent Life-Threatening Event (ALTE).</li>
                        <li>Event occurring in infant < 1 year old reported by observer involving ≥1 of: cyanosis or pallor; absent, decreased, or irregular breathing; marked change in muscle tone (hyper- or hypotonia); altered level of responsiveness.</li>
                        <li>Duration typically < 1 minute (often 20-30 sec), followed by return to baseline state.</li>
                        <li>Diagnosis of exclusion after H&P rule out identifiable cause.</li>
                        <li>Categorized as Lower-Risk or Higher-Risk based on specific criteria (age >60 days, gestational age ≥32 wks and PMA ≥45 wks, first event, duration <1 min, no CPR required, no concerning Hx/PE findings).</li>
                        <li>Lower-risk BRUE: Minimal workup, education, shared decision-making about discharge.</li>
                        <li>Higher-risk BRUE: Requires admission and further investigation based on suspected underlying cause (e.g., GERD, seizure, infection, arrhythmia, airway anomaly, abuse).</li>
                        <li>BRUE itself is NOT predictive of SIDS, but underlying cause might be.</li>
                     </ul>
                 </div>
            </details>
             <details>
                <summary>Apnea</summary>
                <div class="details-content">
                     <ul>
                        <li><strong>Pathologic Apnea:</strong> Cessation of breathing > 20 seconds, OR shorter pause associated with bradycardia, cyanosis, or pallor. Needs evaluation.</li>
                        <li><strong>Apnea of Prematurity:</strong> See above.</li>
                        <li><strong>Obstructive Sleep Apnea (OSA) in Children:</strong> Repetitive partial or complete upper airway obstruction during sleep. Most common cause is adenotonsillar hypertrophy. Symptoms: snoring, restless sleep, witnessed apneas/gasping, daytime neurobehavioral issues (hyperactivity, inattention, moodiness), mouth breathing, failure to thrive (severe cases). Dx: Polysomnography (sleep study). Tx: Adenotonsillectomy is first-line. CPAP if surgery not effective/indicated.</li>
                        <li><strong>Central Apnea Syndromes:</strong>
                            <ul>
                                <li><strong>Congenital Central Hypoventilation Syndrome (CCHS):</strong> Rare genetic disorder (PHOX2B mutation). Failure of automatic respiratory control, especially during sleep (absent/blunted response to hypercapnia/hypoxia). Requires lifelong ventilatory support (tracheostomy/ventilator or BiPAP).</li>
                                <li>Secondary central apneas (e.g., due to CNS injury, drugs, neuromuscular disease).</li>
                            </ul>
                        </li>
                        <li><strong>Breath-Holding Spells:</strong> Common benign phenomenon in toddlers (6 mo - 6 yr). Triggered by anger, frustration, pain, or startle. Types:
                            <ul>
                                <li><strong>Cyanotic:</strong> Crying stops in expiration → breath hold → cyanosis → brief LOC/limpness/stiffening → spontaneous breathing resumes.</li>
                                <li><strong>Pallid:</strong> Minor injury/startle → vagal response → pallor, bradycardia, LOC/limpness → rapid recovery.</li>
                            </ul>
                            Usually outgrown. Differentiate from seizures. Reassurance is key. Iron deficiency may be associated.</li>
                     </ul>
                 </div>
            </details>
            <h3>Silly Teenagers (Inhalational Injuries)</h3>
             <details>
                <summary>E-cig vaping associated lung injury (EVALI)</summary>
                <div class="details-content"><p>Acute respiratory illness characterized by pneumonitis +/- ARDS. Strongly linked to vaping THC-containing products, particularly those with <strong>Vitamin E acetate</strong> as a diluent/thickening agent. Presents with respiratory symptoms (cough, SOB, chest pain), constitutional symptoms (fever, chills, weight loss), +/- GI symptoms. CXR/CT show bilateral opacities. Dx of exclusion. Tx: Supportive care (O2, ventilation if needed), corticosteroids often used.</p></div>
            </details>
             <details>
                <summary>Hydrocarbon inhalation</summary>
                <div class="details-content"><p>"Huffing" or inhalation abuse of volatile hydrocarbons (gasoline, solvents, aerosols, paint thinner). Causes acute lung injury (chemical pneumonitis, hemorrhagic pulmonary edema, ARDS) due to direct toxicity and surfactant destruction. Also significant systemic toxicity: CNS depression/excitation, seizures, cardiac arrhythmias ("sudden sniffing death"), hepatic/renal damage. Tx: Supportive care, decontamination (remove contaminated clothing), cardiac monitoring, manage systemic effects.</p></div>
            </details>

            <h3>Respiratory Infections in Pediatrics</h3>
            <details>
                <summary>Acute otitis media (AOM)</summary>
                <div class="details-content">
                     <ul>
                        <li>Infection of the middle ear space. Peak age 6-18 months. Often follows viral URI causing Eustachian tube dysfunction.</li>
                        <li>Common bacteria: <strong>Strep pneumoniae, Haemophilus influenzae (non-typeable), Moraxella catarrhalis</strong>. Viruses also play role.</li>
                        <li>Dx Criteria: 1) Acute onset of symptoms (ear pain/otalgia, irritability, fever); 2) Middle ear effusion (bulging TM, limited TM mobility on pneumatic otoscopy, air-fluid level, otorrhea); 3) Signs/symptoms of middle ear inflammation (distinct TM erythema, otalgia).</li>
                        <li>Tx: Pain management (acetaminophen/ibuprofen). Antibiotics vs. observation depends on age/severity/certainty.
                            <ul>
                                <li>Immediate Abx for: Age <6 mo; Age 6 mo - 2 yr with bilateral or severe AOM; Any age with severe symptoms (mod-severe otalgia, otalgia >48h, temp ≥39°C); Otorrhea.</li>
                                <li>Observation option for: Age 6 mo - 2 yr unilateral non-severe; Age ≥2 yr non-severe.</li>
                            </ul>
                            First-line Abx: <strong>High-dose Amoxicillin</strong> (80-90 mg/kg/day). Use <strong>Amoxicillin-clavulanate</strong> if amoxicillin in last 30 days, concurrent purulent conjunctivitis ("otitis-conjunctivitis syndrome" - often H. flu), or history of recurrent AOM unresponsive to amoxicillin. PCN allergy: Cefdinir, Cefuroxime, Ceftriaxone (IM); Azithromycin/Clarithromycin (less effective); Clindamycin (if concern for resistant Strep pneumo).</li>
                        <li>Complications: Mastoiditis, meningitis, facial nerve palsy, hearing loss, TM perforation, chronic suppurative OM, cholesteatoma.</li>
                        <li>Recurrent AOM (≥3 episodes in 6 mo or ≥4 in 12 mo): Consider tympanostomy tubes.</li>
                     </ul>
                 </div>
            </details>
            <details>
                <summary>Acute otitis externa (AOE – “swimmers ear")</summary>
                <div class="details-content">
                     <ul>
                        <li>Inflammation/infection of the external auditory canal (EAC). Common in swimmers, humid climates, trauma (Q-tips).</li>
                        <li>Common bacteria: <strong>Pseudomonas aeruginosa, Staphylococcus aureus</strong>. Fungi (Aspergillus, Candida) less common.</li>
                        <li>Sx: Ear pain (otalgia), itching (pruritus), discharge (otorrhea), feeling of fullness, hearing loss. Pain often exacerbated by manipulating tragus or auricle. Exam: EAC edema, erythema, debris/discharge. TM may be hard to visualize but should be mobile if seen (unless concurrent AOM).</li>
                        <li>Tx: Clean EAC (aural toilet). Topical therapy is mainstay.
                            <ul>
                                <li>Mild: Acetic acid +/- hydrocortisone drops.</li>
                                <li>Moderate/Severe: Topical antibiotic +/- steroid drops (e.g., <strong>Ciprofloxacin/dexamethasone</strong>; Neomycin/polymyxin B/hydrocortisone - avoid if TM perforation suspected due to neomycin ototoxicity; Ofloxacin).</li>
                            </ul>
                            Wick placement if canal severely swollen. Oral antibiotics generally not needed unless extension beyond canal (cellulitis) or immunocompromise. Pain control. Keep ear dry.</li>
                     </ul>
                 </div>
            </details>
            <details>
                <summary>Croup (Laryngotracheobronchitis)</summary>
                <div class="details-content">
                     <ul>
                        <li>Viral infection causing inflammation and narrowing of the larynx and subglottic airway. Most common cause of infectious upper airway obstruction in children 6 months - 3 years.</li>
                        <li>Common virus: <strong>Parainfluenza virus</strong> (types 1, 2, 3). Others: RSV, influenza, adenovirus, rhinovirus, measles.</li>
                        <li>Sx: Prodrome of URI symptoms (runny nose, low fever) followed by characteristic triad: <strong>inspiratory stridor</strong>, <strong>barking cough</strong> ("seal bark"), and <strong>hoarseness</strong>. Symptoms often worse at night, may improve with cool air.</li>
                        <li>Dx: Clinical. Severity assessed using scoring systems (e.g., Westley Croup Score). Lateral neck X-ray (optional, if diagnosis uncertain) may show subglottic narrowing ("<strong>steeple sign</strong>").</li>
                        <li>Tx (Based on severity):
                            <ul>
                                <li>Mild (no stridor at rest): Supportive care (cool mist, fluids), single dose oral dexamethasone often given.</li>
                                <li>Moderate (stridor at rest, mild/mod retractions): Single dose <strong>Dexamethasone</strong> (oral, IM, or IV) + Nebulized <strong>Epinephrine</strong> (racemic or L-epi). Observe for ≥3-4 hours after epi for rebound.</li>
                                <li>Severe (significant stridor/retractions at rest, agitation, decreased air entry): Dexamethasone + Nebulized Epinephrine + Supplemental O2. Admit to hospital. Consider Heliox if severe.</li>
                            </ul>
                     </ul>
                 </div>
            </details>
             <details>
                <summary>Epiglottitis</summary>
                <div class="details-content">
                     <ul>
                        <li>Bacterial infection causing inflammation and massive swelling of the epiglottis and supraglottic structures. <strong>Life-threatening airway emergency.</strong> Incidence dramatically decreased due to Hib vaccine, but still occurs (un/under-immunized, other bacteria, adults).</li>
                        <li>Common bacteria: Historically <strong>Haemophilus influenzae type b (Hib)</strong>. Now more often Group A Strep, Strep pneumo, Staph aureus.</li>
                        <li>Sx: Rapid onset (hours) of high fever, severe sore throat, dysphagia, <strong>drooling</strong>, muffled voice ("hot potato voice"), anxiety, preference for <strong>tripod position</strong> (sitting up, leaning forward, neck extended). Inspiratory stridor is a LATE sign indicating critical airway narrowing.</li>
                        <li>Dx: Clinical suspicion is key. **DO NOT attempt to visualize pharynx/epiglottis with tongue depressor or any instrument outside a controlled setting (OR)** - can precipitate complete airway obstruction. If stable enough for imaging, lateral neck X-ray may show enlarged epiglottis ("<strong>thumb sign</strong>"). Definitive diagnosis by direct visualization (laryngoscopy) during intubation.</li>
                        <li>Tx: Immediate airway management is priority! Secure airway via endotracheal intubation (usually in OR by experienced personnel). IV antibiotics (e.g., <strong>Ceftriaxone</strong> or Cefotaxime +/- Vancomycin if MRSA suspected). Keep child calm, avoid agitation.</li>
                     </ul>
                 </div>
            </details>
            <details>
                <summary>Strep throat (Group A Strep Pharyngitis)</summary>
                <div class="details-content">
                     <ul>
                        <li>Bacterial pharyngitis caused by <strong>Streptococcus pyogenes</strong> (Group A Beta-Hemolytic Streptococcus - GABHS or GAS). Peak age 5-15 years.</li>
                        <li>Sx: Sudden onset sore throat, fever, headache, nausea/vomiting/abdominal pain (esp. younger kids). Exam: pharyngeal erythema, tonsillar exudates, palatal petechiae, tender anterior cervical lymphadenopathy. Often **lacks** cough, rhinorrhea, conjunctivitis, diarrhea (helps distinguish from viral).</li>
                        <li>Dx: Clinical suspicion using Centor criteria (or modified McIsaac criteria including age). Confirmation required:
                            <ul>
                                <li><strong>Rapid Antigen Detection Test (RADT):</strong> High specificity, variable sensitivity.</li>
                                <li><strong>Throat Culture:</strong> Gold standard. Recommended if RADT negative in children/adolescents (due to risk of rheumatic fever). Not needed if RADT negative in adults.</li>
                            </ul>
                        </li>
                        <li>Tx: Antibiotics primarily to prevent acute rheumatic fever (ARF), also shorten symptom duration slightly and reduce transmission.
                            <ul>
                                <li>First-line: <strong>Penicillin V</strong> (oral) or <strong>Amoxicillin</strong> (oral, often preferred for taste/dosing) x 10 days. Benzathine Penicillin G (IM single dose) option if adherence concern.</li>
                                <li>PCN Allergy: Cephalexin/Cefadroxil (if non-anaphylactic allergy). Clindamycin or Macrolides (<strong>Azithromycin</strong> x 5 days, Clarithromycin x 10 days) if severe/anaphylactic PCN allergy (check local resistance patterns for macrolides).</li>
                            </ul>
                            Return to school/daycare after 24h of antibiotics.</li>
                        <li>Complications: Suppurative (peritonsillar abscess, retropharyngeal abscess, otitis media, sinusitis). Non-suppurative (Acute Rheumatic Fever - preventable with timely abx; Post-Streptococcal Glomerulonephritis - not preventable with abx). Scarlet fever (rash associated with GAS toxin). PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections).</li>
                     </ul>
                 </div>
            </details>
             <details>
                <summary>Sinusitis (Pediatric)</summary>
                <div class="details-content">
                     <ul>
                        <li>Inflammation of paranasal sinuses. Often follows viral URI. Ethmoid/maxillary sinuses present early, sphenoid/frontal develop later.</li>
                        <li>Dx of Acute Bacterial Rhinosinusitis (ABRS) based on clinical course (see criteria under Hoarseness/Sinusitis section: persistent ≥10d, severe onset ≥3d, or worsening/"double sickening").</li>
                        <li>Symptoms: Persistent nasal discharge (any quality), persistent daytime cough (often worse at night), +/- fever, facial pain/pressure (less reliable in young children), headache, halitosis.</li>
                        <li>Tx: Similar to adults. First-line: <strong>Amoxicillin</strong> or <strong>Amoxicillin-clavulanate</strong>. High-dose recommended if risk factors for resistance. Duration 10-14 days.</li>
                        <li>Complications (rare but serious): Orbital cellulitis (preseptal/postseptal), subperiosteal abscess, cavernous sinus thrombosis, meningitis, epidural/subdural abscess, brain abscess, Pott's puffy tumor (frontal osteomyelitis).</li>
                     </ul>
                 </div>
            </details>
             <details>
                <summary>Pneumonia (Pediatric)</summary>
                <div class="details-content">
                     <ul>
                        <li>Lower respiratory tract infection involving lung parenchyma.</li>
                        <li>Etiology varies by age:
                            <ul>
                                <li>Neonates (<1 mo): Group B Strep, E. coli, Listeria, Klebsiella, Chlamydia trachomatis (afebrile, staccato cough), viruses (RSV, HSV).</li>
                                <li>Infants/Young Children (1 mo - 5 yr): <strong>Viruses</strong> most common (RSV, influenza, parainfluenza, adenovirus, metapneumovirus). Bacterial: <strong>Strep pneumoniae</strong>, H. influenzae (NTHi), Staph aureus.</li>
                                <li>Older Children/Adolescents (>5 yr): <strong>Mycoplasma pneumoniae</strong> and <strong>Chlamydia pneumoniae</strong> ("atypicals") become more common, along with Strep pneumoniae. Viruses still common.</li>
                            </ul>
                        </li>
                        <li>Sx: Fever, cough, tachypnea (key sign), increased work of breathing (retractions, nasal flaring, grunting), abnormal lung sounds (crackles/rales, rhonchi, decreased breath sounds), chest pain, abdominal pain.</li>
                        <li>Dx: Clinical. CXR often obtained for hospitalized patients or if diagnosis uncertain/severe: Lobar consolidation suggests typical bacterial (esp. S. pneumo); Bilateral interstitial infiltrates suggest viral or atypical. Blood cultures rarely positive unless severe/bacteremic. Sputum culture difficult in young children.</li>
                        <li>Tx:
                            <ul>
                                <li>Viral: Supportive care (O2, fluids, antipyretics). Oseltamivir if influenza suspected/confirmed within 48h.</li>
                                <li>Bacterial (suspected outpatient): <strong>Amoxicillin</strong> (high dose) first-line for typical bacterial CAP. Macrolide (e.g., <strong>Azithromycin</strong>) if atypical pneumonia suspected (e.g., >5 yrs old, less acute onset, interstitial pattern).</li>
                                <li>Bacterial (suspected inpatient): Ampicillin or Penicillin G (if susceptible S. pneumo). Ceftriaxone or Cefotaxime often used empirically. Add Macrolide if atypical suspected. Add Vancomycin or Clindamycin if MRSA suspected (e.g., severe necrotizing pneumonia, post-influenza).</li>
                            </ul>
                        </li>
                        <li><strong>Acute Chest Syndrome (in Sickle Cell Disease):</strong> Medical emergency. New pulmonary infiltrate on CXR + fever and/or respiratory symptoms (cough, tachypnea, chest pain, hypoxia). Causes: Vaso-occlusion, infection, fat embolism. Tx: Supportive care (O2, fluids, pain control), broad-spectrum antibiotics (covering typicals + atypicals, e.g., Ceftriaxone + Azithromycin), simple or exchange transfusion.</li>
                     </ul>
                 </div>
            </details>
            <details>
                <summary>Bronchiolitis</summary>
                <div class="details-content">
                     <ul>
                        <li>Viral lower respiratory tract infection causing inflammation and obstruction of small airways (bronchioles). Typically affects infants and children < 2 years old, peak age 2-6 months. Seasonal (winter/spring).</li>
                        <li>Common virus: <strong>Respiratory Syncytial Virus (RSV)</strong> (~50-80%). Others: Rhinovirus, metapneumovirus, influenza, parainfluenza, adenovirus, coronavirus.</li>
                        <li>Sx: Starts with URI prodrome (runny nose, cough, low fever) for 1-3 days, then progresses to lower respiratory symptoms: tachypnea, prominent <strong>wheezing</strong> (often diffuse, expiratory > inspiratory), cough, increased work of breathing (retractions, nasal flaring), irritability, feeding difficulties. Apnea can occur, especially in young infants/preemies.</li>
                        <li>Dx: Clinical, based on age and typical symptoms/signs during appropriate season. Viral testing (e.g., rapid RSV antigen) often done but doesn't usually change management. CXR (if done) typically shows hyperinflation, peribronchial thickening/cuffing, atelectasis (variable).</li>
                        <li>Tx: Primarily <strong>supportive care</strong>. Key is maintaining hydration and oxygenation.
                            <ul>
                                <li>Nasal suctioning (bulb syringe or deeper suction) before feeds/sleep to clear secretions.</li>
                                <li>Supplemental oxygen if SpO2 < 90-92%. High-flow nasal cannula (HFNC) may be used for moderate/severe distress.</li>
                                <li>IV fluids if poor oral intake.</li>
                                <li><strong>Routine use of bronchodilators (Albuterol) is NOT recommended</strong> (lack of proven benefit). Trial may be considered in select infants with history suggesting underlying asthma, discontinued if no response.</li>
                                <li>Corticosteroids NOT recommended. Antibiotics only if bacterial co-infection suspected.</li>
                            </ul>
                            Hospitalization if: respiratory distress, hypoxia, apnea, inability to maintain hydration.</li>
                        <li>Prevention: Handwashing. Palivizumab (Synagis) - monoclonal antibody against RSV, given monthly during RSV season to high-risk infants (severe prematurity, chronic lung disease, congenital heart disease) to reduce severity/hospitalization.</li>
                     </ul>
                 </div>
            </details>
            <details>
                <summary>Pertussis (Whooping Cough)</summary>
                <div class="details-content">
                     <ul>
                        <li>Highly contagious respiratory infection caused by bacterium <em>Bordetella pertussis</em>. Preventable by DTaP/Tdap vaccines, but immunity wanes. Infants < 6 months are at highest risk for severe disease/death.</li>
                        <li>Transmission via respiratory droplets.</li>
                        <li>Classic Stages:
                            <ul>
                                <li><strong>Catarrhal Stage (1-2 weeks):</strong> Insidious onset, resembles common cold (rhinorrhea, mild cough, low fever). **Most contagious period**.</li>
                                <li><strong>Paroxysmal Stage (2-8 weeks):</strong> Cough becomes severe and occurs in bursts (paroxysms). Multiple rapid coughs followed by forceful inspiratory effort against a narrowed glottis, causing characteristic "whoop" (may be absent in infants/adults). Post-tussive emesis and exhaustion common. Apnea is common and dangerous in infants.</li>
                                <li><strong>Convalescent Stage (weeks-months):</strong> Gradual resolution of cough, though paroxysms may recur with subsequent URIs.</li>
                            </ul>
                        </li>
                        <li>Dx: Clinical suspicion based on cough characteristics. Confirmation via PCR or culture of nasopharyngeal swab/aspirate (highest yield in first 2-3 weeks). Marked lymphocytosis often present but not specific.</li>
                        <li>Tx: Supportive care (O2, hydration, nutrition). **Antibiotics** primarily to decrease infectivity/transmission (may lessen severity only if started early in catarrhal stage).
                            <ul>
                                <li>Drug of choice: <strong>Macrolides</strong> (<strong>Azithromycin</strong> preferred, especially infants <1mo; Clarithromycin; Erythromycin).</li>
                                <li>Alternative: TMP-SMX (if >2 mo and macrolide intolerant/allergic).</li>
                            </ul>
                            Hospitalization often required for infants < 3-6 months due to risk of apnea, cyanosis, feeding difficulties. Droplet precautions. **Post-exposure prophylaxis** with antibiotics recommended for close contacts (household, childcare).</li>
                     </ul>
                 </div>
            </details>
             <details>
                <summary>Abscess (Pediatric Head/Neck)</summary>
                <div class="details-content">
                     <ul>
                        <li><strong>Retropharyngeal Abscess (RPA):</strong> Infection/pus collection in the potential space behind the pharynx, anterior to prevertebral fascia. Usually occurs in children < 6 years (retropharyngeal nodes regress with age). Often follows URI, pharyngitis, otitis media, or penetrating trauma. Polymicrobial (GAS, S. aureus, anaerobes, H. flu).
                            <ul>
                                <li>Sx: Fever, sore throat, dysphagia, odynophagia, neck stiffness/torticollis, muffled voice ("hot potato"), drooling, stridor/respiratory distress if airway compressed.</li>
                                <li>Dx: Lateral neck X-ray may show widened prevertebral space (> half vertebral body width at C2, > full width at C6). <strong>CT scan with contrast</strong> is preferred imaging to confirm abscess and extent.</li>
                                <li>Tx: Airway management crucial. IV antibiotics (e.g., Ampicillin-sulbactam or Clindamycin +/- Vancomycin). Surgical drainage (incision & drainage - I&D) usually required.</li>
                            </ul>
                        </li>
                        <li><strong>Peritonsillar Abscess (PTA) / Quinsy:</strong> Collection of pus between tonsillar capsule and superior constrictor muscle. Most common deep neck infection, typically occurs in adolescents/young adults (rare < 8-10 yrs). Often complication of tonsillitis. Polymicrobial (GAS, Fusobacterium, other anaerobes).
                            <ul>
                                <li>Sx: Severe unilateral sore throat, fever, muffled "hot potato" voice, trismus (difficulty opening mouth), drooling, ipsilateral ear pain. Exam: Unilateral tonsillar swelling/bulging, uvular deviation *away* from affected side.</li>
                                <li>Dx: Clinical diagnosis usually sufficient. Ultrasound or CT can confirm if needed.</li>
                                <li>Tx: Drainage (needle aspiration or I&D) + Antibiotics (e.g., Amoxicillin-clavulanate or Clindamycin). IV hydration/pain control often needed initially. Tonsillectomy may be considered for recurrent PTA.</li>
                            </ul>
                        </li>
                     </ul>
                 </div>
            </details>

            <h3>Pediatric Case Studies</h3>
            <div class="case-study">
                <p class="case-title">Case 1 (Peds):</p>
                <p>26 yo G3P2 woman undergoes standard anatomy US at 20 weeks gestation. Cystic lesion noted to be connected to the lung.</p>
                <details>
                    <summary>What does this lesion most likely represent?</summary>
                    <div class="details-content">
                        <ul>
                            <li>Bronchogenic cyst: Usually NOT connected to airway, fluid-filled.</li>
                            <li>Congenital lobar emphysema (CLE): Hyperinflated lobe, not typically described as cystic lesion connected to lung on prenatal US.</li>
                            <li><strong>Congenital pulmonary airway malformation (CPAM): Most common congenital lung lesion, can be cystic, solid, or mixed, arises from airway.</strong></li>
                            <li>Cystic fibrosis: Systemic disease, not a focal lesion.</li>
                            <li>Pulmonary sequestration: Lung tissue NOT connected to airway, has systemic blood supply.</li>
                        </ul>
                    </div>
                </details>
            </div>
             <div class="case-study">
                <p class="case-title">Case 2 (Peds):</p>
                <p>7 yo previously healthy child with cough for the last week. Low-grade temp. hoarse cough. Chest x-ray shows air bronchograms.</p>
                 <details>
                    <summary>What is the most likely etiology?</summary>
                    <div class="details-content">
                         <ul>
                            <li>Chlamydia trachomatis (Neonatal pneumonia - afebrile, staccato cough).</li>
                            <li><strong>Mycoplasma pneumoniae: Common cause of atypical/"walking" pneumonia in school-aged children (>5 yrs). Gradual onset, low fever, persistent cough, wheezing possible. CXR often shows interstitial or patchy infiltrates (air bronchograms can be seen but less classic than lobar).</strong></li>
                            <li>RSV (Bronchiolitis, usually younger kids <2, prominent wheeze).</li>
                            <li>Staph aureus (More severe, consolidation/abscess/pneumatoceles).</li>
                            <li>Strep pneumoniae (Typical lobar pneumonia, higher fever, more acute onset).</li>
                        </ul>
                    </div>
                </details>
                 <details>
                    <summary>Best treatment?</summary>
                    <div class="details-content"><p><strong>Macrolide: Azithromycin</strong> (or Doxycycline/Levofloxacin in older children/adolescents).</p></div>
                </details>
            </div>
             <div class="case-study">
                <p class="case-title">Case 3 (Peds):</p>
                <p>4 yo with cough, congestion, fever up to 103.5 F (39.7 C) x 3 days, labored fast breathing with rales, crackles over right mid-lung field.</p>
                 <details>
                    <summary>What is the most likely etiology of this child's presentation?</summary>
                    <div class="details-content">
                         <ul>
                            <li>Chlamydia trachomatis (Neonatal).</li>
                            <li>Mycoplasma pneumoniae (Usually older kids, less acute/high fever).</li>
                            <li>RSV (Bronchiolitis picture, wheezing, younger usually).</li>
                            <li>Staph aureus (Possible, but S. pneumo more common for lobar CAP).</li>
                            <li><strong>Strep pneumoniae: Classic presentation for typical bacterial lobar pneumonia (high fever, focal lung findings - crackles, tachypnea, labored breathing). Most common bacterial cause in this age group.</strong></li>
                         </ul>
                         <p>Tx: High-dose <strong>Amoxicillin</strong> outpatient, or Ampicillin/Ceftriaxone inpatient.</p>
                     </div>
                 </details>
            </div>
            <div class="case-study">
                <p class="case-title">Case 4 (Peds):</p>
                <p>3 yo unimmunized child with 3-day history of high fever of 105.6 F (40.9 C), one day history of refusal to eat or drink. Refuses to lay down, mom thought was teething due to drool, but now has excessive drooling.</p>
                 <details>
                    <summary>What finding would you expect to find on x-ray?</summary>
                    <div class="details-content">
                         <p>Presentation highly suspicious for <strong>Epiglottitis</strong> (rapid onset, high fever, drooling, refusal to lie down - tripod posture implied).</p>
                         <ul>
                            <li>Air crescent sign (Aspergilloma).</li>
                            <li>Lightbulb sign (Posterior shoulder dislocation).</li>
                            <li>Sail sign (Normal thymus in infant CXR).</li>
                            <li>Steeple sign (Croup - subglottic narrowing).</li>
                            <li><strong>Thumb sign: Enlarged, swollen epiglottis seen on lateral neck X-ray. Likely Hib in unimmunized child.</strong></li>
                         </ul>
                     </div>
                 </details>
                 <details>
                    <summary>Best next step in management?</summary>
                    <div class="details-content">
                         <p><strong>Airway Emergency!</strong></p>
                         <ul>
                            <li>CT scan (Delay, unnecessary).</li>
                            <li>High-flow O2 (Supportive, but doesn't secure airway).</li>
                            <li>I&D (Not relevant).</li>
                            <li><strong>Intubation: Secure the airway immediately in a controlled setting (OR) by experienced personnel (Anesthesia/ENT).</strong></li>
                            <li>IV antibiotics (Crucial, but AFTER airway secured - e.g., Ceftriaxone +/- Vanc).</li>
                         </ul>
                     </div>
                 </details>
                  <details>
                    <summary>If patient IS immunized → what else to worry about?</summary>
                    <div class="details-content"><p>If Hib immunized, bacterial epiglottitis still possible (Strep, Staph). Also consider Retropharyngeal Abscess (RPA) - presents similarly with fever, sore throat, dysphagia, drooling, neck stiffness/torticollis. Peritonsillar abscess less common at this age. Severe viral pharyngitis/tonsillitis less likely to cause this acute distress/drooling picture.</p></div>
                </details>
            </div>
             <div class="case-study">
                <p class="case-title">Case 5 (Peds):</p>
                <p>15-months with barky cough and noisy breathing, worse at night, overall worsening in last 2-3 days. Low grade fever of 100.5 F (38.1 C).</p>
                  <details>
                    <summary>Most likely etiology?</summary>
                    <div class="details-content"><p>Classic presentation for <strong>Croup</strong> (Laryngotracheobronchitis). Most likely agent: <strong>Parainfluenza</strong> virus.</p></div>
                </details>
                 <details>
                    <summary>Management?</summary>
                    <div class="details-content"><p>Depends on severity. If mild (no stridor at rest): Supportive care (cool mist, fluids), maybe single dose dexamethasone. If moderate/severe (stridor at rest): Single dose <strong>Dexamethasone</strong> + Nebulized <strong>Racemic Epinephrine</strong> + Observation.</p></div>
                </details>
                 <details>
                    <summary>Clues?</summary>
                    <div class="details-content">
                         <ul>
                            <li>Age: Peak 6 months - 3 years.</li>
                            <li>Symptoms: Barky cough, inspiratory stridor, hoarseness. Worse at night.</li>
                            <li>Often preceded by URI symptoms.</li>
                            <li>May improve with cool air exposure.</li>
                            <li>X-ray (if done): Steeple sign (subglottic narrowing).</li>
                         </ul>
                     </div>
                 </details>
            </div>
             <div class="case-study">
                <p class="case-title">Case 6 (Peds):</p>
                <p>21-month-old previously healthy male, brought to clinic by his parents turning blue with crying and possible seizures. Posture of his body changes.</p>
                 <details>
                    <summary>Best next step in his management?</summary>
                    <div class="details-content">
                         <p>Description classic for a cyanotic <strong>Breath-Holding Spell</strong>.</p>
                         <ul>
                            <li>Chest x-ray (Unnecessary).</li>
                            <li>Echocardiogram (Only if cardiac cause suspected, unlikely here).</li>
                            <li>Pulse ox (Useful during event if possible, but diagnosis is clinical).</li>
                            <li><strong>Reassurance: Explain benign nature to parents. Check CBC for iron deficiency (associated). Rule out seizure if atypical features.</strong></li>
                         </ul>
                     </div>
                 </details>
            </div>
             <div class="case-study">
                <p class="case-title">Case 7 (Peds):</p>
                <p>9-month-old female with 2-day history of worsening cough, congestion, “wheezing". Today, was breathing "really hard" so mom wanted to get her checked out. Lots of nasal discharge. Afebrile, P 160, O2 is 92%. All signs of respiratory distress and accessory muscle use. Attends day-care, fully immunized, worsening with decreased oral intake. T-max 100.4 F (38 C). Copious rhinorrhea.</p>
                 <details>
                    <summary>Most likely underlying cause?</summary>
                    <div class="details-content">
                         <p>Classic presentation of <strong>Bronchiolitis</strong>.</p>
                         <ul>
                            <li>Aspirated foreign body (Less likely diffuse wheeze/rhinorrhea).</li>
                            <li>Inappropriate smooth muscle contraction of the airways (Asthma - less common this age, usually more focal/recurrent pattern).</li>
                            <li>Infection within lung parenchyma (Pneumonia - less likely prominent wheeze/copious rhinorrhea).</li>
                            <li><strong>Mucus and debris within the airways: Inflammation and necrosis of bronchiolar epithelium lead to mucus plugging and obstruction.</strong></li>
                         </ul>
                     </div>
                 </details>
                 <details>
                    <summary>Most likely agent?</summary>
                    <div class="details-content">
                         <p><strong>RSV</strong> is the most common cause.</p>
                         <p>Management: Supportive care (nasal suctioning, hydration, O2 if SpO2 <90-92%). Admit if hypoxic, dehydrated, or significant respiratory distress. No routine role for bronchodilators or steroids.</p>
                     </div>
                 </details>
            </div>
             <div class="case-study">
                <p class="case-title">Case 8 (Peds):</p>
                <p>5-month-old female with worsening cough over last weeks. Struggling to breathe with coughing.</p>
                 <details>
                    <summary>Best next step in management?</summary>
                    <div class="details-content">
                         <p>Suspicious for <strong>Pertussis</strong> given age and worsening paroxysmal cough (struggling to breathe with cough).</p>
                         <ul>
                            <li>Admit to hospital (Infants <6mo often require admission due to risk of apnea/severity).</li>
                            <li>Prepare for SI (Severe Increased work of breathing/apnea might require intubation - Monitor closely).</li>
                            <li>Start amoxicillin (Ineffective).</li>
                            <li><strong>Start azithromycin: Treat patient to reduce transmission (even if late in course) and treat close contacts prophylactically.</strong></li>
                            <li>Supportive care (Essential: O2, hydration, monitoring for apnea/bradycardia).</li>
                         </ul>
                     </div>
                 </details>
            </div>
             <div class="case-study">
                <p class="case-title">Case 9 (Peds):</p>
                <p>2 yo female, chief complaint of ear pain, mom states fever got up to 103.5 F (39.7 C), child has been fussy, she's had a cold for the last week but seemed like she was getting better, PE is significant for ill-appearing child, febrile, tachycardic, and mild rhinorrhea. Lungs are CTAB finds on otoscopy are shown (Implied bulging, erythematous TM).</p>
                 <details>
                    <summary>What is the most likely underlying etiology for this patient's symptoms?</summary>
                    <div class="details-content">
                         <p>Classic presentation of <strong>Acute Otitis Media (AOM)</strong>.</p>
                         <ul>
                            <li>Candida albicans (Thrush).</li>
                            <li>Human metapneumovirus (Could cause preceding URI).</li>
                            <li>Staph aureus (Possible, less common).</li>
                            <li><strong>Strep pneumo: Most common bacterial cause of AOM.</strong> (H. flu, M. cat also common).</li>
                         </ul>
                         <p>Tx: High-dose <strong>Amoxicillin</strong> (or Amox-clav if risk factors).</p>
                     </div>
                 </details>
            </div>
            <div class="case-study">
                <p class="case-title">Case 10 (Peds):</p>
                <p>9 month old female born full-term to 28 yo G2P2. Discharged home after 24 hours, Vaccines up to date, growth is excellent, noisy breathing. Three prior episodes of pneumonia, 5 AOM 1 sinusitis requiring abx.</p>
                 <details>
                    <summary>What is best next diagnostic step?</summary>
                    <div class="details-content">
                         <p>Recurrent sinopulmonary infections + noisy breathing (stridor/wheeze?) in infant raises suspicion for underlying issue affecting clearance or immunity.</p>
                         <ul>
                            <li>IgG and IgE levels (Immunodeficiency/Allergy workup - possible, but PCD fits better).</li>
                            <li><strong>Nasal ciliary biopsy / Nasal Nitric Oxide: Screens for Primary Ciliary Dyskinesia (PCD).</strong></li>
                            <li>Respiratory viral panels (Unlikely to explain chronic/recurrent pattern).</li>
                            <li>Sweat chloride testing: Consider CF, but excellent growth makes it less likely than PCD initially.</li>
                            <li>Vitamin D level (Irrelevant).</li>
                         </ul>
                     </div>
                 </details>
                 <details>
                    <summary>Biopsy returned abnormal dynein arms of cilia. What other associated abnormalities else should be considered?</summary>
                    <div class="details-content">
                         <p>PCD is associated with defects in embryologic rotation.</p>
                         <ul>
                            <li>Clinodactyly (Not associated).</li>
                            <li>Early onset blindness (Not associated).</li>
                            <li>Fanconi syndrome (Not associated).</li>
                            <li><strong>Heterotaxy syndrome: Abnormal arrangement of thoracic/abdominal organs, including situs inversus (~50%), situs ambiguus.</strong></li>
                            <li>Prune belly syndrome (Not associated).</li>
                         </ul>
                         <p>Kartagener Syndrome = PCD + Situs Inversus + Chronic Sinusitis + Bronchiectasis.</p>
                     </div>
                 </details>
            </div>
             <div class="case-study">
                <p class="case-title">Case 11 (Peds):</p>
                <p>9-month-old born full term; baby did not pass stool until 64 hours of life. Vaccines up to date, sluggish, not growing well, 3 prior episodes of pneumonia, 5 AOM.</p>
                  <details>
                    <summary>Best next diagnostic step?</summary>
                    <div class="details-content">
                         <p>Failure to thrive + delayed meconium passage (suggests meconium ileus equivalent) + recurrent sinopulmonary infections = highly suspicious for <strong>Cystic Fibrosis (CF)</strong>.</p>
                         <ul>
                            <li>IgG and IgE levels (Less likely).</li>
                            <li>Nasal ciliary biopsy (Consider if CF negative).</li>
                            <li>Respiratory viral panels (Less likely).</li>
                            <li><strong>Sweat chloride testing: Gold standard for diagnosing CF.</strong></li>
                            <li>Vitamin D level (May be low due to malabsorption in CF, but not diagnostic).</li>
                         </ul>
                     </div>
                 </details>
                 <details>
                    <summary>At age 5, same patient has worsening cough, fever, increased secretions over last 2 days. Family went out of town and forgot his chest physiotherapy vest. Assisted sputum culture: encapsulated strictly anaerobic rod with single flagella. Next step?</summary>
                    <div class="details-content">
                         <p>This describes a <strong>CF Pulmonary Exacerbation</strong>. The culture result ("encapsulated strictly anaerobic rod") is highly unusual for CF (typically Pseudomonas, Staph, H. flu, Burkholderia, etc.) and may be erroneous or represent a co-pathogen. However, management is based on treating the exacerbation.</p>
                         <p>Requires hospitalization and IV antibiotics targeting likely CF pathogens (especially Pseudomonas).</p>
                         <ul>
                            <li>Initiate inhaled tobramycin (Part of chronic management or exacerbation, but IV needed).</li>
                            <li>Initiate oral levofloxacin (May have role, but IV usually preferred for exacerbation).</li>
                            <li><strong>Initiate IV levofloxacin AND likely another anti-pseudomonal IV agent (e.g., Piperacillin-Tazobactam, Ceftazidime, Meropenem) based on previous sensitivities. Intensify airway clearance.</strong> (IV Levo alone is insufficient coverage typically).</li>
                            <li>Initiate a combination of all the above (IV + inhaled often used, oral less common during acute IV phase).</li>
                         </ul>
                         <p><em>Rationale provided in original text points to IV Levo as the answer, implying it's sufficient, but standard practice often involves two IV agents for Pseudomonas coverage in CF exacerbations.</em></p>
                     </div>
                 </details>
            </div>
             <div class="case-study">
                <p class="case-title">Case 12 (Peds):</p>
                <p>Previously healthy 3 yo male with mom cc “wheezing' starting abruptly a couple of days ago. No URI sx, no signs of allergy, no change in activity level. Fixed point respiratory wheeze in right mid lung field.</p>
                 <details>
                    <summary>Best next step?</summary>
                    <div class="details-content">
                         <p>Sudden onset focal wheeze in a toddler is highly suspicious for <strong>Foreign Body Aspiration</strong>.</p>
                         <ul>
                            <li><strong>Chest x-ray (inspiratory and expiratory views, or bilateral decubitus): Look for radiopaque object, unilateral hyperinflation (air trapping), atelectasis, mediastinal shift.</strong></li>
                            <li>Short burst of oral steroid (Not indicated).</li>
                            <li>Supportive care (Insufficient).</li>
                            <li>Trial of albuterol (May provide temporary relief if inflammation present, but doesn't address obstruction).</li>
                            <li>Trial of albuterol + ipratropium bromide (Same as above).</li>
                         </ul>
                     </div>
                 </details>
                 <details>
                    <summary>Best next step after x-ray (assuming XR suggestive or high clinical suspicion persists)?</summary>
                    <div class="details-content">
                         <ul>
                            <li>Direct admit to hospital for IV abx (No sign of infection).</li>
                            <li>Referral to cardiothoracic surg for needle decomp (No sign of tension pneumo).</li>
                            <li>Referral to ED for airway support (Only if acutely unstable).</li>
                            <li><strong>Referral to pulmonology/ENT for rigid bronchoscopy: Gold standard for diagnosis and removal of airway foreign body.</strong></li>
                         </ul>
                         <p class="mt-1 text-[--text-secondary] italic">Note: Vascular ring can compress trachea alone, or trachea/esophagus → important differential for wheezing (but usually presents earlier/more chronically).</p>
                     </div>
                 </details>
            </div>
             <div class="case-study">
                <p class="case-title">Case 13 (Peds):</p>
                <p>16 yo female with worsening wheeze and exercise intolerance during softball. Always healthy and active, does good in school. Urgent care in a few weeks go with bronchodilator and steroids with no improvement. PFT curve shows variable extra-thoracic obstruction (inspiratory loop flattening).</p>
                 <details>
                    <summary>Most likely diagnosis?</summary>
                    <div class="details-content">
                         <p>Symptoms triggered by exercise, lack of response to asthma meds, and PFT finding of inspiratory loop flattening point towards <strong>Vocal Cord Dysfunction (VCD) / Paradoxical Vocal Fold Motion (PVFM)</strong>.</p>
                         <ul>
                            <li>Allergic rhinitis (Doesn't fit).</li>
                            <li>Foreign body aspiration (Unlikely this age/presentation).</li>
                            <li>New-onset asthma (Possible, but lack of response to tx and PFT pattern less typical).</li>
                            <li>Vascular ring (Fixed obstruction, usually earlier onset).</li>
                            <li><strong>Vocal cord dysfunction (VCD).</strong></li>
                         </ul>
                         <p>Tx: Speech therapy (breathing exercises), manage triggers.</p>
                     </div>
                 </details>
            </div>
             <div class="case-study">
                <p class="case-title">Case 14 (Peds):</p>
                <p>4 yo male with 2 month history of night time cough and progressing worsening exercise tolerance. Takes frequent breaks when running. Scattered expiratory wheeze. O2 is 92%.</p>
                  <details>
                    <summary>Best next step?</summary>
                    <div class="details-content">
                         <p>Presentation suggestive of asthma, patient is hypoxic.</p>
                         <ul>
                            <li>Chest x-ray (Reasonable for first presentation of wheeze, especially with hypoxia, but immediate treatment needed).</li>
                            <li>Short burst of oral steroid (Will be needed, but acute bronchodilation first).</li>
                            <li>Supportive care (Insufficient).</li>
                            <li><strong>Trial of albuterol: Immediate treatment for wheezing and hypoxia. Assess response.</strong></li>
                            <li>Trial of albuterol + ipratropium bromide (Also reasonable, often used together in acute setting).</li>
                         </ul>
                     </div>
                 </details>
                 <details>
                    <summary>Chest x-ray is normal. Diagnosis?</summary>
                    <div class="details-content"><p>Given symptoms (night cough, exercise limitation, wheeze) and response to albuterol (implied from previous step), likely <strong>Asthma</strong>.</p></div>
                 </details>
                 <details>
                    <summary>Patient given albuterol. Using daily, waking up at night. How would you classify?</summary>
                    <div class="details-content">
                         <p>Based on NHLBI/GINA guidelines (simplified):</p>
                         <ul>
                            <li>Intermittent (Sx ≤2 days/wk, Night awakenings ≤2x/mo, SABA use ≤2 days/wk).</li>
                            <li>Mild persistent (Sx >2 days/wk but not daily, Night 3-4x/mo, SABA >2 days/wk but not daily).</li>
                            <li><strong>Moderate persistent: Symptoms Daily, Night awakenings >1x/week but not nightly, SABA use Daily. (Fits description).</strong></li>
                            <li>Severe persistent (Sx Throughout day, Night Often 7x/wk, SABA Several times per day).</li>
                         </ul>
                     </div>
                 </details>
                 <details>
                    <summary>Best adjustment to his therapy?</summary>
                    <div class="details-content">
                         <p>Needs controller therapy for moderate persistent asthma.</p>
                         <ul>
                            <li>Continue current management (Insufficient).</li>
                            <li>Add low-dose ICS (Step 2 therapy - for Mild Persistent).</li>
                            <li><strong>Add medium dose ICS OR Low-dose ICS + LABA</strong> (Step 3 therapy for Moderate Persistent Asthma in 6-11 yo age group per NHLBI guidelines. GINA might favor low-dose ICS/LABA).</li>
                            <!-- <li>Add medium dose ICS plus LABA (Step 4 therapy)</li> -->
                         </ul>
                     </div>
                 </details>
                 <details>
                    <summary>Few years later, patient presents to the ED on the 5th day of URI with symptoms with worsening difficulty breathing and wheezing. Using albuterol q4. RR 45, HR 145, O2 89%. Next best step?</summary>
                    <div class="details-content"><p>Moderate-Severe Asthma Exacerbation.</p>
                    <p>Requires: Supplemental O2, frequent/continuous SABA (Albuterol), add SAMA (Ipratropium) for initial doses, Systemic Corticosteroids (Oral Prednisolone or IV Methylprednisolone).</p>
                    <p><strong>Combination Albuterol + Ipratropium nebulization</strong> is standard initial ED bronchodilator therapy.</p></div>
                 </details>
            </div>
             <div class="case-study">
                <p class="case-title">Case 15 (Peds):</p>
                <p>37.5 week baby CS, maternal gestational diabetes, baby with breathing hard and fast.</p>
                 <details>
                    <summary>Likely Diagnosis and Management?</summary>
                    <div class="details-content"><p>Likely <strong>Transient Tachypnea of the Newborn (TTN)</strong> given risk factors (late preterm, CS, GDM). Management: Supportive care (O2 if needed, monitoring), usually resolves within 72 hours.</p></div>
                 </details>
            </div>
             <div class="case-study">
                <p class="case-title">Case 16 (Peds):</p>
                <p>24 yo previously healthy female went into premature labor at 26 weeks.</p>
                 <details>
                    <summary>Intervention to improve neonatal pulmonary outcome?</summary>
                    <div class="details-content"><p><strong>Antenatal Corticosteroids</strong> (e.g., Betamethasone or Dexamethasone) given to mother ≥24 hours before anticipated preterm delivery (between 24-34 weeks gestation) to accelerate fetal lung maturation and reduce risk/severity of RDS.</p></div>
                 </details>
                 <details>
                    <summary>Baby is delivered 12 hours later, APGAR are 4, 6, and 7. Best method to improve respiratory status?</summary>
                    <div class="details-content"><p>Low APGARs, extreme prematurity (26 weeks) = high risk for RDS. Requires immediate resuscitation and respiratory support.</p>
                    <p>Best initial method specifically targeting RDS pathophysiology: <strong>Exogenous Surfactant administration via endotracheal tube</strong>. Often given prophylactically or early rescue. Requires intubation.</p></div>
                 </details>
                  <details>
                    <summary>Initially doing well, baby does worse and is grunting → Explanation?</summary>
                    <div class="details-content"><p>Grunting is an attempt to increase end-expiratory pressure (auto-PEEP) by exhaling against a partially closed glottis, splinting airways open and improving oxygenation. Signifies ongoing respiratory distress and worsening lung mechanics (e.g., worsening RDS, developing BPD, infection).</p></div>
                 </details>
                 <details>
                    <summary>Put on nasal CPAP, but not working, so we intubate. What else can we use?</summary>
                    <div class="details-content"><p>If intubated and still requiring significant support/hypoxic, consider:</p>
                    <ul>
                        <li>Optimizing ventilation settings (e.g., appropriate PEEP, tidal volume).</li>
                        <li>Repeat dose of surfactant if indicated.</li>
                        <li>Assess for complications (pneumothorax, PDA).</li>
                        <li>If severe hypoxemia persists, especially with evidence of pulmonary hypertension: <strong>Inhaled Nitric Oxide (iNO)</strong> can be used as a selective pulmonary vasodilator.</li>
                        <li>ECMO if refractory respiratory failure.</li>
                    </ul>
                    </div>
                 </details>
            </div>
        </div> <!-- End Section: Pediatric Pulmonology -->

        <div class="pixel-art-divider"></div>

        <!-- Section: Obstructive Sleep Apnea -->
        <div id="obstructive-sleep-apnea" class="content-section">
             <svg viewBox="0 0 16 16" xmlns="http://www.w3.org/2000/svg" class="section-svg"><path d="M1 7H0V8H1V7ZM1 8H0V9H1V8ZM2 6H3V7H2V6ZM3 5H4V6H3V5ZM4 4H5V5H4V4ZM5 3H6V4H5V3ZM6 2H7V3H6V2ZM7 1H9V2H7V1ZM9 2H10V3H9V2ZM10 3H11V4H10V3ZM11 4H12V5H11V4ZM12 5H13V6H12V5ZM13 6H14V7H13V6ZM14 7H15V8H14V7ZM15 8H16V9H15V8ZM15 9H16V10H15V9ZM14 10H15V11H14V10ZM13 11H14V12H13V11ZM12 12H13V13H12V12ZM11 13H12V14H11V13ZM10 14H11V15H10V14ZM9 15H7V16H9V15ZM7 15H6V14H7V15ZM6 14H5V13H6V14ZM5 13H4V12H5V13ZM4 12H3V11H4V12ZM3 11H2V10H3V11ZM2 10H1V9H2V10ZM4 7H5V8H4V7ZM5 8H6V9H5V8ZM6 9H7V10H6V9ZM7 10H8V11H7V10ZM8 11H9V12H8V11ZM9 10H10V11H9V10ZM10 9H11V10H10V9ZM11 8H12V9H11V8ZM12 7H13V8H12V7ZM13 8H14V9H13V8ZM14 9H15V10H14V9ZM12 10H13V11H12V10ZM11 11H12V12H11V11ZM10 12H11V13H10V12ZM9 13H10V14H9V13ZM8 14H9V15H8V14ZM7 13H8V14H7V13ZM6 12H7V13H6V12ZM5 11H6V12H5V11ZM4 10H5V11H4V10ZM3 9H4V10H3V9ZM2 8H3V9H2V8ZM2 7H1V8H2V7Z" fill="currentColor"/></svg>
            <h2>Obstructive Sleep Apnea (OSA)</h2>

            <h3>OSAHS (Obstructive Sleep Apnea-Hypopnea Syndrome)</h3>
            <details>
                <summary>Definition Criteria (AASM)</summary>
                <div class="details-content">
                     <p>Diagnosis requires either A or B:</p>
                     <p><strong>A.</strong> Presence of ≥ 1 of the following:</p>
                     <ul>
                        <li>Complaint of sleepiness, nonrestorative sleep, fatigue, or insomnia symptoms.</li>
                        <li>Waking up with breath holding, gasping, or choking.</li>
                        <li>Habitual snoring, breathing interruptions, or both reported by bed partner or observer.</li>
                        <li>Patient has been diagnosed with hypertension, mood disorder, cognitive dysfunction, coronary artery disease, stroke, congestive heart failure, atrial fibrillation, or type 2 diabetes mellitus.</li>
                     </ul>
                     <p><strong>AND</strong> Polysomnography (PSG) or Home Sleep Apnea Test (HSAT) shows:</p>
                     <ul>
                        <li>Apnea-Hypopnea Index (AHI) or Respiratory Event Index (REI) <strong>≥ 5 events per hour</strong>.</li>
                     </ul>
                     <p><strong>B.</strong> PSG or HSAT shows:</p>
                     <ul>
                        <li>AHI or REI <strong>≥ 15 events per hour</strong> (regardless of associated symptoms).</li>
                     </ul>
                     <p><em>Note: Hypopnea definition often includes ≥3% O2 desaturation OR an arousal from sleep.</em></p>
                 </div>
            </details>
            <details>
                <summary>Physiology of Obstruction</summary>
                <div class="details-content">
                     <ul>
                        <li>During sleep, especially REM sleep, muscle tone decreases throughout the body, including the pharyngeal dilator muscles (e.g., genioglossus) that keep the upper airway patent.</li>
                        <li>In susceptible individuals (due to anatomy, obesity), the airway narrows or collapses during inspiration when negative pressure is generated.</li>
                        <li>Collapse leads to <strong>apnea</strong> (complete cessation of airflow ≥10s) or <strong>hypopnea</strong> (partial reduction in airflow ≥10s with desaturation/arousal).</li>
                        <li>Resulting hypoxia and hypercapnia stimulate chemoreceptors, triggering a brief arousal from sleep.</li>
                        <li>Arousal restores muscle tone, airway opens, breathing resumes (often with gasping/snorting).</li>
                        <li>Patient falls back asleep, muscle tone decreases again, and the cycle repeats throughout the night, leading to fragmented sleep and intermittent hypoxia.</li>
                     </ul>
                 </div>
            </details>
            <details>
                <summary>Epidemiology & Risk Factors</summary>
                <div class="details-content">
                     <ul>
                        <li>Prevalence increases with age, higher in males until menopause, then similar rates.</li>
                        <li><strong>Obesity (BMI > 30)</strong> is the strongest risk factor (present in ~60-70% of OSA patients). Increased neck circumference (>17 inches men, >16 inches women) is a strong predictor.</li>
                        <li>Craniofacial abnormalities: Retrognathia (recessed jaw), micrognathia (small jaw), macroglossia (large tongue), tonsillar/adenoidal hypertrophy (esp. children).</li>
                        <li>Other factors: Smoking, alcohol/sedative use (worsens muscle relaxation), nasal obstruction, family history, certain medical conditions (hypothyroidism, acromegaly, neuromuscular disorders).</li>
                     </ul>
                 </div>
            </details>
            <details>
                <summary>Features/Symptoms</summary>
                <div class="details-content">
                     <ul>
                        <li><strong>Excessive Daytime Sleepiness (EDS):</strong> Most common presenting complaint. Feeling tired despite adequate hours in bed.</li>
                        <li><strong>Loud, Habitual Snoring:</strong> Often disruptive to bed partner.</li>
                        <li><strong>Witnessed Apneas / Gasping / Choking:</strong> Reported by bed partner.</li>
                        <li>Non-restorative sleep ("Waking up tired").</li>
                        <li>Morning headaches.</li>
                        <li>Difficulty concentrating, memory problems, irritability, mood changes (depression/anxiety).</li>
                        <li>Nocturia (frequent nighttime urination).</li>
                        <li>Decreased libido / erectile dysfunction.</li>
                     </ul>
                 </div>
            </details>
            <details>
                <summary>Health Consequences & Comorbidities</summary>
                <div class="details-content">
                     <p>Untreated OSA is associated with significant health risks:</p>
                     <ul>
                        <li><strong>Cardiovascular:</strong> Systemic Hypertension (difficult to control), Coronary Artery Disease, Heart Failure, Arrhythmias (especially Atrial Fibrillation, nocturnal brady/tachyarrhythmias), Stroke, Pulmonary Hypertension. Mechanisms involve intermittent hypoxia, sympathetic activation, inflammation, endothelial dysfunction.</li>
                        <li><strong>Metabolic:</strong> Insulin resistance, Type 2 Diabetes Mellitus, Metabolic Syndrome, Dyslipidemia.</li>
                        <li><strong>Neurocognitive:</strong> Impaired attention, vigilance, memory, executive function. Increased risk of motor vehicle accidents and workplace errors due to sleepiness.</li>
                        <li><strong>Mental Health:</strong> Depression, anxiety.</li>
                        <li>Perioperative complications: Increased risk during surgery/sedation.</li>
                     </ul>
                 </div>
            </details>
            <details>
                <summary>Diagnosis</summary>
                <div class="details-content">
                     <ul>
                        <li>History and Physical Exam: Assess symptoms (Epworth Sleepiness Scale), risk factors, comorbidities. Examine airway (Mallampati score, tonsil size, neck circumference).</li>
                        <li><strong>Polysomnogram (PSG):</strong> Gold standard. In-laboratory, overnight study monitoring multiple physiological signals: EEG (sleep stages), EOG (eye movements), EMG (muscle tone), ECG (heart rhythm), airflow (nasal/oral), respiratory effort (chest/abdomen belts), O2 saturation, body position, snoring sounds. Quantifies AHI, RDI, oxygen desaturation, sleep architecture.</li>
                        <li><strong>Home Sleep Apnea Testing (HSAT):</strong> Portable monitor used at home. Records fewer signals (typically airflow, effort, O2 sat, heart rate). Suitable for patients with high pre-test probability of moderate-to-severe OSA without significant comorbidities (e.g., severe COPD, CHF, neuromuscular disease). Cannot definitively rule out OSA if negative (may need PSG).</li>
                        <li>Differential Diagnosis: Insufficient sleep, poor sleep hygiene, other sleep disorders (narcolepsy, restless legs syndrome, circadian rhythm disorders), medical conditions (hypothyroidism, HF), psychiatric conditions (depression), medication side effects.</li>
                     </ul>
                 </div>
            </details>
            <details>
                <summary>OSAHS Severity Scale (based on AHI)</summary>
                <div class="details-content">
                     <ul>
                        <li><strong>Apnea-Hypopnea Index (AHI):</strong> Average number of apneas + hypopneas per hour of sleep.</li>
                        <li>Respiratory Disturbance Index (RDI): Includes AHI + Respiratory Effort-Related Arousals (RERAs - flow limitation leading to arousal without full apnea/hypopnea).</li>
                        <li><strong>Normal:</strong> AHI < 5 events/hour</li>
                        <li><strong>Mild OSA:</strong> AHI 5 to 14 events/hour</li>
                        <li><strong>Moderate OSA:</strong> AHI 15 to 29 events/hour</li>
                        <li><strong>Severe OSA:</strong> AHI ≥ 30 events/hour</li>
                        <li><em>Severity also considers degree of oxygen desaturation and symptom severity.</em></li>
                     </ul>
                 </div>
            </details>
            <details>
                <summary>Treatment</summary>
                <div class="details-content">
                     <ul>
                        <li><strong>Positive Airway Pressure (PAP) Therapy:</strong> First-line treatment for moderate-severe OSA, and mild OSA with significant symptoms/comorbidities.
                            <ul>
                                <li><strong>CPAP (Continuous PAP):</strong> Delivers constant pressure to splint airway open. Most common.</li>
                                <li>APAP (Auto-titrating PAP): Adjusts pressure automatically based on detected events.</li>
                                <li>BiPAP (Bilevel PAP): Delivers higher pressure on inspiration, lower on expiration. Used if high CPAP pressures needed, intolerance, or concurrent hypoventilation.</li>
                            </ul>
                            Requires mask interface (nasal, nasal pillows, full face), adherence is key.
                        </li>
                        <li><strong>Behavioral Modifications:</strong>
                            <ul>
                                <li>Weight loss (if overweight/obese) - can significantly improve or resolve OSA.</li>
                                <li>Avoid alcohol and sedatives, especially before sleep.</li>
                                <li>Positional therapy (avoiding supine position, e.g., tennis ball technique, specialized pillows/devices) - for patients with primarily supine OSA.</li>
                            </ul>
                        </li>
                        <li><strong>Oral Appliances (Mandibular Advancement Devices - MAD):</strong> Custom-made devices by dentists trained in sleep medicine. Advance mandible forward, opening airway. Option for mild-moderate OSA, or severe OSA intolerant/refusing PAP. Less effective than PAP for severe OSA.</li>
                        <li><strong>Surgery:</strong> Considered if PAP/OA fail or intolerance, or specific anatomical obstruction identified.
                            <ul>
                                <li>Uvulopalatopharyngoplasty (UPPP): Resects uvula, soft palate, tonsils. Variable success rates, less common now.</li>
                                <li>Maxillomandibular Advancement (MMA): More complex, advances upper/lower jaws. Higher success rate for severe OSA but more invasive.</li>
                                <li>Genioglossus Advancement, Hyoid Suspension: Target tongue base collapse.</li>
                                <li>Tonsillectomy/Adenoidectomy: Primary treatment for pediatric OSA if hypertrophy present.</li>
                                <li>Tracheostomy: Bypasses upper airway. Historically definitive treatment, now reserved for rare, life-threatening cases refractory to all other therapies.</li>
                            </ul>
                        </li>
                        <li><strong>Upper Airway Stimulation (Hypoglossal Nerve Stimulator):</strong> Implanted device (e.g., Inspire) that stimulates genioglossus muscle synchronously with inspiration to protrude tongue and open airway. Option for moderate-severe OSA intolerant/failing PAP, meeting specific criteria (BMI limits, certain collapse patterns on sleep endoscopy).</li>
                     </ul>
                 </div>
            </details>
        </div> <!-- End Section: Obstructive Sleep Apnea -->

        <div class="pixel-art-divider"></div>

        <!-- Section: Pathology -->
        <div id="pathology" class="content-section">
            <svg viewBox="0 0 16 16" xmlns="http://www.w3.org/2000/svg" class="section-svg"><path d="M1 1H2V2H1V1ZM3 1H4V2H3V1ZM5 1H6V2H5V1ZM7 1H8V2H7V1ZM9 1H10V2H9V1ZM11 1H12V2H11V1ZM13 1H14V2H13V1ZM15 1H16V2H15V1ZM1 3H2V4H1V3ZM15 3H16V4H15V3ZM2 4H3V5H2V4ZM4 4H5V5H4V4ZM6 4H7V5H6V4ZM8 4H9V5H8V4ZM10 4H11V5H10V4ZM12 4H13V5H12V4ZM14 4H15V5H14V4ZM1 5H2V6H1V5ZM15 5H16V6H15V5ZM2 6H3V7H2V6ZM4 6H5V7H4V6ZM6 6H7V7H6V6ZM8 6H9V7H8V6ZM10 6H11V7H10V6ZM12 6H13V7H12V6ZM14 6H15V7H14V6ZM1 7H2V8H1V7ZM15 7H16V8H15V7ZM2 8H3V9H2V8ZM4 8H5V9H4V8ZM6 8H7V9H6V8ZM8 8H9V9H8V8ZM10 8H11V9H10V8ZM12 8H13V9H12V8ZM14 8H15V9H14V8ZM1 9H2V10H1V9ZM15 9H16V10H15V9ZM2 10H3V11H2V10ZM4 10H5V11H4V10ZM6 10H7V11H6V10ZM8 10H9V11H8V10ZM10 10H11V11H10V10ZM12 10H13V11H12V10ZM14 10H15V11H14V10ZM1 11H2V12H1V11ZM15 11H16V12H15V11ZM2 12H3V13H2V12ZM4 12H5V13H4V12ZM6 12H7V13H6V12ZM8 12H9V13H8V12ZM10 12H11V13H10V12ZM12 12H13V13H12V12ZM14 12H15V13H14V12ZM1 13H2V14H1V13ZM15 13H16V14H15V13ZM2 14H3V15H2V14ZM4 14H5V15H4V14ZM6 14H7V15H6V14ZM8 14H9V15H8V14ZM10 14H11V15H10V14ZM12 14H13V15H12V14ZM14 14H15V15H14V14ZM1 15H2V16H1V15ZM3 15H4V16H3V15ZM5 15H6V16H5V15ZM7 15H8V16H7V15ZM9 15H10V16H9V15ZM11 15H12V16H11V15ZM13 15H14V16H13V15ZM15 15H16V16H15V15Z" fill="currentColor"/></svg>
            <h2>Pathology</h2>

            <div class="case-study">
                <p class="case-title">Case 1 (Path):</p>
                <p>60 yo female with COVID.</p>
                 <details>
                    <summary>Which of the following is true of the Coronaviridae Family of viruses?</summary>
                    <div class="details-content">
                         <ul>
                            <li>ssDNA, nonenveloped</li>
                            <li>DSDNA, enveloped</li>
                            <li>ssRNA, (+) sense nonenveloped</li>
                            <li><strong>ssRNA (+) sense enveloped → spike proteins embedded in the envelope</strong>
                                <ul>
                                    <li>Positive sense RNA can be directly translated by host ribosomes (like mRNA).</li>
                                    <li>Virulence mechanism mentioned: filopod formation, S protein-mediated syncytium formation (fusion of cells).</li>
                                </ul>
                            </li>
                            <li>ssRNA (-) sense enveloped</li>
                         </ul>
                     </div>
                 </details>
                 <details>
                    <summary>SARS CoV-2 is considered one of the ___ RNA viruses?</summary>
                    <div class="details-content">
                         <ul>
                            <li><strong>Larger → ~30kb genome</strong>
                                <ul>
                                    <li>Largest known RNA virus genome. Belongs to Order Nidovirales (nested subgenomic RNAs). Has proofreading capacity (ExoN), unusual for RNA viruses, leading to lower mutation rate than some others like influenza.</li>
                                </ul>
                            </li>
                            <li>Average-sized (e.g., influenza ~13.5kb)</li>
                            <li>Smaller (e.g., West Nile ~11kb, Polio ~7.5kb)</li>
                         </ul>
                     </div>
                 </details>
                 <details>
                    <summary>Which viral membrane component is the major inducer of T-cell and neutralizing antibody (nAb) responses?</summary>
                    <div class="details-content">
                         <ul>
                            <li>Envelope protein (E)</li>
                            <li>Membrane protein (M)</li>
                            <li><strong>Spike glycoprotein (S) → Binds ACE2 receptor, mediates entry. Main target for vaccines and neutralizing antibodies.</strong></li>
                            <li>Nucleocapsid protein (N) - Abundant, often targeted in diagnostic tests, induces T-cell responses but less nAb.</li>
                            <li>Lipid bilayer (Host-derived)</li>
                         </ul>
                     </div>
                 </details>
                 <details>
                    <summary>Which receptors are utilized by SARS CoV-2 for viral entry?</summary>
                    <div class="details-content">
                         <ul>
                            <li><strong>ACE-2 (Angiotensin-Converting Enzyme 2): Primary receptor.</strong> Expressed on lung alveolar epithelial cells (Type II), nasal/oral mucosa, vascular endothelium, heart, kidneys, intestines, testes. Expression may increase with age, HTN, diabetes.</li>
                            <li>DPP4 (Receptor for MERS-CoV)</li>
                            <li>CCR5 (HIV co-receptor)</li>
                            <li><strong>TMPRSS2 (Transmembrane Protease, Serine 2): Host cell surface protease that cleaves/primes the Spike protein after ACE2 binding, facilitating viral membrane fusion and entry.</strong> Other proteases like furin and cathepsins can also be involved.</li>
                         </ul>
                     </div>
                 </details>
                 <details>
                    <summary>What is ARDS and what is the initiation factor?</summary>
                    <div class="details-content">
                         <ul>
                            <li>ARDS = <strong>Acute Respiratory Distress Syndrome</strong>. Clinical syndrome of acute, diffuse, inflammatory lung injury leading to increased pulmonary vascular permeability, increased lung weight, and loss of aerated lung tissue. Results in severe hypoxemia and bilateral radiographic opacities.</li>
                            <li>Initiation factor: <strong>Diffuse Alveolar Damage (DAD)</strong>, which is the histologic hallmark. DAD results from injury to the alveolar capillary barrier, primarily involving <strong>Endothelial cell injury/activation AND/OR Type I Pneumocyte injury</strong>. This leads to leakage of protein-rich edema fluid into interstitium and alveoli.</li>
                         </ul>
                     </div>
                 </details>
                 <details>
                    <summary>What is the histologic lesion associated with ARDS/DAD?</summary>
                    <div class="details-content">
                         <ul>
                            <li>Caveating lesion with necrotizing vasculitis (Seen in GPA/Wegener's)</li>
                            <li>Central caseation surrounded by histocytes, giant cells, and fibrous tissue (Granuloma - TB, fungal)</li>
                            <li><strong>Eosinophilic hyaline membranes lining alveoli</strong> (Classic finding in the acute/exudative phase of DAD/ARDS - composed of fibrin, cellular debris, plasma proteins). Also see interstitial edema, inflammation, Type II pneumocyte hyperplasia (in later organizing phase).</li>
                            <li>Gray hepatization (Stage of lobar pneumonia)</li>
                            <li>Red hepatization (Stage of lobar pneumonia)</li>
                         </ul>
                     </div>
                 </details>
                 <details>
                    <summary>What is the best position for the patient to improve mobilization of fluids and manage V/Q mismatch?</summary>
                    <div class="details-content">
                         <ul>
                            <li>Left lateral recumbent</li>
                            <li><strong>Prone positioning: Improves V/Q matching by recruiting dependent (dorsal) lung regions that are often atelectatic/edematous in supine position, improves drainage of secretions, reduces ventilator-induced lung injury. Standard therapy for moderate-severe ARDS.</strong></li>
                            <li>Right lateral recumbent</li>
                            <li>Supine (Often worsens V/Q mismatch in ARDS).</li>
                            <li>Trendelenburg (Head down - generally not used for V/Q, may worsen ICP).</li>
                         </ul>
                     </div>
                 </details>
            </div> <!-- End Case 1 Path -->

            <div class="case-study">
                <p class="case-title">Case 2 (Path):</p>
                <p>25 month old previously fit AMAB admitted to ED with fever x 3 days, cough, rhinorrhea, lethargic, cyanotic, dyspneic. Cough is barking quality, hoarseness, noisy breathing. O2 sat 84%, given nebulized adrenaline and improved to 97% of O2. Chest x-ray shows hilar patchiness. Becomes cyanotic again sats fall to 60%. Laryngoscopy and bronchoscopy with intubation – no masses but vocal cords and trachea show mucosal swelling and vomitus present.</p>
                 <details>
                    <summary>What pathology explains this type of cough this patient has?</summary>
                    <div class="details-content"><p>The barking cough and noisy breathing (inspiratory stridor) are characteristic of <strong>Croup (Laryngotracheobronchitis)</strong>. Pathology involves inflammation and edema of the larynx, trachea, and bronchi, particularly in the subglottic region (narrowest part of pediatric airway), leading to upper airway obstruction.</p></div>
                 </details>
                 <details>
                    <summary>What etiologic agents do you suspect in this case?</summary>
                    <div class="details-content">
                         <ul>
                            <li>Influenza A (Can cause croup, but less common than parainfluenza).</li>
                            <li>Haemophilus influenzae (Causes epiglottitis, a different clinical picture - rapid onset, drooling, toxic appearance).</li>
                            <li>Corynebacterium diphtheriae (Causes diphtheria - pseudomembranes, systemic toxicity).</li>
                            <li><strong>Parainfluenza virus (Types 1, 2, 3): Most common cause of croup.</strong> RSV, Adenovirus, Influenza, Measles are other viral causes.</li>
                            <li>(Bacterial tracheitis can be a complication, often S. aureus).</li>
                         </ul>
                     </div>
                 </details>
                 <details>
                    <summary>If microscope results showed Gram (+) rods with palisades/V-shapes, what would be the diagnosis, and what should you do next?</summary>
                    <div class="details-content">
                        <p>Gram-positive rods in palisading ("Chinese letters") or V-shaped arrangements are characteristic of <strong>Corynebacterium diphtheriae</strong>.</p>
                        <p>Diagnosis: <strong>Diphtheria</strong>.</p>
                        <p>Next Steps:</p>
                        <ol>
                            <li><strong>Isolate patient</strong> (respiratory droplet precautions).</li>
                            <li>Administer <strong>Diphtheria Antitoxin</strong> immediately (to neutralize circulating toxin).</li>
                            <li>Start <strong>Antibiotics</strong> (e.g., Penicillin G or Erythromycin) to eradicate bacteria and prevent further toxin production/spread.</li>
                            <li>Supportive care (airway monitoring).</li>
                            <li>Notify public health authorities.</li>
                            <li>Ensure patient and close contacts are appropriately vaccinated (DTaP/Tdap).</li>
                        </ol>
                     </div>
                 </details>
            </div> <!-- End Case 2 Path -->

            <div class="case-study">
                <p class="case-title">Case 3 (Path):</p>
                <p>59 yo AMAB in WA state admitted with cc chronic cough and malaise x 3 month. Traveled to Arizona. Transient low-grade fever, lymphadenopathy, denied night sweats or skinrashes. Labs WNL, elevated ESR. Sputum positive normal flora. CT: irregular-margined opacity in sub-pleural region in right middle lobe.</p>
                 <details>
                    <summary>What is your diagnosis?</summary>
                    <div class="details-content">
                         <p>Chronic respiratory symptoms + travel to endemic area (Arizona) + CT findings.</p>
                         <ul>
                            <li>Blastomycosis (Endemic to Mississippi/Ohio river valleys, Great Lakes).</li>
                            <li><strong>Coccidioidomycosis ("Valley Fever"): Endemic to Southwestern US (Arizona, California, etc.).</strong> Can cause chronic pulmonary disease.</li>
                            <li>Hanta virus pulmonary syndrome (Acute severe illness, rodent exposure).</li>
                            <li>Histoplasmosis (Ohio/Mississippi river valleys, bird/bat droppings).</li>
                            <li>TB (Always on differential for chronic cough, but travel history points strongly to Coccidio).</li>
                         </ul>
                     </div>
                 </details>
                 <details>
                    <summary>What is the etiology?</summary>
                    <div class="details-content"><p><strong><em>Coccidioides immitis</em></strong> or <strong><em>Coccidioides posadasii</em></strong>.</p></div>
                 </details>
                 <details>
                    <summary>What kingdom? Characteristics?</summary>
                    <div class="details-content">
                         <ul>
                            <li>Kingdom: <strong>Fungi</strong></li>
                            <li>Class: Dimorphic fungus.
                                <ul>
                                    <li>Mold form (arthroconidia) in environment (soil).</li>
                                    <li>Spherule form (containing endospores) in host tissue (at body temperature).</li>
                                </ul>
                            </li>
                            <li>Transmission: Inhalation of airborne <strong>arthroconidia</strong>.</li>
                            <li><strong>NOT transmitted person-to-person</strong>.</li>
                         </ul>
                     </div>
                 </details>
                 <details>
                    <summary>What type of pneumonia is this considered?</summary>
                    <div class="details-content">
                         <ul>
                            <li>Aspiration pneumonia</li>
                            <li><strong>Chronic pneumonia:</strong> Symptoms lasting > 3 months.</li>
                            <li>Community-acquired pneumonia: Acquired outside healthcare setting. (This is also true).</li>
                            <li>Health care-associated</li>
                            <li>Pneumonia of immunocompromised host: Can occur in immunocompetent, but more severe/disseminated in immunocompromised. (This patient's immune status not specified as compromised).</li>
                            <li><em>Best classification based on duration is Chronic Pneumonia. It's also a CAP.</em></li>
                         </ul>
                     </div>
                 </details>
                 <details>
                    <summary>What is the histologically characteristic of this infection (Coccidioidomycosis)?</summary>
                    <div class="details-content">
                         <ul>
                            <li>Alveoli filled with foamy, bubbly exudate → Pneumocystis jirovecii</li>
                            <li>Central caseation surrounded by histocytes, giant cells, and fibrous tissue → Granuloma (TB, Histoplasmosis)</li>
                            <li>Owl's eye inclusions → Cytomegalovirus (CMV)</li>
                            <li><strong>Large (20-60 µm), thick-walled spherules, often containing numerous small endospores. Ruptured spherules releasing endospores may be seen.</strong> Associated granulomatous inflammation.</li>
                            <li>Rounded budding yeasts with characteristic thick wall and broad-based bud → Blastomyces dermatitidis</li>
                            <li>Smudge cells with indistinct, basophilic nuclear inclusions → Adenovirus</li>
                         </ul>
                     </div>
                 </details>
            </div> <!-- End Case 3 Path -->

            <div class="case-study">
                <p class="case-title">Case 4 (Path):</p>
                <p>39 yo AFAB presents to oncologist with intermittent fever, lethargy, weakness, and cough. She has ALL in consolidation phase of her chemo tx. Blood shows pancytopenia with decreased cell counts of polymorphonuclear cells, bands, and lymphocytes. Pulmonary imaging: peripheral upper lung consolidation?</p>
                 <details>
                    <summary>What type of pneumonia?</summary>
                    <div class="details-content">
                         <ul>
                            <li>Aspiration</li>
                            <li>Chronic</li>
                            <li>Community-acquired</li>
                            <li>Health-care associated</li>
                            <li>Hospital-acquired</li>
                            <li><strong>Pneumonia of immunocompromised host: Patient undergoing chemotherapy for ALL, neutropenic/lymphopenic.</strong></li>
                         </ul>
                     </div>
                 </details>
                 <details>
                    <summary>Lung biopsy: necrotizing lesion with pale center and hemorrhagic border invading blood vessels. Organism had 5-10 uM thick branching septate hyphae. Most likely agent?</summary>
                    <div class="details-content">
                         <p>Necrotizing, angioinvasive fungal infection with septate hyphae branching at acute angles in an immunocompromised host.</p>
                         <ul>
                            <li><strong>Aspergillus fumigatus (or other Aspergillus species): Classic description of Invasive Pulmonary Aspergillosis (IPA).</strong></li>
                            <li>Blastomyces dermatitidis (Yeast form in tissue, broad-based buds).</li>
                            <li>CMV (Viral inclusions - Owl's eye).</li>
                            <li>Histoplasma capsulatum (Small intracellular yeasts).</li>
                            <li>Pneumocystis jirovecii (Cysts/trophozoites in foamy exudate).</li>
                            <li>(Mucorales would have broad, non-septate/pauciseptate hyphae branching at right angles).</li>
                         </ul>
                     </div>
                 </details>
                 <details>
                    <summary>What would be the etiologic agent if biopsy shows alveoli are filled with foamy exudate and organism looked like round bubbles or indented "crescent moons"?</summary>
                    <div class="details-content">
                         <p>Foamy/eosinophilic alveolar exudate containing cysts/trophozoites (often seen with Silver stain - GMS or Giemsa).</p>
                         <ul>
                            <li>Aspergillus fumigatus</li>
                            <li>Blastomyces dermatitidis</li>
                            <li>CMV</li>
                            <li>Histoplasma capsulatum</li>
                            <li><strong>Pneumocystis jirovecii: Classic description of PJP (Pneumocystis Pneumonia).</strong></li>
                         </ul>
                     </div>
                 </details>
                 <details>
                    <summary>What if biopsy showed intense interstitial lymphocytic infiltration and large cells with an "owls eye" cytopathology – single, dark, basophilic nuclear inclusion with a peripheral halo?</summary>
                    <div class="details-content">
                         <p>Large cells (cytomegaly) with large intranuclear inclusion surrounded by a clear halo ("Owl's eye").</p>
                         <ul>
                            <li>Aspergillus fumigatus</li>
                            <li>Blastomyces dermatitidis</li>
                            <li><strong>CMV (Cytomegalovirus): Classic cytopathic effect.</strong> Often causes interstitial pneumonitis in immunocompromised hosts.</li>
                            <li>Histoplasma capsulatum</li>
                            <li>Pneumocystis jirovecii</li>
                         </ul>
                     </div>
                 </details>
            </div> <!-- End Case 4 Path -->

            <div class="case-study">
                <p class="case-title">Case 5 (Path):</p>
                <p>69 yo man born in Russia immigrated to US at age 40. Ohio. Cc chronic morning cough. Smoker has had chronic cough for many years, but this morning he noticed streak of blood in handkerchief when coughing. Does light hiking with his wife and is asplenic due to sledding accident as a child. Vitals and PE are normal. Sputum sample: AFB smear: patient has TB. CT: opacity in posterior segment right lower lobe.</p>
                 <details>
                    <summary>What is the characteristic lesion of mycobacterium infection and pathogenesis?</summary>
                    <div class="details-content">
                         <ul>
                            <li>Characteristic Lesion: <strong>Granuloma</strong>, typically with central <strong>caseous necrosis</strong> (cheese-like appearance grossly).</li>
                            <li>Pathogenesis: Inhaled M. tuberculosis bacilli are phagocytosed by alveolar macrophages but resist killing. Infected macrophages present antigens, activating T-cells (Th1 response). Activated T-cells release cytokines (like IFN-gamma) that activate macrophages (forming <strong>epithelioid histiocytes</strong>) and recruit other immune cells. Macrophages fuse to form multinucleated giant cells (Langhans type). Immune cells aggregate to wall off the infection, forming a granuloma. Central necrosis occurs due to host immune response and bacterial factors.</li>
                         </ul>
                     </div>
                 </details>
                 <details>
                    <summary>What is the difference between primary, secondary, and miliary TB?</summary>
                    <div class="details-content">
                         <ul>
                            <li><strong>Primary TB:</strong> Initial infection, usually in childhood or non-immune host. Often asymptomatic or mild flu-like. Typically involves <strong>middle or lower lung zones</strong>. Forms <strong>Ghon focus</strong> (peripheral parenchymal granuloma) + involvement of draining hilar/mediastinal lymph nodes = <strong>Ghon Complex</strong>. Usually contained by CMI, leading to LTBI (lesions may heal/calcify - Ranke complex).</li>
                            <li><strong>Secondary (Reactivation) TB:</strong> Reactivation of latent TB infection, often years later when immunity wanes. Typically involves lung <strong>apices (upper lobes, superior segments of lower lobes)</strong> due to higher oxygen tension favoring aerobic Mtb growth. Characterized by tissue destruction, fibrosis, and <strong>cavitation</strong>. More symptomatic (cough, fever, night sweats, weight loss) and source of transmission.</li>
                            <li><strong>Miliary TB:</strong> Hematogenous or lymphatic dissemination of Mtb from primary or secondary site. Results in numerous, tiny (1-2 mm, "millet seed"-sized) granulomas widely distributed throughout lungs and potentially other organs (liver, spleen, bone marrow, kidneys, brain, etc.). Can occur with primary infection (esp. infants/immunocompromised) or reactivation.</li>
                         </ul>
                     </div>
                 </details>
                 <details>
                    <summary>What if the patient's smear and culture indicated they were negative for TB? What might then be on differential (given Ohio location, granulomas)?</summary>
                    <div class="details-content">
                         <p>Granulomatous lung disease in Ohio River Valley region, TB negative:</p>
                         <ul>
                            <li><strong>Histoplasmosis:</strong> Caused by <em>Histoplasma capsulatum</em>. Endemic fungus in Ohio/Mississippi River Valleys, associated with bird/bat droppings. Inhaled spores → yeast form in macrophages. Can cause acute pulmonary infection, chronic pulmonary histoplasmosis (resembling TB, often in smokers with COPD), or disseminated disease (immunocompromised). Forms granulomas (often caseating, can calcify). Microscopy: Small, oval yeasts, often intracellular within macrophages.</li>
                            <li><strong>Blastomycosis:</strong> Caused by <em>Blastomyces dermatitidis</em>. Also endemic in Ohio/Mississippi River Valleys, Great Lakes region. Can cause pulmonary disease (acute/chronic), skin lesions, bone involvement. Forms granulomas (often suppurative). Microscopy: Large, round yeasts with thick walls and characteristic broad-based budding.</li>
                            <li><strong>Sarcoidosis:</strong> Systemic inflammatory disease of unknown cause characterized by non-caseating granulomas. Lungs and intrathoracic lymph nodes commonly involved (bilateral hilar adenopathy classic). Diagnosis of exclusion.</li>
                            <li>NTM infection (less likely to be primary consideration without positive AFB smear/culture, but possible).</li>
                         </ul>
                     </div>
                 </details>
            </div> <!-- End Case 5 Path -->

             <div class="case-study">
                <p class="case-title">Case 6 (Path):</p>
                <p>32 yo AFAB with well-controlled asthma with cc dyspnea, fever, rhinorrhea, cough, myalgias x 3 days. Taking acetaminophen and nebulizer but feeling worse and produces yellow-green colored sputum. Daughter ill with influenza – dx with rapid test. PE: fever, 150 HR, BP 112/64, RR 20, O2 sat 98%. Appears ill but no significant respiratory distress. Crackles in lower left lung.</p>
                 <details>
                    <summary>What type of pneumonia?</summary>
                    <div class="details-content">
                         <ul>
                            <li>Aspiration pneumonia</li>
                            <li>Chronic pneumonia</li>
                            <li><strong>Community-acquired pneumonia (CAP):</strong> Acquired outside hospital/healthcare setting. Likely triggered by influenza.</li>
                            <li>Health care-associated</li>
                            <li>Pneumonia of immunocompromised</li>
                         </ul>
                     </div>
                 </details>
                 <details>
                    <summary>What type of pneumonia pattern is characteristic of viral infections?</summary>
                    <div class="details-content">
                         <ul>
                            <li>Bronchopneumonia (Patchy consolidation centered on airways - can be bacterial or viral).</li>
                            <li>Intra-alveolar pneumonitis (Alveoli filled with exudate - more typical of bacterial).</li>
                            <li><strong>Interstitial pneumonia:</strong> Inflammation primarily involving the alveolar walls (interstitium) and adjacent airways. Common pattern for viral pneumonias (Influenza, RSV, Adenovirus, CMV, COVID-19) and atypical bacterial pneumonias (Mycoplasma, Chlamydia). Radiographically appears as reticular opacities, GGOs.</li>
                            <li>Lobar pneumonia (Consolidation of entire lobe - classic bacterial, esp. S. pneumo).</li>
                         </ul>
                     </div>
                 </details>
                 <details>
                    <summary>Describe pathogenesis of viral pneumonia</summary>
                    <div class="details-content"><p>Viruses typically infect airway epithelial cells and/or alveolar pneumocytes (often Type I). Viral replication leads to cell damage/lysis and triggers an inflammatory response, primarily involving lymphocytes and macrophages infiltrating the alveolar walls (interstitium) and airways. This leads to interstitial edema and inflammation (interstitial pneumonitis). Damage to Type I cells prompts proliferation of Type II pneumocytes for repair. In severe cases (like influenza, COVID-19), can progress to Diffuse Alveolar Damage (DAD) with hyaline membrane formation.</p></div>
                 </details>
                 <details>
                    <summary>If this were a primary bacterial pneumonia, describe bronchopneumonia and lobar pneumonia, and its stages?</summary>
                    <div class="details-content">
                         <ul>
                            <li><strong>Bronchopneumonia:</strong> Infection spreads via airways, resulting in patchy foci of consolidation centered around bronchioles, often bilateral and involving lower lobes. Grossly: multiple small, raised, consolidated areas. Histology: Neutrophilic exudate filling bronchioles and adjacent alveoli.</li>
                            <li><strong>Lobar pneumonia:</strong> Infection rapidly spreads through alveolar pores (of Kohn), leading to consolidation of a large portion or entire lobe. Classic example: <em>Streptococcus pneumoniae</em>. Pathologic Stages (less distinct with antibiotics):
                                <ol>
                                    <li><strong>Congestion (Day 1-2):</strong> Vascular engorgement, proteinaceous fluid, numerous bacteria, few neutrophils in alveoli. Lung is heavy, boggy, red.</li>
                                    <li><strong>Red Hepatization (Day 2-4):</strong> Massive exudation with neutrophils, red blood cells, and fibrin filling alveoli. Lobe is red, firm, airless (resembles liver).</li>
                                    <li><strong>Gray Hepatization (Day 4-8):</strong> Red cells disintegrate, fibrinosuppurative exudate persists. Lobe is grayish-brown, firm.</li>
                                    <li><strong>Resolution (Day 8+):</strong> Exudate enzymatically digested and cleared by macrophages or coughed up. Lung architecture restored (usually).</li>
                                </ol>
                            </li>
                         </ul>
                     </div>
                 </details>
                 <details>
                    <summary>Patient sent home, condition deteriorates over 7 days. ED with fever. PE: tachycardia, BP 95/52, tachypnea, O2 sat 85%. Ill-appearing. X-ray: homogenous left mid-lung infiltrate with possible cavitation. Lab: pancytopenia, Left shift. Sputum is blood-streaked and purulent. What is an important concern?</summary>
                    <div class="details-content">
                        <p>Deterioration after initial viral illness (influenza) with signs of severe pneumonia (hypoxia, shock, cavitation, purulent sputum) strongly suggests <strong>Secondary Bacterial Pneumonia</strong>.</p>
                        <ul>
                            <li><strong><em>Staphylococcus aureus</em> (including MRSA)</strong> is a classic and often severe cause of post-influenza bacterial pneumonia. Frequently associated with necrosis, abscess formation, cavitation, and empyema.</li>
                            <li><em>Streptococcus pneumoniae</em> is also a common cause of secondary bacterial pneumonia post-influenza.</li>
                            <li>Other possibilities: <em>H. influenzae</em>, Group A Strep.</li>
                        </ul>
                        <p>The cavitation, sepsis picture, and history of influenza make <strong>S. aureus pneumonia</strong> a primary concern.</p>
                     </div>
                 </details>
            </div> <!-- End Case 6 Path -->

             <div class="case-study">
                <p class="case-title">Case 7 (Path):</p>
                <p>66 yo AMAB biology professor in CCU x 3 days post-MI. Develops dyspnea, wheezing, fever, productive cough, foul-smelling, purulent, blood-tinged sputum. CT: consolidation with distinct round shape and thick irregular wall.</p>
                 <details>
                    <summary>What type of pneumonia?</summary>
                    <div class="details-content">
                         <p>Hospital setting (CCU), debilitated state (post-MI), foul-smelling sputum, CT showing consolidation with thick-walled cavity strongly suggest <strong>Aspiration Pneumonia with Lung Abscess</strong>.</p>
                         <ul>
                            <li><strong>Aspiration Pneumonia:</strong> Aspiration of oropharyngeal or gastric contents. Risk factors: altered mental status, impaired swallowing, neurologic disorders, alcoholism, poor dentition, hospitalization/instrumentation. Often involves dependent lung segments. Can be chemical pneumonitis (from acid) or bacterial infection (often polymicrobial including anaerobes).</li>
                            <li>Chronic</li>
                            <li>Community-acquired</li>
                            <li>Health-care associated (Could be, but aspiration features prominent)</li>
                            <li>Hospital-acquired (Could be, but aspiration features prominent)</li>
                            <li>Pneumonia of immunocompromised host</li>
                         </ul>
                     </div>
                 </details>
                 <details>
                    <summary>What is the etiology of aspiration pneumonia?</summary>
                    <div class="details-content">
                         <ul>
                            <li><strong>Polymicrobial infection, often including Anaerobic bacteria</strong> from the oral cavity (e.g., Peptostreptococcus, Fusobacterium, Prevotella, Bacteroides). Responsible for foul-smelling sputum and abscess formation.</li>
                            <li>Aerobic bacteria (e.g., Streptococci, Staphylococci, Gram-negative rods) can also be involved, especially in hospital-acquired aspiration.</li>
                            <li>Chemical pneumonitis from aspiration of gastric acid (can predispose to secondary bacterial infection).</li>
                         </ul>
                     </div>
                 </details>
                  <details>
                    <summary>What are important lesions associated?</summary>
                    <div class="details-content">
                         <ul>
                             <li><strong>Lung Abscess:</strong> Localized area of suppurative necrosis within lung parenchyma, resulting in cavity formation (often with air-fluid level on imaging). Cardinal feature of anaerobic aspiration pneumonia. Can also be caused by S. aureus, Klebsiella, other pyogenic bacteria, septic emboli, or bronchial obstruction (e.g., tumor).</li>
                             <li>Necrotizing Pneumonia: More diffuse necrosis without discrete abscess formation.</li>
                             <li>Empyema: Pus collection in the pleural space, can result from extension of abscess/pneumonia.</li>
                             <li>Gangrene of lung (rare, extensive necrosis).</li>
                         </ul>
                     </div>
                 </details>
            </div> <!-- End Case 7 Path -->
        </div> <!-- End Section: Pathology -->

        <div class="pixel-art-divider"></div>

        <!-- Section: Pharmacology Rhinitis/Allergy -->
        <div id="pharmacology-rhinitis-allergy" class="content-section">
             <svg viewBox="0 0 16 16" xmlns="http://www.w3.org/2000/svg" class="section-svg"><path d="M1 1H2V2H1V1ZM3 1H4V2H3V1ZM5 1H6V2H5V1ZM7 1H9V2H7V1ZM9 1H11V2H9V1ZM11 1H12V2H11V1ZM13 1H14V2H13V1ZM15 1H16V2H15V1ZM1 3H2V4H1V3ZM3 3H4V4H3V3ZM5 3H6V4H5V3ZM7 3H8V4H7V3ZM9 3H10V4H9V3ZM11 3H12V4H11V3ZM13 3H14V4H13V3ZM15 3H16V4H15V3ZM1 5H2V6H1V5ZM3 5H4V6H3V5ZM5 5H6V6H5V5ZM6 6H7V7H6V6ZM7 7H8V8H7V7ZM8 8H9V9H8V8ZM9 9H10V10H9V9ZM10 10H11V11H10V10ZM11 11H12V12H11V11ZM12 12H13V13H12V12ZM13 13H14V14H13V13ZM14 14H15V15H14V14ZM15 15H16V16H15V15ZM13 15H14V16H13V15ZM11 15H12V16H11V15ZM9 15H10V16H9V15ZM7 15H8V16H7V15ZM5 15H6V16H5V15ZM3 15H4V16H3V15ZM1 15H2V16H1V15ZM1 13H2V14H1V13ZM1 11H2V12H1V11ZM1 9H2V10H1V9ZM1 7H2V8H1V7ZM4 6H5V7H4V6ZM12 6H13V7H12V6ZM14 5H15V6H14V5ZM14 7H15V8H14V7ZM14 9H15V10H14V9ZM14 11H15V12H14V11ZM14 13H15V14H14V13ZM12 14H13V15H12V14ZM10 14H11V15H10V14ZM8 14H9V15H8V14ZM6 14H7V15H6V14ZM4 14H5V15H4V14ZM2 13H3V14H2V13ZM2 11H3V12H2V11ZM2 9H3V10H2V9ZM2 7H3V8H2V7ZM2 5H3V6H2V5ZM4 12H5V13H4V12ZM5 11H6V12H5V11ZM6 10H7V11H6V10ZM7 9H8V10H7V9ZM8 7H9V8H8V7ZM9 6H10V7H9V6ZM10 5H11V6H10V5ZM11 7H12V8H11V7ZM12 9H13V10H12V9ZM11 13H10V14H11V13ZM9 13H8V14H9V13ZM7 13H6V14H7V13ZM5 13H4V14H5V13Z" fill="currentColor"/></svg>
            <h2>Pharmacology: Drugs for Rhinitis/Allergy</h2>
            <p class="mb-4 text-[--text-secondary]">Allergen avoidance is the first step, but often insufficient. Pharmacotherapy targets symptoms and underlying inflammation.</p>

            <h3>Oral Antihistamines (H1 Receptor Antagonists)</h3>
             <details>
                <summary>General Info</summary>
                <div class="details-content"><p>Block histamine H1 receptors, reducing sneezing, itching (pruritus), rhinorrhea, and ocular symptoms (conjunctivitis). Less effective for nasal congestion compared to decongestants or nasal steroids.</p></div>
            </details>
             <details>
                <summary>First Generation</summary>
                <div class="details-content">
                     <ul>
                        <li>Examples: Diphenhydramine (Benadryl), Hydroxyzine (Atarax), Chlorpheniramine (Chlor-Trimeton), Brompheniramine.</li>
                        <li>Characteristics: Lipophilic, readily cross BBB causing significant <strong>sedation</strong> and cognitive impairment. Potent <strong>anticholinergic effects</strong> (dry mouth, urinary retention, blurred vision, constipation, confusion - esp. elderly).</li>
                        <li>Use: Generally avoided for routine allergic rhinitis due to side effects. Used for acute allergic reactions, hives, motion sickness, sleep aid (diphenhydramine).</li>
                     </ul>
                 </div>
            </details>
             <details>
                <summary>Second Generation</summary>
                <div class="details-content">
                     <ul>
                        <li>Examples: Loratadine (Claritin), Desloratadine (Clarinex), Cetirizine (Zyrtec), Levocetirizine (Xyzal), Fexofenadine (Allegra).</li>
                        <li>Characteristics: Less lipophilic, minimal BBB penetration = <strong>less/non-sedating</strong> (Cetirizine/Levocetirizine may cause mild sedation in some). Minimal anticholinergic effects. Longer duration of action (usually once daily).</li>
                        <li>Use: Preferred oral agents for allergic rhinitis and chronic urticaria. Best taken regularly during allergy season for optimal effect.</li>
                     </ul>
                 </div>
            </details>

            <h3>Topical Antihistamines (Nasal Sprays, Eye Drops)</h3>
             <details>
                <summary>Azelastine (Astelin, Astepro - Nasal Spray)</summary>
                <div class="details-content">
                     <ul>
                        <li>H1 receptor antagonist nasal spray.</li>
                        <li><strong>PK:</strong> Rapid onset (~15-30 minutes). Some systemic absorption (~40%).</li>
                        <li><strong>A/E:</strong> <strong>Bitter taste</strong> (dysgeusia), headache, somnolence (can occur due to systemic absorption), nasal irritation.</li>
                        <li>Use: Allergic rhinitis (seasonal/perennial). Effective for nasal congestion, sneezing, itching, rhinorrhea. Often considered second-line after or add-on to nasal steroids.</li>
                     </ul>
                 </div>
            </details>
             <details>
                <summary>Olopatadine (Patanase - Nasal Spray; Pataday/Pazeo - Eye Drops)</summary>
                <div class="details-content">
                     <ul>
                        <li>H1 receptor antagonist with mast cell stabilizing properties.</li>
                        <li><strong>PK:</strong> Nasal spray onset ~30 min. Ocular drops onset within minutes. Lower systemic absorption than azelastine.</li>
                        <li><strong>A/E:</strong> Nasal spray: Epistaxis (nosebleed), headache, altered taste. Eye drops: Local irritation, dry eye, headache.</li>
                        <li><strong>Use:</strong> Nasal spray for allergic rhinitis. Eye drops highly effective for allergic conjunctivitis.</li>
                     </ul>
                 </div>
            </details>


            <h3>Glucocorticoids (Steroids)</h3>
             <details>
                <summary>MOA & Warnings</summary>
                <div class="details-content">
                     <ul>
                        <li><strong>MOA:</strong> Broad anti-inflammatory effects. Bind intracellular glucocorticoid receptors → translocate to nucleus → alter gene transcription. Suppress synthesis of cytokines, chemokines, adhesion molecules. Inhibit phospholipase A2 (via lipocortin), reducing production of prostaglandins and leukotrienes. Decrease inflammatory cell recruitment (eosinophils, lymphocytes). Reduce vascular permeability.</li>
                        <li><strong>Warnings (Systemic effects - dose/duration dependent):</strong> HPA axis suppression, Cushing's syndrome, growth suppression (children), osteoporosis, cataracts, glaucoma, hyperglycemia, immunosuppression, mood changes, skin thinning, impaired wound healing.</li>
                     </ul>
                 </div>
            </details>
             <details>
                <summary>Topical (Intranasal) Steroids (INS)</summary>
                <div class="details-content">
                     <ul>
                        <li>Examples: Fluticasone propionate (Flonase), Fluticasone furoate (Flonase Sensimist), Mometasone (Nasonex), Budesonide (Rhinocort Aqua), Ciclesonide (Omnaris, Zetonna), Beclomethasone (Beconase AQ, Qnasl), Triamcinolone (Nasacort AQ).</li>
                        <li><strong>Most effective single maintenance therapy</strong> for allergic rhinitis, particularly for nasal congestion.</li>
                        <li>Mechanism: Reduce local inflammation, eosinophils, mast cells, mediator release.</li>
                        <li>Onset: May take hours to days for initial effect, full effect after 1-2 weeks of regular use.</li>
                        <li>Bioavailability varies (lower with fluticasone furoate, mometasone, ciclesonide = potentially fewer systemic effects).</li>
                        <li><strong>A/E (Local):</strong> Nasal dryness, burning, stinging, epistaxis (most common), headache. Rare: nasal septal perforation (improper technique). Systemic effects minimal at standard doses but possible with high doses/long term.</li>
                        <li><strong>Use:</strong> First-line for moderate-to-severe or persistent allergic rhinitis. Also used for non-allergic rhinitis, nasal polyps.</li>
                     </ul>
                 </div>
            </details>
             <details>
                <summary>Systemic Steroids</summary>
                <div class="details-content"><p>Oral or parenteral steroids (e.g., Prednisone) generally NOT used for routine allergic rhinitis due to systemic side effects. May be considered for short bursts (e.g., 5-7 days) for severe, refractory symptoms or severe nasal polyposis, often as bridge to other therapies.</p></div>
            </details>

            <h3>Leukotriene Modifiers</h3>
            <details>
                <summary>Montelukast (Singulair)</summary>
                <div class="details-content">
                     <ul>
                        <li>MOA: Selective cysteinyl leukotriene receptor (CysLT1) antagonist. Blocks effects of LTC4, LTD4, LTE4.</li>
                        <li><strong>Use:</strong> Allergic rhinitis (seasonal/perennial), asthma prophylaxis/maintenance. Oral tablet, once daily. Less effective than INS for rhinitis, especially congestion. May be useful add-on or alternative, particularly if comorbid asthma.</li>
                        <li><strong>A/E:</strong> Generally well-tolerated. Headache, GI upset. **Neuropsychiatric events** (agitation, aggression, anxiety, depression, sleep disturbances, suicidal ideation) - **FDA Black Box Warning**. Rare: Churg-Strauss syndrome (eosinophilic granulomatosis with polyangiitis - potentially related to steroid withdrawal).</li>
                     </ul>
                 </div>
            </details>
            <!-- Zafirlukast & Zileuton rarely used for rhinitis -->

            <h3>Mast Cell Stabilizers (Chromones)</h3>
             <details>
                <summary>Cromolyn Sodium (NasalCrom - Nasal Spray; Opticrom - Eye Drops)</summary>
                <div class="details-content">
                     <ul>
                        <li><strong>MOA:</strong> Stabilizes mast cells, preventing degranulation and release of histamine/other mediators upon allergen exposure. May also inhibit neuronal reflexes.</li>
                        <li><strong>PK:</strong> Poorly absorbed systemically.</li>
                        <li><strong>Use:</strong> Prophylactic treatment of allergic rhinitis/conjunctivitis. Must be used regularly *before* exposure. Less effective than INS or antihistamines. Requires frequent dosing (3-4 times daily). Excellent safety profile.</li>
                        <li><strong>A/E:</strong> Local irritation (nasal stinging, sneezing; eye burning).</li>
                     </ul>
                 </div>
            </details>
            <!-- Nedocromil not available in US -->

            <h3>Anticholinergic Agents</h3>
            <details>
                <summary>Ipratropium Bromide Nasal Spray (Atrovent Nasal)</summary>
                <div class="details-content">
                     <ul>
                        <li>MOA: Non-selective muscarinic antagonist. Blocks acetylcholine effects on nasal glands, reducing watery secretions.</li>
                        <li>Quaternary amine = poorly absorbed, minimal systemic effects, does not cross BBB.</li>
                        <li><strong>Use:</strong> Primarily effective for reducing <strong>rhinorrhea</strong> (runny nose) associated with allergic or non-allergic (vasomotor) rhinitis. Little effect on sneezing, itching, or congestion.</li>
                        <li>Dosing: Usually 2 sprays per nostril 2-3 times daily.</li>
                        <li><strong>A/E:</strong> Nasal dryness, epistaxis (common). Rare systemic anticholinergic effects (dry mouth, blurred vision, urinary retention - use caution in glaucoma, BPH).</li>
                     </ul>
                 </div>
            </details>

            <h3>Decongestants (Alpha-Adrenergic Agonists)</h3>
             <details>
                <summary>Topical (Nasal Sprays/Drops)</summary>
                <div class="details-content">
                     <ul>
                        <li>MOA: Alpha-1 agonists cause vasoconstriction of nasal mucosal blood vessels, reducing swelling and congestion.</li>
                        <li>Examples: <strong>Oxymetazoline</strong> (Afrin), Phenylephrine (Neo-Synephrine), Naphazoline (Privine), Xylometazoline.</li>
                        <li>Characteristics: Rapid onset (seconds to minutes), highly effective for temporary congestion relief.</li>
                        <li><strong>A/E:</strong> Local stinging/burning/dryness. **Rhinitis Medicamentosa (Rebound Congestion):** Occurs with use for > 3-5 consecutive days. Downregulation of alpha receptors leads to worsening congestion when spray stopped, prompting further use (vicious cycle).</li>
                        <li><strong>Use:</strong> Short-term relief (≤ 3 days) of severe congestion (e.g., during URI, before air travel). Not for chronic rhinitis.</li>
                     </ul>
                 </div>
            </details>
             <details>
                <summary>Systemic (Oral)</summary>
                <div class="details-content">
                     <ul>
                        <li>Examples: Pseudoephedrine (Sudafed - behind-the-counter), Phenylephrine (Sudafed PE - OTC).</li>
                        <li>Characteristics: Less intense, slower onset, longer duration than topical. Less rebound congestion.</li>
                        <li><strong>A/E (Systemic):</strong> CNS stimulation (insomnia, anxiety, tremor), cardiovascular effects (tachycardia, palpitations, <strong>increased blood pressure</strong>), urinary retention (esp. BPH).</li>
                        <li><strong>Contraindications/Cautions:</strong> Uncontrolled HTN, severe CAD, MAOI use within 14 days. Use caution in controlled HTN, heart disease, hyperthyroidism, diabetes, glaucoma, BPH. Phenylephrine generally less effective than pseudoephedrine orally due to high first-pass metabolism.</li>
                        <li>Use: Temporary relief of nasal congestion associated with URI or allergic rhinitis. Often found in combination cold/allergy products.</li>
                     </ul>
                 </div>
            </details>

            <h3>Immunotherapy</h3>
            <details>
                <summary>Omalizumab (Xolair - Anti-IgE)</summary>
                <div class="details-content">
                     <ul>
                        <li>MOA: Recombinant humanized monoclonal antibody that binds to free IgE, preventing it from binding to mast cells/basophils, reducing allergic response.</li>
                        <li>Use: Primarily approved for moderate-to-severe persistent <strong>allergic asthma</strong> inadequately controlled on ICS. Also approved for chronic idiopathic urticaria and nasal polyps. Sometimes used off-label for severe refractory allergic rhinitis.</li>
                        <li>Administration: Subcutaneous injection every 2-4 weeks (dose based on IgE level/weight). Expensive.</li>
                        <li>A/E: Injection site reactions. **Anaphylaxis** (Black Box Warning - can occur anytime). Potential small increased risk of cardiovascular events, malignancy (controversial).</li>
                     </ul>
                 </div>
            </details>
            <details>
                <summary>Allergen Immunotherapy (AIT)</summary>
                <div class="details-content">
                     <p>Process of administering gradually increasing doses of specific allergens to induce immune tolerance.</p>
                     <ul>
                        <li>Types:
                            <ul>
                                <li><strong>Subcutaneous Immunotherapy (SCIT):</strong> "Allergy shots". Administered in physician's office. Build-up phase then maintenance phase (3-5 years). Most established form.</li>
                                <li><strong>Sublingual Immunotherapy (SLIT):</strong> Tablets or drops placed under tongue daily at home. Available for specific allergens (grass pollens, ragweed, dust mites).</li>
                            </ul>
                        </li>
                        <li>Use: Moderate-severe allergic rhinitis/conjunctivitis and/or allergic asthma confirmed by IgE testing (skin or serum specific IgE) when symptoms poorly controlled by meds/avoidance, or patient prefers potential for long-term remission.</li>
                        <li>Mechanism: Shifts immune response from Th2 (allergic) towards Th1/Treg (tolerance), increases IgG4 blocking antibodies.</li>
                        <li>A/E: Local reactions common (itching/swelling at injection site or mouth). Systemic allergic reactions possible (esp. SCIT, requires observation period post-injection, patient must carry epinephrine auto-injector). Anaphylaxis rare but possible.</li>
                     </ul>
                 </div>
            </details>

            <h3>Surgery</h3>
            <details>
                <summary>Indications</summary>
                <div class="details-content"><p>Considered for structural issues or complications refractory to medical therapy:</p>
                <ul>
                    <li>Functional Endoscopic Sinus Surgery (FESS): For chronic rhinosinusitis (CRS) unresponsive to medical therapy, especially with nasal polyps or fungal sinusitis. Aims to enlarge sinus ostia, remove diseased tissue/polyps, improve drainage.</li>
                    <li>Septoplasty: Corrects deviated nasal septum causing significant obstruction.</li>
                    <li>Turbinate Reduction (Turbinoplasty): Reduces size of hypertrophied inferior turbinates causing obstruction refractory to medical therapy (e.g., INS).</li>
                </ul>
                </div>
            </details>

            <hr class="my-6 border-[--border-color] border-dashed opacity-50">

            <h3>Acute Rhinosinusitis (ARS) - Treatment Focused</h3>
             <details>
                <summary>Definition & Causes</summary>
                <div class="details-content">
                     <ul>
                        <li>Symptomatic inflammation of nasal cavity and paranasal sinuses lasting < 4 weeks.</li>
                        <li>Vast majority (~90-98%) caused by <strong>viruses</strong> (rhinovirus, influenza, parainfluenza, adenovirus).</li>
                        <li>Acute Bacterial Rhinosinusitis (ABRS) develops as complication in small percentage (~0.5-2%).</li>
                        <li>Common bacterial pathogens in ABRS:
                            <ul>
                                <li><strong><em>Streptococcus pneumoniae</em></strong> (~30-40%)</li>
                                <li><strong><em>Haemophilus influenzae</em></strong> (non-typeable) (~30-40%)</li>
                                <li><em>Moraxella catarrhalis</em> (~10-20%)</li>
                                <li><em>Staphylococcus aureus</em>, other Strep species, anaerobes (less common, more in chronic/odontogenic source).</li>
                            </ul>
                        </li>
                     </ul>
                 </div>
            </details>
             <details>
                <summary>Antibiotic Selection (for ABRS)</summary>
                <div class="details-content">
                     <p>Antibiotics indicated only if criteria for ABRS met (persistent ≥10d, severe onset ≥3d, or worsening/"double sickening"). Observation ("watchful waiting") is an option for non-severe cases.</p>
                     <ul>
                        <li><strong>First-line Therapy (Standard Dose):</strong> <strong>Amoxicillin-clavulanate</strong> (Augmentin). Preferred over amoxicillin alone due to H. flu/M. cat resistance (beta-lactamase production).</li>
                        <li><strong>High-Dose Amoxicillin-clavulanate (2g BID or 90mg/kg/day peds):</strong> Recommended if: Geographic region with high rates (>10%) of invasive penicillin-non-susceptible S. pneumoniae, severe infection (fever >39C, systemic illness), age >65, recent hospitalization, antibiotic use within past month, immunocompromise, daycare attendance (peds).</li>
                        <li><strong>Penicillin Allergy:</strong>
                            <ul>
                                <li>Non-anaphylactic allergy: Oral 3rd gen cephalosporin (Cefixime, Cefpodoxime) + Clindamycin OR Doxycycline (adults/older children) OR Levofloxacin/Moxifloxacin (adults).</li>
                                <li>Anaphylactic allergy: Doxycycline OR Levofloxacin/Moxifloxacin. Clindamycin alone has poor G- coverage.</li>
                            </ul>
                        </li>
                        <li>Duration: <strong>5-7 days for uncomplicated ABRS in adults</strong>. 10-14 days for children or complicated cases.</li>
                     </ul>
                 </div>
            </details>
            <details>
                <summary>Adjunctive Therapies</summary>
                <div class="details-content">
                     <ul>
                        <li><strong>Intranasal Saline Irrigation:</strong> Recommended, helps clear secretions.</li>
                        <li><strong>Intranasal Corticosteroids:</strong> Recommended, particularly if underlying allergic rhinitis. Reduces inflammation, may shorten duration/severity.</li>
                        <li>Analgesics/Antipyretics (Acetaminophen, Ibuprofen): For pain/fever relief.</li>
                        <li><strong>Not Generally Recommended:</strong> Oral/Topical Decongestants (limited evidence, side effects), Antihistamines (unless underlying allergy, may thicken secretions). Antifungals only if fungal sinusitis confirmed.</li>
                     </ul>
                 </div>
            </details>
             <details>
                <summary>Therapy for Non-Responders (Failure after 3-5 days)</summary>
                <div class="details-content">
                     <ul>
                        <li>Reassess diagnosis (could it be non-bacterial? Complication?).</li>
                        <li>Broaden antibiotic coverage / Switch class (e.g., switch from Augmentin to Respiratory Fluoroquinolone or vice versa). Consider resistant pathogens.</li>
                        <li>Obtain imaging (CT scan) to evaluate for complications (orbital/intracranial extension, abscess, mucocele) or anatomical issues.</li>
                        <li>Consider referral to ENT for sinus culture via endoscopy/puncture if refractory.</li>
                     </ul>
                 </div>
            </details>

            <hr class="my-6 border-[--border-color] border-dashed opacity-50">

            <h3>Acute Pharyngitis (Strep Throat) - Treatment Focused</h3>
             <details>
                <summary>General Info & Diagnosis</summary>
                <div class="details-content">
                     <ul>
                        <li>Most cases (~80-90% adults, ~70% children) are <strong>viral</strong> (adenovirus, rhinovirus, coronavirus, influenza, EBV, HSV, etc.).</li>
                        <li>Bacterial cause: Primarily <strong>Group A Beta-Hemolytic Streptococcus (GABHS / GAS / <em>S. pyogenes</em>)</strong>. Others less common (Groups C/G Strep, Fusobacterium necrophorum - Lemierre's, N. gonorrhoeae, C. diphtheriae, Mycoplasma, Chlamydia).</li>
                        <li>Distinguishing Viral vs. GAS: Clinical criteria (Centor/McIsaac) help assess probability but are not definitive.
                            <ul>
                                <li><strong>Centor Criteria:</strong> Fever (>38C), Absence of Cough, Tender Anterior Cervical Lymphadenopathy, Tonsillar Exudates. (Score 0-1 low risk, 2-3 intermediate, 4 high risk).</li>
                                <li>McIsaac adds Age: 3-14 yrs (+1), 15-44 yrs (0), ≥45 yrs (-1).</li>
                            </ul>
                        </li>
                        <li>Testing: Recommended for scores ≥ 2-3.
                            <ul>
                                <li><strong>Rapid Antigen Detection Test (RADT):</strong> High specificity (~95%), variable sensitivity (~70-90%).</li>
                                <li><strong>Throat Culture:</strong> Gold standard. Perform if RADT negative in children/adolescents (due to ARF risk). Not needed if RADT negative in adults.</li>
                            </ul>
                        </li>
                     </ul>
                 </div>
            </details>
             <details>
                <summary>Complications of GABHS</summary>
                <div class="details-content">
                     <ul>
                        <li><strong>Suppurative (Direct extension/spread):</strong> Peritonsillar abscess (PTA), Retropharyngeal abscess (RPA), Otitis Media, Sinusitis, Mastoiditis, Cervical Lymphadenitis, Bacteremia (rare).</li>
                        <li><strong>Non-suppurative (Immune-mediated, delayed):</strong>
                            <ul>
                                <li><strong>Acute Rheumatic Fever (ARF):</strong> Occurs 2-4 weeks after untreated/inadequately treated GAS pharyngitis. Inflammatory disease affecting heart (carditis, valvular damage), joints (migratory polyarthritis), skin (erythema marginatum, subcutaneous nodules), CNS (Sydenham chorea). **Preventable with timely antibiotic treatment (within 9 days of onset)**.</li>
                                <li><strong>Post-Streptococcal Glomerulonephritis (PSGN):</strong> Occurs 1-3 weeks after GAS pharyngitis OR skin infection (impetigo). Immune complex deposition in glomeruli → hematuria, edema, hypertension, renal insufficiency. **Not preventable with antibiotics**.</li>
                                <li>Scarlet Fever: Rash (sandpaper texture, spares palms/soles, Pastia's lines) + strawberry tongue, associated with GAS toxin.</li>
                                <li>PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections): Controversial association with OCD/tics.</li>
                            </ul>
                        </li>
                     </ul>
                 </div>
            </details>
            <details>
                <summary>Treatment</summary>
                <div class="details-content">
                     <ul>
                        <li>Viral Pharyngitis: Symptomatic relief (analgesics, fluids, lozenges, rest).</li>
                        <li>GAS Pharyngitis: Antibiotics recommended to prevent ARF, shorten duration slightly, reduce transmission.
                            <ul>
                                <li><strong>First-line: Penicillin V</strong> (oral, 10 days) or <strong>Amoxicillin</strong> (oral, 10 days - often preferred peds). Benzathine Penicillin G (IM, single dose) if adherence is a concern.</li>
                                <li><strong>Penicillin Allergy:</strong>
                                    <ul>
                                        <li>Non-anaphylactic: Cephalexin or Cefadroxil (1st gen Ceph, 10 days).</li>
                                        <li>Anaphylactic: Clindamycin (10 days) OR Macrolides (<strong>Azithromycin</strong> 5 days, Clarithromycin 10 days) - check local resistance.</li>
                                    </ul>
                                </li>
                            </ul>
                        </li>
                        <li>Symptomatic relief alongside antibiotics.</li>
                     </ul>
                 </div>
            </details>
        </div> <!-- End Section: Pharmacology Rhinitis/Allergy -->

        <div class="pixel-art-divider"></div>

        <!-- Section: Pharmacology Resp Infections -->
        <div id="pharmacology-resp-infections" class="content-section">
            <svg viewBox="0 0 16 16" xmlns="http://www.w3.org/2000/svg" class="section-svg"><path d="M1 1H3V2H1V1ZM4 1H6V2H4V1ZM7 1H9V2H7V1ZM10 1H12V2H10V1ZM13 1H15V2H13V1ZM1 3H2V4H1V3ZM3 3H4V4H3V3ZM5 3H6V4H5V3ZM7 3H8V4H7V3ZM9 3H10V4H9V3ZM11 3H12V4H11V3ZM13 3H14V4H13V3ZM15 3H16V4H15V3ZM1 5H2V6H1V5ZM3 5H4V6H3V5ZM5 5H6V6H5V5ZM6 6H7V7H6V6ZM7 7H8V8H7V7ZM8 8H9V9H8V8ZM9 9H10V10H9V9ZM10 10H11V11H10V10ZM11 11H12V12H11V11ZM12 12H13V13H12V12ZM13 13H14V14H13V13ZM14 14H15V15H14V14ZM15 15H16V16H15V15ZM13 15H14V16H13V15ZM11 15H12V16H11V15ZM9 15H10V16H9V15ZM7 15H8V16H7V15ZM5 15H6V16H5V15ZM3 15H4V16H3V15ZM1 15H2V16H1V15ZM1 13H2V14H1V13ZM1 11H2V12H1V11ZM1 9H2V10H1V9ZM1 7H2V8H1V7ZM4 7H5V8H4V7ZM6 8H5V9H6V8ZM7 9H6V10H7V9ZM8 10H7V11H8V10ZM9 11H8V12H9V11ZM10 12H9V13H10V12ZM11 13H10V14H11V13ZM12 14H11V15H12V14ZM13 11H14V12H13V11ZM14 10H15V11H14V10ZM15 9H16V10H15V9ZM15 7H16V8H15V7ZM15 5H16V6H15V5ZM12 5H13V6H12V5ZM10 5H11V6H10V5ZM8 5H9V6H8V5ZM10 7H11V8H10V7ZM12 7H13V8H12V7ZM11 9H12V10H11V9ZM9 7H10V8H9V7Z" fill="currentColor"/></svg>
            <h2>Pharmacology: Drugs for Respiratory Infections</h2>

             <h3>General Antibiotic Classes</h3>
             <details>
                <summary>Beta-lactams (Penicillins, Cephalosporins, Carbapenems, Monobactams)</summary>
                <div class="details-content">
                     <ul>
                        <li><strong>MOA:</strong> Inhibit bacterial cell wall synthesis by binding to Penicillin-Binding Proteins (PBPs, transpeptidases), preventing peptidoglycan cross-linking. Generally Bactericidal. Time-dependent killing.</li>
                        <li><strong>Resistance:</strong> Beta-lactamase enzymes (hydrolyze beta-lactam ring - overcome by adding inhibitor like clavulanate, sulbactam, tazobactam), altered PBPs (e.g., MRSA), decreased permeability.</li>
                        <li><strong>A/E:</strong> Hypersensitivity reactions (most common - rash to anaphylaxis), GI upset, diarrhea, C. difficile colitis, seizures (esp. imipenem at high doses/renal failure), interstitial nephritis, hematologic effects (rare).</li>
                        <li><strong>Spectrum varies widely:</strong>
                            <ul>
                                <li>Natural PCNs (Pen G, Pen V): Strep, some anaerobes.</li>
                                <li>Aminopenicillins (Amoxicillin, Ampicillin): Strep, Enterococcus, some GNRs (H. flu, E. coli - resistance common).</li>
                                <li>Anti-staphylococcal PCNs (Nafcillin, Oxacillin, Dicloxacillin): MSSA, Strep.</li>
                                <li>Extended-spectrum (Anti-pseudomonal) PCNs (Piperacillin): Broad GNR coverage including Pseudomonas, GPC, anaerobes. Usually combined with Tazobactam.</li>
                                <li>Cephalosporins (Generations 1-5): Increasing GNR coverage, decreasing GPC coverage (gen 1-3); Gen 4 (Cefepime) broad GPC/GNR including Pseudomonas; Gen 5 (Ceftaroline) covers MRSA.</li>
                                <li>Carbapenems (Imipenem, Meropenem, Ertapenem, Doripenem): Very broad spectrum (GPC, GNR including Pseudomonas [except Ertapenem], ESBL producers, anaerobes). Reserved for resistant infections.</li>
                                <li>Monobactams (Aztreonam): Gram-negative aerobic coverage ONLY (including Pseudomonas). No cross-reactivity with other beta-lactams (except ceftazidime) - useful in severe PCN allergy.</li>
                            </ul>
                        </li>
                     </ul>
                 </div>
            </details>
            <details>
                <summary>Macrolides</summary>
                <div class="details-content">
                     <ul>
                        <li>Examples: <strong>Azithromycin, Clarithromycin, Erythromycin</strong>.</li>
                        <li><strong>MOA:</strong> Inhibit protein synthesis by binding reversibly to the 50S ribosomal subunit, blocking translocation. Generally Bacteriostatic.</li>
                        <li><strong>Spectrum:</strong> Good coverage of "Atypical" pathogens (<em>Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella pneumophila</em>). Also covers some GPC (Strep pneumo - resistance increasing, GAS) and some GNRs (H. flu, M. catarrhalis). Azithromycin has best GNR activity.</li>
                        <li><strong>A/E:</strong> <strong>GI distress</strong> (N/V/D - esp. Erythromycin due to motilin agonism), metallic taste (Clarithro), cholestatic hepatitis (rare), <strong>QT prolongation</strong> (risk of Torsades de Pointes), hypersensitivity.</li>
                        <li><strong>Interactions:</strong> Erythromycin and Clarithromycin are potent CYP3A4 inhibitors (increase levels of warfarin, statins, etc.). Azithromycin has fewer interactions.</li>
                        <li>Use: CAP (esp. outpatient, or combination inpatient), Strep throat (PCN allergy), Pertussis, Chlamydia infections, MAC prophylaxis/treatment.</li>
                     </ul>
                 </div>
            </details>
             <details>
                <summary>Clindamycin</summary>
                <div class="details-content">
                     <ul>
                        <li><strong>MOA:</strong> Lincosamide class. Inhibits protein synthesis by binding to 50S ribosomal subunit (overlaps with macrolide site). Bacteriostatic.</li>
                        <li><strong>Spectrum:</strong> Excellent activity against Gram-positive cocci (Strep, Staph including many <strong>CA-MRSA</strong> strains) and most <strong>Anaerobes</strong> (including above-diaphragm anaerobes like Peptostreptococcus, Fusobacterium; also B. fragilis). Poor GNR coverage.</li>
                        <li><strong>A/E:</strong> <strong>High risk of <em>Clostridioides difficile</em> colitis (pseudomembranous colitis) - Black Box Warning</strong>. Diarrhea, rash, nausea.</li>
                        <li>Use: Skin/soft tissue infections (esp. if MRSA suspected), infections of oral cavity/head/neck, aspiration pneumonia, lung abscess, alternative for GPC infections in PCN-allergic patients, adjunct therapy for toxic shock syndrome (suppresses toxin production).</li>
                     </ul>
                 </div>
            </details>
             <details>
                <summary>Sulfonamides & Trimethoprim (TMP-SMX)</summary>
                <div class="details-content">
                     <ul>
                        <li><strong>MOA:</strong> Sequential blockade of folic acid synthesis. Sulfamethoxazole (SMX) inhibits dihydropteroate synthase (competes with PABA). Trimethoprim (TMP) inhibits dihydrofolate reductase. Bacteriostatic alone, Bactericidal in combination (TMP-SMX).</li>
                        <li><strong>Spectrum:</strong> Broad coverage including many GPC (Staph including many MRSA, Strep pneumo - resistance varies), many GNRs (Enterobacterales - resistance increasing, H. flu, M. cat), *Nocardia*, *Stenotrophomonas maltophilia*, *Toxoplasma gondii*, <strong>*Pneumocystis jirovecii*</strong>. Poor anaerobic coverage.</li>
                        <li><strong>A/E:</strong> <strong>Hypersensitivity reactions</strong> (rash, urticaria, photosensitivity, Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis - SJS/TEN), GI upset, bone marrow suppression (anemia, leukopenia, thrombocytopenia - esp. with prolonged use/folate deficiency), hyperkalemia (TMP effect), crystalluria/renal damage (SMX - maintain hydration), hemolytic anemia (in G6PD deficiency).</li>
                        <li><strong>Use:</strong> UTIs, <strong>PJP treatment and prophylaxis</strong>, Nocardiosis, Stenotrophomonas infections, skin/soft tissue infections (CA-MRSA), traveler's diarrhea, sinusitis/otitis (less common now due to resistance).</li>
                        <li><strong>Contraindications:</strong> Sulfa allergy, G6PD deficiency, pregnancy (esp. 1st/3rd trimester - kernicterus risk), infants <2 months, megaloblastic anemia due to folate deficiency.</li>
                     </ul>
                 </div>
            </details>
             <details>
                <summary>Tetracyclines</summary>
                <div class="details-content">
                     <ul>
                        <li>Examples: <strong>Doxycycline</strong>, Minocycline, Tetracycline. Tigecycline (glycylcycline derivative).</li>
                        <li><strong>MOA:</strong> Inhibit protein synthesis by binding reversibly to the 30S ribosomal subunit, preventing tRNA binding. Bacteriostatic.</li>
                        <li><strong>Spectrum:</strong> Broad, including "Atypicals" (Mycoplasma, Chlamydia, Rickettsia, Ehrlichia), Spirochetes (Borrelia - Lyme, Treponema - Syphilis), some GPC (Staph including some MRSA, Strep pneumo - resistance varies), some GNRs (H. flu, M. cat). Good activity against Plasmodium (malaria prophylaxis/tx).</li>
                        <li><strong>A/E:</strong> GI upset (N/V/D, esophagitis - take with water, remain upright), <strong>photosensitivity</strong>, deposition in developing bones and teeth causing <strong>permanent tooth discoloration</strong> (contraindicated in pregnancy and children < 8 years), hepatotoxicity (rare), dizziness/vertigo (Minocycline).</li>
                        <li>Use: CAP (outpatient alternative/combo), skin/soft tissue infections (CA-MRSA, acne), tick-borne diseases (Lyme, RMSF, Ehrlichiosis), STIs (Chlamydia), malaria prophylaxis/treatment.</li>
                     </ul>
                 </div>
            </details>
            <details>
                <summary>Fluoroquinolones (FQs)</summary>
                <div class="details-content">
                     <ul>
                        <li>Examples: Ciprofloxacin, Levofloxacin, Moxifloxacin, Gemifloxacin, Delafloxacin.</li>
                        <li><strong>MOA:</strong> Inhibit bacterial DNA replication by targeting DNA gyrase (topoisomerase II) and topoisomerase IV. Bactericidal. Concentration-dependent killing.</li>
                        <li><strong>Spectrum:</strong>
                            <ul>
                                <li>Ciprofloxacin: Excellent GNR coverage including Pseudomonas. Weak GPC and atypical coverage.</li>
                                <li>"Respiratory Quinolones" (<strong>Levo, Moxi, Gemi</strong>): Enhanced GPC (esp. Strep pneumo) and atypical coverage compared to Cipro. Levo retains Pseudomonas activity; Moxi has better anaerobic activity but loses Pseudomonas. Gemi primarily respiratory pathogens.</li>
                                <li>Delafloxacin: Broadest; covers GPC (including MRSA), GNRs (including Pseudomonas), atypicals, anaerobes.</li>
                            </ul>
                        </li>
                        <li><strong>A/E:</strong> GI upset, CNS effects (dizziness, headache, confusion, hallucinations, seizures), <strong>tendinitis/tendon rupture</strong> (Achilles most common - Black Box Warning), <strong>peripheral neuropathy</strong> (can be permanent - BBW), <strong>QT prolongation</strong> (risk of Torsades - esp. Moxi), photosensitivity, dysglycemia (hyper/hypo), aortic aneurysm/dissection risk (BBW), C. difficile colitis, mental health side effects (BBW). Use should be reserved for situations where benefits outweigh risks.</li>
                        <li>Use: CAP (Resp FQs), HAP/VAP, complicated UTIs/pyelonephritis (Cipro/Levo), prostatitis, intra-abdominal infections (Moxi or others + Metronidazole), bone/joint infections, traveler's diarrhea (Cipro).</li>
                     </ul>
                 </div>
            </details>
            <details>
                <summary>Aminoglycosides</summary>
                <div class="details-content">
                     <ul>
                        <li>Examples: Gentamicin, Tobramycin, Amikacin, Streptomycin, Plazomicin.</li>
                        <li><strong>MOA:</strong> Inhibit protein synthesis by irreversibly binding to 30S ribosomal subunit, causing mRNA misreading and premature termination. Bactericidal. Concentration-dependent killing with post-antibiotic effect (PAE).</li>
                        <li><strong>Spectrum:</strong> Excellent aerobic Gram-negative coverage (including Pseudomonas). Used synergistically with cell wall agents (beta-lactams or vancomycin) for serious Gram-positive infections (e.g., Staph/Enterococcal endocarditis). Streptomycin used for TB, Tularemia, Plague.</li>
                        <li><strong>A/E:</strong> <strong>Nephrotoxicity</strong> (ATN, reversible), <strong>Ototoxicity</strong> (irreversible auditory/vestibular damage), neuromuscular blockade (rare, risk with rapid infusion or myasthenia gravis). Require therapeutic drug monitoring (TDM - peak/trough or AUC monitoring with extended-interval dosing).</li>
                        <li>Use: Serious GNR infections (sepsis, pneumonia - HAP/VAP, complicated UTI), often in combination therapy. Inhaled Tobramycin for CF.</li>
                     </ul>
                 </div>
            </details>
             <details>
                <summary>Vancomycin</summary>
                <div class="details-content">
                     <ul>
                        <li><strong>MOA:</strong> Glycopeptide. Inhibits cell wall synthesis by binding tightly to D-Alanyl-D-Alanine terminus of peptidoglycan precursors, blocking transglycosylation and transpeptidation. Bactericidal (slowly).</li>
                        <li><strong>Spectrum:</strong> Gram-positive organisms ONLY, including MRSA, Methicillin-resistant S. epidermidis (MRSE), Enterococcus (not VRE), Penicillin-resistant Strep pneumo. Oral formulation (not absorbed) used ONLY for <em>C. difficile</em> colitis.</li>
                        <li><strong>A/E:</strong> <strong>Nephrotoxicity</strong> (risk increases with higher troughs, duration, concomitant nephrotoxins), Ototoxicity (rare), <strong>Red Man Syndrome</strong> (infusion-related histamine release - flushing, itching, rash on face/neck/upper torso; slow infusion rate, premedicate with antihistamines), thrombocytopenia, neutropenia (rare). Requires TDM (trough levels typically targeted).</li>
                        <li>Use: Serious MRSA infections (bacteremia, endocarditis, pneumonia, osteomyelitis), empiric coverage for severe infections where MRSA suspected (e.g., severe CAP, HAP/VAP, sepsis), treatment of serious GPC infections in patients with severe beta-lactam allergy.</li>
                     </ul>
                 </div>
            </details>
            <details>
                <summary>Linezolid</summary>
                <div class="details-content">
                     <ul>
                        <li><strong>MOA:</strong> Oxazolidinone class. Unique mechanism - inhibits protein synthesis by binding to 50S ribosomal subunit near interface with 30S, preventing formation of the 70S initiation complex. Bacteriostatic (bactericidal vs Strep).</li>
                        <li><strong>Spectrum:</strong> Gram-positive organisms ONLY, including MRSA, VRE (both E. faecalis and E. faecium), Penicillin-resistant Strep pneumo. Also covers Nocardia, some Mycobacteria.</li>
                        <li><strong>A/E:</strong> <strong>Bone marrow suppression</strong> (thrombocytopenia, anemia, leukopenia - esp. with use > 2 weeks, requires monitoring), peripheral neuropathy and optic neuropathy (with prolonged use > 28 days, can be irreversible), lactic acidosis (rare), nausea, diarrhea. Weak, reversible, non-selective MAOI activity - risk of <strong>serotonin syndrome</strong> if co-administered with SSRIs, SNRIs, other serotonergic agents (requires careful monitoring/avoidance).</li>
                        <li>Use: Pneumonia (HAP/VAP) caused by MRSA, complicated skin/soft tissue infections (MRSA), VRE infections. Good oral bioavailability (IV to PO switch easy).</li>
                     </ul>
                 </div>
            </details>
            <!-- Add other classes if needed: Metronidazole, Rifampin, etc. -->

            <h3>Specific Infection Management Notes</h3>
             <details>
                <summary>Diphtheria</summary>
                <div class="details-content">
                     <ul>
                        <li>Agent: Corynebacterium diphtheriae (toxigenic strains).</li>
                        <li>Key feature: Pharyngeal pseudomembranes (gray, adherent), sore throat, fever, potential for airway obstruction, myocarditis, neuropathy due to exotoxin.</li>
                        <li>Tx: <strong>Diphtheria Antitoxin</strong> (equine) to neutralize unbound toxin + Antibiotics (<strong>Penicillin G</strong> IV/IM or <strong>Erythromycin</strong> PO/IV x 14 days) to eradicate bacteria. Respiratory isolation.</li>
                     </ul>
                 </div>
            </details>
             <details>
                <summary>Acute Bronchitis</summary>
                <div class="details-content">
                     <ul>
                        <li>Inflammation of large airways, usually viral (>90%). Presents with cough (+/- sputum, often follows URI), lasts 1-3 weeks. Wheezing may occur.</li>
                        <li>Tx: Primarily supportive (rest, fluids, antitussives if cough severe/disruptive - limited evidence). Bronchodilators (e.g., albuterol) if wheezing present.</li>
                        <li><strong>Antibiotics are NOT recommended</strong> for uncomplicated acute bronchitis as cause is usually viral. Consider antibiotics only if pertussis suspected or high suspicion of bacterial pneumonia develops.</li>
                        <li>Antivirals (Oseltamivir, Zanamivir, Baloxavir) only if Influenza confirmed/suspected within 48h of onset during flu season.</li>
                     </ul>
                 </div>
            </details>
             <details>
                <summary>Pneumonia - General Tx Principles</summary>
                <div class="details-content">
                     <p>See Microbiology Table 2 for specific pathogen/syndrome treatments.</p>
                     <ul>
                        <li><strong>Community-acquired pneumonia (CAP):</strong>
                            <ul>
                                <li>Severity assessment (CURB-65, PSI) guides site of care (outpatient vs inpatient vs ICU).</li>
                                <li>Empiric therapy targets most likely pathogens (S. pneumo, atypicals, H. flu, viruses).</li>
                                <li>Duration typically 5-7 days if clinically improving.</li>
                            </ul>
                        </li>
                         <li><strong>Hospital-acquired pneumonia (HAP) / Ventilator-associated pneumonia (VAP):</strong>
                            <ul>
                                <li>Higher risk of resistant pathogens (MRSA, Pseudomonas, ESBLs, Acinetobacter).</li>
                                <li>Empiric therapy based on patient risk factors for MDR organisms and local antibiogram. Often requires broad-spectrum coverage initially.</li>
                                <li>De-escalate therapy based on culture results. Duration typically 7 days.</li>
                            </ul>
                         </li>
                         <li><strong>CURB-65 Score (1 point each):</strong>
                            <ul>
                                <li><strong>C</strong>onfusion (New onset)</li>
                                <li><strong>U</strong>rea > 7 mmol/L (BUN > 19 mg/dL)</li>
                                <li><strong>R</strong>espiratory rate ≥ 30 breaths/min</li>
                                <li><strong>B</strong>lood pressure (Systolic < 90 mmHg or Diastolic ≤ 60 mmHg)</li>
                                <li>Age ≥ <strong>65</strong> years</li>
                                <li>Score 0-1: Outpatient; Score 2: Consider Inpatient; Score ≥ 3: Inpatient (often ICU).</li>
                            </ul>
                         </li>
                     </ul>
                 </div>
            </details>
             <details>
                <summary>Chronic Bronchitis Exacerbation (AECOPD)</summary>
                <div class="details-content">
                     <ul>
                        <li>Acute worsening of respiratory symptoms (dyspnea, cough, sputum) beyond normal day-to-day variation. Often triggered by infection (viral or bacterial) or environmental factors.</li>
                        <li>Tx: Optimize bronchodilators (SABA +/- SAMA). Systemic corticosteroids (e.g., Prednisone 40mg x 5 days). Supplemental O2. Consider non-invasive ventilation if respiratory failure.</li>
                        <li><strong>Antibiotics:</strong> Recommended if patient has increased sputum purulence PLUS either increased dyspnea or increased sputum volume (2 of 3 Cardinal Symptoms - Anthonisen criteria), OR if requiring mechanical ventilation.
                            <ul>
                                <li>Target likely pathogens (H. flu, S. pneumo, M. cat).</li>
                                <li>Choice depends on local resistance, severity, risk factors (e.g., Amox/Clav, Doxycycline, Azithromycin, Levofloxacin). Duration 5-7 days.</li>
                            </ul>
                        </li>
                     </ul>
                 </div>
            </details>
             <details>
                <summary>Pertussis (Whooping Cough)</summary>
                <div class="details-content">
                     <ul>
                        <li>Agent: Bordetella pertussis.</li>
                        <li>Tx: Primarily supportive. Antibiotics decrease transmission and may shorten duration if started early (catarrhal stage).
                            <ul>
                                <li>First-line: <strong>Macrolides</strong> (Azithromycin preferred, esp. infants <1mo; Clarithromycin; Erythromycin).</li>
                                <li>Alternative (>2mo): TMP-SMX.</li>
                            </ul>
                        </li>
                        <li>Treat patient AND provide post-exposure prophylaxis to close contacts.</li>
                     </ul>
                 </div>
            </details>
             <details>
                <summary>Adjunctive Therapies for Cough</summary>
                <div class="details-content">
                     <ul>
                        <li>Antitussives (cough suppressants):
                            <ul>
                                <li>Centrally acting: Dextromethorphan (OTC), Codeine/Hydrocodone (opioids, prescription). Limited evidence for acute cough, potential side effects (sedation, constipation). May help chronic cough or sleep disruption.</li>
                                <li>Peripherally acting: Benzonatate (Tessalon Perles).</li>
                            </ul>
                        </li>
                        <li>Expectorants (e.g., Guaifenesin): Questionable efficacy for acute cough.</li>
                        <li>Honey (for children > 1 year): Some evidence for nighttime cough relief.</li>
                        <li>Bronchodilators: Only if associated wheezing/bronchospasm.</li>
                     </ul>
                 </div>
            </details>

             <h3>Antifungal / Anti-TB / Anti-Parasitic / Other</h3>
              <details>
                <summary>Pulmonary TB</summary>
                <div class="details-content">
                     <ul>
                        <li>Standard initial phase (2 months): <strong>RIPE</strong> (Rifampin, Isoniazid, Pyrazinamide, Ethambutol).</li>
                        <li>Continuation phase (4 months): INH + RIF.</li>
                        <li>Monitor for toxicity: Hepatotoxicity (INH, RIF, PZA), Optic neuritis (EMB - check vision/color), Peripheral neuropathy (INH - give Pyridoxine/B6 concurrently), Hyperuricemia (PZA), Drug interactions (esp. RIF - potent CYP inducer).</li>
                     </ul>
                 </div>
            </details>
             <details>
                <summary>Nocardiosis</summary>
                <div class="details-content">
                     <ul>
                        <li>Caused by <em>Nocardia</em> species (Gram-positive, branching, filamentous, weakly acid-fast bacteria). Opportunistic infection, often pulmonary, can disseminate (brain abscess common).</li>
                        <li>Tx: <strong>TMP-SMX</strong> is cornerstone. Duration is long (months). Severe/disseminated disease often requires combination therapy initially (e.g., TMP-SMX + Amikacin + Imipenem/Ceftriaxone). Tailor based on species/susceptibility.</li>
                     </ul>
                 </div>
            </details>
             <details>
                <summary>Pneumocystis jirovecii Pneumonia (PJP)</summary>
                <div class="details-content">
                     <ul>
                        <li>Fungal pneumonia, primarily in immunocompromised (HIV with CD4 < 200, chronic steroids, transplant, chemotherapy).</li>
                        <li>Sx: Subacute onset fever, dry cough, progressive dyspnea. Hypoxia often out of proportion to CXR findings (diffuse bilateral interstitial/ground-glass opacities). Elevated LDH common.</li>
                        <li>Dx: Organism identification in sputum (induced), BAL fluid, or biopsy (GMS or Giemsa stain, immunofluorescence).</li>
                        <li>Tx/Prophylaxis: <strong>TMP-SMX</strong> is first-line (high dose for treatment, lower dose for prophylaxis).
                            <ul>
                                <li>Alternatives (Treatment): Clindamycin + Primaquine (check G6PD); Pentamidine IV (toxic); Atovaquone (mild-mod disease). Add corticosteroids if moderate-severe hypoxemia (PaO2 < 70 or A-a gradient > 35).</li>
                                <li>Alternatives (Prophylaxis): Dapsone, Atovaquone, Pentamidine inhaled.</li>
                            </ul>
                        </li>
                     </ul>
                 </div>
            </details>
            <details>
                <summary>Histoplasmosis</summary>
                <div class="details-content">
                     <ul>
                        <li>Dimorphic fungus (<em>H. capsulatum</em>), endemic to Ohio/Mississippi River Valleys. Spores inhaled from soil contaminated with bird/bat droppings.</li>
                        <li>Spectrum: Asymptomatic (~90%), Acute pulmonary (flu-like), Chronic cavitary pulmonary (resembles TB), Disseminated (immunocompromised). Mediastinal granuloma/fibrosis.</li>
                        <li>Tx: Mild/Moderate acute/chronic pulmonary: <strong>Itraconazole</strong> (PO, months). Severe pulmonary / Disseminated: Lipid formulation <strong>Amphotericin B</strong> (IV) initially, followed by long course of Itraconazole.</li>
                     </ul>
                 </div>
            </details>
             <details>
                <summary>Coccidioidomycosis</summary>
                <div class="details-content">
                     <ul>
                        <li>Dimorphic fungus (<em>C. immitis/posadasii</em>), endemic to SW US ("Valley Fever"). Spores (arthroconidia) inhaled from soil.</li>
                        <li>Spectrum: Asymptomatic (~60%), Acute pulmonary ("Valley Fever" - flu-like, rash, arthralgias), Persistent pulmonary nodules/cavities, Disseminated (skin, bone, CNS - meningitis).</li>
                        <li>Tx: Mild/Moderate pulmonary: Often no treatment needed in immunocompetent. Severe/progressive pulmonary or Disseminated (non-meningeal): <strong>Fluconazole or Itraconazole</strong> (PO, long duration). Meningitis: <strong>Fluconazole</strong> (high dose, lifelong). Very severe/refractory: Amphotericin B.</li>
                     </ul>
                 </div>
            </details>
            <details>
                <summary>Blastomycosis</summary>
                <div class="details-content">
                     <ul>
                        <li>Dimorphic fungus (<em>B. dermatitidis</em>), endemic to Ohio/Mississippi River Valleys, Great Lakes, SE US. Spores inhaled from soil/decaying wood.</li>
                        <li>Spectrum: Pulmonary (acute/chronic, can mimic pneumonia/mass), Skin (verrucous/ulcerated lesions), Bone, GU, CNS.</li>
                        <li>Tx: Mild/Moderate pulmonary/non-CNS disseminated: <strong>Itraconazole</strong> (PO, 6-12 months). Severe pulmonary / CNS / Immunocompromised: Lipid formulation <strong>Amphotericin B</strong> (IV) initially, followed by step-down to Itraconazole.</li>
                     </ul>
                 </div>
            </details>
             <details>
                <summary>Cryptococcosis</summary>
                <div class="details-content">
                     <ul>
                        <li>Encapsulated yeast (<em>Cryptococcus neoformans/gattii</em>). Found in soil, pigeon droppings. Inhalation leads to pulmonary infection +/- dissemination (predilection for CNS - meningitis). Primarily affects immunocompromised (esp. HIV).</li>
                        <li>Tx: Pulmonary (mild/mod, immunocompetent): <strong>Fluconazole</strong> (PO, 6-12 months). Severe pulmonary or CNS disease (Meningitis): Induction therapy with Lipid formulation <strong>Amphotericin B + Flucytosine</strong> (IV, 2+ weeks), followed by consolidation (Fluconazole high dose, 8+ weeks), then maintenance (Fluconazole lower dose, ≥1 year or until immune reconstitution). Requires lumbar punctures to manage ICP.</li>
                     </ul>
                 </div>
            </details>
             <details>
                <summary>Mucormycosis</summary>
                <div class="details-content">
                     <ul>
                        <li>Invasive fungal infection caused by molds in order Mucorales (e.g., Rhizopus, Mucor, Lichtheimia). Angioinvasive, rapidly progressive, high mortality. Risk factors: <strong>Diabetes (esp. DKA)</strong>, immunosuppression (neutropenia, transplant), iron overload, trauma/burns.</li>
                        <li>Forms: Rhino-orbital-cerebral (most common), Pulmonary, Cutaneous, GI, Disseminated.</li>
                        <li>Tx: Requires aggressive approach: <strong>Surgical debridement</strong> of necrotic tissue + High-dose lipid formulation <strong>Amphotericin B</strong> (IV). Step-down/salvage therapy: Posaconazole or Isavuconazole. Control underlying condition (e.g., hyperglycemia, neutropenia).</li>
                     </ul>
                 </div>
            </details>
             <details>
                <summary>Aspergillosis</summary>
                <div class="details-content">
                     <ul>
                        <li>Caused by <em>Aspergillus</em> species (ubiquitous mold). Spectrum depends on host immunity/lung status.
                            <ul>
                                <li><strong>Allergic Bronchopulmonary Aspergillosis (ABPA):</strong> Hypersensitivity reaction in asthma/CF patients. Wheezing, eosinophilia, high IgE, infiltrates. Tx: Corticosteroids + Itraconazole.</li>
                                <li><strong>Aspergilloma (Fungus Ball):</strong> Colonization of pre-existing lung cavity (e.g., old TB cavity). Often asymptomatic or hemoptysis. Tx: Observation, surgery if severe hemoptysis (antifungals ineffective).</li>
                                <li><strong>Chronic Pulmonary Aspergillosis (CPA):</strong> Subacute/chronic infection in patients with underlying lung disease. Cavities, fibrosis, nodules. Tx: Long-term oral azoles (Voriconazole, Itraconazole).</li>
                                <li><strong>Invasive Pulmonary Aspergillosis (IPA):</strong> Life-threatening infection in severely immunocompromised (esp. neutropenia, transplant). Angioinvasion, necrosis, hemorrhage. Halo sign/air crescent on CT. Tx: <strong>Voriconazole</strong> (drug of choice). Alternatives: Isavuconazole, Lipid Ampho B, Echinocandins (salvage).</li>
                            </ul>
                        </li>
                     </ul>
                 </div>
            </details>
             <details>
                <summary>Candidiasis</summary>
                <div class="details-content">
                     <ul>
                        <li>Caused by <em>Candida</em> species (yeast, normal flora). Pulmonary infection rare, usually represents colonization or hematogenous spread (invasive candidiasis) in severely ill/immunocompromised.</li>
                        <li>Tx (Invasive/Pneumonia): Echinocandins (e.g., Caspofungin, Micafungin) or Fluconazole (if susceptible species like C. albicans and patient stable). Amphotericin B for severe/resistant cases.</li>
                     </ul>
                 </div>
            </details>
             <details>
                <summary>Severe Acute Respiratory Syndrome (SARS) / Avian Influenza</summary>
                <div class="details-content">
                     <ul>
                        <li>SARS (SARS-CoV-1): Coronavirus outbreak (2002-2003). Severe viral pneumonia/ARDS. No specific proven antiviral therapy. Supportive care crucial.</li>
                        <li>Avian Influenza (e.g., H5N1, H7N9): Sporadic human infections from poultry contact. High mortality rate. Supportive care. Neuraminidase inhibitors (Oseltamivir) recommended early, but efficacy uncertain/resistance possible.</li>
                     </ul>
                 </div>
            </details>
             <details>
                <summary>Misc Pharm Facts</summary>
                <div class="details-content">
                     <ul>
                        <li><strong>Tetracyclines:</strong> Contraindicated in pregnancy (Category D) and children < 8 years old due to permanent tooth discoloration and potential bone deposition.</li>
                        <li><strong>Severe IgE-mediated beta-lactam allergy (anaphylaxis):</strong> Avoid all penicillins, cephalosporins (cross-reactivity ~1-10%), carbapenems (except maybe meropenem in specific cases). Safe alternative for Gram-negative coverage: <strong>Aztreonam</strong> (monobactam - structurally different, very low cross-reactivity). Use other classes (FQ, AG, Vanc, Linezolid, Clinda, TMP-SMX, etc.) based on suspected pathogen.</li>
                     </ul>
                 </div>
            </details>
        </div> <!-- End Section: Pharmacology Resp Infections -->

        <div class="pixel-art-divider"></div>

         <!-- Section: Pharmacology Asthma/COPD -->
        <div id="pharmacology-asthma-copd" class="content-section">
            <svg viewBox="0 0 16 16" xmlns="http://www.w3.org/2000/svg" class="section-svg"><path fill-rule="evenodd" clip-rule="evenodd" d="M1 5H0V6H1V5ZM1 6H0V7H1V6ZM1 7H0V8H1V7ZM1 8H0V9H1V8ZM1 9H0V10H1V9ZM1 10H0V11H1V10ZM2 4H3V5H2V4ZM3 3H4V4H3V3ZM4 2H5V3H4V2ZM5 1H6V2H5V1ZM6 1H7V2H6V1ZM7 1H8V2H7V1ZM8 1H9V2H8V1ZM9 1H10V2H9V1ZM10 1H11V2H10V1ZM11 2H12V3H11V2ZM12 3H13V4H12V3ZM13 4H14V5H13V4ZM14 5H15V6H14V5ZM15 6H16V7H15V6ZM15 7H16V8H15V7ZM15 8H16V9H15V8ZM15 9H16V10H15V9ZM15 10H16V11H15V10ZM14 11H15V12H14V11ZM13 12H14V13H13V12ZM12 13H13V14H12V13ZM11 14H12V15H11V14ZM10 15H11V16H10V15ZM9 15H10V16H9V15ZM8 15H9V16H8V15ZM7 15H8V16H7V15ZM6 15H7V16H6V15ZM5 15H6V16H5V15ZM4 15H5V16H4V15ZM3 14H4V15H3V14ZM2 13H3V14H2V13ZM2 11H3V12H2V11ZM2 9H3V10H2V9ZM2 7H3V8H2V7ZM4 6H5V7H4V6ZM6 5H7V6H6V5ZM8 4H9V5H8V4ZM10 3H11V4H10V3ZM12 5H13V6H12V5ZM14 7H13V8H14V7ZM14 9H13V10H14V9ZM14 11H13V12H14V11ZM12 12H11V13H12V12ZM10 13H9V14H10V13ZM8 14H7V15H8V14ZM6 13H5V14H6V13ZM4 11H5V12H4V11ZM4 9H5V10H4V9ZM4 7H5V8H4V7ZM6 7H7V8H6V7ZM8 6H9V7H8V6ZM10 5H11V6H10V5ZM12 4H13V5H12V4ZM11 6H10V7H11V6ZM9 7H10V8H9V7ZM7 8H8V9H7V8ZM5 8H6V9H5V8ZM5 10H6V11H5V10ZM7 11H8V12H7V11ZM9 12H10V13H9V12ZM11 10H12V11H11V10ZM13 9H12V10H13V9ZM13 7H12V8H13V7Z" fill="currentColor"/></svg>
            <h2>Pharmacology: Drugs Used in Asthma and/or COPD</h2>

            <h3>General Asthma Concepts</h3>
            <div class="details-content bg-[--bg-muted] p-4 rounded mb-4">
                <ul>
                    <li>Chronic inflammatory disorder of the airways characterized by reversible bronchoconstriction, airway hyperresponsiveness (AHR), and airway inflammation (esp. eosinophilic).</li>
                    <li>Pathophysiology involves complex interplay of genetics, environment, immune cells (mast cells, eosinophils, Th2 lymphocytes), mediators (histamine, leukotrienes, cytokines like IL-4, IL-5, IL-13), and structural changes (airway remodeling).</li>
                    <li>Goals of therapy: Achieve and maintain control of symptoms, prevent exacerbations, maintain normal activity levels, maintain normal (or near-normal) lung function, minimize adverse effects of treatment.</li>
                </ul>
            </div>

            <h3>Sympathomimetic Agents (Bronchodilators)</h3>
            <details>
                <summary>MOA</summary>
                <div class="details-content"><p>Activate Beta-2 adrenergic receptors on airway smooth muscle. This activates adenylyl cyclase via Gs protein coupling, increasing intracellular cyclic AMP (cAMP). Increased cAMP leads to protein kinase A activation, phosphorylation of target proteins, decreased intracellular calcium, and ultimately smooth muscle relaxation (bronchodilation). Beta-2 agonists may also inhibit mediator release from mast cells and decrease microvascular leakage.</p></div>
            </details>
            <details>
                <summary>Non-Selective / Older Agents</summary>
                <div class="details-content">
                     <ul>
                        <li><strong>Epinephrine:</strong> Potent, rapid-acting non-selective agonist (α1, α2, β1, β2). Causes bronchodilation (β2), but also significant cardiac stimulation (β1 - tachycardia, arrhythmias) and vasoconstriction (α1). Use now limited to anaphylaxis treatment (IM injection). Inhaled forms (Primatene Mist) previously OTC but removed/reformulated (less effective).</li>
                        <li><strong>Ephedrine:</strong> Mixed-acting (direct/indirect agonist). Longer duration, oral bioavailability, more CNS effects than epinephrine. Obsolete for respiratory use.</li>
                        <li><strong>Isoproterenol:</strong> Potent non-selective β-agonist (β1=β2). Effective bronchodilator but significant cardiac side effects (tachycardia, arrhythmias). Largely replaced by selective β2 agonists.</li>
                     </ul>
                 </div>
            </details>

            <h4>Selective Beta-2 Agonists</h4>
            <details>
                <summary>Short-Acting Beta Agonists (SABA)</summary>
                <div class="details-content">
                     <ul>
                        <li>"Reliever" or "Rescue" medications. Rapid onset (minutes), duration 4-6 hours. Used for acute symptom relief in asthma and COPD.</li>
                        <li><strong>Albuterol (Salbutamol outside US) (Ventolin, ProAir, Proventil):</strong> Most common SABA. Available as MDI, DPI, nebulizer solution, oral syrup/tablets (oral less preferred).</li>
                        <li><strong>Levalbuterol (Xopenex):</strong> R-enantiomer of albuterol. Claimed fewer side effects (less β1 activity), but clinical significance debated, more expensive. MDI, nebulizer solution.</li>
                        <li><strong>Terbutaline (Brethine):</strong> Available as tablet, injection (SubQ for severe exacerbations). Inhaler less common.</li>
                        <li><strong>Metaproterenol / Pirbuterol:</strong> Older SABAs, less β2-selective, largely replaced.</li>
                        <li><strong>A/E (Dose-related):</strong> Tremor (most common, β2 effect on skeletal muscle), tachycardia/palpitations (some β1 activity, reflex tachycardia), nervousness, headache, hypokalemia (β2 drives K+ into cells), hyperglycemia. Tolerance (tachyphylaxis) can develop with frequent use. Over-reliance indicates poor underlying control.</li>
                     </ul>
                 </div>
            </details>
            <details>
                <summary>Long-Acting Beta Agonists (LABA)</summary>
                <div class="details-content">
                     <ul>
                        <li>"Controller" medications. Duration ≥ 12 hours (Formoterol, Salmeterol, Vilanterol, Olodaterol) or 24 hours (Indacaterol). Provide sustained bronchodilation.</li>
                        <li><strong>Asthma Use:</strong> **NEVER use as monotherapy** due to increased risk of asthma-related death (masked inflammation). **MUST be combined with an Inhaled Corticosteroid (ICS)** in a combination inhaler or as separate inhalers. Used for step 3+ therapy in persistent asthma.</li>
                        <li><strong>COPD Use:</strong> Can be used as monotherapy or in combination with LAMA and/or ICS for maintenance treatment.</li>
                        <li>Examples:
                            <ul>
                                <li><strong>Salmeterol (Serevent):</strong> Slow onset. DPI. Combo w/ Fluticasone (Advair).</li>
                                <li><strong>Formoterol (Foradil, Perforomist):</strong> Faster onset than Salmeterol (can be used in some reliever strategies with ICS). DPI, Nebulizer. Combo w/ Budesonide (Symbicort), Mometasone (Dulera).</li>
                                <li><strong>Arformoterol (Brovana):</strong> R-enantiomer of formoterol. Nebulizer solution for COPD.</li>
                                <li><strong>Indacaterol (Arcapta):</strong> Ultra-LABA (24h). DPI for COPD. Combo w/ Glycopyrrolate (Utibron).</li>
                                <li><strong>Olodaterol (Striverdi):</strong> Ultra-LABA (24h). Respimat inhaler for COPD. Combo w/ Tiotropium (Stiolto).</li>
                                <li><strong>Vilanterol:</strong> Ultra-LABA (24h). Only available in combination inhalers. DPI. Combos: w/ Fluticasone furoate (Breo - Asthma/COPD), Umeclidinium (Anoro - COPD), Umeclidinium + Fluticasone (Trelegy - Asthma/COPD).</li>
                            </ul>
                        </li>
                        <li><strong>A/E:</strong> Similar to SABAs (tremor, tachycardia, hypokalemia), but risk minimized with inhaled route. QT prolongation possible. Risk in asthma monotherapy noted above.</li>
                     </ul>
                 </div>
            </details>

            <h3>Corticosteroids</h3>
             <details>
                <summary>MOA & General Effects</summary>
                <div class="details-content">
                    <p>Potent anti-inflammatory agents. Do NOT directly relax airway smooth muscle (not bronchodilators).</p>
                     <ul>
                        <li><strong>MOA:</strong> Bind intracellular glucocorticoid receptors → complex translocates to nucleus → alters gene transcription:
                            <ul>
                                <li>↑ Synthesis of anti-inflammatory proteins (e.g., lipocortin-1, annexin A1).</li>
                                <li>↓ Synthesis of pro-inflammatory cytokines (IL-1, TNF-α, IL-4, IL-5, IL-13), chemokines, adhesion molecules.</li>
                                <li>Inhibit phospholipase A2 → ↓ production of prostaglandins and leukotrienes.</li>
                                <li>Reduce inflammatory cell infiltration/activation (eosinophils, T-lymphocytes, mast cells, macrophages).</li>
                                <li>Reduce microvascular permeability.</li>
                                <li>Over time, reduce airway hyperresponsiveness.</li>
                            </ul>
                        </li>
                        <li>Use in Asthma: Cornerstone of long-term control for persistent asthma.</li>
                        <li>Use in COPD: Reduce frequency/severity of exacerbations in patients with history of exacerbations, often used in combination with LABA +/- LAMA. Do not slow long-term decline in FEV1.</li>
                     </ul>
                 </div>
            </details>
             <details>
                <summary>Inhaled Corticosteroids (ICS)</summary>
                <div class="details-content">
                     <ul>
                        <li>Deliver drug directly to airways, minimizing systemic exposure/side effects. Preferred route for long-term asthma/COPD control.</li>
                        <li>Examples: Beclomethasone (Qvar), Budesonide (Pulmicort), Ciclesonide (Alvesco), Flunisolide (Aerospan), Fluticasone propionate (Flovent), Fluticasone furoate (Arnuity, in Breo, Trelegy), Mometasone (Asmanex, in Dulera).</li>
                        <li>Available as MDI, DPI, Nebulizer solution (Budesonide).</li>
                        <li>Dosed based on potency (low, medium, high dose).</li>
                        <li><strong>A/E (Local):</strong> <strong>Oropharyngeal candidiasis (thrush)</strong> - prevent by rinsing mouth/gargling after use, using spacer device with MDI. <strong>Dysphonia (hoarseness)</strong>. Cough.</li>
                        <li><strong>A/E (Systemic - higher doses/long term):</strong> Potential for adrenal suppression, decreased bone mineral density, skin thinning/bruising, cataracts, glaucoma, decreased growth velocity in children (small effect, generally final adult height unaffected). Risk lower than with oral steroids.</li>
                        <li><strong>Ciclesonide:</strong> Prodrug activated by esterases in lung, potentially fewer local/systemic effects.</li>
                     </ul>
                 </div>
            </details>
             <details>
                <summary>Systemic Corticosteroids (Oral/IV)</summary>
                <div class="details-content">
                     <ul>
                        <li>Examples: Prednisone, Prednisolone, Methylprednisolone, Dexamethasone.</li>
                        <li>Use:
                            <ul>
                                <li><strong>Acute Exacerbations (Asthma/COPD):</strong> Short course ("burst") typically 5-10 days (e.g., Prednisone 40-60mg/day adults) to rapidly reduce inflammation. Tapering usually not needed for courses < 2 weeks.</li>
                                <li><strong>Severe Persistent Asthma/COPD:</strong> Long-term daily or alternate-day therapy for patients refractory to maximal inhaled therapy (use lowest effective dose).</li>
                            </ul>
                        </li>
                        <li><strong>A/E (Systemic):</strong> Numerous and significant, especially with long-term use. See MOA/Warnings section above (Cushingoid features, hyperglycemia, osteoporosis, mood changes, immunosuppression, etc.).</li>
                     </ul>
                 </div>
            </details>

             <h3>Leukotriene Modifiers</h3>
             <details>
                <summary>Receptor Antagonists (LTRAs) & Synthesis Inhibitors</summary>
                <div class="details-content">
                     <p>Target the effects of cysteinyl leukotrienes (LTC4, LTD4, LTE4), which cause bronchoconstriction, mucus secretion, and airway inflammation.</p>
                     <ul>
                         <li>Use: Primarily as alternative or add-on therapy for mild-to-moderate persistent asthma, especially useful in patients with concurrent allergic rhinitis or exercise-induced bronchoconstriction (EIB). Less effective than ICS as monotherapy for asthma control. Oral administration.</li>
                         <li><strong>Montelukast (Singulair):</strong> CysLT1 receptor antagonist. Once daily dosing. Generally well-tolerated but carries **FDA Black Box Warning** for neuropsychiatric events (agitation, depression, suicidality).</li>
                         <li><strong>Zafirlukast (Accolate):</strong> CysLT1 receptor antagonist. BID dosing. Associated with rare but potentially fatal hepatotoxicity (requires monitoring). Drug interactions (CYP2C9 inhibitor). Rarely used.</li>
                         <li><strong>Zileuton (Zyflo):</strong> Inhibits 5-lipoxygenase enzyme, blocking synthesis of LTB4 and cysteinyl LTs. Requires QID or BID (ER) dosing. Potential for hepatotoxicity (requires LFT monitoring). Drug interactions (CYP1A2, 3A4 inhibitor). Rarely used due to inconvenience and toxicity profile.</li>
                     </ul>
                 </div>
            </details>

             <h3>Phosphodiesterase Inhibitors</h3>
             <details>
                <summary>Theophylline (Methylxanthine)</summary>
                <div class="details-content">
                     <ul>
                        <li>Older bronchodilator, largely replaced by safer/more effective agents.</li>
                        <li><strong>MOA:</strong> Non-selective phosphodiesterase (PDE) inhibitor → ↑cAMP → bronchodilation. Also adenosine receptor antagonism, histone deacetylase (HDAC) activation (anti-inflammatory effects).</li>
                        <li><strong>Effects:</strong> Bronchodilation, increased diaphragmatic contractility, mild CNS stimulation, cardiac stimulation (tachycardia, arrhythmias), increased gastric acid secretion, weak diuretic.</li>
                        <li>Use: Historically used for asthma/COPD maintenance (oral) and acute exacerbations (IV aminophylline). Now considered alternative/add-on therapy only.</li>
                        <li>PK: Narrow therapeutic index (target <strong>5-15 mcg/mL</strong>). Metabolism varies widely (CYP1A2, 3A4), affected by age, smoking, diseases, many drug interactions. Requires TDM.</li>
                        <li><strong>A/E (Toxicity - dose related):</strong> N/V/D, headache, insomnia, anxiety (at therapeutic levels). Seizures and fatal arrhythmias (at levels > 20-25 mcg/mL).</li>
                     </ul>
                 </div>
            </details>
             <details>
                <summary>Roflumilast (Daliresp) (PDE-4 Inhibitor)</summary>
                <div class="details-content">
                     <ul>
                        <li>MOA: Selective inhibitor of PDE4 (predominant PDE in inflammatory cells like neutrophils, eosinophils, macrophages). Increases intracellular cAMP in these cells, reducing inflammatory mediator release. Primarily anti-inflammatory, minimal bronchodilation.</li>
                        <li>Use: Oral agent approved to <strong>reduce risk of COPD exacerbations</strong> in patients with severe COPD associated with chronic bronchitis and a history of frequent exacerbations. Not for acute relief.</li>
                        <li>A/E: Common: <strong>Diarrhea</strong>, nausea, headache, weight loss, insomnia. Neuropsychiatric effects (anxiety, depression, suicidality) reported.</li>
                     </ul>
                 </div>
            </details>

             <h3>Antimuscarinic Agents (Anticholinergics)</h3>
              <details>
                <summary>MOA & General Effects</summary>
                <div class="details-content">
                     <p>Block the effects of acetylcholine on muscarinic receptors (primarily M3) on airway smooth muscle and submucosal glands. This inhibits vagally-mediated bronchoconstriction and reduces mucus secretion.</p>
                     <p>More potent bronchodilators in COPD (where vagal tone is a major component of bronchoconstriction) than in asthma.</p>
                     <p>Administered via inhalation (MDI, DPI, nebulizer) to minimize systemic effects.</p>
                     <p><strong>A/E (Inhaled):</strong> Usually minimal. Most common is <strong>dry mouth</strong>. Less common: metallic taste, urinary retention (caution in BPH), blurred vision/precipitation of glaucoma (if sprayed in eyes), constipation, tachycardia (rare).</p>
                 </div>
            </details>
             <details>
                <summary>Short-Acting Muscarinic Antagonist (SAMA)</summary>
                <div class="details-content">
                     <ul>
                        <li><strong>Ipratropium Bromide (Atrovent):</strong>
                            <ul>
                                <li>Non-selective muscarinic antagonist. Quaternary amine (poor absorption).</li>
                                <li>Duration ~4-8 hours. Dosed QID usually.</li>
                                <li>Use: COPD maintenance (less common now with LAMAs available). Preferred anticholinergic for <strong>acute asthma exacerbations</strong> (added to SABA in ED, usually for first few doses). Also used for rhinitis (nasal spray). Available as MDI, nebulizer solution, nasal spray. Combination with Albuterol (Combivent MDI, DuoNeb nebulizer).</li>
                            </ul>
                        </li>
                     </ul>
                 </div>
            </details>
             <details>
                <summary>Long-Acting Muscarinic Antagonist (LAMA)</summary>
                <div class="details-content">
                     <ul>
                        <li>"Controller" medication, usually once or twice daily dosing. Cornerstone of COPD maintenance therapy. Also used as add-on therapy in severe asthma.</li>
                        <li><strong>Tiotropium (Spiriva):</strong>
                            <ul>
                                <li>First LAMA, long duration (24h). Kinetically selective for M1/M3 over M2.</li>
                                <li>Use: COPD maintenance (reduces symptoms and exacerbations). Add-on therapy for moderate-severe Asthma (age 6+) inadequately controlled on ICS/LABA.</li>
                                <li>Available as HandiHaler (DPI - capsule) or Respimat (soft mist inhaler).</li>
                            </ul>
                        </li>
                        <li><strong>Aclidinium (Tudorza Pressair):</strong> BID dosing DPI for COPD.</li>
                        <li><strong>Umeclidinium (Incruse Ellipta):</strong> Once-daily DPI for COPD. Available in combo with Vilanterol (Anoro) or Fluticasone/Vilanterol (Trelegy).</li>
                        <li><strong>Glycopyrrolate (Seebri Neohaler, Lonhala Magnair):</strong> BID DPI or nebulizer solution for COPD. Available in combo with Indacaterol (Utibron) or Formoterol (Bevespi). (Note: Glycopyrrolate is also used systemically as antisialagogue).</li>
                        <li><strong>Revefenacin (Yupelri):</strong> Once-daily nebulized LAMA for COPD.</li>
                     </ul>
                 </div>
            </details>

            <h3>Monoclonal Antibodies (Biologics) - Primarily for Severe Asthma</h3>
            <details>
                <summary>Anti-IgE Monoclonal Antibody</summary>
                <div class="details-content">
                     <ul>
                        <li><strong>Omalizumab (Xolair):</strong>
                            <ul>
                                <li>MOA: Binds free IgE, prevents binding to FcεR1 on mast cells/basophils.</li>
                                <li>Use: Moderate-to-severe persistent <strong>allergic asthma</strong> (age 6+) with elevated IgE levels and sensitivity to perennial aeroallergen, inadequately controlled on ICS. Also for chronic idiopathic urticaria, nasal polyps.</li>
                                <li>Admin: SubQ injection every 2-4 weeks.</li>
                                <li>A/E: Injection site reactions, **Anaphylaxis** (BBW), possible small increased risk CV events/malignancy (controversial).</li>
                            </ul>
                        </li>
                     </ul>
                 </div>
            </details>
            <details>
                <summary>Anti-IL-5 / Anti-IL-5 Receptor Monoclonals</summary>
                <div class="details-content">
                     <p>Target Interleukin-5 (key cytokine for eosinophil development/survival/activation).</p>
                     <ul>
                        <li>Use: Add-on maintenance for severe <strong>eosinophilic asthma</strong> (age varies by agent, typically ≥6 or ≥12 yrs) with elevated blood eosinophil counts.</li>
                        <li><strong>Mepolizumab (Nucala):</strong> Binds IL-5. SubQ every 4 weeks.</li>
                        <li><strong>Reslizumab (Cinqair):</strong> Binds IL-5. IV infusion every 4 weeks. Higher risk of anaphylaxis.</li>
                        <li><strong>Benralizumab (Fasenra):</strong> Binds IL-5 Receptor Alpha (IL-5Rα) on eosinophils → ADCC causes eosinophil depletion. SubQ every 4 weeks x3, then every 8 weeks.</li>
                        <li>A/E: Headache, injection site reactions, fatigue. Anaphylaxis rare. Possible increased herpes zoster risk (Mepo).</li>
                     </ul>
                 </div>
            </details>
            <details>
                <summary>Anti-IL-4 Receptor Alpha Monoclonal</summary>
                <div class="details-content">
                     <ul>
                        <li><strong>Dupilumab (Dupixent):</strong>
                            <ul>
                                <li>MOA: Blocks IL-4 Receptor Alpha subunit, inhibiting signaling of both <strong>IL-4 and IL-13</strong> (key Th2 cytokines involved in IgE production, eosinophil recruitment, mucus production, AHR).</li>
                                <li>Use: Add-on maintenance for moderate-to-severe <strong>eosinophilic asthma</strong> OR <strong>oral steroid-dependent asthma</strong> (age 6+). Also for atopic dermatitis, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis.</li>
                                <li>Admin: SubQ injection every 2 weeks.</li>
                                <li>A/E: Injection site reactions, conjunctivitis, oral herpes, eosinophilia (transient).</li>
                            </ul>
                        </li>
                     </ul>
                 </div>
            </details>
            <details>
                <summary>Anti-TSLP Monoclonal</summary>
                <div class="details-content">
                     <ul>
                        <li><strong>Tezepelumab (Tezspire):</strong>
                            <ul>
                                <li>MOA: Blocks Thymic Stromal Lymphopoietin (TSLP), an upstream epithelial cytokine ("alarmin") that initiates multiple downstream inflammatory cascades (including Th2/eosinophilic and non-eosinophilic pathways).</li>
                                <li>Use: Add-on maintenance for <strong>severe asthma</strong> (age 12+) regardless of eosinophil count or allergic status.</li>
                                <li>Admin: SubQ injection every 4 weeks.</li>
                                <li>A/E: Pharyngitis, arthralgia, back pain, injection site reactions.</li>
                            </ul>
                        </li>
                     </ul>
                 </div>
            </details>
             <!-- Lebrikizumab (Anti-IL-13) not yet approved -->

            <h3>Mast Cell Stabilizers</h3>
            <details>
                <summary>Cromolyn Sodium & Nedocromil</summary>
                <div class="details-content">
                     <ul>
                        <li>MOA: Poorly understood, thought to stabilize mast cells by inhibiting chloride channels? Prevents release of histamine/other mediators. Anti-inflammatory, not a bronchodilator.</li>
                        <li>Use: Prophylactic therapy for mild persistent asthma or EIB. Requires regular use (QID) before exposure/exercise. Much less effective than ICS. Excellent safety profile.</li>
                        <li>Formulations: Nebulizer solution (Cromolyn), MDI (Nedocromil - discontinued in US). Also nasal spray/eye drops for allergy.</li>
                        <li>A/E: Throat irritation, cough, unpleasant taste.</li>
                     </ul>
                 </div>
            </details>

            <h3>Asthma Management Approach (Simplified Steps - GINA/NHLBI Influence)</h3>
             <details>
                <summary>Stepwise Therapy</summary>
                <div class="details-content">
                     <p>Goal: Achieve control using lowest effective dose. Step up if uncontrolled, step down if well-controlled for ≥3 months.</p>
                     <ol>
                        <li><strong>Step 1 (Infrequent symptoms <2x/month):</strong> As-needed low-dose ICS-Formoterol (preferred reliever) OR As-needed SABA + take low-dose ICS whenever SABA used.</li>
                        <li><strong>Step 2 (Symptoms ≥2x/month but not daily):</strong> Daily low-dose ICS OR As-needed low-dose ICS-Formoterol (preferred reliever). Alt: LTRA.</li>
                        <li><strong>Step 3 (Symptoms most days, or waking with asthma ≥1x/week):</strong> Low-dose ICS + LABA (combination inhaler preferred). Alt: Medium-dose ICS or Low-dose ICS + LTRA.</li>
                        <li><strong>Step 4 (Symptoms most days, waking ≥1x/week, low lung function):</strong> Medium-dose ICS + LABA. Alt: High-dose ICS + LABA, may add Tiotropium or LTRA.</li>
                        <li><strong>Step 5 (Symptoms uncontrolled on Step 4):</strong> High-dose ICS + LABA. Refer for specialist assessment +/- Add-on therapy (e.g., Tiotropium, Anti-IgE, Anti-IL5/5R, Anti-IL4Rα, Anti-TSLP). Consider low-dose oral corticosteroids (minimize use).</li>
                     </ol>
                     <p><em>All steps include SABA for quick relief if not using ICS-Formoterol as reliever. Education, trigger avoidance, action plan are crucial at all steps.</em></p>
                 </div>
            </details>
             <details>
                <summary>Asthma Exacerbation Management (Status Asthmaticus)</summary>
                <div class="details-content">
                     <ul>
                        <li>Assess severity (PEFR, SpO2, RR, accessory muscle use, speech).</li>
                        <li><strong>Oxygen:</strong> Titrate to maintain SpO2 93-95% (adults), 94-98% (children).</li>
                        <li><strong>SABA:</strong> High doses via MDI+spacer or nebulizer, frequently (q20min x 3 doses then hourly or continuous).</li>
                        <li><strong>SAMA (Ipratropium):</strong> Add to SABA for initial treatment in ED for moderate-severe exacerbations.</li>
                        <li><strong>Systemic Corticosteroids:</strong> Oral (Prednisone/Prednisolone) or IV (Methylprednisolone) given early for all but mildest exacerbations. Continue for 5-7 days typically.</li>
                        <li><strong>Adjuncts (Severe/Refractory):</strong> IV Magnesium Sulfate, Heliox, Non-invasive ventilation (BiPAP/CPAP), Intubation/Mechanical Ventilation if impending/actual respiratory failure.</li>
                     </ul>
                 </div>
            </details>

            <h3>COPD Management Approach (Simplified - GOLD 2023 Influence)</h3>
             <details>
                <summary>Assessment & Initial Therapy</summary>
                <div class="details-content">
                     <p>Assessment considers: 1) Spirometry confirmation (FEV1/FVC < 0.7 post-bronchodilator); 2) Symptom burden (CAT score or mMRC dyspnea scale); 3) Exacerbation history.</p>
                     <p>Initial Pharmacotherapy based on <strong>GOLD Group (A, B, E)</strong>:</p>
                     <ul>
                        <li><strong>Group A (Low risk, fewer symptoms: mMRC 0-1, CAT <10, 0-1 mod exacerbation not leading to hospital admission):</strong> A Bronchodilator (SABA or SAMA PRN, or LABA or LAMA scheduled).</li>
                        <li><strong>Group B (Low risk, more symptoms: mMRC ≥2, CAT ≥10, 0-1 mod exacerbation not leading to hospital admission):</strong> Long-acting Bronchodilator (<strong>LAMA or LABA</strong>).</li>
                        <li><strong>Group E (High risk: ≥2 mod exacerbations OR ≥1 leading to hospital admission):</strong> Start with <strong>LAMA + LABA</strong> combination therapy. (Consider LAMA+LABA+ICS if blood eosinophils ≥ 300 cells/μL).</li>
                     </ul>
                 </div>
            </details>
              <details>
                <summary>Follow-up & Escalation</summary>
                <div class="details-content">
                     <p>Adjust therapy based on predominant treatable trait (Dyspnea or Exacerbations):</p>
                     <ul>
                        <li><strong>Persistent Dyspnea:</strong>
                            <ul>
                                <li>On LABA or LAMA → Escalate to LAMA + LABA.</li>
                                <li>On LAMA + LABA → Consider switching device/molecules, investigate/treat other causes of dyspnea.</li>
                            </ul>
                        </li>
                        <li><strong>Persistent Exacerbations:</strong>
                            <ul>
                                <li>On LABA or LAMA → Escalate to LAMA + LABA.</li>
                                <li>On LAMA + LABA:
                                    <ul>
                                        <li>If Blood Eosinophils <strong>≥ 300</strong> → Add ICS (LAMA+LABA+ICS).</li>
                                        <li>If Blood Eosinophils <strong>< 300</strong> → Consider adding Roflumilast (if FEV1 <50% & chronic bronchitis) OR Azithromycin (long-term, esp. former smokers).</li>
                                    </ul>
                                </li>
                                <li>On LAMA+LABA+ICS: Consider adding Roflumilast or Azithromycin. Consider de-escalating ICS if no benefit/pneumonia risk (esp. if eos <100).</li>
                            </ul>
                        </li>
                     </ul>
                     <p>Other therapies: Smoking cessation, vaccinations (flu, pneumococcal, pertussis, COVID-19), pulmonary rehabilitation, oxygen therapy (if chronic hypoxemia PaO2 ≤ 55 or SpO2 ≤ 88%), surgical options (LVRS, transplant) in select patients.</p>
                 </div>
            </details>
        </div> <!-- End Section: Pharmacology Asthma/COPD -->

        <div class="pixel-art-divider"></div>

        <!-- Section: Microbiology Summary -->
        <div id="microbiology-summary" class="content-section">
            <svg viewBox="0 0 16 16" xmlns="http://www.w3.org/2000/svg" class="section-svg"><path d="M1 1H3V2H4V3H5V4H6V5H7V6H8V7H9V6H10V5H11V4H12V3H13V2H15V1H16V2H15V3H14V4H13V5H12V6H11V7H10V8H9V9H8V10H7V11H6V12H5V13H4V14H3V15H1V16H0V15H1V14H2V13H3V12H4V11H5V10H6V9H7V8H8V9H7V10H8V11H9V12H10V13H11V14H12V15H14V16H15V15H14V14H13V13H12V12H11V11H10V10H9V8H10V7H11V6H12V5H13V4H14V3H15V2H13V1H11V0H9V1H7V0H5V1H3V0H1V1Z M2 4H3V5H2V4ZM4 5H5V6H4V5ZM6 7H7V8H6V7ZM8 2H9V3H8V2ZM10 4H11V5H10V4ZM12 6H13V7H12V6ZM14 8H15V9H14V8ZM14 10H15V11H14V10ZM13 11H14V12H13V11ZM11 12H12V13H11V12ZM9 13H10V14H9V13ZM7 14H8V15H7V14ZM5 14H6V15H5V14ZM3 13H4V14H3V13ZM2 12H3V13H2V12ZM2 10H3V11H2V10ZM2 8H3V9H2V8ZM2 6H3V7H2V6ZM4 9H5V10H4V9ZM6 11H7V12H6V11ZM8 12H9V13H8V12ZM10 11H11V12H10V11ZM12 10H13V11H12V10ZM13 8H14V9H13V8ZM12 7H11V8H12V7ZM10 6H9V7H10V6ZM8 5H7V6H8V5ZM6 3H5V4H6V3ZM10 8H11V9H10V8Z" fill="currentColor"/></svg>
            <h2>Microbiology Summary Tables</h2>

            <!-- Table derived from Page 38 -->
            <h4>Table 1: Common Respiratory Pathogens & Diseases (Upper Airway / Related)</h4>
            <div class="table-container">
                 <table>
                     <thead>
                         <tr><th>Disease</th><th>Common Microbe(s)</th><th>Presentation Key Points</th><th>Diagnosis</th><th>Treatment Notes</th></tr>
                     </thead>
                     <tbody>
                         <tr>
                             <td data-label="Disease">Acute Rhinosinusitis (ARS)</td>
                             <td data-label="Microbe(s)">Mostly viruses; Bacterial (ABRS): <strong>S. pneumo, H. influenzae (NTHi), M. catarrhalis</strong></td>
                             <td data-label="Presentation">Nasal drainage, congestion, facial pain/pressure, headache, +/- fever. Bacterial if ≥10d, severe onset ≥3d, or "double sickening".</td>
                             <td data-label="Diagnosis">Clinical; CT if complications suspected.</td>
                             <td data-label="Treatment">Viral: supportive. ABRS: Amox/Clav first-line. Adjuncts: INS, saline irrigation.</td>
                         </tr>
                         <tr>
                             <td data-label="Disease">Chronic Rhinosinusitis (CRS)</td>
                             <td data-label="Microbe(s)">Complex/Inflammatory: S. aureus, anaerobes, GNRs, fungi possible role. Often polymicrobial/biofilms.</td>
                             <td data-label="Presentation">Symptoms > 12 weeks (congestion, drainage, facial pain, hyposmia). +/- Nasal polyps.</td>
                             <td data-label="Diagnosis">Clinical + Objective evidence (Endoscopy or CT scan). Culture/biopsy guided by ENT.</td>
                             <td data-label="Treatment">Long-term INS, saline irrigation, short course oral steroids +/- antibiotics based on culture/severity. Surgery (FESS) if refractory. Biologics for polyps.</td>
                         </tr>
                         <tr>
                             <td data-label="Disease">Otitis Externa (AOE)</td>
                             <td data-label="Microbe(s)"><strong>P. aeruginosa, S. aureus</strong></td>
                             <td data-label="Presentation">Ear canal pain, itching, discharge, tragal/auricular tenderness.</td>
                             <td data-label="Diagnosis">Clinical.</td>
                             <td data-label="Treatment">Topical antibiotic +/- steroid drops (Fluoroquinolone or Neomycin/Polymyxin B based - avoid Neo if TM perf). Acetic acid for mild. Keep dry.</td>
                         </tr>
                         <tr>
                             <td data-label="Disease">Acute Otitis Media (AOM)</td>
                             <td data-label="Microbe(s)"><strong>S. pneumo, H. influenzae (NTHi), M. catarrhalis</strong></td>
                             <td data-label="Presentation">Acute onset ear pain, fever, irritability. Bulging, erythematous, immobile TM.</td>
                             <td data-label="Diagnosis">Otoscopy (pneumatic crucial).</td>
                             <td data-label="Treatment">Pain control. Abx vs Observation based on age/severity. First-line: High-dose Amoxicillin or Amox/Clav.</td>
                         </tr>
                         <tr>
                             <td data-label="Disease">Mastoiditis</td>
                             <td data-label="Microbe(s)">Often extension from AOM (S. pneumo, H. flu, S. pyogenes, S. aureus)</td>
                             <td data-label="Presentation">Postauricular pain, erythema, swelling, tenderness. Protruding auricle. Fever. Often follows AOM.</td>
                             <td data-label="Diagnosis">Clinical, CT scan confirms bone destruction/fluid.</td>
                             <td data-label="Treatment">IV antibiotics (broad, covering AOM pathogens +/- MRSA/Pseudo depending on context). Mastoidectomy/tympanostomy tubes often needed.</td>
                         </tr>
                         <tr>
                             <td data-label="Disease">Acute Pharyngitis</td>
                             <td data-label="Microbe(s)">Mostly viruses; Bacterial: <strong>S. pyogenes (GAS)</strong></td>
                             <td data-label="Presentation">Sore throat, fever. Exudates, cervical LAD, absence of cough suggest GAS.</td>
                             <td data-label="Diagnosis">Clinical (Centor/McIsaac score) + RADT +/- Throat culture.</td>
                             <td data-label="Treatment">Viral: supportive. GAS: Penicillin/Amoxicillin x 10d (prevents ARF). Allergy: Cephalexin, Clindamycin, Macrolide.</td>
                         </tr>
                          <tr>
                             <td data-label="Disease">Vincent's Angina (ANUG)</td>
                             <td data-label="Microbe(s)">Oral anaerobes (spirochetes - Treponema, fusobacteria)</td>
                             <td data-label="Presentation">Acute Necrotizing Ulcerative Gingivitis ("Trench Mouth"). Painful, bleeding gums, ulcerated interdental papillae, pseudomembranes, foul breath, fever, malaise.</td>
                             <td data-label="Diagnosis">Clinical.</td>
                             <td data-label="Treatment">Debridement, improved oral hygiene, antiseptic rinses (chlorhexidine). Antibiotics (Penicillin + Metronidazole, or Clindamycin).</td>
                         </tr>
                          <tr>
                             <td data-label="Disease">Ludwig's Angina</td>
                             <td data-label="Microbe(s)">Polymicrobial (Oral Strep + anaerobes), often from dental infection source (mandibular molars).</td>
                             <td data-label="Presentation">Rapidly spreading bilateral cellulitis of submandibular, sublingual, submental spaces. Floor of mouth elevated, tongue displaced upward/backward, neck swelling ("bull neck"), fever, chills, malaise. **Airway compromise risk**.</td>
                             <td data-label="Diagnosis">Clinical, CT scan confirms extent.</td>
                             <td data-label="Treatment">Secure Airway! IV Antibiotics (Ampicillin-sulbactam or Penicillin + Metronidazole or Clindamycin). Surgical drainage often needed.</td>
                         </tr>
                         <tr>
                             <td data-label="Disease">Postanginal Septicemia (Lemierre's Syndrome)</td>
                             <td data-label="Microbe(s)"><strong>Fusobacterium necrophorum</strong> (anaerobe)</td>
                             <td data-label="Presentation">Often follows pharyngitis/tonsillitis in adolescents/young adults. Septic thrombophlebitis of internal jugular vein → septic emboli (often lungs - nodules/cavities/effusions). Fever, neck pain/swelling along SCM, rigors, respiratory symptoms.</td>
                             <td data-label="Diagnosis">Blood cultures (anaerobic), CT neck/chest with contrast.</td>
                             <td data-label="Treatment">High-dose IV antibiotics (Penicillin, Clindamycin, Metronidazole, Carbapenem - often combo initially). Duration weeks. Anticoagulation controversial. Surgical drainage if abscess.</td>
                         </tr>
                         <tr>
                             <td data-label="Disease">Laryngitis</td>
                             <td data-label="Microbe(s)">Viruses mostly (rhino, adeno, influenza). Bacterial less common (M. cat, H. flu, GAS). Chronic: LPR, smoking, vocal abuse.</td>
                             <td data-label="Presentation">Hoarseness, aphonia, dry cough, sore throat.</td>
                             <td data-label="Diagnosis">Clinical. Laryngoscopy if persistent > 2-4 wks or red flags.</td>
                             <td data-label="Treatment">Voice rest, hydration, humidification. Treat underlying cause if identified (e.g., PPI for LPR). Antibiotics generally not indicated for acute viral laryngitis.</td>
                         </tr>
                         <tr>
                             <td data-label="Disease">Epiglottitis / Croup</td>
                             <td data-label="Microbe(s)">Epiglottitis: H. influenzae type b (unimmunized), Strep species, Staph aureus. Croup: Parainfluenza virus.</td>
                             <td data-label="Presentation">Epiglottitis: Rapid onset, high fever, drooling, dysphagia, distress, tripod position. Croup: Barking cough, inspiratory stridor, hoarseness, often follows URI.</td>
                             <td data-label="Diagnosis">Epiglottitis: Clinical suspicion, DO NOT EXAMINE THROAT, lateral neck X-ray (thumb sign), direct visualization in OR. Croup: Clinical, neck X-ray (steeple sign).</td>
                             <td data-label="Treatment">Epiglottitis: Intubation, IV Ceftriaxone +/- Vanc. Croup: Dexamethasone +/- Nebulized Epinephrine based on severity.</td>
                         </tr>
                     </tbody>
                 </table>
             </div>

            <!-- Table derived from Page 39 -->
            <h4>Table 2: Pneumonia Syndromes & Pathogens (Lower Airway)</h4>
            <div class="table-container">
                 <table>
                     <thead>
                         <tr><th>Disease</th><th>Common Microbe(s)</th><th>Presentation Key Points</th><th>Diagnosis</th><th>Treatment Notes</th></tr>
                     </thead>
                     <tbody>
                         <tr>
                             <td data-label="Disease">Community-Acquired Pneumonia (CAP)</td>
                             <td data-label="Microbe(s)"><strong>Typical:</strong> <strong>S. pneumoniae</strong>, H. influenzae, M. catarrhalis, S. aureus. <br><strong>Atypical:</strong> Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella pneumophila. <br><strong>Viruses:</strong> Influenza, RSV, Adeno, Metapneumo, Corona (inc COVID-19).</td>
                             <td data-label="Presentation">Acute onset fever, cough (+/- sputum), dyspnea, pleuritic chest pain. Crackles, consolidation on exam. Atypicals often more insidious, dry cough, extrapulmonary sx.</td>
                             <td data-label="Diagnosis">Clinical + CXR (infiltrate). Sputum Gram stain/culture, blood cultures (esp. inpatient). Urinary antigen (S. pneumo, Legionella). PCR panels.</td>
                             <td data-label="Treatment">See Pharm Resp Infections section. Empiric coverage based on severity, comorbidities, local resistance. Outpatient: Amox, Doxy, or Macrolide (healthy); Combo (Beta-lactam + Mac/Doxy) or Resp FQ (comorbid). Inpatient: Combo or Resp FQ. ICU adds MRSA/Pseudo coverage if needed.</td>
                         </tr>
                         <tr>
                             <td data-label="Disease">Hospital-Acquired Pneumonia (HAP)</td>
                             <td data-label="Microbe(s)">Higher risk MDR pathogens: <strong>Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae (inc ESBL), Enterobacter spp., Serratia spp., S. aureus (inc MRSA)</strong>. Also CAP pathogens possible.</td>
                             <td data-label="Presentation">New/progressive infiltrate on CXR developing ≥ 48 hours after hospital admission + signs of infection (fever, leukocytosis, purulent sputum).</td>
                             <td data-label="Diagnosis">Clinical + CXR. Respiratory cultures (sputum, endotracheal aspirate, BAL) crucial for targeted therapy. Blood cultures.</td>
                             <td data-label="Treatment">Empiric broad-spectrum Abx based on MDR risk factors & local data, covering MRSA & Pseudomonas +/- double coverage. E.g., Pip/Tazo or Cefepime/Carbapenem + Vanc/Linezolid +/- AG/FQ. De-escalate based on cultures. Duration ~7 days.</td>
                         </tr>
                         <tr>
                             <td data-label="Disease">Ventilator-Associated Pneumonia (VAP)</td>
                             <td data-label="Microbe(s)">Similar pathogens to HAP, often higher resistance. Anaerobes also possible.</td>
                             <td data-label="Presentation">New/progressive infiltrate on CXR developing ≥ 48 hours after endotracheal intubation + signs of infection (fever, leukocytosis, purulent secretions, worsening oxygenation).</td>
                             <td data-label="Diagnosis">Clinical + CXR. Quantitative cultures (BAL, protected specimen brush) preferred if possible.</td>
                             <td data-label="Treatment">Similar empiric approach to HAP based on MDR risk/local data. Often requires combination therapy covering MRSA + double Pseudomonas coverage initially. De-escalate. Duration ~7 days. Prevention strategies crucial.</td>
                         </tr>
                         <tr>
                             <td data-label="Disease">Aspiration Pneumonia / Lung Abscess</td>
                             <td data-label="Microbe(s)">Often polymicrobial including <strong>Oral Anaerobes</strong> (Peptostreptococcus, Prevotella, Fusobacterium, Bacteroides). Aerobes (Strep, Staph, GNRs) also common, esp. hospital setting.</td>
                             <td data-label="Presentation">Pneumonia: Often insidious onset, cough, fever, putrid (foul-smelling) sputum classic for anaerobes. Abscess: Subacute sx (weeks) - fever, cough, night sweats, weight loss, putrid sputum, chest pain. Risk factors for aspiration.</td>
                             <td data-label="Diagnosis">Clinical Hx + CXR/CT showing infiltrate in dependent segment (posterior upper lobes, superior lower lobes) +/- cavitation/abscess (air-fluid level). Sputum culture often misleading (oral contamination); invasive sampling (BAL, biopsy) if needed.</td>
                             <td data-label="Treatment"><strong>Clindamycin</strong> OR <strong>Beta-lactam/Beta-lactamase inhibitor</strong> (Amox/Clav, Amp/Sulbactam) OR Carbapenem. Metronidazole often added to cover anaerobes if using agent with poor anaerobic coverage (e.g., Ceftriaxone). Duration often longer (weeks-months for abscess). Drainage may be needed for large abscess/empyema.</td>
                         </tr>
                     </tbody>
                 </table>
             </div>

            <!-- Table derived from Page 40 -->
            <h4>Table 3: Gram Positive Bacteria Overview</h4>
             <div class="table-container">
                 <table>
                     <thead>
                         <tr><th>Bacteria Group</th><th>Key Species</th><th>Common Diseases</th><th>Clinical Notes</th><th>Diagnosis</th><th>Treatment Notes</th></tr>
                     </thead>
                     <tbody>
                         <tr>
                             <td data-label="Group"><strong>Pneumococcus</strong><br>(G+ lancet diplococci, α-hemolytic)</td>
                             <td data-label="Species"><em>S. pneumoniae</em></td>
                             <td data-label="Diseases"><strong>CAP (most common bacterial)</strong>, Meningitis, Otitis media, Sinusitis, Bacteremia.</td>
                             <td data-label="Clinical">Polysaccharide capsule (virulence, vaccine target). Optochin sensitive. Bile soluble. <strong>Rusty sputum</strong> classic.</td>
                             <td data-label="Diagnosis">Gram stain, Culture, Urinary antigen.</td>
                             <td data-label="Treatment">Penicillin (if susceptible), Amoxicillin, Ceftriaxone/Cefotaxime, Respiratory FQ, Vancomycin (for high resistance). Resistance increasing (PCN, macrolide). Vaccines (PCV13/15/20, PPSV23).</td>
                         </tr>
                         <tr>
                             <td data-label="Group" rowspan="3"><strong>Staphylococcus</strong><br>(G+ cocci in clusters)</td>
                             <td data-label="Species"><em>S. aureus</em> (Coagulase +, Catalase +)</td>
                             <td data-label="Diseases">Skin/soft tissue (abscess, cellulitis, impetigo, folliculitis), Osteomyelitis, Septic arthritis, Endocarditis (esp. IVDU), Bacteremia, Pneumonia (HAP/VAP, post-viral), Toxin-mediated (TSS, Scalded Skin, Food Poisoning).</td>
                             <td data-label="Clinical">Golden colonies. Protein A (virulence). Many toxins/enzymes.</td>
                             <td data-label="Diagnosis" rowspan="3">Gram stain, Culture. Coagulase test (S. aureus +). Catalase test (+ for Staph, - for Strep). MRSA detection (mecA gene PCR, specific agar).</td>
                             <td data-label="Treatment"><strong>MSSA:</strong> Nafcillin/Oxacillin, Cefazolin/Cephalexin. <br><strong>MRSA:</strong> Vancomycin, Linezolid, Daptomycin, Ceftaroline, TMP-SMX, Doxy, Clinda (depending on site/severity).</td>
                         </tr>
                         <tr>
                             <td data-label="Species">Coagulase-Neg Staph (CoNS) (e.g., <em>S. epidermidis</em>)</td>
                             <td data-label="Diseases">Prosthetic device infections (joints, valves, catheters), Endocarditis (prosthetic valve), Bacteremia (line-related). Contaminant in blood cultures.</td>
                             <td data-label="Clinical">Biofilm formation common. Often Methicillin-resistant (MRSE).</td>
                             <td data-label="Treatment">Vancomycin often needed due to resistance. Device removal often necessary.</td>
                         </tr>
                          <tr>
                             <td data-label="Species"><em>S. saprophyticus</em> (CoNS)</td>
                             <td data-label="Diseases">UTIs (cystitis) in young, sexually active women.</td>
                             <td data-label="Clinical">Novobiocin resistant (distinguishes from S. epidermidis).</td>
                             <td data-label="Treatment">TMP-SMX, Nitrofurantoin, Fluoroquinolone.</td>
                         </tr>
                         <tr>
                             <td data-label="Group" rowspan="4"><strong>Streptococcus</strong><br>(G+ cocci in chains/pairs, Catalase -)</td>
                             <td data-label="Species"><em>S. pyogenes</em> (Group A Strep - GAS, β-hemolytic)</td>
                             <td data-label="Diseases"><strong>Pharyngitis (Strep Throat)</strong>, Skin (Impetigo, Erysipelas, Cellulitis, Necrotizing Fasciitis), Scarlet Fever, Strep TSS, Bacteremia. Post-infectious: Acute Rheumatic Fever (ARF), PSGN.</td>
                             <td data-label="Clinical">Bacitracin sensitive. PYR positive. M protein (virulence).</td>
                             <td data-label="Diagnosis" rowspan="4">Gram stain, Culture, Lancefield grouping (A, B, D), Hemolysis (α, β, γ), Rapid antigen tests (GAS). PYR test. Bile esculin/6.5% NaCl (Enterococcus). Optochin (S. pneumo).</td>
                             <td data-label="Treatment"><strong>GAS:</strong> Penicillin/Amoxicillin. Allergy: Cephalexin, Clindamycin, Macrolide. Nec Fasc/TSS: Penicillin + Clindamycin.</td>
                         </tr>
                          <tr>
                             <td data-label="Species"><em>S. agalactiae</em> (Group B Strep - GBS, β-hemolytic)</td>
                             <td data-label="Diseases">Neonatal sepsis, pneumonia, meningitis. Postpartum infections (endometritis). Infections in elderly/diabetics (skin, UTI, bacteremia).</td>
                             <td data-label="Clinical">Bacitracin resistant. CAMP test positive. Hippurate hydrolysis positive. Normal vaginal flora.</td>
                             <td data-label="Treatment"><strong>GBS:</strong> Penicillin/Ampicillin. Neonatal sepsis prophylaxis (intrapartum PCN to colonized mothers). Gentamicin synergy for serious infections. Vancomycin if severe allergy.</td>
                         </tr>
                         <tr>
                             <td data-label="Species">Viridans Group Strep (α-hemolytic) (e.g., <em>S. mutans, S. mitis, S. sanguinis</em>)</td>
                             <td data-label="Diseases">Dental caries, <strong>Subacute Bacterial Endocarditis (SBE)</strong> (esp. damaged valves), Bacteremia (esp. after dental procedures), Abscesses.</td>
                             <td data-label="Clinical">Normal oral flora. Optochin resistant. Not bile soluble.</td>
                             <td data-label="Treatment"><strong>Viridans:</strong> Penicillin, Ceftriaxone. Vancomycin +/- Gentamicin for endocarditis (depends on MICs).</td>
                         </tr>
                         <tr>
                             <td data-label="Species"><em>Enterococcus</em> species (Group D Strep, variable hemolysis) (e.g., <em>E. faecalis, E. faecium</em>)</td>
                             <td data-label="Diseases">UTIs, Bacteremia (often nosocomial, central lines), Endocarditis, Intra-abdominal/pelvic infections.</td>
                             <td data-label="Clinical">Normal GI flora. Grow in 6.5% NaCl. Bile esculin positive. PYR positive. Intrinsic resistance common (esp. E. faecium). VRE (Vancomycin-Resistant Enterococcus) major concern.</td>
                             <td data-label="Treatment"><strong>Enterococcus:</strong> Ampicillin/Penicillin (if susceptible E. faecalis). Vancomycin (if Amp-res E. faecalis or E. faecium). Often need synergy (Amp/Vanc + Gentamicin/Streptomycin) for endocarditis. <strong>VRE:</strong> Linezolid, Daptomycin, Tigecycline. Nitrofurantoin/Fosfomycin for VRE cystitis.</td>
                         </tr>
                          <!-- Note: S. bovis/gallolyticus (Group D Non-enterococcus) associated with endocarditis and colon cancer -->
                     </tbody>
                 </table>
             </div>

            <!-- Table derived from Page 41 -->
            <h4>Table 4: Gram Negative & Other Bacteria Overview</h4>
            <div class="table-container">
                 <table>
                     <thead>
                         <tr><th>Bacteria Group</th><th>Key Species</th><th>Common Diseases</th><th>Clinical Notes</th><th>Diagnosis</th><th>Treatment Notes</th></tr>
                     </thead>
                     <tbody>
                          <tr>
                             <td data-label="Group"><strong>Corynebacterium</strong><br>(G+ rods, club/pleomorphic)</td>
                             <td data-label="Species"><em>C. diphtheriae</em> & other Corynebacteria (diphtheroids)</td>
                             <td data-label="Diseases"><strong>Diphtheria</strong> (toxigenic strains - pharyngeal/cutaneous), Bacteremia, Endocarditis (diphtheroids - often contaminants or device-related).</td>
                             <td data-label="Clinical">Diphtheria: Sore throat, fever, malaise, adherent <strong>gray pseudomembranes</strong>, "bull neck", potential airway obstruction, systemic toxin effects (myocarditis, neuropathy).</td>
                             <td data-label="Diagnosis">Culture (special media - Tinsdale, Loeffler), Toxin assay (Elek test or PCR for tox gene).</td>
                             <td data-label="Treatment"><strong>Diphtheria: Antitoxin</strong> + Antibiotics (Penicillin G or Erythromycin). Diphtheroids: Treat based on susceptibility if true infection.</td>
                         </tr>
                          <tr>
                             <td data-label="Group"><strong>Haemophilus & Moraxella</strong><br>(G- coccobacilli)</td>
                             <td data-label="Species"><em>H. influenzae</em> (type b - Hib, & non-typeable - NTHi), <em>H. ducreyi</em>, <em>M. catarrhalis</em></td>
                             <td data-label="Diseases"><strong>NTHi/M.cat:</strong> Otitis Media, Sinusitis, COPD exacerbations, Pneumonia (CAP). <br><strong>Hib (pre-vaccine):</strong> Meningitis, Epiglottitis, Pneumonia, Septic Arthritis, Cellulitis. <br><em>H. ducreyi:</em> <strong>Chancroid (STI)</strong>.</td>
                             <td data-label="Clinical">H. flu requires factors X (hemin) & V (NAD) for growth ("chocolate agar"). M. cat often produces beta-lactamase. Chancroid: Painful genital ulcer(s) + tender inguinal LAD (bubo).</td>
                             <td data-label="Diagnosis">Gram stain, Culture (special media for H. flu). PCR for H. ducreyi.</td>
                             <td data-label="Treatment"><strong>OM/Sinusitis/COPD Exac:</strong> Amox/Clav, 2nd/3rd gen Ceph, Macrolide, Doxy, FQ. <br><strong>Hib Invasive:</strong> Ceftriaxone/Cefotaxime. Rifampin prophylaxis for contacts. <br><strong>Chancroid:</strong> Azithromycin, Ceftriaxone, Cipro, Erythromycin.</td>
                         </tr>
                          <tr>
                             <td data-label="Group"><strong>Bordetella</strong><br>(G- coccobacillus)</td>
                             <td data-label="Species"><em>B. pertussis</em></td>
                             <td data-label="Diseases"><strong>Whooping Cough (Pertussis)</strong>.</td>
                             <td data-label="Clinical">Stages: Catarrhal (cold-like, most contagious) → Paroxysmal (severe coughing fits + "whoop", post-tussive emesis, apnea in infants) → Convalescent (gradual recovery).</td>
                             <td data-label="Diagnosis">Nasopharyngeal swab/aspirate for Culture (special media - Regan-Lowe/Bordet-Gengou) or PCR (preferred). Lymphocytosis common.</td>
                             <td data-label="Treatment">Supportive care. Antibiotics (primarily to reduce transmission): <strong>Macrolides</strong> (Azithromycin, Erythromycin, Clarithromycin). Alt: TMP-SMX. Treat patient & close contacts.</td>
                            </tr>
                             <tr>
                                <td data-label="Group"><strong>Pseudomonas</strong><br>(G- rod, aerobic, oxidase +)</td>
                                <td data-label="Species"><em>P. aeruginosa</em></td>
                                <td data-label="Diseases">HAP/VAP, Hot tub folliculitis, Otitis externa (swimmer's ear, malignant OE), Ecthyma gangrenosum (bacteremia), Infections in CF, burns, neutropenia. UTIs (catheter), Corneal ulcers (contacts).</td>
                                <td data-label="Clinical">Opportunistic. Often MDR. Produces pigments (pyocyanin - blue/green), fruity odor. Found in water/soil.</td>
                                <td data-label="Diagnosis">Culture.</td>
                                <td data-label="Treatment">Requires <strong>Anti-pseudomonal</strong> agent: Pip/Tazo, Ceftazidime, Cefepime, Aztreonam, Meropenem/Imipenem/Doripenem, Ciprofloxacin/Levofloxacin, Aminoglycosides (Gent/Tobra/Amikacin). Often combination therapy for serious infections.</td>
                            </tr>
                            <tr>
                                <td data-label="Group" rowspan="3"><strong>Burkholderia</strong><br>(G- rod)</td>
                                <td data-label="Species"><em>B. cepacia</em> complex</td>
                                <td data-label="Diseases">Opportunistic infections, esp. <strong>pneumonia/sepsis in Cystic Fibrosis</strong> (associated with rapid decline) & Chronic Granulomatous Disease (CGD). Nosocomial infections.</td>
                                <td data-label="Clinical">Highly resistant to multiple antibiotics. Environmental organism.</td>
                                <td data-label="Diagnosis">Culture.</td>
                                <td data-label="Treatment">Difficult. Based on susceptibilities. Options may include: TMP-SMX, Meropenem, Ceftazidime, Minocycline. Often requires combination.</td>
                            </tr>
                             <tr>
                                <td data-label="Species"><em>B. pseudomallei</em></td>
                                <td data-label="Diseases"><strong>Melioidosis</strong> (Pneumonia, abscesses, sepsis). Endemic SE Asia, N Australia.</td>
                                <td data-label="Clinical">Exposure to contaminated soil/water. Can have latent period. "Safety pin" appearance on Gram stain.</td>
                                <td data-label="Diagnosis">Culture. Serology.</td>
                                <td data-label="Treatment">Intensive phase (IV): Ceftazidime or Carbapenem. Eradication phase (Oral): TMP-SMX +/- Doxycycline (long duration).</td>
                            </tr>
                             <tr>
                                <td data-label="Species"><em>B. mallei</em></td>
                                <td data-label="Diseases"><strong>Glanders</strong> (primarily affects horses, rare zoonosis). Pneumonia, sepsis, skin lesions. Bioterrorism potential.</td>
                                <td data-label="Clinical">Occupational exposure. Non-motile (unlike other Burkholderia).</td>
                                <td data-label="Diagnosis">Culture. Serology.</td>
                                <td data-label="Treatment">Similar to Melioidosis (Carbapenem or Ceftazidime +/- TMP-SMX/Doxy). Prolonged therapy.</td>
                            </tr>
                            <tr>
                                <td data-label="Group"><strong>Stenotrophomonas</strong><br>(G- rod, oxidase -)</td>
                                <td data-label="Species"><em>S. maltophilia</em></td>
                                <td data-label="Diseases">Nosocomial infections (pneumonia/VAP, bacteremia), esp. in immunocompromised, ventilated, prior broad-spectrum abx use.</td>
                                <td data-label="Clinical">Environmental organism. Intrinsically resistant to many abx (esp. carbapenems).</td>
                                <td data-label="Diagnosis">Culture.</td>
                                <td data-label="Treatment"><strong>TMP-SMX</strong> drug of choice. Alternatives based on susceptibility: Levofloxacin, Ceftazidime (variable), Minocycline, Ticarcillin-clavulanate.</td>
                            </tr>
                             <!-- H. ducreyi already covered under Haemophilus -->
                        </tbody>
                    </table>
               </div>
           </div> <!-- End Section: Microbiology Summary -->

        <div class="pixel-art-divider"></div>

           <!-- Section: Pharmacology CIL -->
           <div id="pharmacology-cil" class="content-section">
                <svg viewBox="0 0 16 16" xmlns="http://www.w3.org/2000/svg" class="section-svg"><path d="M1 1H2V2H1V1ZM3 1H4V2H3V1ZM5 1H6V2H5V1ZM7 1H9V2H7V1ZM9 1H11V2H9V1ZM11 1H12V2H11V1ZM13 1H14V2H13V1ZM15 1H16V2H15V1ZM1 3H2V4H1V3ZM3 3H4V4H3V3ZM5 3H6V4H5V3ZM7 3H8V4H7V3ZM9 3H10V4H9V3ZM11 3H12V4H11V3ZM13 3H14V4H13V3ZM15 3H16V4H15V3ZM1 5H2V6H1V5ZM3 5H4V6H3V5ZM5 5H6V6H5V5ZM6 6H7V7H6V6ZM7 7H8V8H7V7ZM8 8H9V9H8V8ZM9 9H10V10H9V9ZM10 10H11V11H10V10ZM11 11H12V12H11V11ZM12 12H13V13H12V12ZM13 13H14V14H13V13ZM14 14H15V15H14V14ZM15 15H16V16H15V15ZM13 15H14V16H13V15ZM11 15H12V16H11V15ZM9 15H10V16H9V15ZM7 15H8V16H7V15ZM5 15H6V16H5V15ZM3 15H4V16H3V15ZM1 15H2V16H1V15ZM1 13H2V14H1V13ZM1 11H2V12H1V11ZM1 9H2V10H1V9ZM1 7H2V8H1V7ZM4 6H5V7H4V6ZM12 6H13V7H12V6ZM14 5H15V6H14V5ZM14 7H15V8H14V7ZM14 9H15V10H14V9ZM14 11H15V12H14V11ZM14 13H15V14H14V13ZM12 14H13V15H12V14ZM10 14H11V15H10V14ZM8 14H9V15H8V14ZM6 14H7V15H6V14ZM4 14H5V15H4V14ZM2 13H3V14H2V13ZM2 11H3V12H2V11ZM2 9H3V10H2V9ZM2 7H3V8H2V7ZM2 5H3V6H2V5ZM4 12H5V13H4V12ZM5 11H6V12H5V11ZM6 10H7V11H6V10ZM7 9H8V10H7V9ZM8 7H9V8H8V7ZM9 6H10V7H9V6ZM10 5H11V6H10V5ZM11 7H12V8H11V7ZM12 9H13V10H12V9ZM11 13H10V14H11V13ZM9 13H8V14H9V13ZM7 13H6V14H7V13ZM5 13H4V14H5V13Z" fill="currentColor"/></svg>
                <h2>Drugs for Rhinitis/Allergy CIL (Clinical Integration Lecture)</h2>

                <div class="case-study">
                    <p class="case-title">Case 1 (Rhinitis/Allergy CIL):</p>
                    <p>25 yo falling asleep during operation, constant rhinorrhea, frequent tearing of eyes, conjunctivitis. A few weeks ago, began an OTC antihistamine, he took more than usual (2 or 3). PMH: HTN rx: atenolol QD. Vitals normal. PE: prominent erythematous boggy nasal turbinates, 2+ enlarged tonsils, no lymphadenopathy, 2+ conjunctivitis.</p>
                    <details>
                        <summary>What is the diagnosis?</summary>
                        <div class="details-content">
                             <ul>
                                <li>Acute pharyngitis</li>
                                <li>Acute rhinosinusitis</li>
                                <li><strong>Allergic Rhinitis:</strong> Constant rhinorrhea, tearing, conjunctivitis, boggy turbinates suggest allergy. Falling asleep suggests sedating antihistamine use.</li>
                                <li>Ludwig's angina</li>
                                <li>Vincent's angina</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>Review immunologic response to allergies:</summary>
                        <div class="details-content"><p>Initial exposure (sensitization) → Allergen processed by APCs → Presented to Th2 cells → Th2 cells release IL-4, IL-13 → Stimulate B cells to class switch and produce allergen-specific IgE → IgE binds to high-affinity FcεR1 receptors on mast cells and basophils. <br> Re-exposure → Allergen cross-links IgE on mast cells → Degranulation → Release of preformed mediators (Histamine, proteases) = Early phase reaction (sneezing, itching, rhinorrhea, vasodilation). Synthesis of new mediators (Leukotrienes, Prostaglandins, Cytokines) → Late phase reaction (sustained inflammation, nasal congestion, eosinophil recruitment).</p></div>
                    </details>
                    <details>
                        <summary>Which of the following initial therapies is CONTRAINDICATED for him?</summary>
                        <div class="details-content">
                             <ul>
                                <li><strong>A first-gen H1 antagonist (e.g., Diphenhydramine): CONTRAINDICATED due to severe sedation (already falling asleep) and anticholinergic effects.</strong></li>
                                <li>A leukotriene receptor antagonist (Montelukast): Option, but not first-line, neuropsych warning.</li>
                                <li>Acupuncture: Alternative therapy.</li>
                                <li>A second-gen H1 antagonist (e.g., Loratadine): Appropriate initial option.</li>
                                <li>An intranasal corticosteroid (e.g., Fluticasone): Most effective long-term, appropriate initial option.</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>If he were not hypertensive, the adrenergic agonist that would be most appropriate targets which receptor?</summary>
                        <div class="details-content">
                             <p>For nasal decongestion:</p>
                             <ul>
                                <li><strong>Alpha-1: Causes vasoconstriction in nasal mucosa, reducing swelling. Target of decongestants (phenylephrine, pseudoephedrine, oxymetazoline).</strong></li>
                                <li>Alpha-2: Primarily CNS effects.</li>
                                <li>Beta-1: Primarily heart.</li>
                                <li>Beta-2: Primarily lungs (bronchodilation).</li>
                                <li>Beta-3: Adipose tissue, bladder.</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>An adrenergic agonist (decongestant) is CONTRAINDICATED/used with caution because it elevates the risk of?</summary>
                        <div class="details-content">
                             <ul>
                                <li><strong>Acute stroke / Hypertensive crisis: Due to systemic vasoconstriction and increased BP, especially in patients with pre-existing HTN.</strong></li>
                                <li>Anaphylaxis (Unrelated).</li>
                                <li>Bradycardia (Causes tachycardia).</li>
                                <li>Epistaxis (More common with topical use).</li>
                                <li>Sedation (Causes stimulation).</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>If he were not hypertensive, the agent that would be most appropriate for *rapid* relief is?</summary>
                        <div class="details-content">
                             <p>For rapid nasal congestion relief:</p>
                             <ul>
                                <!-- <li>Ephedrine (Banned/restricted).</li> -->
                                <li><strong>Oxymetazoline (Topical nasal spray): Very rapid onset (seconds to minutes).</strong></li>
                                <li>Phenylephrine (Topical spray also rapid; Oral form less effective).</li>
                                <li>Pseudoephedrine (Oral, slower onset than topical).</li>
                             </ul>
                         </div>
                    </details>
                     <details>
                        <summary>Due to young age, low stroke risk. He wants the “fastest possible” therapy to stop his nose from running (rhinorrhea), with least interference. Which is most appropriate?</summary>
                        <div class="details-content">
                             <p>Targeting rhinorrhea specifically and quickly:</p>
                             <ul>
                                <li>Cromolyn sodium (Prophylactic, slow).</li>
                                <li>Diphenhydramine (Sedating).</li>
                                <li>Montelukast (Prophylactic, slow).</li>
                                <li>Oxymetazoline (Decongestant - targets congestion primarily, less effect on histamine-mediated rhinorrhea).</li>
                                <li><strong>Ipratropium bromide nasal spray: Anticholinergic, directly reduces watery nasal secretions (rhinorrhea). Relatively rapid onset, minimal systemic effects.</strong></li>
                                <li>(Topical antihistamine like Azelastine also good option for rapid relief of multiple symptoms including rhinorrhea).</li>
                             </ul>
                         </div>
                    </details>
                     <details>
                        <summary>The major reason oxymetazoline (topical decongestant) could be safer systemically than oral pseudoephedrine/phenylephrine is?</summary>
                        <div class="details-content">
                             <ul>
                                <li><strong>Limited topical administration results in very low systemic absorption / bioavailability.</strong></li>
                                <li>Oral agents undergo first-pass metabolism (True, especially phenylephrine, but systemic effects still occur).</li>
                                <li>Oxymetazoline is available in oral pill form (False).</li>
                                <li>Oxymetazoline is not a substrate for monoamine oxidase (Irrelevant).</li>
                                <li>Purchasing pseudoephedrine is difficult (True, but not a safety reason).</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>If the patient were to use oxymetazoline more than recommended (>3-5 days), he would be at risk for?</summary>
                        <div class="details-content">
                             <ul>
                                <li>Bronchospasm (Unrelated).</li>
                                <li>Difficulty voiding (Unlikely from topical).</li>
                                <li>Drowsiness (Unlikely).</li>
                                <li>Glaucoma (Unlikely from topical).</li>
                                <li><strong>Rebound vasodilation / Rhinitis Medicamentosa: Worsening nasal congestion due to receptor downregulation after prolonged use.</strong></li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>If this physician was very risk-averse, the most appropriate therapy (considering safety profile primarily) might be?</summary>
                        <div class="details-content">
                             <p>Considering options with lowest risk profiles:</p>
                             <ul>
                                <li>Intranasal corticosteroid (Very safe locally, minimal systemic risk at standard doses).</li>
                                <li>Cromolyn sodium nasal spray (Extremely safe, but less effective).</li>
                                <li>Diphenhydramine (Significant sedation/anticholinergic risk).</li>
                                <li>Immunotherapy (Risk of systemic reactions/anaphylaxis).</li>
                                <li><strong>Ipratropium bromide nasal spray: Targets rhinorrhea with minimal systemic absorption/effects, generally very safe.</strong></li>
                                <li>Second-gen Antihistamine (Oral): Generally very safe (e.g., Loratadine, Fexofenadine).</li>
                                <li>*(Choice depends on target symptom and acceptable efficacy)*</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>Ipratropium bromide nasal spray has its largest therapeutic effect on which symptom?</summary>
                        <div class="details-content">
                             <ul>
                                <li>Conjunctivitis</li>
                                <li>Nasal congestion</li>
                                <li>Postnasal drip (May reduce volume slightly)</li>
                                <li><strong>Rhinorrhea (Watery nasal discharge - primary target).</strong></li>
                                <li>Sneezing</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>If risk-averse, the most appropriate therapy MOA?</summary>
                        <div class="details-content">
                             <p>Relating to safest options:</p>
                             <ul>
                                <li>Non-selective H-1 receptor antagonist (1st gen - risks).</li>
                                <li><strong>Anticholinergic agent (Topical Ipratropium - relatively safe).</strong></li>
                                <li>Decreases serum levels of specific IgE (Immunotherapy - risks).</li>
                                <li><strong>Interferes with the delayed chloride channel (Cromolyn - very safe).</strong></li>
                                <li>Phospholipase A2 inhibitor (Glucocorticoids - nasal steroids relatively safe).</li>
                                <li>Selective H-1 receptor antagonist (2nd gen - very safe).</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>If risk-averse..., common/characteristic adverse effects?</summary>
                        <div class="details-content">
                             <p>Matching AEs to safest options (Ipratropium, Cromolyn, INS, 2nd gen AH):</p>
                             <ul>
                                <li><strong>Local irritation: cough, dry mouth/nose, stinging, sneezing, epistaxis</strong> (Common with Ipratropium, Cromolyn, INS).</li>
                                <li>Glaucoma, blurred vision, urinary retention (Systemic anticholinergic - rare with ipratropium nasal).</li>
                                <li>Glaucoma, hyperglycemia, osteoporosis, weight gain (Systemic steroids - minimal risk with standard dose INS).</li>
                                <li>Sedation, dry mouth (1st gen antihistamines).</li>
                                <li>Time off work, expense, anaphylaxis risk (Immunotherapy).</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>Patient wants fastest-acting therapy to stop rhinorrhea (back in OR in 2 hrs). Most appropriate?</summary>
                        <div class="details-content">
                             <ul>
                                <li>Nasal cromolyn inhaler (Slow, prophylactic).</li>
                                <li><strong>Nasal ipratropium bromide spray: Targets rhinorrhea, onset within 30-60 min.</strong></li>
                                <li>Nasal corticosteroid inhaler (Slow onset >12 hrs).</li>
                                <li>Oral loratadine (Slower onset ~1-3 hrs, less targeted for rhinorrhea).</li>
                                <li>Oral montelukast (Slow, prophylactic).</li>
                                <li>(Nasal Azelastine also rapid onset option for rhinorrhea/other sx).</li>
                             </ul>
                         </div>
                    </details>
                     <details>
                        <summary>Patient decides he would prefer a therapy other than ipratropium bromide because?</summary>
                        <div class="details-content">
                             <ul>
                                <li>Risk spraying into eyes (Possible concern).</li>
                                <li>Acute urinary retention (Unlikely risk).</li>
                                <li>Diabetes, weight gain, etc. (Steroid side effects).</li>
                                <li>Erectile dysfunction (Unrelated).</li>
                                <li><strong>May improve rhinorrhea but will do little for his other symptoms (itching, sneezing, congestion, ocular symptoms).</strong> (Most accurate limitation).</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>Fastest-acting therapy (NOT ipratropium) for multiple symptoms (back in OR in 2 hrs)?</summary>
                        <div class="details-content">
                             <ul>
                                <li><strong>Nasal azelastine: Topical antihistamine, rapid onset (~15-30 min), targets multiple symptoms (rhinorrhea, sneezing, itching, some congestion).</strong></li>
                                <li>Nasal cromolyn inhaler (Slow).</li>
                                <li>Nasal corticosteroid inhaler (Slow).</li>
                                <li>Oral fexofenadine (Slower onset ~1-2 hrs).</li>
                                <li>Oral montelukast (Slow).</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>Most troublesome/common adverse effects of azelastine?</summary>
                        <div class="details-content">
                             <ul>
                                <li>Glaucoma or cataracts and weight gain (Steroids).</li>
                                <li>Headache and maybe Churg-Strauss syndrome (Montelukast).</li>
                                <li>Maybe waste of money and local irritation (Cromolyn).</li>
                                <li><strong>Bitter taste (very common) and potential for somnolence (especially with alcohol/other sedatives).</strong></li>
                                <li>Sedation and difficulties passing urine (1st gen AH / Systemic Anticholinergics).</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>Most effective long-term (prophylactic) therapy?</summary>
                        <div class="details-content">
                             <ul>
                                <li>Nasal azelastine (Okay long term, less effective than INS).</li>
                                <li>Nasal cromolyn inhaler (Safe long term, less effective).</li>
                                <li><strong>Nasal topical glucocorticoid: Most effective single maintenance therapy for allergic rhinitis.</strong></li>
                                <li>Oral fexofenadine (Okay long term, less effective than INS).</li>
                                <li>Oral montelukast (Okay long term, less effective than INS).</li>
                             </ul>
                         </div>
                    </details>
                     <details>
                        <summary>According to meta-analysis, most effective long-term treatment MOA?</summary>
                        <div class="details-content">
                             <ul>
                                <li>Blocks H-1 receptors (Antihistamines).</li>
                                <li>Blocks leukotriene receptors (LTRAs).</li>
                                <li>Blocks muscarinic receptors (Ipratropium).</li>
                                <li><strong>Inhibits PLA2 / Broad anti-inflammatory effects via glucocorticoid receptor activation (Glucocorticoids - INS).</strong></li>
                                <li>Interferes with the delayed chloride channel (Cromolyn).</li>
                             </ul>
                         </div>
                    </details>
               </div> <!-- End Case 1 CIL -->

               <div class="case-study">
                   <p class="case-title">Case 2 (Rhinitis/Allergy CIL):</p>
                   <p>25 yo woman c/o severe nasal congestion x 3 days. Hx of severe allergies, bad atopic asthma from ages 1-16 and has "grown out" of the need for chronic meds for asthma. Every fall she has cough, sneezing, rhinorrhea, tearing eyes, conjunctivitis. A few days ago, she acquired an OTC decongestant in nasal spray which helped for 3 days but is now using 6 sprays per day in each nostril (rather than 2), her nasal congestion and difficulty breathing have worsened. She is unable to sleep, study, and takes birth control. Vitals are WNL with upper airway wheezing. PE: prominent erythematous boggy nasal turbinates, 2+ enlarged tonsils, no lymphadenopathy, 2+ conjunctivitis.</p>
                    <details>
                        <summary>The offending agent has which primary MOA?</summary>
                        <div class="details-content">
                             <p>Overuse of OTC decongestant nasal spray causing worsening congestion = Rhinitis Medicamentosa.</p>
                             <ul>
                                <li>Blocks H-1 receptors (Antihistamine).</li>
                                <li>Blocks cysteinyl leukotriene receptors (LTRA).</li>
                                <li>Delays flux in chloride channels (Cromolyn).</li>
                                <li>Inhibits muscarinic receptors (Ipratropium).</li>
                                <li><strong>Agonist at adrenergic receptors (Topical Alpha-1 agonist decongestant like Oxymetazoline).</strong></li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>Most appropriate recommendation to reduce her severe nasal congestion?</summary>
                        <div class="details-content">
                             <p>Management of Rhinitis Medicamentosa:</p>
                             <ol>
                                 <li><strong>STOP the offending topical decongestant spray completely.</strong></li>
                                 <li><strong>Start an Intranasal Corticosteroid (INS)</strong> - treats underlying inflammation and helps manage rebound congestion during withdrawal (takes days to work).</li>
                                 <li>Consider short course of oral steroids if rebound is severe.</li>
                                 <li>Saline irrigation can help.</li>
                             </ol>
                             <p>Evaluating the provided options based on this:</p>
                             <ul>
                                <li>Use lower dose (Incorrect - need to stop).</li>
                                <li>Less frequently, add muscarinic agonist (Incorrect MOA).</li>
                                <li><strong>Less frequently (implies tapering/stopping) + add neutrophil chemotaxis inhibitor (convoluted way of saying add INS/Steroid). This is likely the intended best answer among poor choices, focusing on adding the steroid.</strong></li>
                                <li>Less frequently + add alpha-1 antagonist (Worsens congestion).</li>
                                <li>More frequently... (Incorrect).</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>Most common adverse effects of the appropriate additional therapy (Intranasal Steroid)?</summary>
                        <div class="details-content">
                             <ul>
                                <li>Blurred vision (Uncommon).</li>
                                <li>Difficulty in urination (Uncommon).</li>
                                <li>Increased blood pressure (Uncommon).</li>
                                <li><strong>Sneezing, nasal dryness, stinging, epistaxis (Common local side effects).</strong></li>
                                <li>Thrush (More common with inhaled steroids for asthma, less with nasal sprays if used correctly).</li>
                             </ul>
                         </div>
                    </details>
               </div> <!-- End Case 2 CIL -->

                <div class="case-study">
                   <p class="case-title">Case 3 (Rhinitis/Allergy CIL):</p>
                   <p>25 yo with difficulty breathing every autumn. Hx of "severe allergies" as a youngster with “cradle cap" at 6 months as a newborn, eczema and impetigo as a toddler, and atopic asthma until age 16. She had to take 2 types of inhalers, but was never an oral steroids, never hospitalized, or intubated. She did go to the ED at least once each fall from age 5-15 years. She could not afford “allergy shots” that her physician recommended. Her current symptoms are related to cough, sneeze, runny nose, and "pinkeye" that start about the first of April, improve in June, and remit after first frost (Seasonal Allergic Rhinoconjunctivitis - SAR). She expresses interest in taking some treatment for herself, so the child will not have the health challenges she faces. Her only med is oral contraceptive. PE: mildly erythematous and boggy nasal turbinates, no lymphadenopathy, 1+ enlarged tonsils, 1+ conjunctivitis.</p>
                    <details>
                        <summary>The most appropriate initial therapy for her is?</summary>
                        <div class="details-content">
                             <p>For SAR, options include INS, oral AH, topical AH.</p>
                             <ul>
                                <li>A first-gen H-1 agonist (Sedating).</li>
                                <li>A first-gen H-2-antagonist (Irrelevant).</li>
                                <li>A second-gen H-1-agonist (No such thing).</li>
                                <li><strong>A second-gen H-1-antagonist: Good starting point, non-sedating, addresses multiple symptoms (sneezing, itching, rhinorrhea, ocular).</strong></li>
                                <li>A second-gen H-2 antagonist (Irrelevant).</li>
                                <li>(INS is most effective overall, but 2nd gen AH is reasonable start).</li>
                             </ul>
                         </div>
                    </details>
                     <details>
                        <summary>Which is most likely of interest (cost effective)?</summary>
                        <div class="details-content">
                             <ul>
                                <li>Azelastine + fluticasone spray (generic, $170.80) (Expensive).</li>
                                <li>Azelastine nasal spray (generic, $27.80) (Moderate).</li>
                                <li>Generic cetirizine pills 10mg (20) (Usually inexpensive).</li>
                                <li><strong>Generic loratadine pills 10mg ($9.50): Very inexpensive OTC option.</strong></li>
                                <li>Olopatadine nasal spray (generic $100) (Expensive).</li>
                             </ul>
                         </div>
                    </details>
                     <details>
                        <summary>Most appropriate additional agent, started 2-3 weeks prior to season?</summary>
                        <div class="details-content">
                             <p>For prophylaxis before season starts:</p>
                             <ul>
                                <li>A Chinese herbal med (Not standard).</li>
                                <li><strong>A neutrophil chemotaxis suppressor / mast cell stabilizer (e.g., Cromolyn Sodium nasal spray): Best used prophylactically, very safe.</strong></li>
                                <li>Receptor agonist that stimulates cysteinyl leukotrienes (Incorrect MOA).</li>
                                <li>A sympathomimetic agent (Decongestant - symptom relief only).</li>
                                <li>An IgE antibody blocker (Omalizumab - not indicated).</li>
                                <li>(Starting INS 2-3 weeks before season is also highly effective prophylaxis).</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>If symptoms not relieved by non-sedating AH and INS after 1-3 weeks, most appropriate addition?</summary>
                        <div class="details-content">
                             <p>Already on two mainstays (INS + Oral AH). Next logical steps:</p>
                             <ul>
                                <li>A first-gen H-1 agonist (Adds side effects).</li>
                                <!-- <li>A first-gen H-1 antagonist (Typo?)</li> -->
                                <li><strong>A leukotriene antagonist (Montelukast): Reasonable add-on, especially if any asthma component.</strong></li>
                                <li>A muscarinic antagonist (Ipratropium): Only helps rhinorrhea.</li>
                                <li>Immunotherapy: Consider if still refractory, patient motivated.</li>
                                <li>(Also consider adding topical antihistamine spray - Azelastine/Olopatadine).</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>If non-sedating AH, INS, and montelukast fail, she might try next?</summary>
                        <div class="details-content">
                             <p>Maximal medical therapy nearly achieved. Need to reconsider approach or add different mechanism.</p>
                             <ul>
                                <li>Continue montelukast, start a cromone (Adding less effective agent).</li>
                                <li>Continue montelukast, start ipratropium (Only targets rhinorrhea).</li>
                                <li><strong>Continue montelukast, start immunotherapy: Best option if meds fail and allergy confirmed.</strong></li>
                                <li>Stop montelukast, start cromone (Replacing potentially ineffective med with less effective one).</li>
                                <li>Stop montelukast, start ipratropium (Stopping controller for symptom-only drug).</li>
                                <li>(Stopping Montelukast and adding Azelastine spray is another option).</li>
                             </ul>
                         </div>
                    </details>
               </div> <!-- End Case 3 CIL -->

                <div class="case-study">
                   <p class="case-title">Case 4 (Rhinitis/Allergy CIL):</p>
                   <p>14 yo boy with 2 weeks of persistent, if not worsening, right suborbital facial pain, intermittent low-grade fever, coughing, sneezing, rhinorrhea, and some post-nasal drip. He had a "bad cold" 3 weeks ago seen in office, but PE was unremarkable, so oral fluids, acetaminophen, and rest were advised. Today, his temp is 38.3 C with mild tenderness over R maxillary sinus, which does not trans-illuminate as well as the L.</p>
                    <details>
                        <summary>The most appropriate next step?</summary>
                        <div class="details-content">
                             <p>Symptoms > 10-14 days + fever + facial pain = meets criteria for Acute Bacterial Rhinosinusitis (ABRS).</p>
                             <ul>
                                <li>Admit to hospital (Not indicated).</li>
                                <li>CT of head (Not indicated unless complications suspected).</li>
                                <li><strong>Oral high-dose amoxicillin + clavulanate: First-line treatment for ABRS.</strong></li>
                                <li>Referral to otorhinolaryngologist (Only if refractory/complications).</li>
                                <li>Sinus series (X-rays) (Low yield).</li>
                             </ul>
                         </div>
                    </details>
                     <details>
                        <summary>The most characteristic adverse effect of this therapy (Amoxicillin/Clavulanate)?</summary>
                        <div class="details-content">
                             <ul>
                                <li><strong>Hypersensitivity reaction (e.g., rash, anaphylaxis): Most characteristic serious reaction to penicillins.</strong></li>
                                <li>Hemolysis in G6PD deficiency (Sulfonamides, etc.).</li>
                                <li>Orange-red bodily secretions (Rifampin).</li>
                                <li>"Red man syndrome" (Vancomycin).</li>
                                <li>Rupture of long tendons (Fluoroquinolones).</li>
                                <li>(Diarrhea is most common AE, often due to clavulanate, but hypersensitivity is more characteristic of the drug class).</li>
                             </ul>
                         </div>
                    </details>
               </div> <!-- End Case 4 CIL -->

                <div class="case-study">
                   <p class="case-title">Case 5 (Rhinitis/Allergy CIL):</p>
                   <p>3 yo boy with 3 days of fever, sore throat, malaise, and anorexia but no cough. Mother was told to give acetaminophen every 6 hours and bring in if no improvement in 24 hours. He barely survived an IM injection of pen G when he was 1 ½ years old (implies severe allergy). Temp is 100 F (37.8 C), “strawberry tonsils" (likely means erythematous, possibly exudative), shotty and non-tender lymph nodes in anterior cervical chain. Rapid strep test was positive.</p>
                     <details>
                        <summary>Most appropriate next step?</summary>
                        <div class="details-content">
                             <p>Positive RADT for GAS + history of near-fatal PCN reaction.</p>
                             <ul>
                                <li>IM penicillin G today (CONTRAINDICATED).</li>
                                <li><strong>Oral azithromycin: Appropriate alternative for severe/anaphylactic PCN allergy.</strong></li>
                                <li>Throat culture and IM pen G (Contraindicated).</li>
                                <li>Throat culture and oral cephalexin (Risky cross-reactivity with severe PCN allergy history).</li>
                                <li>Throat culture and return tomorrow (Delaying treatment unnecessarily with positive RADT).</li>
                             </ul>
                         </div>
                    </details>
               </div> <!-- End Case 5 CIL -->
           </div> <!-- End Section: Pharmacology CIL -->

           <div class="pixel-art-divider"></div>

           <!-- Section: CIL Antimicrobials -->
           <div id="cil-antimicrobials" class="content-section">
                <svg viewBox="0 0 16 16" xmlns="http://www.w3.org/2000/svg" class="section-svg"><path d="M1 1H3V2H1V1ZM4 1H6V2H4V1ZM7 1H9V2H7V1ZM10 1H12V2H10V1ZM13 1H15V2H13V1ZM1 3H2V4H1V3ZM3 3H4V4H3V3ZM5 3H6V4H5V3ZM7 3H8V4H7V3ZM9 3H10V4H9V3ZM11 3H12V4H11V3ZM13 3H14V4H13V3ZM15 3H16V4H15V3ZM1 5H2V6H1V5ZM3 5H4V6H3V5ZM5 5H6V6H5V5ZM6 6H7V7H6V6ZM7 7H8V8H7V7ZM8 8H9V9H8V8ZM9 9H10V10H9V9ZM10 10H11V11H10V10ZM11 11H12V12H11V11ZM12 12H13V13H12V12ZM13 13H14V14H13V13ZM14 14H15V15H14V14ZM15 15H16V16H15V15ZM13 15H14V16H13V15ZM11 15H12V16H11V15ZM9 15H10V16H9V15ZM7 15H8V16H7V15ZM5 15H6V16H5V15ZM3 15H4V16H3V15ZM1 15H2V16H1V15ZM1 13H2V14H1V13ZM1 11H2V12H1V11ZM1 9H2V10H1V9ZM1 7H2V8H1V7ZM4 6H5V7H4V6ZM12 6H13V7H12V6ZM14 5H15V6H14V5ZM14 7H15V8H14V7ZM14 9H15V10H14V9ZM14 11H15V12H14V11ZM14 13H15V14H14V13ZM12 14H13V15H12V14ZM10 14H11V15H10V14ZM8 14H9V15H8V14ZM6 14H7V15H6V14ZM4 14H5V15H4V14ZM2 13H3V14H2V13ZM2 11H3V12H2V11ZM2 9H3V10H2V9ZM2 7H3V8H2V7ZM2 5H3V6H2V5ZM4 12H5V13H4V12ZM5 11H6V12H5V11ZM6 10H7V11H6V10ZM7 9H8V10H7V9ZM8 7H9V8H8V7ZM9 6H10V7H9V6ZM10 5H11V6H10V5ZM11 7H12V8H11V7ZM12 9H13V10H12V9ZM11 13H10V14H11V13ZM9 13H8V14H9V13ZM7 13H6V14H7V13ZM5 13H4V14H5V13Z" fill="currentColor"/></svg>
                <h2>CIL: Antimicrobials for Common Respiratory Infections</h2>

                <div class="case-study">
                    <p class="case-title">Case 1 (Antimicrobial CIL):</p>
                    <p>Previously healthy, 47 yo male with 3 days of fever, chills, dyspnea, cough, yellow-green sputum turned brownish-red, malaise, 5 lb. weight loss. No PMH or meds. Temp 101.5 F (38.6 C). RR 24 and shallow. BP 138/84 P 104 and regular. PE: rales, rhonchi at R base posteriorly, w/o egophony, whispered pectoriloquy, or tactile fremitus. Sputum specimen: thick, foul-smelling and brown.</p>
                    <details>
                        <summary>The most likely diagnosis is acute?</summary>
                        <div class="details-content">
                             <ul>
                                <li>Decompensated heart failure</li>
                                <li>Miliary TB</li>
                                <li>Myocardial infarction</li>
                                <li><strong>Pneumonia: Acute respiratory illness with fever, cough, sputum, dyspnea, lung findings. Foul sputum suggests anaerobes/abscess; brownish-red suggests blood (rusty = S. pneumo).</strong></li>
                                <li>Purulent sinusitis</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>The most specific diagnosis is acute?</summary>
                        <div class="details-content">
                             <ul>
                                <li>Atypical pneumonia</li>
                                <li><strong>Community-acquired pneumonia (CAP): Acquired outside healthcare setting.</strong></li>
                                <li>Healthcare-associated pneumonia (HAP definition revised - now usually just HAP/VAP).</li>
                                <li>Hospital-acquired pneumonia (HAP: ≥48h after admission).</li>
                                <li>Ventilator-associated pneumonia (VAP: ≥48h after intubation).</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>The most likely pathogen causing his pneumonia is?</summary>
                        <div class="details-content">
                             <ul>
                                <li>Mycoplasma pneumonia (Atypical, usually less severe, dry cough).</li>
                                <li>Mycobacterium TB (Chronic usually).</li>
                                <li>Pneumocystis jirovecii (Immunocompromised).</li>
                                <li>Pseudomonas aeruginosa (HAP/VAP, CF, immunocompromised).</li>
                                <li><strong>Streptococcus pneumoniae: Most common CAP pathogen. Rusty sputum classic. (Foul smell suggests possible anaerobic co-infection/aspiration component).</strong></li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>The most appropriate next step in his management is?</summary>
                        <div class="details-content">
                             <p>Assess severity (CURB-65: Age<65=0, Confusion=0, Urea=UNK, RR=24(<30)=0, BP>90/60=0. Score 0-1 suggests outpatient possible, BUT tachypnea, fever, possible aspiration component might warrant admission).</p>
                             <ul>
                                <li>AP/lat chest x-ray (Needed for diagnosis confirmation/severity).</li>
                                <li>Hospitalization for IV abx (Strong consideration given presentation).</li>
                                <li><strong>Prescription for an appropriate outpatient antibiotic + CXR + Close follow-up instructions: If choosing outpatient based on low CURB-65.</strong></li>
                                <li>Sputum for bacterial culture and sensitivity (Useful, esp. if inpatient or fails therapy).</li>
                                <li>TB skin test (Low yield acutely).</li>
                                <li>*(Decision outpatient vs inpatient is key here. Given ambiguity, outpatient start is plausible per text's rationale, but admission is safer)*</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>The most appropriate outpatient abx for him is?</summary>
                        <div class="details-content">
                             <p>For previously healthy adult outpatient CAP:</p>
                             <ul>
                                <li><strong>Amoxicillin (High dose) OR Doxycycline OR Macrolide (Azithromycin/Clarithromycin - if local pneumococcal resistance <25%).</strong></li>
                                <li>(Original text chose Azithromycin).</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>The primary MOA of the most appropriate abx (Macrolide - Azithromycin)?</summary>
                        <div class="details-content">
                             <ul>
                                <li>Bacterial cell wall synthesis and repair (Beta-lactam, Vanc).</li>
                                <li><strong>Bacterial protein synthesis by binding to 50S ribosomal subunit.</strong></li>
                                <li>Bacterial topoisomerase II (DNA gyrase) and IV (Fluoroquinolones).</li>
                                <li>Ergosterol synthesis (Antifungals).</li>
                                <li>Two successive steps in bacterial folate metabolism (TMP-SMX).</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>An abx with which MOA is less likely recommended due to "abx stewardship"?</summary>
                        <div class="details-content">
                             <ul>
                                <li>Cell wall synthesis (Beta-lactams - still widely used).</li>
                                <li>Protein synthesis 30S (Tetracyclines/AG - Doxy common outpatient).</li>
                                <li>Protein synthesis 50S (Macrolides - use declining due to resistance but still option).</li>
                                <li><strong>Bacterial topoisomerase II and IV (Fluoroquinolones): Use discouraged as first-line for uncomplicated infections due to side effect profile (BBWs) and promoting resistance.</strong></li>
                                <li>Folate metabolism (TMP-SMX - not first-line CAP).</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>An abx with which characteristic A/E is less likely recommended due to "abx stewardship"?</summary>
                        <div class="details-content">
                             <ul>
                                <li>Acute syncope, hypotension, wheezing (Anaphylaxis - risk with many, esp. beta-lactams).</li>
                                <li>Anemia due to hemolysis in G6PD def (Sulfonamides, etc.).</li>
                                <li>Gray baby syndrome (Chloramphenicol).</li>
                                <li><strong>Rupture of tendons of long muscles (Fluoroquinolones - key safety concern driving stewardship).</strong></li>
                                <li>Stains bodily fluids pink/orange (Rifampin).</li>
                             </ul>
                         </div>
                    </details>
               </div> <!-- End Case 1 Antimicrobial CIL -->

               <div class="case-study">
                    <p class="case-title">Case 2 (Antimicrobial CIL):</p>
                    <p>57 yo man admitted with fever, shaking chills, and cough with thick, white sputum for last 12 hours. Stopped smoking 10 years ago, but 50 pack-year history prior. No chronic meds, PMH, or surgeries. Allergic to penicillin. PE: BP 120/62, P 120 and regular, RR 28 and shallow, temp 102 F (38.9 C). Rales, rhonchi posteriorly on R and R mid-lung field anteriorly. Clear to percussion, no egophony, whispered pectoriloquy, or tactile fremitus. 89% O2 sat, elevated WBC. ECG: sinus tachycardia and no suggestions of MI. X-ray: right lower lobe infiltrate.</p>
                    <details>
                        <summary>Most appropriate initial diagnosis is acute?</summary>
                        <div class="details-content">
                             <ul>
                                <li><strong>Community-acquired pneumonia: Patient presenting from community with acute respiratory illness and infiltrate.</strong></li>
                                <li>Coronary syndrome (ECG negative).</li>
                                <li>Decompensated heart failure (Possible, but fever/chills/WBC less typical).</li>
                                <li>Exacerbation of chronic obstructive pulmonary disease (Has smoking hx, but no known COPD dx or chronic sx).</li>
                                <li>Pulmonary embolism (Possible, but fever/sputum less typical).</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>The most appropriate initial therapy for him is?</summary>
                        <div class="details-content">
                             <p>Patient is hypoxic (SpO2 89%).</p>
                             <ul>
                                <li>Acetaminophen orally (Symptomatic relief only).</li>
                                <li>Aspirin 325 mg chew and swallow (Not indicated).</li>
                                <li>Nebulized albuterol (Only if wheezing present).</li>
                                <li>Reteplase IV (Irrelevant).</li>
                                <li><strong>Supplemental oxygen by inhalation: First step to correct hypoxemia.</strong></li>
                             </ul>
                         </div>
                    </details>
                     <details>
                        <summary>The most appropriate next step?</summary>
                        <div class="details-content">
                             <p>Patient requires admission (Hypoxia, tachypnea, tachycardia, fever = CURB-65 score likely ≥2). Need diagnostics before/concurrent with antibiotics.</p>
                             <ul>
                                <li>Echocardiogram (Low yield initially).</li>
                                <li><strong>Blood cultures x 2 AND Sputum Gram stain & Culture: Standard workup for hospitalized CAP before starting antibiotics.</strong></li>
                                <li>Spiral CT (Only if complications or alternative dx suspected).</li>
                                <li>Serum D-dimer (Low suspicion for PE).</li>
                                <li>Torsemide IV (Only if HF suspected).</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>An abx with which MOA is CONTRAINDICATED?</summary>
                        <div class="details-content">
                             <p>Patient has Penicillin allergy.</p>
                             <ul>
                                <li><strong>Inhibits cell wall synthesis via PBP binding (Beta-lactams: Penicillins, Cephalosporins, Carbapenems). Avoid if true allergy.</strong></li>
                                <li>Binds to 30S subunit (Tetracyclines, Aminoglycosides).</li>
                                <li>Binds to 50S ribosomal subunit (Macrolides, Clindamycin, Linezolid).</li>
                                <li>Inhibits topoisomerase IV and II (Fluoroquinolones).</li>
                                <li>Inhibits folate biosynthesis (TMP-SMX).</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>The most appropriate initial therapy has which MOA? (Inpatient CAP, PCN Allergy)</summary>
                        <div class="details-content">
                             <p>Standard inpatient CAP regimens (non-ICU) avoiding beta-lactams:</p>
                             <ol>
                                 <li>Respiratory Fluoroquinolone monotherapy.</li>
                                 <li>(Aztreonam + Macrolide/Doxy - less common).</li>
                             </ol>
                             <ul>
                                <li>Binds RNA polymerase (Rifampin).</li>
                                <li>Binds 30S (Doxycycline - usually part of combo).</li>
                                <li>Binds 50S (Macrolide - usually part of combo).</li>
                                <li><strong>Inhibits topoisomerase IV and II (Respiratory Fluoroquinolone - Levo/Moxi/Gemi): Appropriate monotherapy covering typicals & atypicals.</strong></li>
                                <li>Inhibits folate biosynthesis (TMP-SMX - not standard).</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>A drug with which A/E is CONTRAINDICATED?</summary>
                        <div class="details-content">
                             <ul>
                                <li><strong>Acute anaphylactic or anaphylactoid reaction (Characteristic severe reaction to Penicillins/Beta-lactams - avoid this class).</strong></li>
                                <li>Hemolysis in G6PD deficiency (Sulfonamides, etc.).</li>
                                <li>Histamine-mediated facial erythema (Vancomycin).</li>
                                <li>Nephrotoxicity and ototoxicity (AG, Vanc).</li>
                                <li>Orange-red secretions (Rifampin).</li>
                             </ul>
                         </div>
                    </details>
                     <details>
                        <summary>The most appropriate initial therapy (Resp FQ) has which characteristic A/E?</summary>
                        <div class="details-content">
                             <ul>
                                <li>Colitis due to C. diff (Risk with FQ, but Clinda higher risk).</li>
                                <li>Photosensitivity (Risk with FQ, also Tetracyclines, Sulfas).</li>
                                <li><strong>Rupture of a tendon of long muscle (Characteristic BBW for Fluoroquinolones).</strong></li>
                                <li>Severe nausea, vomiting, diarrhea (More common with Macrolides).</li>
                                <li>Urinary stones (Sulfonamides).</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>If he had impaired renal function, most appropriate FQ therapy?</summary>
                        <div class="details-content">
                             <p>Need FQ primarily eliminated by liver, not kidney.</p>
                             <ul>
                                <li>Ciprofloxacin (Renal adjustment needed).</li>
                                <li>Levofloxacin (Renal adjustment needed).</li>
                                <li>Lomefloxacin (Renal adjustment needed).</li>
                                <li><strong>Moxifloxacin: Primarily hepatic metabolism/biliary excretion, no dose adjustment needed for renal impairment.</strong></li>
                                <li>Norfloxacin (Renal adjustment needed).</li>
                                <li>(Azithromycin also hepatic; Ceftriaxone biliary).</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>If sputum showed G+ diplococci (S. pneumo) and normal renal function, appropriate FQ (given PCN allergy)?</summary>
                        <div class="details-content">
                             <p>Need FQ with good Strep pneumo coverage.</p>
                             <ul>
                                <li>Ampicillin (Contraindicated).</li>
                                <li>Ciprofloxacin (Poor S. pneumo coverage).</li>
                                <li><strong>Levofloxacin: Respiratory FQ with reliable S. pneumo coverage.</strong></li>
                                <li>Norfloxacin (Not for pneumonia).</li>
                                <li>Pen G (Contraindicated).</li>
                                <li>(Moxifloxacin, Gemifloxacin also appropriate Resp FQs).</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>Which quinolone has LITTLE/NO activity against atypicals (Chlamydia, Mycoplasma, Legionella) and is NOT a respiratory quinolone?</summary>
                        <div class="details-content">
                             <ul>
                                <li>Levofloxacin (Respiratory FQ - covers atypicals).</li>
                                <li>Gemifloxacin (Respiratory FQ - covers atypicals).</li>
                                <li>Moxifloxacin (Respiratory FQ - covers atypicals).</li>
                                <li><strong>Norfloxacin: Older FQ, poor systemic absorption, poor lung penetration, limited S. pneumo and atypical coverage. Primarily UTI use.</strong></li>
                                <li>(Ciprofloxacin also has poor atypical coverage compared to Resp FQs).</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>If allergic to Cipro (FQ) but NOT penicillin, appropriate combo would include beta-lactam AND another drug with which MOA?</summary>
                        <div class="details-content">
                             <p>Standard inpatient CAP combo (non-ICU): Beta-lactam (e.g., Ceftriaxone) + Macrolide OR Doxycycline.</p>
                             <ul>
                                <li>Binds 30S (Doxycycline - Yes; Aminoglycoside - No).</li>
                                <li><strong>Binds 50S (Macrolide - Yes).</strong></li>
                                <li>Blocks enolpyruvate transferase (Fosfomycin).</li>
                                <li>Inhibits beta-lactamase (Inhibitor, not separate drug class MOA).</li>
                                <li>Inhibits topoisomerase (FQ - allergic).</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>Does following CAP guidelines matter for mortality/LOS?</summary>
                        <div class="details-content">
                             <ul>
                                <!-- <li>No, RCT never done... (False).</li> -->
                                <!-- <li>No, resistance only matters elsewhere... (False).</li> -->
                                <!-- <li>No, sensitivities fix everything... (False).</li> -->
                                <!-- <li>No, theoretical... (False).</li> -->
                                <li><strong>Yes, multiple large observational studies show significant reductions in mortality, length of stay (LOS), and duration of parenteral therapy when guideline-concordant empiric antibiotic therapy is used.</strong></li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>Best statistical method to compare survival in cohorts with baseline differences?</summary>
                        <div class="details-content">
                             <ul>
                                <li>Chi-square analysis (Compares proportions, doesn't handle time or confounders well).</li>
                                <li><strong>Cox proportional hazards analysis: Standard method for survival/time-to-event analysis comparing groups while adjusting for baseline covariates (confounders).</strong></li>
                                <li>Kaplan-Meier analysis (Visualizes survival curves, Log-rank test compares curves but doesn't easily adjust for confounders).</li>
                                <li>Paired t-test (Compares means of paired continuous data).</li>
                                <li>Unpaired t-test (Compares means of independent continuous data).</li>
                             </ul>
                         </div>
                    </details>
               </div> <!-- End Case 2 Antimicrobial CIL -->

               <div class="case-study">
                    <p class="case-title">Case 3 (Antimicrobial CIL):</p>
                    <p>25 yo woman who immigrated 2.5 years ago admitted with a 3 month hx of productive cough. No hemoptysis, weight loss, or night sweats. Denied previous treatment with anti-TB drugs or exposure to patients with active TB. Ex-smoker and drank occasionally. Afebrile, O2 sats 99%. X-ray on admission is shown:</p>
                    <!-- Placeholder for CXR image description -->
                    <p class="mt-2 text-sm italic text-[--text-secondary]">(Image description: Chest X-ray showing bilateral hilar adenopathy and possibly subtle reticular opacities or upper lobe infiltrates. Arrows pointing to hilar region and a possible upper lobe lesion.)</p>
                    <details>
                        <summary>What is the dark shadow below the diaphragm on the left?</summary>
                        <div class="details-content">
                             <ul>
                                <li>Accessory spleen</li>
                                <li>Flatus in transverse colon</li>
                                <li><strong>Gastric air bubble (Normal finding).</strong></li>
                                <li>Pneumoperitoneum (Would see free air under diaphragm).</li>
                                <li>Metastatic breast cancer</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>What are the bilateral ovoid opacities overlying the lung fields from about T7-T10?</summary>
                        <div class="details-content">
                             <ul>
                                <li>Bilateral pleural effusions</li>
                                <li>Bilateral pneumothoraces</li>
                                <li>Hampton's humps</li>
                                <li><strong>Mammary glands (Breast shadows - normal female anatomy).</strong></li>
                                <li>Metastatic colon cancer</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>What are the opacities in the mediastinum?</summary>
                        <div class="details-content">
                             <ul>
                                <li><strong>Bilateral hilar adenopathy (Enlarged lymph nodes at lung roots).</strong></li>
                                <li>Bilateral pleural effusions</li>
                                <li>Hampton's humps</li>
                             </ul>
                         </div>
                    </details>
                     <details>
                        <summary>The arrows point (blue circle on image) to what is most likely?</summary>
                        <div class="details-content">
                          <!-- Image description: Arrows A, B, C, D, E point to different areas. Blue circle around area C/D. -->
                          <p>Assuming C points to RUL opacity and D points to R hilum.</p>
                         <ul>
                            <li>Aspergilloma</li>
                            <li><strong>Cavitary lesion / Infiltrate in right upper/mid lung field (Consistent with post-primary TB, though could be other things like fungal, malignancy, sarcoid).</strong></li>
                            <li>Hampton's hump (PE sign - peripheral wedge opacity).</li>
                            <li>Mycoplasma pneumonia (Usually interstitial/patchy).</li>
                            <li>Solitary pulmonary metastasis</li>
                         </ul>
                         </div>
                    </details>
                    <details>
                        <summary>The Ghon complex is most likely located between the tips of which arrows?</summary>
                        <div class="details-content">
                             <p>Ghon complex = Peripheral lung focus (often mid/lower zone initially) + Ipsilateral hilar node.</p>
                             <ul>
                                <!-- <li>A and C</li> -->
                                <!-- <li>B and E</li> -->
                                <li><strong>C and D: Represents parenchymal lesion (C) and associated hilar adenopathy (D). If these calcify later, it's a Ranke complex.</strong></li>
                                <!-- <li>D and E</li> -->
                                <!-- <li>E and A</li> -->
                             </ul>
                         </div>
                    </details>
                    <!-- Placeholder for Ziehl-Neelsen image description -->
                    <p class="mt-4 text-sm italic text-[--text-secondary]">(Image description: Ziehl-Neelsen stained specimen of sputum showing red-stained rod-shaped organisms against a blue background.)</p>
                    <details>
                        <summary>A Ziehl-Neelsen stained specimen of sputum shows "red snappers". These are?</summary>
                        <div class="details-content">
                             <ul>
                                <li>Bacterial endospores</li>
                                <li>Cryptosporidium parvum (Acid-fast protozoa).</li>
                                <li>Human spermatozoa</li>
                                <li><strong>Mycobacterium species (Acid-Fast Bacilli - AFB).</strong></li>
                                <li>Nocardia species (Weakly acid-fast, filamentous).</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>Appropriate initial therapy includes a drug with which MOA? (TB)</summary>
                        <div class="details-content">
                             <p>Standard RIPE therapy includes:</p>
                             <ul>
                                <li>Cell wall PBP binding (Beta-lactams - not used).</li>
                                <li>30S subunit binding (Aminoglycosides like Streptomycin - 2nd line).</li>
                                <li>50S subunit binding (Macrolides - not used).</li>
                                <li><strong>Inhibits mycolic acid synthesis (Isoniazid - INH).</strong></li>
                                <li><strong>Inhibits RNA polymerase (Rifampin - RIF).</strong></li>
                                <li><strong>Inhibits arabinosyl transferase (cell wall) (Ethambutol - EMB).</strong></li>
                                <li><strong>Disrupts cell membrane/energy (Pyrazinamide - PZA).</strong></li>
                                <li>Inhibits folate synthesis (TMP-SMX - not used).</li>
                                <li>*(INH MOA listed as option)*</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>Contact lenses turn orange. MOA of likely drug?</summary>
                        <div class="details-content">
                             <ul>
                                <li><strong>Binds RNA polymerase (Rifampin - causes orange discoloration of body fluids).</strong></li>
                                <li>Inhibits mycolic acid synthesis (Isoniazid).</li>
                                <li>Inhibits arabinosyl transferases (Ethambutol).</li>
                                <li>Inhibits folate synthesis (TMP-SMX).</li>
                                <li>Activated by pncA enzyme (Pyrazinamide).</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>3 weeks later, elevated LFTs (ALT/AST). MOA of likely drug(s)?</summary>
                        <div class="details-content">
                             <p>INH, RIF, PZA are all hepatotoxic.</p>
                             <ul>
                                <li>30S subunit binding.</li>
                                <li><strong>Binds RNA polymerase (Rifampin - common cause).</strong></li>
                                <li><strong>Inhibits mycolic acid synthesis (Isoniazid - common cause, potentially severe hepatitis).</strong></li>
                                <li>Inhibits arabinosyl transferases (Ethambutol - not hepatotoxic).</li>
                                <li><strong>Activated by pncA enzyme (Pyrazinamide - dose-related hepatotoxicity).</strong></li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>After 6 weeks, difficulty distinguishing red/green. MOA of likely drug?</summary>
                        <div class="details-content">
                             <ul>
                                <li>30S subunit binding.</li>
                                <li>Binds RNA polymerase (Rifampin).</li>
                                <li>Inhibits mycolic acid synthesis (Isoniazid).</li>
                                <li><strong>Inhibits arabinosyl transferase (Ethambutol - causes optic neuritis, often affecting color vision first).</strong></li>
                                <li>Activated by pncA enzyme (Pyrazinamide).</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>After 12 weeks, severe pain/swelling R great toe (Gout). MOA of likely drug?</summary>
                        <div class="details-content">
                             <ul>
                                <li>30S subunit binding.</li>
                                <li>Binds RNA polymerase (Rifampin).</li>
                                <li>Inhibits mycolic acid synthesis (Isoniazid).</li>
                                <li>Inhibits arabinosyl transferase (Ethambutol).</li>
                                <li><strong>Activated by pncA enzyme (Pyrazinamide - inhibits uric acid excretion, causing hyperuricemia and gout).</strong></li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>MDR-TB tx (Capreomycin, Moxi, Ethionamide, Cycloserine, PAS). Elevated AST after 1 week. MOA of most likely drug?</summary>
                        <div class="details-content">
                             <p>Several can cause hepatotoxicity (Moxi, Ethionamide, PAS).</p>
                             <ul>
                                <li>Alanine racemase inhibition (Cycloserine).</li>
                                <li><strong>Inhibits mycolic acid synthesis (Ethionamide - structurally similar to INH, known hepatotoxicity).</strong></li>
                                <li>Folate metabolism inhibition (PAS - hepatotoxic, but GI more prominent).</li>
                                <li>30S ribosomal subunit inhibition (Capreomycin - nephro/ototoxic).</li>
                                <li>Topoisomerase II/IV inhibition (Moxifloxacin - can cause LFT elevation, less common than Ethionamide).</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>MDR-TB tx. After 4 weeks, gastric ulcer/hemorrhage. MOA of most likely drug?</summary>
                        <div class="details-content">
                             <ul>
                                <li>Alanine racemase inhibition (Cycloserine).</li>
                                <li>Inhibits mycolic acid synthesis (Ethionamide - GI upset common).</li>
                                <li><strong>Inhibits folate metabolism (Para-aminosalicylic acid - PAS: notorious for severe GI intolerance, including ulceration, bleeding).</strong></li>
                                <li>Inhibits 30S subunit (Capreomycin).</li>
                                <li>Inhibits topoisomerase IV and II (Moxifloxacin).</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>MDR-TB tx. Develops bilateral tinnitus. MOA of likely drug?</summary>
                        <div class="details-content">
                             <ul>
                                <li>Alanine racemase inhibition (Cycloserine - CNS effects).</li>
                                <li>Inhibits mycolic acid synthesis (Ethionamide).</li>
                                <li>Inhibits folate metabolism (PAS).</li>
                                <li><strong>Inhibits 30S ribosomal subunit (Capreomycin - injectable aminoglycoside-like drug, known for ototoxicity and nephrotoxicity).</strong></li>
                                <li>Inhibits topoisomerase IV and II (Moxifloxacin).</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>12 months later, follow-up chest x-ray shows?</summary>
                        <div class="details-content">
                             <p>Successful TB treatment usually results in:</p>
                             <ul>
                                <li>Cardiomegaly... (Suggests HF).</li>
                                <li>Loss of lung volume... (Possible severe fibrosis, but not guaranteed).</li>
                                <li><strong>Resolution of infiltrates, possibly with residual stable scarring, fibrosis, or calcified granulomas (Ranke complex). Normal CXR possible but less common after significant disease/cavitation.</strong></li>
                                <!-- <li>Old granulomatous disease (This describes residual findings).</li> -->
                                <li>Persistent cavitary lesion... (Indicates treatment failure or complication like aspergilloma).</li>
                             </ul>
                         </div>
                    </details>
               </div> <!-- End Case 3 Antimicrobial CIL -->

               <div class="case-study">
                    <p class="case-title">Case 4 (Antimicrobial CIL):</p>
                    <p>37 yo man hospitalized with fever, cough productive of white sputum for 3 days. No chronic meds, no pertinent past med or surgical hx. Allergic to penicillin. PE: BP 120/62, P 120, RR 28, Temp 102 F (38.9 C). Prominent rales and a few rhonchi diffusely in all lung fields, but clear to percussion. O2 sats 79% on room air. WBC elevated. ECG: sinus tach, no MI. Initial x-ray:</p>
                    <!-- Placeholder for CXR image description -->
                    <p class="mt-2 text-sm italic text-[--text-secondary]">(Image description: Chest X-ray showing diffuse bilateral pulmonary infiltrates, consistent with widespread pneumonia or ARDS.)</p>
                    <details>
                        <summary>Chest x-ray findings described:</summary>
                        <div class="details-content">
                             <ul>
                                <li>Cardiomegaly with pulmonary vascular redistribution (Suggests HF).</li>
                                <li>Cavitary lesion in right mid-lung field (Abscess/TB).</li>
                                <li><strong>Diffuse bilateral pulmonary infiltrate (Consistent with image description, suggests severe process like viral pneumonia, atypical pneumonia, ARDS, edema).</strong></li>
                                <li>Loss of lung volume in R upper lobe (Atelectasis/fibrosis).</li>
                                <li>Normal</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>Most appropriate initial therapy? (Severe CAP, Hypoxic, PCN Allergy)</summary>
                        <div class="details-content">
                             <p>Requires ICU admission likely. Empiric therapy needs broad coverage for typicals and atypicals, avoiding beta-lactams.</p>
                             <ul>
                                <li>Ampicillin and sulbactam (Contraindicated).</li>
                                <li>Ceftriaxone (Contraindicated if true severe allergy).</li>
                                <li>RIPE (TB therapy - unlikely acute presentation).</li>
                                <li><strong>Levofloxacin (Respiratory fluoroquinolone monotherapy is appropriate for severe CAP with PCN allergy).</strong></li>
                                <li>Vancomycin and gentamicin (Covers MRSA/Pseudo, poor atypical coverage, too broad initially unless specific risk factors).</li>
                                <li>(Moxifloxacin also appropriate FQ option).</li>
                             </ul>
                         </div>
                    </details>
               </div> <!-- End Case 4 Antimicrobial CIL -->
           </div> <!-- End Section: CIL Antimicrobials -->

           <div class="pixel-art-divider"></div>

           <!-- Section: Asthma/COPD CIL -->
           <div id="asthma-copd-cil" class="content-section">
               <svg viewBox="0 0 16 16" xmlns="http://www.w3.org/2000/svg" class="section-svg"><path fill-rule="evenodd" clip-rule="evenodd" d="M1 5H0V6H1V5ZM1 6H0V7H1V6ZM1 7H0V8H1V7ZM1 8H0V9H1V8ZM1 9H0V10H1V9ZM1 10H0V11H1V10ZM2 4H3V5H2V4ZM3 3H4V4H3V3ZM4 2H5V3H4V2ZM5 1H6V2H5V1ZM6 1H7V2H6V1ZM7 1H8V2H7V1ZM8 1H9V2H8V1ZM9 1H10V2H9V1ZM10 1H11V2H10V1ZM11 2H12V3H11V2ZM12 3H13V4H12V3ZM13 4H14V5H13V4ZM14 5H15V6H14V5ZM15 6H16V7H15V6ZM15 7H16V8H15V7ZM15 8H16V9H15V8ZM15 9H16V10H15V9ZM15 10H16V11H15V10ZM14 11H15V12H14V11ZM13 12H14V13H13V12ZM12 13H13V14H12V13ZM11 14H12V15H11V14ZM10 15H11V16H10V15ZM9 15H10V16H9V15ZM8 15H9V16H8V15ZM7 15H8V16H7V15ZM6 15H7V16H6V15ZM5 15H6V16H5V15ZM4 15H5V16H4V15ZM3 14H4V15H3V14ZM2 13H3V14H2V13ZM2 11H3V12H2V11ZM2 9H3V10H2V9ZM2 7H3V8H2V7ZM4 6H5V7H4V6ZM6 5H7V6H6V5ZM8 4H9V5H8V4ZM10 3H11V4H10V3ZM12 5H13V6H12V5ZM14 7H13V8H14V7ZM14 9H13V10H14V9ZM14 11H13V12H14V11ZM12 12H11V13H12V12ZM10 13H9V14H10V13ZM8 14H7V15H8V14ZM6 13H5V14H6V13ZM4 11H5V12H4V11ZM4 9H5V10H4V9ZM4 7H5V8H4V7ZM6 7H7V8H6V7ZM8 6H9V7H8V6ZM10 5H11V6H10V5ZM12 4H13V5H12V4ZM11 6H10V7H11V6ZM9 7H10V8H9V7ZM7 8H8V9H7V8ZM5 8H6V9H5V8ZM5 10H6V11H5V10ZM7 11H8V12H7V11ZM9 12H10V13H9V12ZM11 10H12V11H11V10ZM13 9H12V10H13V9ZM13 7H12V8H13V7Z" fill="currentColor"/></svg>
                <h2>Asthma/COPD CIL (Clinical Integration Lecture)</h2>

                <div class="case-study">
                    <p class="case-title">Case 1 (Asthma/COPD CIL):</p>
                    <p>55 yo to ED with wheezing, extreme SOB x 2 hours refractory to OTC inhaler. Was feeling well until a week ago, when he got a “cold" that manifested as fever of 101.5, muscle aches, dry cough that changed to a cough productive of yellow-green sputum over next 5 days, and anorexia. Last seen by doctor 2 years ago for acute SOB that responded to nebulizer, IV abx, and an infusion that "made my heart do flip-flops in my chest". No current meds, can't afford time off. BP 128/88, pulse 120, temp 100.4 F (38 C), RR 28 with accessory muscle use. PE: rhonchi and wheezes diffusely throughout the chest, protuberant abdomen with paradoxical movement when he breathes, and 1+ clubbing of fingers. Arterial blood gas: pH 7.32, pCO2 48 mm Hg, pO2 68 mm Hg. Low potassium, high bicarb, high glucose. Elevated WBC. UA 1+ glucose, 1+ ketones. ECG: tachycardia no acute signs of acute MI. A PA and lateral chest x-ray shows a patchy right lower lobe infiltrate, with some evidence of chronic hyperinflation, and a prominent right atrial shadow. (Smoking history implied by clubbing/hyperinflation, assumed present).</p>
                    <details>
                        <summary>The most appropriate diagnosis is?</summary>
                        <div class="details-content">
                             <p>Severe acute exacerbation of underlying obstructive lung disease (likely COPD given smoking history/hyperinflation/clubbing, but could be severe asthma or overlap) complicated by pneumonia, presenting in respiratory distress with hypercapnic respiratory acidosis.</p>
                             <ul>
                                <li>Mild intermittent asthma</li>
                                <li>Mild persistent asthma</li>
                                <li>Moderate persistent asthma</li>
                                <li>Severe persistent asthma</li>
                                <li><strong>Status Asthmaticus / Severe COPD Exacerbation: Best fits the acute, severe, refractory presentation with respiratory acidosis.</strong></li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>The IV medication 2 years ago causing palpitations was most likely?</summary>
                        <div class="details-content">
                             <ul>
                                <li>Beta-adrenoceptor antagonist</li>
                                <li>Corticosteroid</li>
                                <li><strong>Methylxanthine (Aminophylline IV - theophylline salt): Known to cause tachycardia/palpitations/arrhythmias. Historically used in severe exacerbations.</strong></li>
                                <li>Muscarinic agonist</li>
                                <li>Muscarinic antagonist</li>
                             </ul>
                    </details>
                    <details>
                        <summary>This class of medication (Methylxanthines) is no longer recommended because?</summary>
                        <div class="details-content">
                             <ul>
                                <li>Cardiac stimulatory properties (Contributes, but not the main reason).</li>
                                <li>Many drug interactions (True, significant issue).</li>
                                <li>Potential toxicity in renal dysfunction (Metabolism primarily hepatic, but clearance affected).</li>
                                <li><strong>Narrow therapeutic index: High risk of toxicity (seizures, arrhythmias) even at levels near therapeutic range. Requires TDM. Safer, more effective alternatives available.</strong></li>
                                <!-- <li>Wide therapeutic window (FALSE).</li> -->
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>The OTC inhaler most likely used has which MOA?</summary>
                        <div class="details-content">
                             <p>(Assuming older OTC like Epinephrine - Primatene Mist)</p>
                             <ul>
                                <li><strong>Activates adenylyl cyclase via Gs protein coupling to produce cAMP (Beta-agonist MOA).</strong></li>
                                <li>Activates nuclear receptors (Steroid MOA).</li>
                                <li>Blocks inhibitory muscarinic receptors (Anticholinergic MOA).</li>
                                <li>Binds to IgE (Anti-IgE MOA).</li>
                                <li>Inhibits cysteinyl leukotrienes (LTRA MOA).</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>The OTC inhaler primarily affects which receptor for therapeutic effect?</summary>
                        <div class="details-content">
                             <ul>
                                <li>α-1</li>
                                <li>β-1 and β-2 (Epinephrine hits both, but bronchodilation is β2 effect).</li>
                                <li>β-1</li>
                                <li><strong>β-2 (Causes bronchodilation).</strong></li>
                                <li>M1 and M3</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>The OTC inhaler (Epinephrine) has which adverse effects?</summary>
                        <div class="details-content">
                             <ul>
                                <li><strong>Hypokalemia (Beta-2 effect).</strong></li>
                                <li>Impaired wound healing, moon facies (Systemic steroids).</li>
                                <li>Oral thrush (Inhaled steroids).</li>
                                <li>Pupillary dilation (Anticholinergics).</li>
                                <li>Seizures, fatal dysrhythmias (Theophylline toxicity).</li>
                                <li>(Also Tachycardia, palpitations, tremor, anxiety due to β1/β2 effects).</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>The hypokalemia after OTC rescue inhaler use is mediated by?</summary>
                        <div class="details-content">
                             <ul>
                                <li>α-1 stimulation</li>
                                <li>β-1 inhibition</li>
                                <li>β-1 stimulation</li>
                                <li>β-2 inhibition</li>
                                <li><strong>β-2 stimulation (Activates Na+/K+ ATPase, shifting K+ into cells).</strong></li>
                             </ul>
                         </div>
                    </details>
                     <details>
                        <summary>The hypokalemia is initially mediated by?</summary>
                        <div class="details-content">
                             <ul>
                                <!-- <li>Decrease in potassium uptake by skeletal muscle (Incorrect - Increases uptake)</li> -->
                                <!-- <li>Enhanced perfusion of skeletal muscle</li> -->
                                <!-- <li>Inhibition of pancreatic insulin secretion (Stimulates insulin)</li> -->
                                <!-- <li>Stimulation of hepatic gluconeogenesis</li> -->
                                <li><strong>Stimulation of Na/K+ ATPase in muscle cells (Direct mechanism).</strong></li>
                             </ul>
                         </div>
                    </details>
                     <details>
                        <summary>The most important initial test to guide further therapy?</summary>
                        <div class="details-content">
                             <ul>
                                <li>DLCO</li>
                                <li>FVC</li>
                                <li><strong>PEFR (Peak Expiratory Flow Rate): Quick, repeatable bedside measure of airflow obstruction severity and response to treatment in acute setting.</strong></li>
                                <li>RV</li>
                                <li>TLC</li>
                                <li>(ABG also critical for assessing gas exchange/acid-base status).</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>The most ominous feature of this man's initial presentation?</summary>
                        <div class="details-content">
                             <ul>
                                <li>Arterial blood pH < 7.4 (7.32 - Acidosis, concerning).</li>
                                <li>eGFR < 60 (Unknown).</li>
                                <li><strong>pCO2 > 45 mmHg (pCO2 48 despite RR 28 indicates inadequate ventilation / respiratory muscle fatigue / impending failure).</strong></li>
                                <li>pO2 < 80 mmHg (pO2 68 - Hypoxia, concerning but treatable).</li>
                                <li>Temp > 37 C (Fever).</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>His initial peak flow is 30% predicted. Most appropriate initial therapy?</summary>
                        <div class="details-content">
                             <p>Severe exacerbation.</p>
                             <ul>
                                <li>Albuterol MDI q6h (Insufficient).</li>
                                <li>Inhaled ipratropium bromide (Adjunct only).</li>
                                <li><strong>Nebulized albuterol q20 minutes or continuously: High-dose, frequent SABA is first-line bronchodilator therapy.</strong></li>
                                <li>Oral prednisone (Essential, but need immediate bronchodilation).</li>
                                <li>Salmeterol inhaler BID (Controller, not rescue).</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>The most common A/E of this therapy (Nebulized Albuterol)?</summary>
                        <div class="details-content">
                             <ul>
                                <li>Bradycardia (Tachycardia).</li>
                                <li>Hypoglycemia (Hyperglycemia).</li>
                                <li>Oral thrush (ICS).</li>
                                <li>Pupillary dilation (Anticholinergic).</li>
                                <li><strong>Tremor (Common β2 side effect).</strong></li>
                             </ul>
                         </div>
                    </details>
                     <details>
                        <summary>Oxygen flow rate increased until patient achieves which SpO2?</summary>
                        <div class="details-content">
                             <p>Target SpO2 in acute exacerbations (balancing oxygenation vs. potential hypercapnia in COPD):</p>
                             <ul>
                                <li>70-79%</li>
                                <li>80-85%</li>
                                <li><strong>88-92% (Common target range for COPD exacerbation to avoid worsening hypercapnia).</strong></li>
                                <li>92-94% (Acceptable, slightly higher end).</li>
                                <li>>95% (Generally avoid hyperoxia in COPD).</li>
                                <li>*(Original text chose 92-94%, but 88-92% is often cited for COPD)*</li>
                             </ul>
                         </div>
                    </details>
                     <details>
                        <summary>Which feature points AWAY from infectious etiology (AGAINST abx)?</summary>
                        <div class="details-content">
                             <ul>
                                <li><strong>Charcot-Leyden crystals and Curschmann's spirals in sputum: Indicate eosinophilic inflammation, characteristic of asthma, not typical bacterial infection.</strong></li>
                                <li>Cough productive of yellow-green sputum (Suggests infection).</li>
                                <li>Current fever of 38 C (Suggests infection).</li>
                                <li>Leukocytosis with a "left shift" (Suggests bacterial infection).</li>
                                <li>Right lower lobe infiltrate on chest x-ray (Suggests pneumonia).</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>Which abx is most appropriate at this time? (Treating possible CAP component)</summary>
                        <div class="details-content">
                             <p>Need coverage for typical CAP pathogens +/- atypicals.</p>
                             <ul>
                                <li><strong>Azithromycin (Macrolide): Covers S. pneumo, H. flu, M. cat, and atypicals (Mycoplasma, Chlamydia, Legionella). Reasonable empiric choice.</strong></li>
                                <li>Chloramphenicol (Toxicity).</li>
                                <li>Gentamicin (Poor lung penetration, GNR focus).</li>
                                <li>Penicillin (Ampicillin) (Doesn't cover atypicals, resistance concerns).</li>
                                <li>Rifampin (TB drug).</li>
                                <li>(Respiratory FQ like Levofloxacin also good option).</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>The most appropriate abx therapy (Azithromycin) increases risk of which A/E?</summary>
                        <div class="details-content">
                             <ul>
                                <li><strong>Gastric distress (N/V/D - common with macrolides).</strong></li>
                                <li>"Grey baby" syndrome (Chloramphenicol).</li>
                                <li>Histamine-mediated facial erythema (Vancomycin).</li>
                                <li>Hypersensitivity reaction (Many drugs, esp. beta-lactams).</li>
                                <li>Ototoxicity (AG, Vanc).</li>
                                <li>(QT prolongation also a risk with macrolides).</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>Which history warrants early IV Steroids?</summary>
                        <div class="details-content">
                             <p>Indicates prior severe, life-threatening exacerbation.</p>
                             <ul>
                                <li><strong>3-day stay in ICU, including 1 day of intubation for status asthmaticus 3 years ago.</strong></li>
                                <li>Acid-fast bacilli in sputum (TB).</li>
                                <li>Family history of CF.</li>
                                <li>Aspirin sensitivity and nasal polyps (AERD).</li>
                                <li>Williams-Campbell syndrome.</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>Clinical effects of IV corticosteroids observed after what time?</summary>
                        <div class="details-content">
                             <ul>
                                <li>1-2 hours</li>
                                <li>3-4 hours</li>
                                <li><strong>6-12 hours: Onset of significant clinical effect (improved airflow, reduced inflammation) typically starts within 4-6 hours, more pronounced by 12-24 hours.</strong></li>
                                <!-- <li>12-24 hours</li> -->
                                <li>48+ hours</li>
                                <li>*(Original text chose 12-24h, but effects begin earlier)*</li>
                             </ul>
                         </div>
                    </details>
                     <details>
                        <summary>Zafirlukast/Montelukast given early in ED to? (Premise questionable)</summary>
                        <div class="details-content">
                             <p>LTRAs are chronic controllers, not standard acute ED therapy.</p>
                             <ul>
                                <!-- <li>Reduce dose of corticosteroids needed (Long term goal).</li> -->
                                <!-- <li>Reduce duration of ED visit (Unlikely acute effect).</li> -->
                                <li><strong>Reduce probability of subsequent ED visit / relapse after discharge (Potential benefit if continued as controller, not acute effect).</strong></li>
                                <!-- <li>Significantly improves peak flow rates during first 4 hours (No).</li> -->
                                <!-- <li>Significantly reduce "rescue inhaler" use after discharge (Controller benefit).</li> -->
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>Peak flow improves to 70%. Appropriate outpatient therapy MOA?</summary>
                        <div class="details-content">
                             <p>Patient needs SABA for rescue AND controller therapy (likely ICS/LABA or LAMA/LABA given severity/COPD features).</p>
                             <ul>
                                <li><strong>Activates adenylyl cyclase (SABA - Albuterol for rescue is essential).</strong></li>
                                <li>Binds nuclear receptor (Steroid - ICS controller also needed).</li>
                                <li>Binds IgE (Omalizumab - not indicated).</li>
                                <li>Blocks muscarinic receptors (LAMA - controller option, esp. COPD).</li>
                                <li>Inhibits leukotrienes (LTRA - less effective controller).</li>
                                <li>*(Best answer focusing on required rescue component is SABA MOA)*</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>If asthma did NOT respond to nebulized albuterol alone, most appropriate ADDITION?</summary>
                        <div class="details-content">
                             <p>Key additions for poor SABA response in severe exacerbation:</p>
                             <ul>
                                <!-- <li>Activates adenylyl cyclase (More SABA - already given).</li> -->
                                <li><strong>Binds nuclear receptor (Systemic Corticosteroid - IV/Oral - CRITICAL addition).</strong></li>
                                <!-- <li>Binds IgE (Not acute).</li> -->
                                <li>Blocks inhibitory muscarinic receptors (Add Ipratropium - Standard addition).</li>
                                <!-- <li>Inhibits leukotrienes (Not acute).</li> -->
                                <li>*(Both Steroids and Ipratropium are standard additions. Steroids address underlying inflammation more fundamentally)*</li>
                             </ul>
                         </div>
                    </details>
               </div> <!-- End Case 1 Asthma/COPD CIL -->

               <div class="case-study">
                    <p class="case-title">Case 3 (Asthma/COPD CIL):</p> <!-- Renumbered from original Case 3 -->
                    <p>9 yo girl brought to ED with 6 hours of cough, wheezing, progressive SOB. She has chronic persistent asthma and just finished a slow taper of prednisone last week. Her last hospitalization for asthma was 3 months ago, when she spent 2 days intubated, and 4 days in the ICU. She had a "cold" 2 days ago, and progressively developed more symptoms since then, despite starting prednisone yesterday, and taking her usual 3 inhalers (salmeterol and fluticasone - LABA/ICS), zafirlukast, and theophylline. She is using accessory muscles, RR 36, BP 100/58, P 136. Arterial blood: pH 7.28, pCO2 58, pO2 68.</p>
                    <details>
                        <summary>The most alarming thing about her status?</summary>
                        <div class="details-content">
                             <ul>
                                <li>Pulse of 136 (Concerning, but expected).</li>
                                <li>Respiratory rate of 36/min (Concerning, but expected).</li>
                                <li>pH of 7.28 (Severe acidosis, very concerning).</li>
                                <li><strong>pCO2 of 58: Severe hypercapnia despite tachypnea indicates critical respiratory muscle fatigue and impending respiratory failure. Most immediately life-threatening sign.</strong></li>
                                <li>pO2 of 68 (Severe hypoxia, concerning).</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>The most likely reason for her hypercapnia?</summary>
                        <div class="details-content">
                             <ul>
                                <li>Mistake in ABG lab (Unlikely).</li>
                                <li>Kidneys overcompensating (Incorrect physiology).</li>
                                <li><strong>Getting tired of breathing / Respiratory muscle fatigue: Due to severe airflow obstruction and increased work of breathing, leading to inability to maintain adequate alveolar ventilation. Requires immediate intervention (likely intubation).</strong></li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>Attending orders epi 0.3 mg IM. Appropriate for her vs. 69 yo grandmother because?</summary>
                        <div class="details-content">
                             <p>(IM Epi reserved for refractory cases/anaphylaxis).</p>
                             <ul>
                                <!-- <li>Developed COPD</li> -->
                                <!-- <li>Inspissations...</li> -->
                                <li><strong>The patient (9yo) is unlikely to suffer the adverse cardiovascular effects (tachycardia, arrhythmia, ischemia) as severely as an elderly patient with potential underlying heart disease.</strong></li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>Breathing slower now, pulse ox drops from 86% to 78%. Most appropriate additional therapy?</summary>
                        <div class="details-content">
                             <p>Slowing RR + worsening hypoxia = Respiratory Failure / Impending Arrest.</p>
                             <ul>
                                <li>Ipratropium (Too late/insufficient).</li>
                                <li>Heliox-driven albuterol (Adjunct, may not be fast/definitive enough).</li>
                                <li>IV magnesium sulfate (Adjunct, may help but airway/ventilation is priority).</li>
                                <li><strong>Intubation and mechanical ventilation: Definitive airway management and ventilatory support needed immediately.</strong></li>
                                <li>Oral montelukast (Irrelevant).</li>
                             </ul>
                         </div>
                    </details>
               </div> <!-- End Case 3 (9yo girl) Asthma/COPD CIL -->

               <div class="case-study">
                    <p class="case-title">Case 4 (Asthma/COPD CIL):</p> <!-- Renumbered from original Case 4 -->
                    <p>15 yo boy unable to keep up with classmates during PE class distance running. Mother says he has a "bad attitude". He is otherwise healthy and takes no medications. PE is unremarkable, until he is sent to run up and down the stairwell. When he reappears, he has audible wheezes throughout both lung fields, RR 36, using accessory muscles, pulse 140. Peak flow effort is only 125 mL. After two inhalations of albuterol, his wheezing improves, and he gradually returns to his baseline state over 15 minutes.</p>
                    <details>
                        <summary>The most likely diagnosis?</summary>
                        <div class="details-content">
                             <ul>
                                <li>Cold-induced asthma</li>
                                <li>Conversion reaction</li>
                                <li>Cough-variant asthma</li>
                                <li><strong>Exercise-induced asthma (EIA) / Exercise-induced bronchoconstriction (EIB): Symptoms specifically triggered by exercise, resolve with rest/SABA.</strong></li>
                                <li>Mild persistent asthma (Could be underlying, but EIB is the presentation).</li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>The most appropriate therapy?</summary>
                        <div class="details-content">
                             <p>For prevention of EIB:</p>
                             <ul>
                                <li>Long-acting beta-agonist and corticosteroid inhalers (Controller therapy for persistent asthma).</li>
                                <li>Long-acting beta-agonist inhaler and cromolyn sodium orally (Incorrect).</li>
                                <li>Long-acting beta-agonist only before gym class (LABA monotherapy contraindicated).</li>
                                <li>Oral prednisone (Not indicated).</li>
                                <li><strong>Short-acting beta-agonist (SABA - Albuterol) inhaled 15-30 minutes before exercise: First-line prevention for EIB.</strong></li>
                             </ul>
                         </div>
                    </details>
                    <details>
                        <summary>If beta-agonists are not allowed by school, most appropriate therapy?</summary>
                        <div class="details-content">
                             <p>Alternatives for EIB prevention:</p>
                             <ul>
                                <li>Corticosteroid inhaler (Daily ICS can reduce EIB frequency, but not ideal immediate pre-exercise prevention).</li>
                                <li><strong>Cromolyn sodium inhaler: Taken 15-30 min before exercise, safe alternative to SABA.</strong></li>
                                <li>Ipratropium inhaler (Ineffective for EIB).</li>
                                <li><strong>Oral montelukast: Taken daily, can reduce EIB frequency. Good alternative if inhaled meds difficult/not allowed.</strong></li>
                                <li>Oral prednisone (Not indicated).</li>
                                <li>*(Both Cromolyn and Montelukast are valid alternatives)*</li>
                             </ul>
                         </div>
                    </details>
               </div> <!-- End Case 4 (15yo boy) Asthma/COPD CIL -->

           </div> <!-- End Section: Asthma/COPD CIL -->

    </main>

<script>
   // Basic sidebar toggle for mobile
   function toggleSidebar() {
       document.body.classList.toggle('sidebar-hidden');
       // Optional: Change button text based on state
       const button = document.getElementById('sidebar-toggle');
       if (document.body.classList.contains('sidebar-hidden')) {
           button.innerHTML = '☰'; // Show menu icon
           button.title = "Show Sidebar";
       } else {
           button.innerHTML = '✕'; // Show close icon
           button.title = "Hide Sidebar";
       }
   }

   document.addEventListener('DOMContentLoaded', () => {
       const sections = document.querySelectorAll('.content-section');
       const navLinks = document.querySelectorAll('#sidebar-nav a');
       const mainContent = document.getElementById('main-content');
       const sidebar = document.getElementById('sidebar');
       const sidebarToggle = document.getElementById('sidebar-toggle');

       // Set initial sidebar state based on screen size
       if (window.innerWidth < 1024) {
           document.body.classList.add('sidebar-hidden');
           sidebarToggle.innerHTML = '☰';
           sidebarToggle.title = "Show Sidebar";
       } else {
           document.body.classList.remove('sidebar-hidden');
           sidebarToggle.innerHTML = '✕';
           sidebarToggle.title = "Hide Sidebar";
       }
        // Add listener for toggle button
        sidebarToggle.addEventListener('click', toggleSidebar);


       // Close sidebar when clicking main content on mobile if sidebar is forced open
       mainContent.addEventListener('click', () => {
            if (window.innerWidth < 1024 && !document.body.classList.contains('sidebar-hidden')) {
                 toggleSidebar();
            }
       });
        // Close sidebar when clicking a link
        navLinks.forEach(link => {
            link.addEventListener('click', () => {
                if (window.innerWidth < 1024 && !document.body.classList.contains('sidebar-hidden')) {
                    // Add a small delay to allow scroll to start before closing
                    setTimeout(toggleSidebar, 100);
                }
            });
        });


       // Function to add is-visible class for fade-in animations
        const animationObserver = new IntersectionObserver((entries, observer) => {
            entries.forEach(entry => {
                if (entry.isIntersecting) {
                    entry.target.style.opacity = 1;
                    entry.target.style.transform = 'translateY(0)';
                    // Optional: Stop observing after animation triggers once
                    // observer.unobserve(entry.target);
                } else {
                     // Optional: Reset animation if element scrolls out of view
                     // entry.target.style.opacity = 0;
                     // entry.target.style.transform = 'translateY(20px)';
                }
            });
        }, { threshold: 0.1 }); // Trigger when 10% visible

        sections.forEach(section => {
            section.style.opacity = 0;
            section.style.transform = 'translateY(20px)';
            section.style.transition = 'opacity 0.6s ease-out, transform 0.6s ease-out';
            animationObserver.observe(section);
        });


       // --- Intersection Observer for Active Sidebar Link ---
       let currentActiveLink = null; // Keep track of the currently active link
       let intersectionRatioMap = new Map(); // Store intersection ratios

        const observerOptions = {
            root: null,
            rootMargin: '0px 0px -50% 0px', // Trigger area is top half of viewport
            threshold: [0, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0] // Multiple thresholds
        };

        const observerCallback = (entries, observer) => {
            entries.forEach(entry => {
                intersectionRatioMap.set(entry.target.getAttribute('id'), entry.intersectionRatio);
            });

            // Find the entry with the highest intersection ratio within the trigger area
            let maxRatio = 0;
            let mostVisibleEntryId = null;

            intersectionRatioMap.forEach((ratio, id) => {
                const element = document.getElementById(id);
                if (element && element.getBoundingClientRect().top < window.innerHeight / 2) { // Check if top is in the top half
                     if (ratio > maxRatio) {
                        maxRatio = ratio;
                        mostVisibleEntryId = id;
                    }
                 }
            });

            // Update active link
            const newActiveLink = mostVisibleEntryId ? document.querySelector(`#sidebar-nav a[href="#${mostVisibleEntryId}"]`) : null;

            if (newActiveLink !== currentActiveLink) {
                if (currentActiveLink) {
                    currentActiveLink.classList.remove('active-link');
                }
                if (newActiveLink) {
                    newActiveLink.classList.add('active-link');
                    // Scroll sidebar if needed
                     if (window.innerWidth >= 1024 || !document.body.classList.contains('sidebar-hidden')) {
                         const sidebarRect = sidebar.getBoundingClientRect();
                         const linkRect = newActiveLink.getBoundingClientRect();
                         if (linkRect.top < sidebarRect.top + 50 || linkRect.bottom > sidebarRect.bottom - 50) { // Add buffer
                             newActiveLink.scrollIntoView({ behavior: 'smooth', block: 'center' });
                         }
                    }
                }
                currentActiveLink = newActiveLink;
            }
        };

       const scrollObserver = new IntersectionObserver(observerCallback, observerOptions);

       sections.forEach(section => {
           scrollObserver.observe(section);
       });

       // --- Smooth Scroll (using CSS scroll-behavior, JS fallback/enhancement) ---
       navLinks.forEach(anchor => {
           anchor.addEventListener('click', function (e) {
               const href = this.getAttribute('href');
               if (href.startsWith('#')) {
                    e.preventDefault();
                   const targetId = href.substring(1);
                   const targetElement = document.getElementById(targetId);
                   if(targetElement) {
                       targetElement.scrollIntoView({
                           behavior: 'smooth',
                           block: 'start'
                       });
                       // Update URL hash without causing jump (optional)
                       // history.pushState(null, null, href);
                   }
               }
           });
       });

        // --- Add data-label attribute to table cells for mobile view ---
        const tables = document.querySelectorAll('table');
        tables.forEach(table => {
            const headers = [];
            table.querySelectorAll('thead th').forEach(th => {
                // Use a specific attribute or the text content for the label
                headers.push(th.getAttribute('data-col-name') || th.textContent.trim());
            });
            // Ensure headers were found before proceeding
            if (headers.length > 0) {
                table.querySelectorAll('tbody tr').forEach(tr => {
                    tr.querySelectorAll('td').forEach((td, index) => {
                        if (headers[index]) {
                            td.setAttribute('data-label', headers[index]);
                        }
                        // Wrap content in span for better mobile alignment if needed
                        // if(td.children.length === 0 && td.textContent.trim() !== ''){
                        //    td.innerHTML = `<span>${td.innerHTML}</span>`;
                        // }
                    });
                });
            } else {
                 // Fallback if no thead - maybe use first row? Or skip.
                 console.warn("Table lacks thead, cannot generate data-labels for mobile view.", table);
            }
        });

        // --- Wrap details content for animation/padding ---
        document.querySelectorAll('details').forEach(detail => {
            const contentNodes = [];
            let summaryNode = null;
            // Collect all nodes that are not the summary
            detail.childNodes.forEach(node => {
                if (node.nodeName.toLowerCase() === 'summary') {
                    summaryNode = node;
                } else if (node.nodeType === Node.ELEMENT_NODE || (node.nodeType === Node.TEXT_NODE && node.textContent.trim() !== '')) {
                     contentNodes.push(node);
                } else if (node.nodeType === Node.COMMENT_NODE) {
                     contentNodes.push(node); // Keep comments if needed
                }
            });

            // If content exists and isn't already wrapped
            if (contentNodes.length > 0 && detail.querySelector(':scope > div.details-content') === null) {
                const wrapper = document.createElement('div');
                wrapper.className = 'details-content';
                contentNodes.forEach(node => {
                    wrapper.appendChild(node); // Move nodes into the wrapper
                });
                // Insert wrapper after summary, or at the end if no summary (shouldn't happen)
                if (summaryNode && summaryNode.nextSibling) {
                     detail.insertBefore(wrapper, summaryNode.nextSibling);
                } else if (summaryNode) {
                     detail.appendChild(wrapper);
                } else {
                     detail.insertBefore(wrapper, detail.firstChild); // Fallback
                }
            } else if (contentNodes.length > 0 && detail.querySelector(':scope > div.details-content') !== null) {
                 // Ensure existing wrapper has the correct class
                 detail.querySelector(':scope > div').classList.add('details-content');
            }
        });


   });
</script>

</body>
</html>